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SUMMARY 
The incidence of Type 2 Diabetes Mellittus (T2DM) is increasing world wide. In 
Africa the limited access to health care and the insidious course of the disease 
lead to more severe illness and diabetic complications. There is a need to find 
alternative approaches to treatment and prevention that address the problems and 
needs of Africa. Sutherlandia frutescens (S.frutescens) is a traditional herbal plant 
with known anti-diabetic properties, the precise mechanism of action of 
S.frutescens is not known.  
In order to develop new approaches for treatment and prevention of T2DM the 
pathophysiology of T2DM must be understood. T2DM is the final outcome of a 
multi-organ disease characterized by early defects in muscle, adipocytes, 
hepatocytes and pancreatic β-cells. In this study the role of the liver was 
investigated because of its central role in glucose and lipid metabolism.  
It is hard to differentiate between all the influences in an in vivo model, so the aim 
of this study was to develop an in vitro model of T2DM in Chang liver cells and to 
determine if S.frutescens can reverse the state of insulin resistance in this model. 
Different culture media conditions were screened to identify a method that can be 
used as the T2DM model in Chang liver cells. Serum free medium (MCBD-201) 
supplemented with human diabetic serum, (2.5%-10%), high insulin 
concentrations (0.1μM-1μM), high fructose concentrations (1-10mM). and a 
combination of high insulin and high fructose was used for this screening. Chang 
liver cells cultured in MCBD-201 medium supplemented with 1mM fructose and 
0.1μM insulin showed reduced glucose uptake and increased lipid accumulation. 
The effect of two S.frutescens extracts, two anti-diabetic drugs, metformin and 
ciglitazone, and a hypolipidemic drug ciprofibrate were determined and shown to 
increase glucose uptake and reduce lipid accumulation.  
It was postulated that exposing the cells to excess nutrients in the form of high 
fructose would stimulate the cells to become adipogenic and accumulate lipids, 
which would interfere with the glucose uptake and induce insulin resistance. Gene 
expression of PPARγ, PPARα, and SREBP-1 transcription factors regulating lipid 
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metabolism was determined in Chang liver cells cultured in insulin resistance 
inducing medium over a 48 hour time course. The expression of PPARγ, known to 
stimulate adipogenesis was increased after 6, 24 and 48 hours of exposure 
(P(H1)<0.0001). The expression of PPARα, known to stimulate β-oxidation 
expression, was significantly decreased after 24 hours of exposure 
(P(H1)<0.0001). The presence of the plant extracts in the insulin resistance 
inducing media protect against this increase in adipogenesis and decrease in β-
oxidation after 48 hours of exposure by increasing PPARα expression and 
decreasing PPARγ expression.  
A PCR Array was performed which identified 32 more potential molecular targets 
of S.frutescens. Five of the 32 targets identified with the PCR Array were validated 
using qRT-PCR. These genes play a role in lipid and glucose metabolism and 
protection against oxidative stress and inflammation.  
In summary a cellular model of insulin resistace in hepatocytes has been 
established and the capacity of S.frutescens to reverse this process has been 
demonstrated by acting as a dual PPARγ/α agonist. New genes have been 
identified in the development of insulin resistance and as targets of S.frutescens. 
Key words: PPARα; PPARγ; Chang liver cells, insulin resistance; S.frutescens 
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CHAPTER 1: LITERATURE REVIEW 
1.1 INTRODUCTION 
Diabetes Mellitus (DM) is a complex, heterogeneous metabolic disease with an 
environmental and genetic component affecting approximately 180 million 
people worldwide (Report of a WHO/IDF Consultation, 2006). This number of 
patients is likely to more than double by 2030. Much of the increase in DM will 
occur in developing countries due to population growth, ageing, unhealthy 
diets, obesity and sedentary lifestyles (Report of a WHO/IDF Consultation, 
2006). There is also a growing incidence of Type 2 Diabetes Mellitus (T2DM), 
which accounts for 90% of DM at a younger age. DM accounts for 2.5-15% of 
the total annual health care budget in many countries, depending on the 
prevalence and sophistication of treatment available. DM imposes a heavy 
burden on the health services in many African countries too.  In the African 
continent limited access to health care, the insidious course of T2DM, and late 
presentation to health facilities lead to more severe illness and diabetic 
complications at diagnosis (Kengne et al., 2005; Katz et al., 2009). These 
complications pose enormous costs on health services, where resources are 
already limited (Abbas & Archibald, 2005). 
 As the prevalence of diabetes increases in Africa there is an urgent need to 
investigate this disease more vigorously and find alternative and novel approaches 
of treatment that address the problems and needs of Africa. The medicinal plant 
Sutherlandia frutescens (S.frutescens) has been shown to have antidiabetic 
properties in a rat diabetic model (Chadwick et al., 2007). In the present study 
S.frutescens is explored as an alternative approach to the treatment of T2DM. The 
focus of the study is to determine the molecular targets of S.frutescens in a human 
hepatocyte cell line. Identification of the molecular targets could shed the light on 
the mechanism of action of S.frutescens in lowering blood glucose levels and 
improving T2DM. 
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1.2 DIABETES MELLITUS 
DM is defined by the World Health Organization (WHO) as a chronic disease that 
occurs when the pancreas does not produce enough insulin, or alternatively, when 
the body cannot effectively use the insulin it produces (Report of WHO, 1999; 
American Diabetes Association, 2006; Report of a WHO/IDF Consultation, 2006). 
Three types of diabetes are distinguished: Type 1 Diabetes Mellitus (T1DM) 
(previously known as insulin-dependent or childhood onset), T2DM (formerly 
known as non-insulin dependent or adult onset) and Gestational diabetes. T2DM 
comprises 90% of the people with diabetes worldwide and is largely the result of 
excess body weight and physical inactivity. Symptoms of diabetes include 
polyuria, polydipsia, constant hunger, weight loss, vision changes and fatigue, 
which might appear suddenly in T1DM and are often less marked in T2DM. As a 
result, in T2DM the disease may be diagnosed several years after onset, once 
complications have already arisen (Report of WHO, 1999; Report of a WHO/IDF 
Consultation, 2006; American Diabetes Association, 2006). 
Biochemical changes associated with a cellular model of T2DM were investigated 
in the present study. T2DM is an extremely heterogeneous disorder. The etiology 
of the disease remains poorly defined and a matter of great controversy. However 
as summarized by Gerich, (1998) it is generally agreed that (1) the disease has 
strong genetic and environmental (acquired) components; (2) its inheritance is 
polygenic, meaning that the simultaneous presence of several abnormal genes or 
polymorphisms is necessary for development of the disease; (3) impairment of 
insulin sensitivity and insulin secretion, each of which is under genetic control, are 
both important elements in its pathogenesis; (4) most patients are obese; and (5) 
obesity, especially intra-abdominal obesity, causes insulin resistance and is under 
genetic control. 
As mentioned above, whilst there are aspects of the etiology of T2DM that are 
agreed on between different research groups, there are also aspects of great 
controversy which are disputed including: (1) The quantitative contribution of 
insulin resistance and impaired insulin secretion to T2DM; (2) The role of insulin 
resistance and impaired insulin secretion as genetic factors; (3) the major sites of 
insulin resistance (liver vs. muscle vs. adipose tissue vs. kidney); and (4) the steps 
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that lead to the development of T2DM (Gerich, 1998).  
One of the great battles in the pathogenesis of T2DM has been the relative 
importance of insulin resistance versus pancreatic β-cell dysfunction (Gerich, 
1998; Bergman, 2002; Gerich & Dailey, 2004). In most individuals with T2DM 
onset of insulin resistance precedes overt β-cell dysfunction, leading to the 
predominant view that genes affecting insulin resistance  are the primary genetic 
factor in T2DM (Nandi et al., 2004). The term insulin resistance in T2DM refers to 
the failure of cells to respond to normal levels of circulating insulin with respect to 
glucose uptake, metabolism or storage (Kahn & Flier, 2000; Mlinar et al., 2007). 
Insulin resistance in obesity and T2DM is manifested by decreased insulin-
stimulated glucose transport and metabolism in adipocytes and skeletal muscle, 
and by impaired suppression of hepatic glucose production (HGP), leading to 
chronically elevated blood glucose (hyperglycaemia) (Kahn & Flier, 2000). Insulin 
is released by the pancreatic β-cells, within the islets of Langerhans, in response 
to hyperglycaemia. In mild cases of insulin resistance, increased insulin production 
by pancreatic β-cells leading to „hyperinsulinaemia‟ can compensate for the 
decreased responsiveness to the hormone (Kim & Ahn, 2004). T2DM results when 
the pancreatic β-cells fail. As long as β-cells are able to increase insulin secretion 
to compensate for insulin resistance, T2DM does not occur. T2DM only develops 
when there is both insulin resistance and β-cell failure (Kim & Ahn, 2004).  
Gerich (1998) concludes that although insulin resistance is viewed as the main 
genetic factor predisposing development of T2DM, the evidence better supports 
impaired insulin secretion as the main genetic factor. He based this hypothesis on 
the fact that not all people with T2DM are insulin resistant and many obese insulin 
resistant people never develop T2DM. All people with T2DM however, show 
impaired insulin secretion (Gerich, 1998; Gerich, 2000; Gerich & Dailey, 2004). In 
the battle between insulin resistance vs impaired insulin secretion the conclusion 
is that the relative importance of these two factors varies considerably from patient 
to patient. In nonobese patients impaired insulin secretion will predominate, 
whereas in obese patients both factors would probably be of equal importance 
(Gerich & Dailey, 2004).  
Other points of dispute are the major tissue sites of insulin resistance and the 
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steps that lead to the development of the disease (Gerich, 1998). There has been 
extensive research to dissect the complex pathophysiology of T2DM, to determine 
the individual contribution of each tissue and the subsequent events in the 
development of the disease.   Animal models of diabetes were mostly used for this 
research (Srinivasan & Ramarao, 2007). However, the key early events that lead 
to hyperglycaemia and insulin deficiency remain uncertain and controversial (Das 
& Elbein, 2006). Current models of diabetes propose a role for multiple pathways 
affecting multiple organs. These include the pancreatic β-cells, peripheral glucose 
uptake in muscle, the secretion of multiple cytokines and other hormone-like 
molecules from adipocytes, hepatic glucose production and the central nervous 
system. Because of this complex web of physiologic defects, the number of risk 
susceptibility genes in T2DM is likely to be very large, and the effect of each gene 
individually would be relatively small (Das & Elbein, 2006).   
As insulin secretion and insulin action are the primary risk factors in the 
development of T2DM, research has focused on the identification and 
characterization of molecules involved in the insulin-signalling pathway. Much 
progress has been made by employing genetically engineered mouse models in 
which genes in insulin signalling, action and secretion are manipulated (Mauvais-
Jarvis & Kahn, 2000;  Baundry et al., 2002; Nandi et al., 2004; Plum et al., 2005; 
Srinivasan & Ramarao, 2007). In the next section the insulin-signalling pathway 
will be discussed briefly. 
1.3  INSULIN SIGNALLING 
Insulin-signalling involves a cascade of events initiated by insulin binding to its 
cell-surface receptor (Figure 1.1) (Kahn & White, 1988; Cheatham & Kahn, 1995; 
Fröjdö et al., 2009). The insulin receptor (IR) is a heterotetrameric protein 
consisting of two extracellular α subunits and two transmembrane β subunits. The 
α subunits contain the insulin-binding domain, and the β subunits contain the 
tyrosine kinase domain (Kasuga et al., 1983; Cheatman & Kahn 1995).  
Insulin binding to the α subunit of the receptor stimulates autophosphorylation of a 
regulatory region in the β subunit, which stimulates intrinsic tyrosine kinase activity 
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(Kasuga et al., 1983; Cheatman & Kahn 1995). The activated receptor then 
phosphorylates a family of insulin receptor substrate (IRS) proteins (Figure 1.1) 
(Chang et al., 2004). Members of this family of proteins include IRS-1, IRS-2, IRS-
3 and IRS-4, which are generally viewed as most specific for insulin signalling 
(White, 2002).  Other substrates include growth factor receptor bound protein 2 
(Grb-2) -associated binder-1 (Gab1), Src homology 2 (SH2) domain-containing 
alpha-2 collagen-related protein (Shc) and the casitas B-lineage lymphoma (Cbl) 
proto-oncogene (Virkamäki et al., 1999; Glund & Zierath, 2004). These substrates 
are commonly referred to as docking proteins, as they bind to the insulin receptor 
only transiently and then dissociate. This interaction promotes attraction and 
activation of the next layer of insulin signalling intermediates that transmit the 
signal downstream (Virkamäki et al., 1999). 
 
 
 
 
 
 
 
 
Figure 1.1 Insulin Signalling Pathway.  
Binding of insulin to α subunit of receptor leads to autophosphorylation of β subnit which stimulates 
the intrinsic tyrosine kinase activity. The activated receptor then phosphorylates the IRS proteins 
including: IRS1-4, Grb2, Shc and Cbl. Subsequently three different pathways transduce the signal: 
the PI3K-dependent pathway mediating metabolic responses, including glucose/lipid/protein 
metabolism and insulin stimulated glucose uptake; the CAP/Cbl pathway which is addionally 
required for GLUT4 translocation; and the MAP kinase pathway that results in cell proliferation and 
differentiation.  
(Figure taken from Leclercq et al., 2007).  
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There are 3 main pathways that propagate the signal generated through the 
insulin receptor further, namely, the IRS/phosphatidylinositol 3 kinase (PI3K) 
pathway; the retrovirus-associated DNA sequences (RAS)/mitogen-activated 
protein kinase (MAPK) pathway; and the Cbl-associated protein (CAP)/Cbl 
pathway (Figure 1.1) (Glund & Zierath, 2004; Tilg & Moschen, 2008; Meshkani & 
Adeli, 2009). The phosphorylated IRS protein substrates create binding sites for 
these intermediate signalling proteins containing src-homology domains 2 (SH2), 
src-homology domains 3 (SH3) and pleckstrin homology (PH) binding domains 
(Goalstone & Draznin, 1997; Virkamäki et al., 1999).  PI3K is the best 
characterized of the three main pathways (Shepherd et al., 1998).  
PI3K is a heterodimeric enzyme comprising an 85 kDa regulatory subunit and a 
110 kDa catalytic subunit (Figure 1.1) (Shepherd et al., 1998). The regulatory 
subunit facilitates the interaction between the IRS proteins and PI3K, resulting in 
an increase in the activity of the catalytic subunit (White, 2002; Olivares-Reyes, et 
al., 2009). The catalytic subunit catalyzes the phosphorylation of 
phosphatidylinositol-4,5-diphosphate (PIP2) into PI-3,4,5-triphosphate(PIP3) 
(White, 2002; Leclercq et al., 2007). These phospholipids recruit the PI3K 
dependent serine/threonine kinases (PDK1 and PDK2), protein kinase C (PKC) 
and at least three protein kinase B (PKB) isoforms from the cytoplasm to the 
plasma membrane by binding to the PH domain of these kinases. This binding and 
translocation lead to subsequent phosphorylation and activation of PKB1, -2, or -3 
by PDK1 or PDK2. The activated PKB, also known as Akt, phosphorylates many 
substrates that control several biological signalling cascades, in various cells and 
tissues including glucose transport, protein synthesis, glycogen synthesis, cell 
proliferation, and cell survival, in various cells and tissues (Figure 1.1) (White, 
2002; Fröjdö et al., 2009). PKB/Akt mediates glucose transport in concert with the 
atypical PKC isoforms, and glucogen synthesis, via the inhibitory phosphorylation 
of glycogen synthase kinase (GSK3), a kinase that negatively regulates glycogen 
synthase. PKB/Akt inhibits gluconeogenesis via activation of FOXO1 (Figure 1.1) 
(White, 2002; Fröjdö et al., 2009). PI3K activation is attenuated by PIP3 
dephosphorylation via phosphatidylinositol-3-phosphatase (PTEN) or SH2 domain-
containing inositol-5-phosphatases (SHIP2) (Chang et al., 2004). 
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While it has been well established that activation of PI3K is essential for insulin-
stimulated GLUT4 translocation; activation of this enzyme is not sufficient for the 
increased glucose transport observed in response to insulin (Chang et al., 2004). 
The CAP/Cbl pathway has been reported to be a PI3K-independent pathway 
participating in insulin-mediated glucose transport through activation of TC10 
(Figure 1.1) (Glund & Zierath, 2004; Meshkani & Adeli, 2009).  Thus two 
independent signalling pathways: PI3K pathway and CAP/Cbl/TC10 pathway are 
required for insulin-induced GLUT4 translocation from intracellular storage 
compartments to the plasma membrane (Kanzaki & Pessin, 2003). These two 
pathways act together to elicit the translocation of GLUT4 protein via membrane 
trafficking systems (Kanzaki & Pessin, 2003). 
The third pathway, the RAS/MAPK cascade, does not play a role in the acute 
regulation of glucose transport, but is largely involved in gene regulatory 
responses in insulin-sensitive tissues (Glund & Zierath, 2004). This pathway is 
activated by tyrosine phosphorylation of Shc, which associates with Grb2, or IRS-
1, which also associates with Grb2. Both the Shc-Grb-2 and the IRS-1-Grb2 
complexes then activate the MAPK pathway independently (Myers et al., 1994). 
Impaired insulin signaling due to mutations or post-translation modification of the 
IR or any of its down stream effector molecules could cause insulin resistance 
(Olivares-Reyes et al., 2009). In the next section animal models in which various 
elements of the insulin signalling pathway were genetically manipulated will be 
discussed. 
1.4 INSIGHTS INTO T2DM THROUGH KNOCKOUT AND TRANSGENIC 
ANIMAL MODELS 
To maintain glucose homeostasis requires the concerted action of the pancreatic 
β-cells, muscle, liver and adipose tissue (Desvergne et al., 2006). The major site 
for glucose disposal after a meal is skeletal muscle. However, fat cells are the 
most sensitive to insulin levels, responding by inhibition of lipolysis and stimulation 
of glucose uptake; followed by liver cells which respond by inhibiting hepatic 
glucose production (Desvergne et al., 2006). Various investigators have developed 
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genetic models to determine the contribution of the individual insulin sensitive 
tissues to the regulation of glucose homeostasis, and development of T2DM. 
These are transgenic and knockout mouse models bearing tissue specific 
mutations in genes important to insulin action and/or insulin secretion (Baudry et 
al., 2002). Potential sites for defects in insulin action include all of the molecules in 
the insulin signalling cascade (Mauvais-Jarvis & Kahn, 2000). Knock out mouse 
technology enables the generation of homozygous null mutant mice that can be 
used to examine the effects of a total lack of a particular gene product (Kadowaki, 
2000). In this way mouse models can be generated that reproduce the main 
features of T2DM. 
1.4.1 Monogenetic defects in major role players in the insulin 
signalling cascade 
1.4.1.1 Insulin Receptor 
Binding of insulin to the insulin receptor initiates the insulin signalling cascade. A 
significant amount of research has been done on the disruption of the IR gene and 
its effect on insulin signalling and the consequences for T2DM. Mice with 
homozygous mutations in the IR gene (IR-/-) develop a severe form of diabetes 
with ketoacidosis, raised triglycerides (TG) and free fatty acids (FFA) leading to 
hepatic steatosis. These mice die within the first week of life confirming the crucial 
role of IR in insulin action (Mauvais-Jarvis & Kahn, 2000; Baudry et al., 2002). 
Heterozygous mutations of the IR gene (IR+/-) result in diabetes in 10% of adult 
mice (Mauvais-Jarvis & Kahn, 2000). In humans different mutations in IR cause 
different phenotypes. Mild insulin resistance is seen in heterozygous mutations of 
IR, and more severe insulin resistance is seen in patients with homozygous 
mutations (Elsas et al., 1989; Kadowaki et al., 1990; Hone et al., 1994; Nandi et 
al., 2004). Humans lacking IR show severe intrauterine growth retardation, failure 
to thrive, lipodystrophy and fasting hypoglycaemia (Nandi et al., 2004).  
1.4.1.2 Insulin Receptor Substrates  
Mutations in IRS-1 have been described in 10-20% of T2DM patients in several 
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populations (Mauvais-Jarvis & Kahn, 2000). In addition, IRS-1 expression and 
phosphorylation are decreased in skeletal muscle from obese and T2DM patients. 
However in mice the disruption of IRS-1 leads to growth retardation and insulin 
resistance, but not diabetes. Disruption of IRS-2 in mice impairs both peripheral 
insulin action and pancreatic β-cell function, leading to the development of overt 
diabetes. Although this might suggest that IRS-2 mutations may predispose 
people to diabetes, in humans no mutations of IRS-2 have been identified (Nandi 
et al., 2004). The phenotype resulting from a lack of insulin receptors is 
substantially more severe than that resulting from a lack of IRS-2. 
1.4.1.3 PI3K 
Another critical aspect of insulin action is the activation of PI3K. However data 
generated with knockout mouse models showed an inverse correlation with insulin 
sensitivity (Taniguchi et al., 2007).  As mentioned in section 1.1 PI3K comprises 
an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. Several isoforms of 
both the regulatory and catalytic subunits exist and further complexity is added by 
the occurrence of several splice variants of the regulatory subunit (Shepherd et al., 
1998). Mice lacking p85α and its truncated splice variants, p55α and p50α (p85α-/-) 
die a few weeks after birth with abnormalities in multiple organs. Deletion of the 
splice variants of the p85α isoform (p50α/p55α) and the minor isoform p85β mildly 
improve insulin sensitivity, whereas knockout of the more abundant p85α isoform 
shows a marked increase in insulin sensitivity, characterized by hypoglycaemia 
and significantly lower plasma insulin concentrations (Ueki et al., 2001; Chen et 
al., 2004; Nandi et al., 2004). These data indicate that in addition to being a 
component in the PI3K holoenzyme, p85α is also a negative regulator of insulin 
signalling (Taniguchi et al., 2007).  
1.4.1.4 Glucose Transporter 4 (GLUT4) 
The fact that glucose transport is the rate-limiting step in insulin-stimulated glucose 
disposal in skeletal muscle and adipose tissue has led to the development of 
models with genetic modification of glucose transport in these tissues (reviewed by 
Herman & Kahn, 2006).  Kim et al. (2001) showed that muscle-specific GLUT4 
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knock out mice have reduced insulin-stimulated glucose uptake in skeletal muscle 
and severe whole body insulin resistance. Adipocyte specific GLUT4 knock out 
mice also show glucose intolerance and insulin resistance (Kotani et al., 2004). 
Mice with complete GLUT4 deletions are growth retarded, show cardiac 
hypertrophy reduced adipose tissue mass, and shortened lifespan but not frank 
diabetes (Nandi et al., 2004).  Ranalletta et al. (2005) hypothesized that the 
GLUT4 null mice have invoked compensatory mechanism in the absence of 
GLUT4 that allow them to resist diabetic hyperglycaemia. They showed that 
GLUT2 is increased in mice homozygous for GLUT4 knockout. They also 
demonstrated that hepatic TG production and secretion is increased and that TG 
oxidation is enhanced in skeletal muscle. Excess fatty acids produced by the liver 
because of greater influx of glucose in liver (GLUT2 upregulated) are delivered to 
the skeletal muscle as an alternative fuel in the absence of GLUT4.  This shift in 
substrate utilization by both liver and muscle protects GLUT4 null mice from the 
development of overt hyperglycaemia and diabetes (Ranalletta et al., 2005). 
Overexpression of glucose transporters has been shown to improve glucose 
tolerance in various models (Mauvais-Jarvis & Kahn, 2000; Herman & Kahn, 
2006). 
 Numerous other genes in the insulin signalling pathway or pathways that interact 
with the insulin signalling pathway have been genetically manipulated to study 
their metabolic effects, but to mention all of them is beyond the scope of this 
thesis. Genetic engineering of IR, IRS-1, IRS-2, PI3K and GLUT4 has been most 
extensively researched. T2DM is a polygenic disorder requiring the interactions of 
multiple genetic factors, thus the pathophysiology of the disorder will not be 
explained by a single gene. In the following section polygenic mouse models will 
be discussed to illustrate the cumulative effect of more than one defect in the 
development of T2DM.  
In the present study, gene expression analysis was performed to identify 
molecular targets of S. frutescens in the cellular model of T2DM developed. Based 
on lessons learned from transgenic and knockout mouse models, it could be 
postulated that no one single gene would be identified to explain the anti-diabetic 
action of the plant extract, instead a number of genes could be affected, each 
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individually showing relatively small effects, but the combination of these effects 
synergistically could explain the anti-diabetic action of S. frutescens. 
1.4.2 Polygenic mouse models 
By crossing mice heterozygous for IR, IRS-1 or IRS-2, Kido et al. (2000) 
generated double heterozygous mice for either IR and IRS-1, or IR and IRS-2 
knock outs, and triple heterozygous mice for knock outs of IR, IRS-1 and IRS-2. 
Diabetes developed in 40% of IR/IRS-1/IRS-2+/–, 20% of IR/IRS-1+/–, 17% of 
IR/IRS-2+/–, and 5% of IR+/– mice.  
IR/IRS-1+/– mice developed severe insulin resistance in skeletal muscle and liver, 
with compensatory β-cell hyperplasia (Kido et al., 2000). In contrast, in IR/IRS-2+/– 
mice insulin resistance was restricted to the liver and β-cell hyperplasmia was less 
pronounced. Triple heterozygous IR, IRS-1, IRS-2 knockout mice develop early 
diabetes with severe insulin resistance in liver and muscle and marked increase in 
β-cell mass. Thus a combination of minor defects in the insulin signalling cascade 
can cause insulin resistance synergistically and lead to T2DM (Kido et al., 2000; 
Baudry et al., 2002).    
Terauchi et al., (1997) investigated the interactions between insulin resistance and 
insulin secretory defects by generating mice that were homozygous for IRS-1 and 
heterozygous for β-cell glucokinase (GK) genes. These knockout mice developed 
hyperglycaemia, despite β-cell hyperplasia, and became overtly diabetic with age. 
Thus the combination of mild insulin resistance and a minor defect in insulin 
secretion can lead to the development of T2DM (Terauchi et al., 1997). 
1.4.3  Role of individual tissues in the development of T2DM 
1.4.3.1 Skeletal Muscle 
Insulin resistance in skeletal muscle is among the earliest detectable defects in 
humans with T2DM (Mauvais-Jarvis & Kahn, 2000; Baudry et al., 2002; Nandi et 
al., 2004; Plum et al., 2005). However muscle-specific insulin receptor knockout 
(MIRKO) mice showed no alteration in glucose homeostasis, but rather manifested 
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alterations in circulating TG, FFA levels, and fat mass (Kim et al., 2000). Although 
MIRKO mice had a significant reduction in both insulin-stimulated glucose 
transport activity and insulin stimulated glucose metabolic flux (i.e., glycolysis and 
glycogen synthesis), these mice still had relatively mild whole-body insulin 
resistance. This suggests the existence of compensatory mechanism(s) in MIRKO 
mice to counter the severe defects in insulin-stimulated muscle glucose disposal. 
Kim et al., (2000) found that MIRKO mice compensate partly by increasing 
glucose transport into white adipose tissue. However insulin-stimulated glucose 
transport and TG synthesis in isolated adipocytes from these mice were not 
altered. Thus the shift of glucose utilization from the muscle to the adipose tissue, 
with a resulting increase in fat mass, suggests that the muscle tissue somehow 
communicates in vivo with adipose tissue to maintain euglycaemia (Kim et al., 
2000).  
Disruption of GLUT4 in muscle (MG4KO) mice leads to glucose intolerance and 
insulin resistance, secondary to a marked decrease in muscle glucose uptake 
(Kim et al., 2005). The absence of whole body insulin resistance in MIRKO mice 
(due to compensatory mechanisms) compared to the phenotype seen with 
MG4KO mice, suggests that glucose uptake rather than early insulin signalling 
events is of importance for normal glucose homeostasis in skeletal muscle 
(Mauvais-Jarvis & Kahn, 2000; Baudry et al., 2002).    
1.4.3.2 Adipose tissue 
Adipose tissue accounts for a small percentage of total glucose uptake, however 
an early component of insulin resistance in T2DM involves increased lipolysis and 
decreased glucose transport in the adipocyte (Nandi et al., 2004). Mice with IR 
knockout limited to white and brown fat tissues (FIRKO) demonstrated no change 
in glucose homeostasis. However there was evidence of increased basal lipolysis 
associated with decreased fat mass and whole body TG content (Nandi et al., 
2004; Bhϋler et al., 2004). Selective knockout of GLUT4 in adipose tissue caused 
impaired insulin sensitivity followed by the development of insulin resistance in 
muscle and liver (by Plum et al., 2005). Over-expression of GLUT4 in adipose 
tissue could reverse insulin resistance caused by muscle-specific GLUT4 knock-
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out (Carvalho et al., 2005).    
1.4.3.3 Liver 
Insulin resistance is one of the primary risk factors of T2DM, characterized by 
resistance to the action of insulin in target tissue. In muscle and adipose tissue it is 
manifested by impaired glucose transport and metabolism (Mauvais-Jarvis & 
Kahn, 2000; Nandi et al., 2004). In liver, insulin‟s function to suppress HGP is 
inhibited in the insulin resistant state. Hepatic insulin receptors may also play a 
role in the degradation and clearance of insulin by the liver (Mauvais-Jarvis & 
Kahn, 2000; Nandi et al., 2004).  
Muscle and adipose specific deletion of the IR gene did not change glucose 
homeostasis or cause insulin resistance in MIRKO and FIRKO mice (Mauvais-
Jarvis & Kahn, 2000; Nandi et al., 2004, Luna, 2005).  In contrast to what is found 
with muscle and adipose tissue specific IR knock out mice, liver-specific IR knock-
out (LIRKO) mice show severe insulin resistance and glucose intolerance. In 
addition there is a failure of insulin to suppress hepatic glucose production and 
regulate hepatic gene expression (Michael et al., 2000). The LIRKO mice have 
extremely high insulin concentrations, because of decreased clearance of insulin 
by the liver, and increased insulin secretion due to an increase in pancreatic β-cell 
mass. The dramatic phenotype seen in LIRKO mice supports a central role for 
hepatic insulin resistance in the pathogenesis of T2DM (Michael et al., 2000; 
Nandi et al., 2004; Rutter, 2000).  
Insulin inhibits HGP not only through direct hepatic action, but also indirectly by 
reducing the availability of substrates and energy for gluconeogenesis. Fisher and 
Kahn (2003) investigated whether the effect of insulin on HGP was direct or 
indirect in LIRKO. In LIRKO mice the direct hepatic effect of insulin was fully 
blocked, due to a lack of liver IR receptors. High-dose insulin, chosen to maximize 
extra-hepatic insulin action, failed to suppress HGP, suggesting the absence of 
any indirect HGP-suppressing effect of insulin in this model. This implies that both 
direct and indirect effects of insulin require an intact insulin receptor signalling in 
liver (Fischer & Kahn, 2003).    
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1.4.3.4 Pancreatic β-cells 
Although insulin resistance is one of the hallmarks of T2DM, the disease only 
develops when the pancreatic β-cells fail to compensate for the insulin resistance 
in other tissues. The importance of β-cell dysfunction is reflected by the fact that 
multiple defects in insulin secretion and β-cell mass have been noted in patients 
with T2DM, and during the insulin resistant prediabetic state (Nandi et al., 2004).  
Mice in which the IR gene in the β-cell is disrupted (βIRKO) show selective loss of 
insulin secretion in response to glucose, and progressive impairment of glucose 
tolerance (Nandi et al., 2004; Okada, et al., 2007). 
1.4.4 Implications of Knock-out Mouse Models for T2DM 
Transgenic and knockout mouse models have shown that there is considerable 
crosstalk among the different organ systems. These studies confirm that T2DM is 
the final outcome of a multi-organ disease, which is characterized by early direct 
or indirect defects in muscle, adipocytes, hepatocytes, β-cells, and possibly the 
central nervous system (CNS) (Das & Elbein, 2006).  
Data generated with the monogenic knock-out mouse models, showed that insulin 
signalling, action and secretion can be impaired by manipulating genes in the 
insulin signalling cascade (Baudry et al., 2002). The phenotypes seen in the 
monogenic knock-out models range from mild defects to severe diabetes. 
Furthermore some of the mild defects exhibit compensatory responses that 
activate alternative metabolic pathways (Baudry et al., 2002).   
Polygenic knock-out mouse models showed that minor defects in insulin secretion 
and/or insulin action can lead to diabetes when combined (Mauvais-Jarvis & Kahn, 
2000). However tissue specific knock-out of genes important to insulin secretion 
and insulin action could be compensated by expression in another tissue which 
overcame the lack of that particular gene; thus confirming that tissues can 
communicate to regulate glucose homeostasis and modulate insulin secretion. 
Insulin resistance at the level of muscle, adipose, liver and pancreatic β-cell may 
act synergistically to induce obesity, insulin resistance, dyslipidaemia and T2DM 
(Mauvais-Jarvis & Kahn, 2000).  
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In the present study the importance of the insulin signalling cascade and the 
effects of disruption of the key players in T2DM development are emphasized, 
because impaired insulin secretion and insulin action are the primary risk factors in 
T2DM development. Since the molecules in the insulin signalling pathway can 
contribute to the development of the disease, these molecules also could serve as 
molecular targets for anti-diabetic treatment.  
1.5 COMPLICATIONS AND TREATMENT OF T2DM  
The T2DM epidemic is complicated by the fact that it is a multifactorial disease 
frequently associated with a cluster of pathologies, including obesity, hypertension, 
atherosclerosis, dyslipidaemia, hypercoagulation, impaired glucose tolerance and 
insulin resistance, collectively referred to as the Metabolic syndrome (Gurnell et 
al., 2003; Basciano et al., 2005).  
Currently, T2DM is diagnosed when plasma glucose levels are elevated above 
126 mg/dl (7 mmol/liter) in the fasting state and/or above 200 mg/dl (11.1 
mmol/liter) 120 minutes after a 75-g glucose load (Matthaei et al., 2000; Report of 
a WHO/IDF Consultation, 2006). Sustained hyperglycaemia over many years may 
cause numerous microvascular and macrovascular complications (Malecki, 2004; 
Mudaliar, 2007; Hays et al., 2008). Microvascular complications include diabetic 
retinopathy, nephropathy and neuropathy which lead to morbidity in the form of 
blindness, end-stage renal disease and limb amputations (Brownlee, 2001). 
Macrovascular complications tend to affect the heart (coronary artery disease), the 
central nervous system (cerebrovascular disease), and the lower limbs (peripheral 
vascular disease) (Kengne et al., 2005).  
Diet and exercise remain the mainstays of therapy (Hussian et al., 2007; Hays et 
al., 2008). However in practice these are very difficult to achieve or sustain. Thus 
novel therapies that are capable of reversing insulin resistance and its unwanted 
complications are needed. A variety of medications are currently available, 
targeting numerous facets of the disease. Some of the first pharmacologic 
treatments for T2DM were aimed at increasing the insulin levels by using oral 
insulin secretagogues, such as sulfonylureas or meglitinides (Goldfine, 2001). 
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Insulin secretagogues function by binding to receptors on the β-cell to stimulate 
insulin secretion (Figure 1.2). If secretagogues fail, exogenous insulin can be 
used. However both insulin secretagogues and, to greater degree, self injection of 
insulin carry the risk of provoking hypoglycaemia (Goldfine, 2001). 
The biguanide metformin is currently the first-line therapy in newly diagnosed 
T2DM patients (Matthaei et al., 1993; Yaun et al., 2003; St. Onge et al., 2009). 
However despite over 40 years of research, the precise cellular mechanism of 
metformin action is not entirely understood. Metformin acts by increasing the 
activation and phosphorylation 5‟-AMP-activated kinase (AMPK). In the liver 
AMPK activation decreases lipid and glucose synthesis and increase fatty acid 
oxidation (Figure 1.2) (Ota et al., 2009; Yoshida et al., 2009). In muscle AMPK 
activation stimulates GLUT4 translocation (Breen et al., 2008). The clinical 
limitation of metformin is that it is cleared through the kidneys, thus renal 
insufficiency could permit toxic accumulation of the drug (Goldfine, 2001; Vivian et 
al., 2008). 
Thiazolidinediones (TZDs) are a relatively new class of drugs that were introduced 
in the late 1990s (Mudaliar, 2007). TZDS are peroxisome proliferator-activated 
receptor-gamma (PPARγ) agonists that improve insulin sensitivity and glycaemic 
control, with beneficial effects on lipid metabolism, blood pressure, vascular tone 
and endothelial function (Figure 1.2). However in clinical use TZDs have been 
shown to cause modest weight gain (Goldfine, 2001; Mankovsky & Kurashvili, 
2007).  
The inadequacy of the current medications has led to the development of new 
glucose lowering agents whose therapeutic action is based on the enhancement of 
gastrointestinal (GI) hormone action (reviewed by Mudaliar, 2007). Incretins such 
as glucagon-like peptide-1 (GLP-1) are naturally occurring hormones released 
from the GI tract in response to the ingestion of food. The pleiotropic effects of 
GLP-1 include enhancement of glucose-dependent insulin secretion from the 
pancreas, suppression of inappropriately elevated glucagon secretion, delaying 
gastric emptying, reducing appetite, preserving β-cell function, and increasing β-
cell mass (in animal models) (Figure1.2) . Meal-stimulated circulating levels of 
GLP-1 are reduced in T2DM, making it an attractive candidate as a therapeutic 
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agent. However GLP-1‟s utility as a pharmacologic agent is limited because it has 
a plasma half life of approximately two minutes before being degraded by 
dipeptidyl peptase IV (DPPIV). Exenatide is the first agent in the class known as 
incretin mimetics that has been approved for use. It is a synthetic GLP-1 analogue 
which has a longer half life because it is not recognized by DPP-IV. Exenatide is 
counter indicated in patients with T1DM, those with severe GI diseases and in 
patients with severe renal impairment. Most commonly reported side effects with 
exenatide therapy are GI complaints (reviewed by Mudaliar, 2007). 
 
Figure 1.2  Pharmacological treatments used for hyperglycaemia.  
The mecahism of action of the drug and the site of activity is shown. 
GLP1 (glucagon-like peptide 1) DPP-IV (dipeptidyl peptidase IV).  
(Figure taken from Stumvoll et al., 2005). 
Inhibitors of DPP-IV are another novel strategy to treat T2DM, as DPP-IV prevents 
inactivation of GLP-1 thereby enhancing and prolonging the action of endogenous 
incretin hormones (Ahrén, 2008). Pramlintide is an analogue of another gut 
hormone amylin, which is co-secreted with insulin from pancreatic β- cells 
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(Muduliar, 2007). Amylin is absent in T1DM and insufficient at meal time in T2DM 
patients requiring insulin. Pramlintide slows gastric emptying and suppresses 
glucagon secretion during the prandial/postprandial period in order to slow and 
reduce the entry of glucose into the circulation (Mudaliar, 2007). 
Despite the availability of several medications for the treatment of T2DM the 
epidemic is still increasing. There is therefore still a need for the development of 
novel anti-diabetic agents. 
1.6 INDIGENOUS MEDICINAL PLANTS AS ALTERNATIVE MEDICATION 
FOR T2DM   
South Africa is a country with both rich floral biodiversity and cultural diversity. Due 
to this diversity, a large number of plant species are used for medicinal purposes 
(Light et al., 2005). The changes in the socio-political climate in South Africa have 
resulted in increased awareness and research into the country‟s natural medicinal 
resource. The use of medicinal plants in their crude form, without scientific 
evaluation of their efficacy and safety could be harmful. Therefore, there is a need 
to evaluate scientifically and to validate the effectiveness of remedies derived from 
these plants (Light et al., 2005). 
S.frutescens is one of the best known multi-purpose medicinal plants in Southern 
Africa, and has diverse medical uses (Van Wyk et al., 1997; Van Wyk, 2008). It 
has been documented locally since 1895. It is thought that the Khoi and Nama 
people were the first to use it against fevers and a variety of other ailments 
including cleansing of open wounds. S.frutescens is a flowering shrub of the pea 
family (Fabaceae/Leguminaceae) found mainly in the Western Cape and Karoo 
regions of Southern Africa. Medicinal preparations are generally produced from 
the leaves, but the stems are often also included.  As mentioned S.frutescens has 
diverse medical uses including the treatment of stomach problems, internal 
cancers, colds, influenza, chicken pox, diabetes, varicose veins, piles, 
inflammation, liver problems, backache, heart failure, urinary tract infections, 
rheumatism, stress and anxiety (Van Wyk et al., 1997; Van Wyk, 2008).  
S.frutescens contains several bioactive chemical compounds including the non-
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protein amino acid L-canavanine, pinitol, gamma-aminobutyric acid (GABA), the 
free amino acids asparagine, proline and arginine, the saponin triterpenoid 
glucoside and flavonoids. (Sia, 2004; Ojewole, 2008; Saklani & Kutty, 2008; Van 
Wyk & Albrecht, 2008). Each of these principle constituents can be linked to a 
therapeutic application of S.frutescens.  
L-canavanine is a natural L-arginine analogue that has documented anti-cancer 
activity (Worthen et al., 1998; Jang et al., 2002). The incorporation of L-
canavanine in the place of L-arginine in cellular proteins, leading to the formation 
of proteins with impaired function, has been proposed for its antitumor activity 
(Worthen et al., 1998). Jang et al., (2002) have shown that the apoptotic cell death 
induced by L-canavanine is mediated by caspase-3 activation and cleavage of 
poly(ADP-ribose) polymerase (PARP). Antiproliferative effects of S.frutescens 
have been reported in a number of cultured cancer cell lines (Chinkwo, 2005; 
Stander et al., 2007; Stander et al., 2009). The presence of L-canavanine in the 
extract is one of many factors that could contribute to the anti-proliferative and 
apoptotic activity of S.frutescens (Stander et al., 2009).  
Pinitol has been shown to have anti-diabetic, anti-inflammatory, anti-cancer and 
stamina enhancing activities in animal studies (Bates et al., 2000; Singh et al., 
2001; Bhat et al., 2009). Pinitol lowers blood glucose in STZ-induced diabetic mice 
by exerting an insulin-like effect down-stream of the receptor in the insulin 
signalling pathway (Bates et al., 2000). Sivakumar and Subramanian (2009) 
showed that pinitol protects the pancreatic β-cells in STZ–treated rats from 
oxidative stress and thereby stimulates the remnant pancreatic β-cells to 
synthesize and secrete more insulin. However oral pinitol supplementation in 
people with insulin resistance did not alter basal glucose and lipid kinetics or the 
effect of insulin on glucose and lipid metabolism (Davis et al., 2000). A study by 
Kim et al., (2007) showed that treatment with pinitol of T2DM patients who did not 
respond adequately to hypoglycemic drugs improves the glucose metabolism of 
these hyperglycaemic patients. Hypoglycaemic, anti-inflammatory and antioxidant 
activities have been reported in S.frutescens extracts (Fernandes et al., 2004; 
Kundu et al., 2005; Chadwick et al., 2007; Prevoo et al., 2008; Van wyk and 
Albrecht, 2008). Although the exact mechanism by which S.frutescens exerts 
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these effects are not known it can be postulated that the presence of pinitol could 
contribute to these activities.    
GABA is an inhibitory neurotransmitter that regulates emotional behavior and can 
modify behaviour relevant to anxiety and depression in genetically modified mice 
(Mombereau et al., 2004). Ojewole et al., (2008) have shown that S.frutescens 
possesses anticonvulsant activity and although the exact mechanism of the 
antiseizure activity is not known it is speculated that the presence of GABA could 
account for it.  
Flavonoids are pigments ubiquitously found in green plant cells, known for their 
antioxidant, hypoglycaemic and hypolipodemic activity (Havsteen, 2002; Jung et 
al., 2006; Wang et al., 2009). Flavonoids have been reported to lower blood 
glucose levels in a T2DM mouse model by upregulating hepatic glukokinase and 
peroxisome-proliferator-activated receptor (PPAR)γ and adipocyte GLUT4 and 
improving lipid metabolism by altering hepatic lipid metabolizing enzyme activities 
(Jung et al., 2006). S. frutescens contains at least six flavonoids (Van Wyk & 
Albrecht, 2008). 
Triterpenoids are structural components of plant cell membranes with a wide 
spectrum of biological activities (Saleem, 2009). Triterpenoids possess potent 
hypoglycaemic, anti-inflammatory, hepatoprotective and anti-cancer activity 
(Kundu et al., 2005; Mukherjee et al., 2006; Tan et al., 2008; Romero et al., 2010; 
Saleem, 2009). PPARα and IR are also stimulated in the presence of triterpenoids 
(Huang et al., 2009). At least 56 different types of triterpene glycosides have been 
identified in S.frutescence (Van Wyk & Albrecht, 2008). 
S.frutescens has been shown to have anti-diabetic, anti-inflammatory, anti-oxidant 
and anti-cancer activity and these activities can be linked to its major bioactive 
components. However it is proposed that the single compounds found in 
S.frutescens may act synergistically mediating a greater clinical benefit than a 
single compound (Sia, 2004). In the present study the molecular mechanisms of S. 
frutescens are investigated in a human hepatocyte cell line, by studying 
Sutherlandia‟s effect on a number of genes involved in glucose and lipid 
metabolism. Similarly in the present study it is hypothesized that small changes in 
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single genes may act synergistically to mediate a greater improvement in glucose 
uptake and utilization.  
In the present study PPARs were considered as potential molecular targets of S. 
frutescens. PPARs are key transcriptional factors that have been shown to 
coordinately regulate the expression of a vast array of genes, including those that 
control nutrient metabolism, energy homeostasis, insulin signalling, inflammation 
and differentiation (Berger et al., 2005). The therapeutic application of 
S.frutescens includes anti-diabetic, anti-stress, pain relieving, wound healing, anti-
cancer, and anti-inflammatory activities. These therapeutic applications show 
some correlation with PPAR functions  
1.7 POTENTIAL CANDIDATES FOR MOLECULAR MECHANISM FOR 
S.FRUTESCENS  
1.7.1 The peroxisome-proliferator-activated receptors (PPARs) 
PPARs belong to a subfamily of nuclear receptors that are ligand dependent 
transcription factors (Wahli, 2002).  Three isotypes have been identified, namely 
PPARα, β/δ and γ (Wahli, 2002; Sharma et al., 2006). All three PPARs possess 
similar structural and functional features and the transcriptional mechanism is 
identical in all PPAR subtypes (Kota et al., 2005).  
The process of transcription begins with the binding of ligands (endogenous or 
exogenous) to the PPAR receptor (Kota et al., 2005). Ligand-bound PPAR 
heterodimerises with retinoid X receptor (RXR) and this heterodimer binds to the 
promoter region of peroxisome proliferator response element (PPRE), with the 
recruitment of co-activators (Figure1.3). This results in an increase in the 
transcriptional activities of various target genes of the PPARs (Figure1.3) (Kota et 
al., 2005). Each PPAR isoform varies in ligand specificity, tissue distribution, target 
gene activation and hence serves different biological functions (Figure1.3). PPARα 
and PPARγ control energy homeostasis and inflammatory responses. Their 
activity can be modulated by hypolipidaemic fibrates and the insulin sensitizers 
TZDs respectively. Accumulating evidence implicates these receptors in the 
control of chronic diseases such as diabetes, obesity, and atherosclerosis (Wahli, 
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2002; Lefebvre et al., 2006). Unlike PPARα and PPARγ there are no PPARβ 
drugs in clinical use. PPARβ has the most wide spread tissue distribution of the 3 
PPARs and has been implicated to play a role in adaptive thermogenesis and lipid 
utilization (Christodoulides & Vidal-Puig, 2009). Emerging data in animal models 
show that PPARβ ligands could also be potential anti-inflammatory agents 
(Bishop-Bailey & Bystrom, 2009).  
1.7.1.1 PPARα 
PPARα is most highly expressed in tissues that gain a high level of their energy 
requirements from lipids, such as the liver, skeletal muscles, brown fat, heart, 
kidneys, and a range of vascular cells including endothelial cells, and 
monocytes/macrophages (Lefebvre et al., 2006). PPARα plays a crucial role in the 
regulation of β-oxidation of fatty acids during fasting in rodents.  Starvation 
enhances the release of FAs from adipose tissue and increases the hepatic 
expression and activity of PPARα, which in turn stimulates β-oxidation of FA 
released from adipose tissue. PPARα null mice display hypoglycaemia, 
hypoketonaemia, hyperlipidaemia and hepatic steatosis upon fasting (Kersten et 
al., 1999). Even in the fed state hepatic fatty acid oxidation is impaired in PPARα 
null mice. Feeding PPARα null mice a high fat diet for several weeks led to huge 
accumulation of lipids in the liver (Kersten et al., 1999). 
PPARα can reduce hepatic fat accumulation in the liver during the development of 
fatty liver disease, and thus prevents steatosis by inducing mitochondrial, 
peroxisomal, and microsomal fatty acid oxidation (Stienstra et al., 2007). In 
addition to stimulating hepatic fatty acid oxidation and ketogenesis, PPARα also 
controls gluconeogenesis (Patsouris et al., 2004). Patsouris et al., (2004) identified 
the gluconeogenic gene glycerol-3-phosphate dehydrogenase (GPDH) as a direct 
target gene of PPARα. This explains the hypoglycaemia seen in PPARα null mice 
upon fasting, as PPARα stimulates the gluconeogenic gene expression associated 
with HGP during fasting.  
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Figure 1.3  PPARs ligand dependent nuclear transcription factors.  
Binding of ligand such as fatty acids or hypolipidemic drugs to the PPARα receptor leads 
subsequently to the expression of target genes that are involve in catabolism of fatty acids. PPARγ 
is activated by prostaglandins, leukotrienes and TZDs and effects the expression of genes involved 
in fatty acid storage. PPARβ is only weakly activated by fatty acids, leukotrienes and 
prostaglandins and has no known physiological relevant ligand. Data from PPARβ null mice 
suggest that PPARβ serves a role in fatty acid metabolism, and possible skin proliferation and 
cancer.  
(Figure taken from Vanden Heuvel, 2009) 
Besides its role in metabolic processes, PPARα also regulates inflammatory 
processes, mainly by inhibiting inflammatory gene expression (Figure1.4) 
(Stienstra et al., 2007). Hepatic inflammation elicited by acute exposure to 
cytokines and other compounds has been shown to be reduced by PPARα 
activation. Adipose inflammation, observed during obesity, is also reduced by 
PPARα activation. Inflammation in the arterial wall is known to promote the 
process of atherosclerosis. PPARα may influence such inflammatory reactions in 
the arterial wall (Stienstra et al., 2007). 
Mono- and polyunsaturated FA are the primary natural PPARα ligands which 
activate fatty acid uptake and oxidative catabolism. Ecosanoids also act as PPARα 
ligands (Francis et al., 2003). Glucocorticoids induce PPARα transcription 
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following diurnal variations in glucocorticoid levels and in response to stress. 
Synthetic ligands for PPARα include the fibrate drugs, phthalate ester plasticizers, 
herbicides, food flavors, and leukotriene D4 receptor antagonists. PPARα agonists 
in the form of fibrates (clofibrate, gemfibrozil, fenofibrate, bezafibrate and 
ciprofibrate) have been in use for over 40 years for the treatment of dyslipidaemia. 
These drugs lower TG levels, raise HDL and decrease the levels of small dense 
low density lipoprotein (LDL) particles (Figure1.4) (Francis et al., 2003).   The 
actions of fibrates in humans have been tested in clinical studies, and have been 
shown to improve endothelial dysfunction in T2DM patients (Lefebvre et al., 2006). 
The actions of PPARα overexpression, or PPARα agonists, in mice and humans in 
the different tissues are summarized in Figure 1.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4  Metabolic actions of PPARα and potential consequences.  
The main effects of PPARα overexpression or of PPARα ligands in mice (denoted by a single 
asterisk) and in humans (denoted by a double asterisk) are shown. (CRP, C-reactive protein; FA, 
fatty acid; FAO, FA oxidation; HDL, high density lipoprotein; TG, triglycerides; sdLDL, small dense 
LDL;GIS, glucose-stimulated insulin secretion).  
(Figure taken from Lefebvre et al., 2006). 
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1.7.1.2 PPARγ 
PPARγ is considered the master regulator of adipogenesis, and accordingly has 
been extensively studied in the context of obesity (Stienstra et al., 2007).   
The PPARγ gene produces two protein isoforms PPARγ1 and PPARγ2 that are 
created by alternative promoter usage and alternative splicing at the 5‟ end of the 
gene, (Semple et al., 2006). Very high expression of PPARγ is found in adipose 
tissue. However in skeletal muscle, liver, and pancreatic β-cells the other tissues 
central to glucose homeostasis, very low levels are found.  The crucial role PPARγ 
plays in adipogenesis is demonstrated in PPARγ null mice, which display 
phenotypes of progressive fat cell loss, hypertrophy of viable cells, 
hyperlipidaemia, reduction of circulating leptin and ACRP30, fatty liver, and 
enhanced hepatic insulin resistance (He et al., 2003). PPARγ and two other 
transcription factors  CCAAT/enhancer-binding proteins (C/EBPs) and a sterol 
response element-binding protein (SREBP) have been shown to play central roles 
in differentiation and maturation of preadipocytes into adipocytes (Rosen et al., 
2000). Several mutations in the human PPARγ gene have been described (Fajas, 
Debril & Auwerx, 2001; Gurnell, 2007). Mutations in the PPARγ gene resulting in 
less active PPARγ form are associated with a lower body mass index (BMI). 
Mutations in PPARγ resulting in a permanently active PPARγ were found in very 
obese individuals (Fajas et al., 2001; Gurnell, 2007).  
 
 
 
 
 
 
Figure 1.5  Effect of PPARγ agonists on fat distribution  
(Figure taken from Bays et al., 2004). 
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As mentioned earlier, T2DM is a complex heterozygous disorder involving both 
genetic and acquired factors. Among the acquired factors are weight gain and 
physical inactivity, which create an imbalance between energy intake and energy 
expenditure, resulting in obesity (Stienstra et al., 2007). The excess energy is 
primarily stored in adipose tissue in the form of TGs. Although adipocytes are 
specifically designed to store energy, the morphological changes associated with 
adipose tissue growth during the development of obesity, could compromise the 
function of the adipose tissue. In addition, obesity could also provoke structural 
and metabolic alterations in other organs, including skeletal muscle and liver. 
Obesity is present in most patients with T2DM, coupled with abnormal distribution 
of fat. Excessive fat depositions occur in muscle, liver and visceral adipocytes 
(Figure 1.5) (Bays et al., 2004). These fat cells are also enlarged and their 
capacity to store TG is compromised (Figure 1.6). They produce excessive 
amounts of adipocytokines that cause insulin resistance, inflammation, 
hypercoagulability, dyslipidaemia and possible hypertension. 
 
Figure 1.6 Fat cells in insulin resistant T2DM and treatment with TZD.  
Left panel: Fat cells in insulin resistant T2DM are larger than in the normal subjects, with increased 
production of FFA, TNFα, and leptin. This leads to insulin resistance in the liver and skeletal 
muscle, resulting in a need for increased peripheral insulin, which is generated by the β-cells in the 
pancreas. Right panel: TZDs stimulate adipocyte differentiation, preferentially generating more 
numerous, smaller adipocytes. These small adipocytes are more insulin-sensitive, producing less 
FFA, TNFα, and leptin. Therefore, insulin is more effective and there is less need for the β-cells to 
increase their secretion of insulin  
(Figure taken from Kahn et al., 2000). 
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TZDs are insulin sensitizing drugs that act as high-affinity ligands for PPARγ.  
Clinical studies have shown that treatment of T2DM patients with TZDs can lower 
serum glucose and insulin levels, increase peripheral glucose uptake, and 
decrease TG levels (Kahn et al., 2000).  Activation of PPARγ by TZDs results in 
enhanced adipocyte insulin signalling, lipid uptake, anabolic lipid metabolism and 
attenuated lipolysis and free fatty acid (FFA) release (Berger et al., 2005). 
Consequently lipid levels in the adipose tissue rise, whereas circulating FFAs 
diminish. One of the hypotheses proposed for how TZDs ameliorate 
hyperglycaemia is by redistributing fat accumulated in muscle, liver and pancreas 
towards subcutaneous fat tissue, which is more sensitive to insulin than visceral 
fat (Mayerson et al., 2002; Bays et al., 2004; Desvergne et al., 2004; Berger et al., 
2005; Skrobuk et al., 2009).  This is consistent with the reduced adipogenesis in 
muscle and liver found in patients treated with TZDs (Figure 1.6).  
In addition to the shift in fat topography, PPARγ agonists could also improve 
insulin sensitivity by modulating  the endocrine activity of adipose tissue to reduce 
the insulin resistant adipokines (such as resistin or TNFα), or increase insulin-
sensitizing adipokines (such as adiponectin) (Bays et al., 2004; Berger et al., 
2005).  It is postulated that by lowering circulating FFA levels and inhibiting the 
release of inflammatory cytokines from adipose tissue, TZDs can reverse the 
lipotoxicity in pancreatic β-cells that result from elevated fat content (Figure1.6) 
(Berger et al., 2005; Stafford & Elasy, 2007). As a result excessive apoptosis is 
inhibited and β-cell mass is increased.  
1.7.2 Sterol Regulatory Element-binding proteins (SREBPs) 
Another potential candidate gene investigated in this study is SREBP.  SREBPs 
are considered master regulators of lipid homeostasis as they activate a cascade 
of enzymes required for endogenous cholesterol, FA, TG and phosholipid 
synthesis (Figure 1.7) (Eberlé et al., 2004). Three members of the SREBP family 
have been described: SREBP-1a and SREBP-1c, produced from a single gene by 
the use of alternative transcription start sites, and SREBP-2, produced from a 
separate gene. SREBP-1 and SREBP-2 share 47% homology, but isoform specific 
functions exist (Eberlé et al., 2004). SREBP-2 activates genes involved in 
cholesterol homeostasis, whereas SREBP-1c actions are focused on lipid 
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synthesis and glucose metabolism (Figure 1.7) (Horton, et al., 1998; Pai et al., 
1998). SREBP transcription factors are regulated at three major levels: (1) 
transcription, (2) proteolytic cleavage of SREBP precursors, and (3) post-
translational modification of nSREBPs. SREBP-1a and SREBP-2 appear to be 
primarily regulated at the level of precursor cleavage. The cleavage of the SREBP-
1a and SREBP2 precursors is controlled by cellular sterol content. However the 
SREBP-1c pathway is activated by insulin independently of sterol levels (Eberlé et 
al., 2004).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Genes regulated by SREBPs.  
The diagram shows the major metabolic intermediates in the pathways for synthesis of cholesterol, 
fatty acids, and TG. In vivo SREBP-2 preferentailly activates genes of cholesterol metabolism, 
whereas SREBP-1c preferentially activates genes of fatty acid TG metabolism. DHCR, 7-
dehydrochloesterol reductase; FPP, farnesyl diphosphate; GPP, geranylgeranyl pyrophosphate 
synthase; CYP51, lanosterol 14α-demethylase; G6PD, glucose-6-phosphate dehydrogenase; 
PGDH, 6-phosphogluconate dehydrogenase; GPAT, glycerol-3-phosphate acyltransferase. 
(Figure taken from Horton et al., 2002).  
Many individuals with obesity and insulin resistance also have fatty livers (Horton 
et al., 2002). Evidence indicates that the fatty liver of insulin resistance is caused 
by SREBP-1c, which is elevated in response to the high insulin levels (Foretz, et 
al., 1999; Shimomura et al., 1999; Yellaturu et al., 2005). Elevated SREBP-1c 
 29 
29 
increases lipogenic gene expression, enhances fatty acid synthesis, and 
accelerates triglyceride accumulation. Metformin reduces hepatic SREBP-1 levels 
and dramatically lowers lipid accumulation in the livers of insulin resistant obese 
mice (Horton et al., 2002; Ferré & Foufelle, 2007). SREBPs stimulate LDL receptor 
expression, but they also enhance lipid synthesis, so their net effect on 
lipoproteins depends on a balance between opposing effects. Mice that lack all 
SREBPs in the liver have lower plasma cholesterol and TG levels. The reduced 
hepatic cholesterol and TG synthesis are likely to cause a decrease in very low 
density lipoproteins (VLDL) secretion (Horton et al., 2002).  
1.8 OBJECTIVE OF PRESENT STUDY 
Our westernized societies are witnessing a frightening increase in the incidence of 
T2DM, linked in good part to inappropriate nutritional and life-style habits and 
favoured by genetic predisposition. It is absolutely essential to fully understand the 
pathogenesis of T2DM in order to develop new approaches for treatment or 
prevention of this disease. However T2DM is a very complex multifactorial 
disease. The transgenic and knockout mouse model studies undertaken to 
determine the relative importance of the major tissues involved in the disease, 
showed that there is considerable crosstalk among the different organ systems. 
These studies confirmed that T2DM is the final outcome of a multi-organ disease 
which is characterized by early defects in muscle, adipocytes, hepatocytes, β-
cells, and possibly central nervous system function.  
The aim of the present study was to determine the contribution of the liver, by 
investigating a hepatocyte cell line exposed to certain factors known to induce 
insulin resistance. The objective was to create a cell culture model of insulin 
resistance in the Chang liver cell line. The term “insulin resistance” in humans is 
frequently used synonymously with “impaired insulin-stimulated glucose disposal” 
(Matthaei et al., 2000). Consequently, tissues responsible for insulin-mediated 
glucose uptake, namely muscle and adipose, have been the focus of research on 
insulin resistance.  Recently there has been a shift from the traditional glucocentric 
view of T2DM to a more lipocentric view (Mittra, et al., 2008). In the present study, 
the liver was chosen for investigation because of the central role it plays in lipid 
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and glucose metabolism. Adipose tissue synthesizes and stores lipids when 
nutrients are plentiful. However constant overexposure to nutrition in the western 
diet causes fat cells to expand beyond a „critical‟ size. Hypertrophy of fat cells 
takes place as genes involved in adipocyte differentiation are down regulated. A 
result of these large insulin-resistant fat cells whose capacity to store TG is 
compromised, is that the lipogenic burden shifts to the liver and lipid deposition in 
non-adipose tissue occurs (Nadler & Attie, 2001; Bergman et al., 2006).  
A correlation between fat accumulation in the liver and insulin resistance has been 
proposed by several studies (Kusunoki et al., 2002; Seppälä-Lindroos et al., 2002, 
Pietilläinen et al., 2004). In the present study the Chang liver cell line will be 
exposed to different medium conditions to induce insulin resistance. The cells 
ability to take up glucose and accumulate fat will be used as a measure of their 
insulin resistant state.         
The effect of two different extracts of S. frutescens on the Chang liver cell model of 
insulin resistance will be determined. The effect of other anti-diabetic agents such 
as metformin, ciprofibrate and ciglitazone will also be determined. In the present 
study, driven by the more lipocentric approach to T2DM, it is hypothesized that 
genes playing a major role in lipid metabolism would be affected in the insulin 
resistant Chang liver cells. It is further hypothesized that the S. frutescens plant 
extracts would reverse or prevent the effect of the insulin resistance inducing 
medium on the Chang liver cells. Therefore, the expression of genes involved in 
regulating lipid metabolism, such as PPARα, PPARγ and SREBP-1c was 
investigated. The objective of the present study was to: 
1. Develop a model of insulin resistance in the Chang liver cell line. 
2. Determine the ability of two different S. frutescens extracts and known anti-
diabetic agents to reverse the state of insulin resistance induced in Chang 
liver cells.   
3.  Identify the molecular targets of S.frutescens in the insulin resistant model.  
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CHAPTER 2: SCREENING DIFFERENT CONDITIONS TO INDUCE 
INSULIN RESISTANCE IN CHANG LIVER CELLS 
2.1 METABOLISM OF THE LIVER 
The liver is by far the most versatile organ of the body; it regulates the blood levels 
of macronutrients and micronutrients from digested food; makes most of the 
proteins present in the blood; and metabolises and excretes waste products, 
hormones, medications and toxins (Gibson & Harris, 2002). One of the key roles of 
the liver is to maintain glucose homeostasis (Postic et al., 2004). In the 
postprandial state, glucose is taken up and is incorporated into glycogen and fatty 
acids, or oxidized into CO2 (Rencurel et al., 1996). In the fasting state, liver 
provides glucose into the bloodstream via glycogenolysis and gluconeogenesis 
(Rencurel et al., 1996).  
Insulin profoundly influences the metabolism of the liver through plasma 
membrane receptors, but unlike the situation with muscle and adipose tissue, 
insulin has no effect on glucose transport by cells of the liver (Gibson & Harris, 
2002). Liver glucose transport requires the presence of a high-Km protein to allow 
a rapid equilibration of the intracellular glucose level with the extracellular glucose 
level, within the physiological range of plasma glucose concentrations (Rencurel et 
al., 1996). GLUT2 is a low affinity, high capacity glucose transporter predominantly 
expressed in liver, pancreatic β cells and to a lesser extent in the kidneys, intestine 
and a restricted area of the brain (Eisenberg et al., 2005). GLUT2 transports 
glucose into, as well as out of hepatocytes, the direction dictated by the glucose 
gradient across the plasma membrane (Fig 2.1) (Eisenberg et al., 2005).Glucose 
homeostasis in the liver is maintained through a delicate balance between hepatic 
glucose uptake and utilization and hepatic glucose production (Collier & Scott, 
2004). Modulations that increase hepatic glucose production either induce or 
exacerbate insulin resistance, leading to diabetes (Fig 2.1). Conversely, increasing 
glucose uptake, utilization and storage in the liver protects against the 
development of hyperglycaemia and overt diabetes (Fig 2.1) (Collier & Scott, 
2004). 
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Figure 2.1 Pathways of hepatic gucose metabolism. Flux through various hepatic 
pathways of glucose metabolism control overall glucose homeostasis.  
The asterisk (*) and the green colour indicate that an increased expression prevents or offsets 
metabolic perturbations associated with either T1DM or T2DM, or sometimes both. The 
exclamation point (!) and the red colour indicate that an increased abundance leads to a phenotype 
of insulin resistance and/or diabetes  
Figure taken from Collier and Scott (2004). 
2.2 KNOWN EXPERIMENTAL INSULIN RESISTANT MODELS 
Insulin resistance is defined as a state in which target cells fail to respond to 
ordinary levels of circulating insulin or, a smaller than normal response to a given 
amount of insulin. (Leclercq et al., 2007; Meshkani and Adeli, 2009; Olivares-
Reyes et al., 2009). It is an important contributing factor to the pathogenesis of 
T2DM  Numerous investigations have thus focused on developing animal and cell 
culture models that resemble the condition of insulin resistance in order to 
establish the underlying mechanism of T2DM. A few of these models will be 
mentioned in this section as one of the aims of this study was to develop an insulin 
resistant cell culture model in a hepatocyte cell line. 
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 Various types of animal models of T2DM are known; some derived either 
spontaneously in inbred animals with a homogeneous genetic background, or 
induced by treating with chemicals (e.g. alloxan and streptozotocin), or dietary or 
surgical manipulations (Srinivasan & Ramarao, 2007). A large number of T2DM 
animal models are also generated with genetic engineered transgenic and knock-
out mice. Generally these animal models exhibit similar characteristic features 
such as hyperglycaemia, hyper- or normo- or hypoinsulinaemia while the clinical 
symptoms of diabetes, polyuria, polydypsia, polyphagia and lethargy may also be 
present in some of the animal models (Srinivasan & Ramarao, 2007).  Given that a 
Westernized diet and patterns of eating associated with a dramatic rise in obesity 
is one of the main driving forces for the development of insulin resistance and 
T2DM, it is not surprising that animal models fed high fat diets can induce insulin 
resistance (Lombardo & Chicco, 2006). It has also been shown that normal rats fed 
high carbohydrate (in particular fructose and sucrose) diets for a short period (3-5 
weeks) develop hypertriglyceridaemia, increased free fatty acids levels, enhanced TG 
accumulation in liver and some peripheral tissues, hyperinsulinaemia, insulin 
resistance in target tissues, moderate adiposity and hypertension (Lombardo & 
Chicco, 2006). 
Chronically elevated insulin levels have been shown to induce insulin resistance in 
cell culture models (Kumar & Dey, 2002; Kumar et al., 2004; Pryor et al., 2000; 
Yuan et al., 2003). Insulin resistant cell culture models have been developed in 
HepG2 hepatocyte, C2C12 mouse myoblasts and 3T3-L1 mouse adipocyte cell 
lines, through chronic exposure to high insulin concentrations (100nmol/L). As 
mentioned previously, insulin resistance may result in part from impaired insulin 
signalling in all three target tissues, and in adipocytes also from down-regulation of 
GLUT4 (Mauvais-Jarvis & Kahn, 2000). Thus to prove that the cell lines were 
insulin resistant, investigators examined the changes in insulin transduction after 
chronic exposure to insulin. They found that insulin-stimulated tyrosine 
phosphorylation of the IR and IRS-1, activation of PI3K and glucose uptake were 
all impaired by chronic treatment with insulin  ( Kumar & Dey, 2002; Kumar et al., 
2004; Pryor et al., 2000; Yuan et al., 2003).   
Insulin resistance is increasingly viewed as a chronic inflammatory disease. This is 
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mainly due to the strong correlation between elevations in the local and circulating 
proinflammatory cytokines (tumour necrosis factor (TNF-α), interleukin (IL)-1, 
interferon-γ, and IL-6) and insulin resistance (Senn et al., 2002). Infusion of 
animals and humans with TNF-α can lead to whole body insulin resistance 
localized to both liver and peripheral tissues especially muscle (Ciaraldi et al., 
1998). Direct exposure of fat cells to TNF-α inhibits insulin-stimulated glucose 
uptake in 3T3-L1 cells, human primary adipocytes, and primary brown adipocytes 
(de Alvaro et al., 2004). IL-6 has also been shown to cause cellular insulin 
resistance in both the HepG2 cell line and primary hepatocytes (Senn et al., 2002). 
Early insulin receptor signal transduction and down-stream insulin action, 
specifically glycogen synthesis is inhibited by IL-6 treatment (Senn et al., 2002). 
In the present study, knowledge of existing insulin resistant cell culture models 
was used to design a screening technique to develop an insulin resistant model for 
use in subsequent analyses. In the established methods using either chronic 
insulin, TNF-α or IL-6 treatment, cells were grown to confluence and then exposed 
to the different treatments for 6-24 hours respectively prior to analysis. The 
analysis entails measuring the effects of these treatments on the insulin signal 
transduction cascade. In this study the initial screening technique involved 
exposure of the cells for a longer period (48 hours), to the putative insulin 
resistance inducing agents. A further downstream component of insulin signal 
transduction was measured; glucose uptake and utilization.     
2.3 MATERIALS AND METHODS 
2.3.1 Routine Cell Culture 
The Chang liver cell line was purchased from Highveld Biological, South Africa. 
Cells were seeded at a density of 2 X 105 cells in 10cm diameter culture dishes 
(Nunc, Denmark) in growth medium consisting of antibiotic free RPMI 1640 
medium (Cambrex) supplemented with 10% fetal calf serum (FCS) (Gibco). They 
were incubated in a humidified 5% CO2 incubator at 37
0C. The cell growth medium 
was replaced every 48 hours and cells were passaged at 70-80% confluence. 
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2.3.2  Methods used to induce insulin resistance 
2.3.2.1 Human Diabetic serum 
Chang liver cells were seeded into 96-well cell culture plates (Nunc, Denmark) at 
5x103 cells per well in 200µl of RPMI 1640 growth medium (RPMI 1640:10%FCS). 
After 48 hours growth medium was removed from the cells and replaced with 
200µl of MCBD-201 medium (Cambrex) containing 2.5%, 5%, 7.5% and 10% 
human serum from T2DM patients or healthy individuals (Human serum obtained 
from the Diabetic Centre of Dr Roux, Port Elizabeth, South Africa). Human serum 
from T2DM patients was used as it was postulated that it could contain factors that 
could induce insulin resistance. Two more control groups were included one 
receiving only MCBD-201 medium (serum free medium) and the other the 
RPMI1640:10%FCS. Cells were set up in eight replicate wells, for each condition 
tested.  The cells were exposed to the various medium conditions for 48 hours 
whereafter the glucose utilization of these cells was determined with a 
colourimetric assay as described below. After the chronic exposure of cells to 
human control or diabetic serum in MCBD-201 medium or RPMI 1640:10%FCS or 
only MCBD-201 medium, 10µl of the spent medium was removed to a new 96 well 
plate to measure the amount of glucose left in the medium. The rest of the medium 
was removed and the cells were incubated with 50μl of fresh RPMI 1640 medium 
containing 8mM glucose with or without 1μM insulin (Roche, South Africa) and 
10% BSA (Roche, South Africa) for three hours. After the incubation 10µl of this 
medium was removed to a new 96 well plate. Glucose uptake in response to 
insulin was measured; although insulin has no direct effect on glucose transport in 
the liver, insulin profoundly influences the metabolism of the liver. Glucose uptake 
in the presence of insulin was thus included to determine if insulin could indirectly, 
via metabolism of glucose, influence glucose uptake by the cells.    
Glucose concentrations in the 10µl aliquots were determined using a Gluci-net 
reagent kit (Bayer, France).  Glucose oxidase in the Gluci-net reagent, oxidise the 
D-glucose to gluconic acid producing hydrogen peroxide. This causes the 
oxidation of sodium hydroxyl-benzoate-aminophenazone to form stable quinine 
complexes varying in colour according to the concentration of glucose in the 
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sample. To each aliquot in the 96-well plates, 200µl of Gluci-net reagent was 
added and incubated for 15 minutes in a humidified 5% CO2 incubator at 37
0C. 
The optical density was read at 492nm using a Bio-Tek KC4 Power Wave XS 
micro plate reader (Analytical and Diagnostic Products, South Africa). 
A measure of the cell population density was also made at the time the three hour 
incubation with fresh RPMI medium with or without insulin was started, using a 
4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay. A 5mg/ml stock 
solution of MTT was made in PBSA and filter sterilized with a 0.2μm filter. A 10% 
working solution was made from the stock solution in RPMI 1640:10%FCS and 200μl 
of the working solution was added to 4 representative wells of each medium condition 
tested. The MTT assay was based on the metabolic reduction of the yellow 
tetrazolium salt (4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) (Sigma, 
UK) to a water-insoluble, dark blue formazan product.  This conversion only took 
place in living cells. The formazan product was dissolved in DMSO. The optical 
density was measured, spectrophotometrically, at 540nm, yielding an absorbance 
as a function of concentration of converted dye, which directly correlated to the 
number of metabolically active cells in the culture (Carmichael et al., 1987, 
DeGraff, Gazdar, Minna & Mitchell, 1987). 
2.3.2.2  High insulin concentrations 
Chang liver cells were seeded into 96-well cell culture plates at 5x103 cells per well 
in 200µl of growth medium. After 48 hours growth medium was removed from the 
cells and replaced with 200µl MCBD-201 medium containing either 0.1 or 1µM 
insulin. Cells that received MCBD-201 medium only were included as controls. 
Cells were set up in eight replicate wells for each condition tested. The cells were 
chronically exposed to these medium conditions for 48 hours after which the 
glucose utilization of the cells was determined with the same assay as described 
in section 2.3.2.1. A second method to measure the cell population density was 
used subsequently, which was quicker and could be performed in the same well in 
which glucose utilization assay was performed. After the glucose utilization assay 
the cells were fixed in 10% formal saline for 15 minutes then stained for 10 
minutes in 0.5% (m/v) crystal violet, 8% (v/v) formalin (40% formaldehyde), 0.17% 
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(m/v) NaCl, 22.3% (v/v) ethanol. The plates were then washed thoroughly in tap 
water, inverted to dry and dried further in a 370C incubator for one hour.  For 
accurate quantification, the dye present in the stained cells was dissolved with 
200µl of 33% acetic acid per well and the optical density of the released dye was 
measured in at 577nm in a Bio-Tek KC4 Power Wave XS micro plate reader.     
2.3.2.3 High fructose concentrations 
Chang liver cells were seeded into 96-well cell culture plates at 5x103 cells per well 
in 200µl of growth medium. After 48 hours growth medium was removed from the 
cells and replaced with 200µl MCBD-201 medium containing 1, 5 and 10mM 
fructose. Two control groups were included; one receiving RPMI 1640:10%FCS 
and the other MCBD-201 medium. Cells were set up in eight replicate wells for 
each condition tested. The cells were chronically exposed to these fructose 
concentrations for 48 hours whereafter the glucose utilization of the cells was 
determined with the same assay as described in section 2.3.2.1. The cell 
population density was measured with the method described in section 2.3.2.2. 
2.3.2.4 High insulin and fructose concentrations 
Chang liver cells were seeded into 96-well cell culture plates at 5X103 cells per 
well in 200µl of growth medium. After 48 hours growth medium was removed from 
the cells and replaced with 200µl of MCBD-201 or MCBD-201 medium containing 
a combination of 0.1µM insulin with either 1mM or 10mM fructose. Two control 
groups were included, one receiving RPMI 1640:10%FCS and the other MCBD-
201 medium. Cells were set up in eight replicate wells for each condition tested. 
The cells were chronically exposed to these conditions for 48 hours whereafter the 
glucose utilization of the cells was determined with the same assay as described 
section 2.3.2.1. The cell population density was measured with the method 
described in section 2.3.2.2. 
2.3.2.5 Calculations 
A glucose standard curve was generated using a serial dilution of the RPMI 1640 
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medium containing 8mM glucose. The amount of glucose taken up by the cells after 
the three hour incubation was calculated by subtracting the amount of glucose left in 
the medium from the amount of glucose added to cells at the beginning of the 
incubation. The percentage of glucose taken up was calculated relative to what was 
added and cell numbers in the respective wells were used to normalise glucose 
utilization data.  
The glucose utilization, after the 48 hour chronic exposure to the insulin resistance 
inducing media was also determined by subtracting the amount of glucose left in 
the medium after the 48 hour exposure from the amount of glucose added at the 
start of the incubation. The Gluci-net reagent was used to determine the amount of 
glucose in the medium. The amount of glucose in the RPMI 1640:10%FCS and 
MCBD-201 medium was also determined with the Gluci-net reagent in order to 
determine the amount of glucose at the start of the 48 hour incubation period.  
2.4 RESULTS AND DISCUSSION 
2.4.1 Effect of human diabetic serum on glucose utilization in Chang 
liver cells 
Chang liver cells were chronically exposed for 48 hours to MCBD-201 medium 
containing different percentages of human serum from either T2DM patients 
(human diabetic serum) or healthy individuals (human control serum).  After the 
chronic exposure the amount of glucose left in the medium was determined using 
a glucose oxidase assay. No significant differences were seen between Chang 
liver cells incubated in MCBD-201 medium with human serum from healthy or 
T2DM individuals (Figure 2.2 a). There was a significant difference (p<0.001) 
between the 2 control groups, Chang liver cells incubated with MCBD-201 or 
RPMI 1640:10%FCS. The amount of glucose left in the medium after the 48 hour 
exposure was significantly less in Chang liver cells incubated with normal growth 
medium RPMI 1640:10%FCS compared to cells grown in MCBD medium. This 
could propably be attributed to the fact that the normal growth medium containing 
serum is optimal for growth of Chang liver cells and the serum free MCBD-201 
medium is suboptimal. The serum in the normal growth medium could contain 
growth factors that stimulate glucose uptake in cells grown in RPMI 1640:10%FCS 
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medium; these factors are absent in the serum free medium.   
    (a) 
 
(b) 
 
Figure 2.2 Glucose utilization in Chang liver cells treated with human serum from 
T2DM patient (diabetic serum) or healthy individuals (control serum).  
Cells were cultured in RPMI-1640:10%FCS medium or MCBD-201 medium alone or MCBD-201 
medium supplemented with 2.5, 5 or 7.5% human serum. (a) The amount of glucose left in the 
medium after 48 hour chronic exposure to the different conditions. Chang liver cells cultured in 
RPMI 1640:10%FCS medium show significantly less glucose in the medium compared to cells 
culted in MCBD-201 medium (b) The amount of glucose taken up by the cells after three hour 
exposure to a fixed amount of glucose (8mM) in the medium in the presence or absence of 1μM 
insulin. Basal glucose uptake in Chang livers cells cultured in RPMI 1640:10%FCS, MCBD-201, or 
MCBD-201 supplemented with 2.5% human control serum was significantly higher compared to 
cells grown in MCBD-201 supplemented with 2.5% human diabetic serum.   
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Cell numbers were determined in representative wells and glucose values normalized to eliminate 
variation due to varying cell numbers. Bars and error bars represent the mean ± SD of eight 
replicate wells. (*p<0.001) 
After the chronic exposure, the cells were incubated for three hours in RPMI 1640 
medium containing 8mM glucose with or without 1μM insulin and 10% BSA. 
Thereafter the amount of glucose left in the medium was determined as described 
in section 2.3.2.5. This experiment was repeated a number of times but because 
the human diabetic serum was difficult to work with it hampered the reproducibility 
of the experiment. When the human diabetic serum was added to the preheated 
medium especially at higher percentages (7.5% and 10%) it coagulated. After the 
chronic treatment, because of the coagulated medium, almost half of the cells 
detached from the plate with aspiration of the medium. 
During the three hour incubation, there was a reduction in the basal glucose 
uptake of cells chronically treated with 2.5% human diabetic serum compared to 
the two control groups and the cells treated with 2.5% human control serum 
(p<0.001) (Figure 2.2b). In response to insulin in the MCBD-201 medium 
containing human diabetic serum Chang liver cells took up more glucose 
compared to in the absence of insulin in the same medium (Figure 2.2b). The 
objective of this experiment was to induce insulin resistance in Chang liver cells; 
the objective was not met as the cells were not less responsive to insulin than cells 
incubated with control human serum, or the two other controls included. In 
response to the 2.5% human diabetic serum there was a reduction in basal 
glucose uptake compared to all control samples, however this result could not be 
repeated because of the difficulty working with the human serum. Other methods 
thus had to be tested to induce insulin resistance. 
2.4.2 Effect of high insulin concentrations on glucose utilization in 
Chang liver cells 
Yuan et al., (2003) showed that chronic exposure of HepG2 cells to insulin 
resulted in down-regulation of insulin signal transduction via PI3K pathway. The 
HepG2 human hepatoma cells were grown to confluence and at confluence 
incubated with a serum-free medium including 100nM insulin. With 
immunoprecipitation and Western Blotting techniques they showed that after cells 
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were treated for 16 hours with 100nM insulin, insulin induced autophosphorylation 
of IRβ, and IRS1 and IRS2 was significantly reduced. Protein levels of IRβ, IRS1 
and IRS2 were also decreased compared to controls (Yuan et al., 2003). 
In the present study Chang liver cells were chronically exposed to 0.1μM and 1μM 
insulin respectively for 48 hours to induce insulin resistance. The cells ability to 
take up of glucose was measured with a glucose oxidase assay.  The amount of 
glucose left in medium in the control group after 48 hours of incubation in MCBD-
201 medium, was significantly higher as compared to cells incubated in MCBD-
201 medium containing 0.1μM and 1μM insulin (p<0.0001) (Figure 2.3.a.).  
The percentage glucose taken up after the three hour incubation of the Chang liver 
cells chronically treated with 0.1 μM and 1μM insulin in the MCBD-201 medium 
was significantly higher (p<0.0001) as compared to control cells incubated with 
only MCBD-201 medium (Figure 2.3.b.). No significant differences were seen in 
response to the acute insulin treatment of three hours in any of the three groups. 
Chronic insulin treatment of Chang liver cells with 0.1 μM and 1μM insulin 
improved their glucose uptake ability.  
This is in contrast to what was found in the study by Yuan et al., (2003) which showed 
that chronic insulin treatment in HepG2 cells for 16 hours induced a significant 
reduction in the phosporylation and protein expression of IRβ, IRS1, and IRS2 which 
could result in a down-regulation in the association of PI3K with IRS. 
PI3K plays an important role in signal-transduction pathways linking insulin with 
many of its specific cellular responses. Thus a down-regulation of PI3K 
association with IRS would result in down-regulation of insulin‟s action. In the 
current study Chang liver cells were used and cells were exposed for 48 hours as 
opposed to 16 hours in the study by Yuan et al. (2003). Under the conditions used 
in the current study Chang cells did not become insulin resistant and consequently 
other methods to induce insulin resistance were investigated. 
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(a)       
                                       
(b) 
  
Figure 2.3 The effect of high insulin concentration on glucose utilization in Chang 
liver cells.  
Cells were incubated for 48 hours in MCBD-201, MCBD-201+0.1 μM insulin or MCBD-201+1μM 
insulin. (a) The amount of glucose left in the medium after 48 hour chronic exposure to the different 
conditions. Significantly less glucose was left in the medium of Chang cells cultured in the MCBD 
medium supplemented with 0.1 or 1μM insulin compared to cell cultured in MCBD medium only. (b) 
The amount of glucose taken up by the cells after three hour exposure to a fixed amount of glucose 
(8mM) in the medium in the presence or absence of 1μM insulin. Chang cells cultured in MCBD 
medium supplemented with 0.1 or 1μM insulin took up significantly more glucose than Chang cells 
cultured in MCBD medium only. Cell numbers were determined with crystal violet staining in the 
same wells the glucose uptake assay was performed and glucose values normalized to eliminate 
variation due to varying cell numbers. Bars and error bars represent the mean ± SD of eight 
replicate wells. (***p<0.0001)  
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2.4.3 Effect of high fructose concentrations on glucose utilization in 
Chang cells 
High dosages of fructose in the diet have been implicated as a contributor to nearly all 
of the classic manifestations of the insulin resistance syndrome (Elliot et al., 2002; 
Gaby, 2005). The fructose fed rat is an established model that demonstrates insulin 
resistance, impaired glucose tolerance, hyperinsulinemia, hypertension and 
hyperlipidemia. Evaluating the effect of fructose in humans resulted in more conflicting 
results showing negative, positive and no effect (reviewed by Daly et al., 1997). The 
studies in humans are more difficult to perform, for a number of reasons, one being 
that dietary compliance cannot be assumed, except possibly in investigations in which 
patients are hospitalized throughout the study. Dirlewanger et al., (2000) however 
have shown that acute fructose infusion in humans could induce both extrahepatic 
and hepatic insulin resistance. Based on this knowledge high fructose concentrations 
in serum free medium was considered as another method to induce insulin resistance 
in Chang liver cells.  
Chang liver cells were exposed to 1mM and 10mM fructose respectively in MCBD-
201 medium for 48 hours whereafter the amount of glucose left in the medium was 
measured. Chang liver cells incubated in MCBD-201 medium were used as a control, 
however cells grown in RPMI 1640:10%FCS medium were also routinely included in 
analysis as the serum free medium is not optimal for cell growth. Cells grown in RPMI 
1640:10%FCS medium had significantly less glucose left in the medium after the 48 
hour exposure compared to cells treated with MCBD-201 medium and MCBD-201 
medium with 1mM and 10mM fructose respectively (p<0.0001) (Figure 2.4.a). 
Comparing the cells receiving MCBD-201 medium only to cells incubated with MCBD-
201 with either 1mM or 10mM fructose, showed that only cultures receiving MCBD-
201 with 10mM fructose had significantly more glucose left in the medium after the 48 
hour exposure (p<0.0001) (Figure 2.4.a). The high fructose concentration in the 
medium competes with the glucose to be taken up by the cell. Less glucose is taken 
up by the cell explaining more glucose left in the medium.  
 
 
 44 
44 
(a)     
 
 
(b)  
 
 
 
 
 
 
Figure 2.4 The effect of high fructose concentration on glucose utilization in Chang 
cells. Cells were exposed to RPMI 1640:10%FCS, MCBD-201 and MCBD-
201 medium supplemented with 1mM or 10mM fructose for 48 hours.  
(a) The amount of glucose left in the medium after 48 hour chronic exposure to the different 
conditions. Cells cultured in MCBD-201, MCBD-201+1mM fructose and MCBD-201+10mM fructose 
had significant more glucose left in the medium compared to cells cultured in RPMI 1640:10% FCS 
medium (p<0.0001). Cells cultured in MCBD-201+10mM fructose had significantly more glucose 
left in the medium compared to cells cultured in MCBD-201 medium (p<0.0001). (b) The amount of 
glucose taken up by the cells after three hour exposure to a fixed amount of glucose (8mM) in the 
medium in the presence or absence of 1μM insulin.  
Cell numbers were determined with crystal violet staining in the same wells the glucose uptake 
assay was performed and glucose values normalized to eliminate variation due to varying cell 
numbers. Bars and error bars represent the mean ± SD of eight replicate wells. (***p<0.0001) 
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After the chronic exposure, cells were exposed for three hours to fresh RPMI 1640 
medium containing 8mM glucose with or without 1μM insulin and 10% BSA. The 
amount of glucose left in the medium was determined with a glucose oxidase 
assay. No significant results were generated between the different medium 
conditions analyzed (Figure 2.3b) in their response to insulin. Although cells grown 
in MCBD-201 with 10mM fructose showed a reduced response to insulin 
compared to cell grown in MCBD-201 or MCBD-201, with 1mM fructose this 
reduction was not significant. In the absence of positive results created with high 
insulin and fructose treatments respectively, combinations of both insulin and 
fructose were subsequently used as a method to induce insulin resistance.    
2.4.4 Effect of high insulin and fructose concentrations on glucose 
utilization in Chang liver cells 
As both high insulin and high fructose concentrations independently have been 
shown previously to cause insulin resistance, in the present study the effect of a 
combination of 0.1μM insulin and 1mM fructose in MCBD-201 medium on glucose 
uptake in Chang liver cells was determined. Chang liver cells were exposed to 
these media conditions for 48 hours and cells cultured in MCBD-201 medium and 
RPMI1640:10%FCS medium were included as controls.  
Treating Chang liver cells with a combination of high insulin and high fructose in 
the medium affected their glucose utilization significantly. The treatment also 
caused injury to the cells, as indicated by the visible morphology of the cells and 
the viability determined with the crystal violet staining. After 48 hours of exposure 
there was significantly more glucose left in the medium in Chang liver cells treated 
with 0.1μM insulin and 1mM fructose in MCBD-201 medium compared to cells 
cultured in MCBD-201 or RPMI 1640:10%FCS medium (p<0.0001 ) (Figure 2.5.a). 
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Figure 2.5 The effect of the combination of 0.1μM insulin and 1mM fructose in MCBD-
201 medium on Chang liver cells glucose utilization.  
Chang liver cells were incubated in RPMI 1640:10%FCS, MCBD-201 and MCBD-201 medium with 
0.1μM insulin and 1mM fructose for 48 hours. (a) The amount of glucose left in the medium after 48 
hour chronic exposure to the different conditions. There was significantly more glucose left in the media 
of Chang liver cells cultured in MCBD-201 medium supplemented with 0.1μM insulin and 1mM fructose. 
(b) The amount of glucose taken up by the cells after three hour exposure to a fixed amount of glucose 
(8mM) in the medium in the presence or absence of 1μM insulin. There was more glucose left in the 
medium than the fixed amount of glucose that was used for the incubation in Chang liver cells culture in 
MCBD-201 medium or MCBD-201 medium supplemented with 0.1μM insulin and 1mM fructose 
indicated by the negative glucose uptake values. In response to insulin the Chang liver cells cultured in 
MCBD-201 medium showed a significant increase in glucose uptake. The cells cultured in MCBD-201 
medium supplemented with 0.1M insulin and 1mM fructose did not show a change in glucose uptake in 
response to insulin.  
Cell numbers were determined with crystal violet staining in the same wells the glucose uptake 
assay was performed and glucose values normalized to eliminate variation due to varying cell 
numbers. Bars and error bars represent the mean ± SD of eight replicate wells. (***p<0.0001)  
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After the chronic exposure the cells were incubated for three hours with RPMI 
1640 medium containing 8mM glucose with or without insulin and 10% BSA. Very 
interesting results were generated when the amount of glucose left in the medium 
was determined. There was more glucose in the medium after the three hour 
incubation than was added to the cells (Figure 2.5b). Modulations that increase 
hepatic glucose production have been implicated in inducing insulin resistance. 
Because there was more glucose in the medium than was added to the cells it 
could be postulated that high insulin and fructose concentration in the medium 
could stimulate hepatic glucose production. Chang liver cells cultured in control 
MCBD-201 medium also had more glucose in the medium than was added before 
the three hour incubation. This phenomenon was not previously seen with MCBD-
201 medium; however this experiment was performed with a new batch of MCBD-
201 medium.  The experiment was repeated and the same result was generated. 
One of the objectives of the present study was to develop a cell culture model of 
insulin resistance in the Chang liver cell line. Insulin resistance in the liver leads to 
increased glucose production contributing to hyperglycaemia. An initial screening 
analysis was performed in which the effect of different insulin resistance inducing 
agents on glucose utilization was determined. The aim of the screening analysis 
was to select a method that will reduce glucose uptake, or increase glucose 
production or make the cells less responsive to insulin. Although insulin has no 
effect on glucose transport into liver cells, insulin profoundly affects glucose 
metabolism in the liver; consequently the response to insulin on glucose utilization 
was also determined.  
The RPMI 1640:10%FCS medium is optimal for Chang liver cell growth. The 
methods used to induce insulin resistance compromise the optimal growth 
conditions of Chang liver cells, and can lead to injury to the cells. The degree of 
injury to the cells may vary; this possibly could be one of the reasons for the 
variation seen in data. Other factors, including transfer number of cells, could also 
influence the degree of injury caused by the insulin resistance inducing agents, as 
cells with a higher transfer number might be more susceptible to the injury. This 
could contribute to variation that was seen between different experiments. Another 
factor that also led to some variation between experiments was different batches 
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of media. In the experiment shown in Figure 2.2 the RPMI 1640 used was 
obtained in powder form, in subsequent experiments RPMI1640 in liquid form was 
used.  
Chang liver cells cultured in MCBD-201 medium supplemented with 0.1μM insulin 
and 1mM fructose was identified in the screening tests as the method to be 
optimized further to induce insulin resistance. In the next chapter the effect of two 
S.frutescens plant extracts and three known anti-diabetic agents, metfomin, 
ciprofibrate and cigitazone were tested to see if they could improve insulin 
sensitivity introduced by the insulin and fructose treatment. 
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CHAPTER 3:  EFFECT OF TWO S.FRUTESCENS EXTRACTS AND 
KNOWN ANTI-DIABETIC AGENTS ON GLUCOSE UTILIZATION 
AND LIPID ACCUMULATION IN A CHANG LIVER CELL MODEL 
OF INSULIN RESISTANCE 
3.1 EFFECT OF FRUCTOSE ON LIVER METABOLISM  
The consumption of fructose, primarily from high-fructose corn syrup (HFCS) has 
increased considerably during the past few decades (Elliot et al., 2002; Gaby, 
2005; Wei et al., 2007). HFCS is extensively used in carbonated beverages and 
other sweetened drinks, baked goods, candies, canned fruits, jams, jellies and 
dairy products (Gaby, 2005). Fructose is regarded as a relatively safe form of 
sugar by some nutritionists, because it does not require insulin for uptake into 
cells and moderate fructose intake does not adversely affect blood-glucose 
levels. Short term fructose consumption appears less likely to cause symptoms of 
reactive hypoglycaemia or trigger hypoglycaemia-related overeating. For these 
reasons, fructose is often recommended for people with diabetes and is included 
in many weight-loss products (Gaby, 2005).  
Hollenbeck (1993) reviewed the effects of dietary fructose on lipoprotein 
metabolism by critically looking at over 18 studies that have been previously 
performed to address this issue. He concluded that there is evidence that 
increasing dietary fructose consumption can significantly increase fasting plasma 
triglyceride and cholesterol concentrations. These changes are associated with 
significant increases in both VLDL and LDL particles without any apparent 
change in HDL-particle concentrations (Hollenbeck 1993). As early as 1968, 
Macdonald (1968) had shown that specific activity of serum TGs was greater after 
14C-fructose ingestion than after 14C-glucose ingestion, suggesting that fructose is 
preferred to glucose by the lipid synthetic pathways in the fasted state. However 
the long term effects of fructose consumption have not been adequately studied 
in humans (Gaby et al., 2005). The extent to which a person might be adversely 
affected by dietary fructose depends both on the amount consumed and on the 
individual tolerance. Considering that a typical western diet not only contains high 
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levels of fructose, but is also rich in both fat and cholesterol, these lethal 
combinations could lead to a greater degree of insulin resistance and 
dyslipidaemia in more susceptible individuals (Basciano et al., 2005).  
Use of high fructose fed (HFF) diets is a well established method to induce insulin 
resistance in rodents (Hallfrisch et al., 1979; Thorburn et al., 1989; Kelley et al., 
2004; Kelley and Azhar, 2005). The liver is the main organ capable of rapidly 
metabolizing fructose (Basciano et al., 2005). The high influx of fructose to the 
liver in HFF experimental models disturbs normal hepatic carbohydrate 
metabolism leading to two major consequences: perturbations in glucose 
metabolism and glucose uptake pathways, and a significantly enhanced rate of 
de novo lipogenesis and TG synthesis. Fructose delivered to the liver is 
phosphorylated by the enzyme fructokinase to form fructose-1 phosphate (Figure 
3.1) (Hallfrish 1990; Basciano et al., 2005; Spruss and Bergheim, 2009). 
Fructose-1 phosphate is split by aldolase B into glyceraldehyde and 
dihydroxyacetone phosphate, both of which can be converted to glyceraldehyde-3 
phosphate (Elliott et al., 2002; Basciano et al., 2005; Spruss and Bergheim, 
2009). These particular fructose end products can then readily converge with the 
glycolytic pathway. Fructose can continuously enter the glycolytic pathway 
because of its ability to bypass the main regulatory step of glycolysis, the 
conversion of glucose-6-phosphate to fructose-1,6-biphosphate, controlled by 
phosphofructokinase (Basciano et al., 2005; Spruss and Bergheim, 2009).  
The products of fructose metabolism in the glycolytic pathway of the liver are 
glucose, glycogen, lactate, and pyruvate (Elliott et al., 2002). Because fructose 
uptake is not inhibited at the level of phosphofructokinase, these products can be 
uncontrollably produced, providing both the glycerol and acyl portions of acyl-
glycerol molecules (Basciano et al., 2005). These particular substrates, and the 
resultant excess energy flux due to unregulated fructose metabolism, will promote 
the overproduction of TG.  These metabolic disturbances appear to underlie the 
induction of insulin resistance commonly observed with high fructose feeding in 
both humans and animal models (Basciano et al., 2005). 
In addition to this, fructose does not stimulate the production of insulin and leptin; 
two key hormones in the long-term regulation of energy homeostasis (Elliot et al., 
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2002). The decrease in insulin responses to meals and leptin production 
associated with chronic consumption of diets high in fructose may have 
deleterious long-term effects on the regulation of energy intake and body 
adiposity.  
  
Figure 3.1 Hepatic fructose metabolism.  
Fructose is readily absorbed from the diet and rapidly metabolized principally in the liver. High 
concentrations of fructose can serve as a relatively unregulated source of acetyl CoA. Unlike 
glucose, dietary fructose does not stimulate insulin or leptin production. Fructose can stimulated 
TG synthesis that can lead to hepatic TG accumulation, which has been shown to reduce insulin 
sensitivity, as well as increased formation of VLDL particles due to higher substrate availability, 
increased apoB stability and higher MTP, the critical factor in VLDL assembly. 
(TG, Triglyceride; MTP, microsomal triglyceride transport protein; VLDL, very-low-density protein)  
(Figure taken from Basciano et al., 2005)  
In the HFF animal model, compounds that lower circulating lipid levels increase 
insulin sensitivity, or inhibit TNF-α production, reduce serum TGs and improve 
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blood pressure (Kelley et al., 2004). An exercise regimen has also been shown to 
ameliorate the diet-induced effects in HFF animals. Thus the HFF animal models 
exhibit many of the hallmarks of an early stage of the metabolic syndrome, in 
which a combination of physical inactivity and diet result in cardiovascular 
disease and metabolic complications.  Kelley et al. (2004) hypothesized that HFF 
animals exhibited altered lipid metabolism due to hepatic stress as a result of the 
burden of fructose metabolism. They showed that there was a correlation 
between activation of the JNK stress pathway leading to activation of the 
transcription factor AP-1 and abnormal TG levels. In a further study by Kelley & 
Azhar (2005) they showed that HFF diets lead to major reductions in the steady 
state levels of both PPARα protein and mRNA. Treatment with anti-
inflammmatory agents, lipoxygenase/cyclooxygenase (LOX/COX) inhibitor 
compounds reversed the fructose-induced suppression of hepatic PPARα 
expression (Kelley & Azhar, 2005).   
The consumption of fructose sweetened beverages for 10 weeks in overweight, 
obese humans increased de novo lipogenesis, promoted dyslipidemia, decreased 
insulin sensitivity, and increased visceral adiposity (Stanhope et al., 2009).   
In this Chapter the effect of two S.frutescens plant extracts and known anti-
diabetic agents, metformin, ciglitazone and the hypolipidaemic agent ciprofibrate 
were assesed in the high insulin and high fructose medium model chosen to 
induce insulin resistance in the Chang liver cells. The glucose utilization of the 
cells exposed to high insulin and fructose concentrations was determined with a 
modified version of the glucose oxidase assay used in the screening process in 
Chapter 2 and also with a 2-deoxy glucose assay. Lipid accumulation was 
measured using an Oil-red-O and a Nile red assay.     
3.2 MATERIALS AND METHODS 
3.2.1 Preparation of plant extracts 
Two different extracts of S.frutescens were used in the present study, named 
plant extract 1 and plant extract 2. Plant extract 1 was prepared by drying the 
leaves away from sunlight and then mixing 2.5 g dried, crushed leaves with 100ml 
 53 
53 
boiling water and allowing the tea to brew overnight. The extract was then filtered 
through a sieve with pores of approximately 1mm in diameter, and freeze dried, 
the powder was stored at 40C.  Plant extract 2 was donated by a pharmaceutical 
company (Value Added Life, South Africa) that make capsules containing the 
S.frutescens plant extract. Of these two plant extracts 0.0015g was weighed 
respectively and dissolved in 150μl DMSO and made up to 3ml with growth 
medium. This plant extract suspension was then syringe filtered with a 0.2μm 
filter under sterile conditions and used in experiments at a final concentration of 
12.5μg/ml. The made up plant extract suspension in DMSO was stored at 40C 
and discarded after a week.  
3.2.2 Preparation of known anti-diabetic agents 
A set of 1mM stock solutions of metformin, ciglitazone  and ciprofibrate (Sigma, 
UK) in DMSO (Merck, South Africa) was made and filter sterilized with 0.2μm 
filters under sterile conditions. Aliquots of 100μl were stored at -200C. On the day 
of addition to cell culture 1mM of the required stock solution was diluted to 20μM 
with growth medium and used at a final concentration per well  of 1μM for 
metformin and 10μM for ciglitazone and ciprofibrate. Diluted stock solutions were 
stored at 40C and discarded after one week. 
3.2.3 Glucose utilization 
3.2.3.1 Glucose-oxidase assay 
The glucose oxidase method described in section 2.3.2.1 was optimized and 
used to determine glucose uptake in Chang liver cells after treatment with the 
insulin resistance inducing agents. Chang liver cells were seeded into two 96-well 
cell culture plates at 5X103 cells per well in 200µl of growth medium. After 48 
hours, growth medium was removed from the cells and replaced in plate one with 
200µl of either RPMI 1640:10%FCS (RPMI) medium or MCBD-201 medium 
(MCBD) or MCBD-201 medium containing plant extract 1 (MCBD+P1) or 
(MCBD+P2), or metformin (MCBD+Met) or ciglitazone (MCBD+Ciglit) respectively 
as indicated in Table 3.1. In plate two MCBD supplemented with 0.1μM insulin 
and 1mM fructose (MIF) was used as culture medium (Table 3.2). In the MIF 
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medium plant extract 1(MIF+P1), plant extract 2 MIF+P2, metformin (MIF+Met), 
ciprofibrate (MIF+Cipro) and ciglitazone (MIF+Ciglit) was included respectively 
(Table 3.2). Chang liver cells were chronically exposed to these media conditions 
for 48 hours. Sixteen replicate wells of each medium condition were prepared. 
 
Table 3:1 Medium conditions of Plate one to determine glucose uptake with the 
glucose-oxidase assay in control cells 
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Table 3:2 Medium conditions of Plate two to determine glucose uptake with the 
glucose-oxidase assay in cells treated with insulin and fructose to 
induce insulin resistance.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
M
C
B
D
 +
 0
.1
μ
m
 I
n
s
u
lin
 +
 1
m
M
 
F
ru
c
to
s
e
 (
M
IF
) 
M
IF
+
 P
la
n
t 
e
x
tr
a
c
t 
1
 
(1
2
.5
μ
g
/m
l)
 
M
IF
 +
 P
la
n
t 
e
x
tr
a
c
t 
2
 
(1
2
.5
μ
g
/m
l)
 
M
IF
 +
 M
e
tf
o
rm
in
 (
1
μ
M
) 
M
IF
 +
 C
ip
ro
fi
b
ra
te
(1
μ
M
) 
M
IF
+
C
ig
lit
a
z
o
n
e
 (
1
μ
M
) B 
C 
D 
E 
F 
G 
H 
After the chronic exposure, 10µl of the spent medium was removed to a new 96 
well plate to measure the amount of glucose left in the medium. The rest of the 
medium was removed and cells were washed with Hanks buffered salt solution 
(HBSS): 0.137M NaCl, 5.4mM KCl, 0.25mM Na2HPO4, 0.44 mM KH2PO4, 1.3mM 
CaCl2, 1mM MgSO4, 4.2mM NaHCO3). Cells were then starved for one hour by 
incubationng with 100μl HBSS. The HBSS was removed and cells were 
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incubated with fresh RPMI 1640 medium containing 8mM glucose and 10% BSA 
with or without 1μM insulin. For each medium condition eight replicates were 
incubated with the incubation medium supplemented with 1μM insulin, the 
remaining eight replicates were incubated with RPMI 1640 medium containing 
8mM glucose and 10% BSA without insulin. An acute dose of plant extract 1, 
plant extract 2, metformin, ciprofibrate or ciglitazone was added to the same wells 
in which the chronic exposure was made. After one hour, two hours and three 
hours 10µl of the medium was removed to a new 96 well plate where 200µl of 
Gluci-net reagent was added to the medium and incubated for 15 minutes in a 
humidified 5% CO2 incubator at 37
0C. The optical density was read at 492nm 
using a Bio-Tek KC4 Power Wave X S plate reader. The cell population density 
was measured with the method described in section 2.3.2.2. 
3.2.3.2 2-Deoxy- Glucose assay 
Glucose uptake was measured using tritium labelled 2-Deoxy-D-glucose ([2-[3H]-
DOG). 2-Deoxy-D-glucose (2-DOG) is a stable glucose analogue, in which the 2-
hydroxyl group of glucose is replaced by hydrogen (Ralser et al., 2008). This 
glucose molecule can actively be taken up by the hexose transporters and 
phosphorylated but cannot be fully metabolized by the cell; consequently 2-DOG-
6-phosphate accumulates in the cell (Ralser et al., 2008). 
Chang liver cells were seeded into two 96-well cell culture plates at 5x103 cells 
per well in 200µl of growth medium. After 48 hours growth medium was removed 
from the cells and replaced with the same medium condition described in section 
3.2.3.1, Table 3.1 and 3.2 with the exception that control group RPMI was omitted 
and more MCBD replicates were included.  
The cells were chronically exposed to these conditions for 48 hours. After the 
chronic exposure cells were washed twice with Krebs-Ringer phosphate (KRP) 
buffer: 10mM phosphate (pH 7.2), 136mM NaCl, 4.7mM KCl, 1.25mM CaCl2, 
1.25mM MgSO4. After washing with KRP-buffer, cells were stimulated with 1μM 
insulin in KRP-buffer without glucose for 10 min. 2-DOG (0.2μCi/ml 2-[3H]-DOG 
(New England Chemicals) in 1μM of unlabelled 2-deoxyglucose) was added and 
 56 
56 
cells were incubated for 10 minutes. Cells were washed three times in ice cold 
PBS and solubilized in 50μl 0.1N NaOH. Solubilized cells were removed to a new 
micro capped tube; a second volume of NaOH was added and removed to micro 
capped tube. Packard Ultima Gold scintallation fluid (1ml) was added to each cell 
suspension, the solution was vortexed until it was clear, and thereafter each of 
the samples was counted for 15 minutes in a Packard Tri-carb 2300TR liquid 
scintillation analyzer. 
3.2.4 Lipid accumulation 
3.2.4.1 Oil-red-O assay 
The two lipid stains Oil-red-O and Nile red were used to determine if the method 
used to induce insulin resistance led to fat accumulation in Chang liver cells. 
Chang liver cells were seeded into two 96-well cell culture plates at 5X103 cells 
per well in 200µl of growth medium. After 48 hours growth medium was removed 
from the cells and replaced with the same media conditions as described in 
section 3.2.3.1, Table 3.1 and 3.2.  
Chang liver cells were chronically exposed to these conditions for 48 hours. After 
the chronic exposure, culture medium was removed and cells were fixed in 10% 
formaldehyde in PBSA. Oil-red-O was prepared by disolving 0.5g of the dye in 
100ml 98% isopropanol. Before use, 6ml of stock solution was diluted with 4ml 
distilled water and allowed to stand for 24 hours and filtered through Whatman no 
42 paper immediately before use. Cells were stained with 200μl Oil-red-O working 
solution for 90 minutes, washed with tap water and left until completely dry, 
before dye was extracted with 200μl isopropanol. Absorbance was read at 
540nm. 
A measure of the cell population density was done using an MTT assay. MTT 
stock and working solution was prepared as described in section 2.3.2.1. MTT 
working solution (200μl) was added to six representative wells of each medium 
condition analyzed, incubated for three hours, solution removed and formazan 
product disolved in 200μl DMSO. The optical density was measured, 
spectrophotometrically at 540nm, yielding an absorbance as a function of 
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concentration of converted dye, which directly correlated to the number of 
metabolically active cells in the culture.  
3.2.4.2 Nile-red assay 
Chang liver cells were seeded into two 96-well cell culture plates at 5x103 cells 
per well in 200µl of growth medium. After 48 hours growth medium was removed 
from the cells and replaced with the same medium conditions as described in 
section 3.2.3.1 Table 3.1 and 3.2.  
The cells were chronically exposed to these conditions for 48 hours. After the 
chronic exposure cells were washed with HBSS, and background fluorescence 
was determined [535nm exicitation, 580nm emission] in a Fluoroskan Ascent FL 
(Thermo Labsystems) plate reader. A 1mM stock solution of Nile red dye (Sigma, 
UK) was prepared in DMSO and stored in the dark at -200C. Nile red was then 
freshly diluted from the 1mM stock solution in DMSO with 1% Pluronic F127 
(Sigma, UK) in HBSS to a 1μM working solution. 100μl of the working solution 
was added to each culture well. After four hour incubation at room temperature in 
the dark, Nile Red was removed and cells were washed once with HBSS. After a 
further incubation for sixteen hours in HBSS at room temperature in the dark, 
fluorescence was again determined as above and background subtracted to 
obtain bound Nile Red fluorescence. After the Nile red assay was completed, cell 
viability was determined with crystal violet staining as described in section 
2.3.2.2.   
3.3 RESULTS AND DISCUSSION 
3.3.1 Effect of plant extracts and known anti-diabetic agents on 
glucose utilization 
In Chapter 2 different methods were used to induce insulin resistance in Chang 
liver cells. Insulin resistance was determined based on the ability of the cells to 
take up glucose. Exposing Chang liver cells to high insulin and fructose 
concentrations in serum free medium chronically, showed that there was more 
glucose in the medium after a three hour incubation with a fixed amount of 
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glucose, than was added before the incubation. However the viability of Chang 
liver cells used in these experiments was much lower than the control cells. The 
transfer number of these cells was close to the end of the range normally used for 
experiments. The high fructose and insulin in the medium causes stress to the 
cell and could lead to cell injury. Cells with a higher transfer number could be 
more vunerable to the destructive effects of the high fructose and insulin in the 
medium, and thus leading to the more severe effects to these cells.  
New cells were taken from cryo-preservation and used for subsequent analysis 
great care was taken concerning transfer numbers of these cells. Glucose 
oxidase assay as described in section 2.3.2.2 with some modifications was 
performed. The modification included a washing step with HBSS, starving the 
cells for an hour by incubation with HBSS, and measuring the amount of glucose 
in the medium every hour for three hours. In addition, the effect of two 
S.frutescens plant extracts, metformin, ciprofibrate and cigltazone was also 
assessed. 
The viability of the cells, as determined with crystal violet staining, after the 
glucose oxidase assay, was in general much better than the cells used in Chapter 
2. As expected cells grown in RPMI 1640:10%FCS were more viable than cells 
grown in MCBD-201 medium (p<0.0001) (Figure 3.1.a). High insulin and fructose 
in MCBD-201 medium did not make Chang liver cells significantly less viable 
compared to cells cultured in MCBD-201 medium only.   
Chang liver cells treated with the two plant extracts, metformin, ciprofibrate or 
ciglitazone appeared more viable than cells cultured in MIF medium only, 
however these changes in viability were not significant due to the great variation 
seen between replicates (Figure 3. 1 a).  
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(a) 
 
(b) 
 
Figure 3.2 The effect of 0.1μM insulin and 1mM fructose in MCBD-201 medium on 
Chang liver cells viability and glucose utilization.  
Chang liver cells were incubated in RPMI 1640:10%FCS, MCBD-201 and MCBD-201 medium 
with 0.1μM insulin and 1mM fructose (MIF), MIF+plant extract 1 (MIF+P1), MIF+plant extract 2 
(MIF+P2), MIF+metformin (MIF+Met), MIF+ciprofibrate (MIF+Cipro), or MIF+ciglitazone 
(MIF+Ciglit) for 48 hours. (a) Cell viability determined with crystal violet staining. Chang liver cells 
cultured in MCBD-201 medium was significantly less viable than cells grown in RPMI 
1640:10%FCS.  (b)The amount of glucose left in the medium after 48 hour chronic exposure to 
the different medium conditions. Chang liver cells cultured in MCBD-201 and MIF medium had 
significantly more glucose left in the medium after the 48 hour chronic exposure compared to cells 
grown in RPMI 1640:10%FCS. Chang liver cells cultured in MIF medium supplemented with plant 
extract 1, plant extract 2, metformin, ciprofibrate or ciglitazone show a significant reduction in 
glucose left in the medium compared to MIF treatment only. Cell numbers determined with crystal 
violet staining was used to normalize glucose values to eliminate variation due to varying cell 
numbers. Bars and error bars represent the mean ± SD of 16 replicate wells. (***p<0.0001; 
*p<0.001 ).  
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After the 48 hour exposure to the different medium conditions as indicated in 
Table 3.1 and 3.2 the amount of glucose left in the medium was determined. 
Chang liver cells grown in RPMI 1640:10%FCS medium had less glucose left in 
the medium compared to cells grown in MCBD-201 and MIF medium (p<0.0001) 
(Figure 3.1.b). MIF treatment decreased the amount of glucose in the medium 
compared to MCBD-201 treatment; however this decrease was not more than in 
RPMI 1640:10%FCS medium. MIF medium supplemented with plant extract 1, 
plant extract 2, metformin, ciprofibrate or ciglitazone significantly reduced levels 
of glucose (p<0.0001) in the medium compared to MIF medium only (Figure 
3.1.b). Thus the plant extracts and other anti-diabetic agents improved the 
glucose utilization of Chang liver cells significantly when included in MIF medium. 
After the chronic 48 hours exposure, cells were washed with HBSS and starved 
for one hour in HBSS. After the hour starvation, cells received RPMI 1640 
medium containing 8mM glucose 10% BSA with or without insulin and an acute 
dose of the plant extracts, metformin, ciprofibrate or ciglitazone in the respective 
wells. After one hour, two hours and three hours the amount of glucose in the 
medium was determined with a glucose oxidase assay and the amount of glucose 
taken up by the cells was calculated based on the amount that was added to the 
cells. 
As mentioned in Chapter 2, insulin profoundly influences the metabolism of liver 
through plasma membrane receptors, but has no effect on glucose transport by 
liver cells (Gibson & Harris, 2002). This is illustrated in this experiment as no 
significant differences in glucose uptake in response to insulin are seen in the 
control groups i.e. Chang liver cells cultured with RPM1640:10%FCS or MCBD-
201 at any time point (Figure 3.3 a, b, & c). GLUT2 transports glucose into as well 
as out of hepatocytes, the direction dictated by the glucose gradient across the 
plasma membrane (Fig 2.1) (Eisenberg et al., 2005). In the present study 
following glucose uptake over time it is illustrated that glucose transport is 
bidirectional (Figure 3.3.a, b & c)  
Glucose uptake one and three hours after starvation in Chang liver cells cultured 
in MIF was significantly lower compared to cells cultured in MCBD-201 and RPMI 
1640:10%FCS medium (Figure 3.3a & c). The inclusion of plant extracts or the 
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other antidiabetic treatments in MIF did not reverse the reduction in glucose 
uptake.  After two hours there was an increase in glucose uptake in all cells 
cultured in all MIF containing media (Figure 3.3b). MIF treatment causes Chang 
liver cells to take longer to respond to refeeding by taking longer to increase 
glucose uptake after a one hour starvation period compared to control cells 
(Figure 3.3a).    
(a) Glucose Uptake after one hour  
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(b) Glucose Uptake after two hours 
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(c) Glucose Uptake after three hours 
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Figure 3.3 Glucose uptake followed over three hours in Chang liver cells treated 
with high fructose and insulin in MCBD-201 medium, and the effect of 
two plant extracts, metformin, ciprofibrate or ciglitazone on the glucose 
uptake.  
Chang liver cells were incubated in RPMI 1640:10%FCS, MCBD-201, MCBD-201 medium with 
0.1μM insulin and 1mM fructose (MIF), MIF+plant extract 1 (MIF+P1), MIF+plant extract 2 
(MIF+P2), MIF+metformin (MIF+Met), MIF+ciprofibrate (MIF+Cipro), or MIF+ciglitazone 
(MIF+Ciglit) for 48 hours. After the chronic exposure Chang liver cells were starved for one hour 
and glucose taken up by the cells compared to a fixed amount of glucose (8mM) added to cells 
after the starvation was measure every hour for three hours. (a) Glucose uptake after one hour. 
Chang liver cells grown in MIF medium have a significant reduced capacity to take up glucose 
compared to the control groups i.e. cells cultured in RPMI 1640:10%FCS (p<0.005) or MCBD-201 
medium (p<0.001). (b). Glucose uptake after two hours. (c). Glucose uptake after three hours. 
Glucose uptake was significantly reduced in Chang liver cells cultured in MIF medium compared 
to cells cultured in RPMI 1640:10%FCS and MCBD-201 medium. Cell numbers were determined 
with crystal violet staining in the same wells the glucose uptake assay was performed and glucose 
values normalized to eliminate variation due to varying cell numbers. Bars and error bars 
represent the mean ± SD of eight replicate wells. Data are shown of one representative 
experiment from three experiments. (***p<0.001; **p<0.005; *p<0.05) 
 
Comparing the time course of glucose uptake in Chang liver cells cultured in 
MCBD-201 medium to cells cultured in MCBD-201 medium supplemented with 
insulin and fructose showed an inverse effect (Figure 3.4 a & b). In Chang liver 
cells cultured with MCBD-201 medium supplemented with plant extract 1, plant 
*** 
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extract 2, metformin, ciprofibrate, or ciglitazone a similar pattern of glucose 
uptake over time as cells cultured in MCBD-201 medium only was observed 
(Figure 3.4a). The pattern of glucose uptake over time in Chang liver cells 
cultured in MIF medium and MIF medium supplemented with plant extract 2, 
metformin, ciprofibrate or ciglitazone was also similar (Figure 3.4b). The pattern 
of glucose uptake over time in Chang liver cells cultured in MIF medium 
containing plant extract 1 differed from the other MIF containing media, however 
this change was not significant due to the variation between replicates. The 
glucose oxidase assay measured the amount of glucose in the medium. The 
glucose transporter in the liver is GLUT2 thus glucose could move into as well as 
out of the cell, this could contribute to the variation seen when the amount of 
glucose in the medium is measured. The even greater variation seen in cells 
cultured in the insulin resistance inducing medium, MIF, could be because this 
treatment causes stress to the cell which could lead to cell injury. The degree of 
injury may vary between the cells contributing to the variation seen in the data.  
Although replicates showed great variability in the oxidase assay it could 
definitely be concluded that Chang liver cells cultured in MCBD-201 medium 
containing 0.1μM insulin and 1mM fructose have a reduced capacity to take up 
glucose. Including the two plant extracts, metformin, ciprofibrate or ciglitazone in 
the MIF did not reverse the reduction in glucose uptake. A second method to 
determine glucose uptake in Chang liver cells was used, because of the variability 
seen in the replicates of the glucose oxidase assay. The 2-DOG assay was 
subsequently performed. 
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Figure 3.4 Time course of glucose uptake in Chang liver cells cultured in MCBD 
medium and MCBD supplemented with 0.1μM insulin and 1mM fructose 
respectively and the effect of the presence of plant extracts and 
antidiabetic agents in these media on glucose uptake.   
(a) Time course of glucose uptake in cells cultured in MCBD-201 medium or MCBD-201 medium 
supplememnted with plant extract 1, plant extract 2, metformin, ciprofibrate or ciglitazone. (b) 
Time course of glucose uptake in cells cultured in MCBD medium with added insulin and fructose 
(MIF) and MIF medium supplemented with plant extract 1, plant extract 2, metformin, ciprofibrate 
or ciglitazone. 
 
Time Course 
Time Course 
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Chang liver cells were incubated for 48 hours under the same medium conditions 
as described in section 3.2.3.1, Table 3.1 and 3.2 with one modification, exclusion 
of RPMI 1640:10%FCS medium and including more replicates of MCBD-201. The 
number of MCBD-201 replicates was increased because of the variability seen in 
the glucose oxidase experiment. After the 48 hour exposure Chang liver cells 
were incubated in KRP-buffer with or without insulin for 10 minutes, followed by 
addition of 2-[3H]-DOG to cells for 10 minutes before cells were solubilized and 
the amount of 2-[3H]-DOG taken up by the cells measured in a scintillation 
counter.  
The percentage 2-[3H]-DOG taken up by the cells was calculated, relative to 
control cells, Chang liver cells cultured with MCBD-201 medium. Compared to 
control cells, cells treated with extra insulin and fructose in the MCBD-201 
medium, took up less 2-[3H]-DOG, in agreement with what was found with the 
glucose oxidase experiment (p<0.0001) (Figure 3.5). The addition of plant 
extracts, metformin and ciglitazone to the MIF medium increased the amount of 
2-[3H]-DOG taken up by the cells compared to the MIF medium only (p<0.0001; 
p<0.01) (Figure 3.5). The presence of plant extract 1 and ciglitazone in the MIF 
medium most profoundly increased 2-[3H]-DOG uptake compared to MIF 
treatment only. The inclusion of ciprofibrate in the insulin resistance inducing 
medium did not increase the glucose uptake capacity of Chang liver cells. This is 
expected as ciglitazone and metformin are antidiabetic drugs that improve insulin 
sensitivity and reduce HGP, whereas ciprofibrate is a hypolipidaemic agent.  
Glucose uptake was not as profoundly increased in Chang liver cells cultured with 
control medium, supplemented with plant extract 1 or ciglitazone as with MIF 
medium supplemented with these two components (Figure 3.5 & 3.6).  Chang 
liver cells grown in MCBD-201 medium supplemented with plant extract 1, plant 
extract 2, metformin and ciglitazone significantly increase glucose uptake in 
response to insulin (p<0.001; p<0.0001) (Figure 3.6). Thus the antidiabetic drugs 
and the plant extracts improve the insulin senisitivity of the Chang liver cells 
cultured under the control conditions used in the present study. MIF medium 
supplemented with the antidiabetic drugs or plant extracts also showed an 
increase in glucose uptake in response to insulin however this increase was not 
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significant (Figure 3.5).  
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Figure 3.5 2-[
3
H]-DOG uptake in Chang liver cells treated with MCBD-201 medium 
with 0.1μM insulin and 1mM fructose (MIF) to induce insulin resistance 
and the effect of the presence of  the two plant extracts, metformin, 
ciprofibrate or ciglitazone in MIF on 2-[
3
H]-DOG uptake.  
Chang liver cells were incubated in MCBD, MIF, MIF+plant extract 1 (MIF+P1), MIF+plant extract 
2 (MIF+P2), MIF+metformin (MIF+Met), MIF+ciprofibrate (MIF+Cipro), or MIF+ciglitazone 
(MIF+Ciglit) for 48 hours. 2-[
3
H]-DOG taken up by the cells was measured after 10 minute 
incubation with or without 1μM insulin in KRP-buffer. Chang liver cells cultured in MIF medium 
took up significantly less glucose compared to cells grown in MCBD-201 medium. Chang liver cell 
cultured in MIF medium supplemented with plant extract 1, plant extract 2, metformin or 
ciglitazone showed a significant increase in glucose uptake compared to MIF treatment only.   
Data are shown of one representative experiment from three experiments. Cell numbers were 
determined in representative wells for each treatment and glucose values normalized to eliminate 
variation due to varying cell numbers. Bars and error bars represent the mean ± SD of five 
replicate wells for all analyzed conditions except for the control medium condition in which ten 
replicates were included. (***p<0.0001; **p<0.01)  
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Figure 3.6 2-[
3
H]-DOG uptake in Chang liver cells treated with MCBD-201 medium 
and the effect of the presence of the two plant extracts, metformin, 
ciprofibrate or ciglitazone in MCBD on 2-[
3
H]-DOG uptake.  
Chang liver cells were incubated in MCBD-201, MCBD-201+plant extract 1 (MCBD+P1), MCBD-
201+plant extract 2 (MCBD+P2), MCBD-201+metformin (MCBD+Met), MCBD-201+ciprofibrate 
(MCBD+Cipro), or MCBD-201+ciglitazone (MCBD+Ciglit) for 48 hours. 2-[
3
H]-DOG taken up by 
the cells was measured after 10 minute incubation with or without 1μM insulin in KRP-buffer. 
Chang liver cells cultured in MCBD-201 medium supplemented with plant extract 1, plant extract 
2, metformin, or ciglitazone significantly increase glucose uptake in response to insulin. Data are 
shown of one representative experiment from three experiments. Cell numbers were determined 
in triplicate for each treatment in representative wells and glucose values normalised to eliminate 
variation due to varying cell numbers. Bars and error bars represent the mean ± SD of five 
replicate wells for all analyzed conditions except for the control medium condition in which ten 
replicates were included. (***p<0.0001; **p<0.001)   
 
3.3.2 Effect of plant extracts and known anti-diabetic agents on lipid 
accumulation 
Obese nondiabetic and individuals with T2DM have increased stores of 
triglycerides in muscle and liver and the increased fat content correlates closely 
with the presence of insulin resistance in these tissues (Desvergne et al., 2006). 
In the present study lipid accumulation due to insulin and fructose treatment of 
Chang liver cells was determined with two lipid staining assays, the Oil-red-O 
stain and the Nile red stain. Oil-red-O is a lipid soluble dye which is commonly 
used for the detection of triacylglycerols and cholesteroyl esters (Howard & Kruth 
1984; Fowler & Greenspan 1985). Nile red is a fluorescent stain used for the 
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detection of cytoplasmic lipid droplets (Greenspan et al., 1985). 
Fowler and Greenspan (1985) compared the staining pattern of Nile red with Oil-
red-O, in fatty liver and aorta tissue obtained from rabbits fed a 1% cholesterol 
diet for 6 months. In sections of the fatty liver Nile red and Oil-red-O staining 
patterns are comparable, but in aortic atheromas which contain high 
concentrations of cholesterol and cholesterol esters Nile red shows lipid rich 
areas not seen with Oil-red-O staining. Nile red was shown to stain phospholipids 
and neutral lipid deposits while Oil-red-O only stains neutral lipids (Fowler & 
Greenspan, 1985). 
In Chang liver cells cultured in MIF medium lipid accumulation determined with 
Oil-red-O staining was significantly increased compared to cells grown in MCBD-
201 medium (p<0.001) (Figure 3.7). The presence of plant extract 1, plant extract 
2, metformin, ciprofibrate, or ciglitazone in the MIF medium significantly reduced 
the amount of lipid accumulation compared to the MIF treatment only (Figure 3.7). 
Nile red staining also showed increased  lipid accumulation in cells cultured in 
MIF medium compared to cells cultured in MCBD-201 medium only (p<0.0001) 
(Figure 3.8). Chang liver cells cultured in MIF medium supplemented with plant 
extract 1, plant extract 2, metformin, ciprofibrate or ciglitazone reduced lipid 
accumulation measured with Nile red staining compared to cells grown in MIF 
medium only (Figure 3.8).  
Both Oil-red-O and Nile red staining showed that MIF treatment of Chang liver 
cells led to significant lipid accumulation compared to cells cultured in MCBD-201 
medium only. Although supplementation of MIF medium with plant extract 1 or 
plant extract 2 both led to a reduction in lipid accumulation when determined with 
Nile red and Oil-red-O staining, the Oil-red-O showed a more pronounced 
reduction compared to the Nile red staining. Both of these dyes can stain lipids, 
however Oil-red-O stains mostly neutral lipids like TG and Nile red can stain 
neutral lipids as well as phospholipids.  
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Figure 3.7 Oil-red-O binding in Chang liver cells cultured in MCBD supplemented 
with 0.1μM insulin and 1mM fructose and the effect of plant extracts, 
metformin, ciglitazone and ciprofibrate on Oil-red-O binding.  
Chang liver cells were incubated in MCBD, MCBD-201 medium with 0.1μM insulin and 1mM 
fructose (MIF), MIF+plant extract 1 (MIF+P1), MIF+plant extract 2 (MIF+P2), MIF+metformin 
(MIF+Met), MIF+ciprofibrate (MIF+Cipro), or MIF+ciglitazone (MIF+Ciglit) for 48 hours. After 48 
hour exposure cells were stained for 90 minutes with the diluted and filtered Oil-red-O working 
solution prepared. Excess dye was washed of with tap water and, the plates were left to dry 
completely. The dye was then extracted with isopropanol and absorbance read at 540nm. Data 
are shown of one representative experiment from three experiments. Cell numbers were 
determined in representative wells for each treatment used for normalization to eliminate variation 
due to varying cell numbers. Bars and error bars represent the mean ± SD of 12 replicate wells for 
all analyzed conditions. (***p=0.0006) 
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Figure 3.8 Nile Red fluorescence in Chang liver cells cultured in MCBD 
supplemented with 0.1μM insulin and 1mM fructose and the effect of 
plant extracts, metformin, ciglitazone and ciprofibrate.  
Chang liver cells were incubated in MCBD, MCBD-201 medium with 0.1μM insulin and 1mM 
fructose (MIF), MIF+plant extract 1 (MIF+P1), MIF+plant extract 2 (MIF+P2), MIF+metformin 
(MIF+Met), MIF+ciprofibrate (MIF+Cipro), or MIF+ciglitazone (MIF+Ciglit) for 48 hours. 
Fluorescence of bound Nile Red was determined. Data are shown of one representative 
experiment from three experiments. Cell numbers were determined with crystal violet staining and 
used for normalization to eliminate variation due to varying cell numbers. Bars and error bars 
represent the mean ± SD of 12 replicate wells for all analyzed conditions. (***p=0.0006).  
One of the main objectives of the present study was to develop a model of insulin 
resistance in the Chang liver cell line. Exposing Chang liver cells to excess 
amounts of fructose and insulin in the MCBD-201 medium caused these cells to 
take up less glucose, and accumulate more fat compared to cells cultured in 
MCBD-201 medium only. Reduced glucose uptake and fat accumulation are 
characteristics of the insulin resistant state. The two S. frutescens plant extracts 
tested and the known anti-diabetic drugs, metformin and ciglitazone increased 
glucose uptake and reduced lipid accumulation in cells. In the next chapter the 
expression of transcription factors regulating lipid and glucose metabolism in the 
liver is investigated, to determine the mechanism of action of this reduced lipid 
accumulation and increased glucose uptake seen in the presence of the two S. 
frutescens plant extracts, metformin and ciglitazone.  
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CHAPTER 4:  QUANTITATIVE REAL-TIME POLYMERASE CHAIN 
REACTION: MULTIPLEXING VERSUS SINGLEPLEXING  
Gene-expression analysis is becoming increasingly important, as understanding 
patterns of expressed genes is expected to provide insight into complex 
regulatory networks (Vandesompele et al., 2002). The quantitative real time 
reverse transcription polymerase chain reaction (qRT-PCR) has developed into 
an important tool for performing accurate and reproducible gene expression 
profiling experiments (Bustin & Nolan, 2004). However, there are also a number 
of problems and pitfalls involved in this method (Bustin & Nolan, 2004), which will 
be discussed in greater detail in Chapter 5. In this chapter the basic principles of 
the technique and the advantages and disadvantages of singleplex compared to 
multiplex reactions are discussed. 
In the qRT-PCR technique data are collected throughout the PCR process as it 
occurs in real time (Wong & Medrano, 2005). This is achieved using a variety of 
different fluorescent chemistries and instrumentation that correlate PCR product 
concentration to fluorescence intensity. Fluorescence is recorded during every 
cycle. 
 
The point in time or PCR cycle where the target amplification is first detected as 
statistically significantly above background is referred to as the cycle threshold 
(Ct) (Bustin, 2000). The greater the quantity of target DNA in the starting material, 
the faster a significant increase in fluorescent signal will appear, yielding a lower 
Ct-value (Bustin, 2000).  
4.1 SPECIFIC AND NON-SPECIFIC CHEMISTRIES 
The detection chemistries of all qRT-PCR procedures are based on one of two 
principles for monitoring amplification products: sequence-independent binding to 
double-stranded (ds) DNA or sequence-specific hybridization to single-stranded 
(ss) DNA (Rickert et al., 2004). Small molecules bind to dsDNA either as 
intercalators e.g., ethidium bromide (Higuchi et al.,1992) or as minor groove 
binders, e.g., SYBR Green I (Morrison et al., 1998). As dsDNA accumulates 
 72 
72 
during cycling more dye can bind and emit fluorescence, thus the fluorescence 
intensity increases proportionally to the dsDNA concentration. The primary 
concern with using sequence-independent dsDNA binding dyes is specificity 
(Bustin, 2000; Valasek & Repa, 2005; Wong & Medrano, 2005).  
Specific detection is possible with template-specific custom made fluorescent 
labeled probes for each target gene (Bustin & Nolan, 2004).  Most of the specific 
fluorescent reporting chemistries utilize fluorescent resonance energy transfer 
(FRET) or similar interactions between donor and quencher molecules as the 
basis of detection (Bustin & Nolan, 2004). FRET is a quantum phenomenon 
occurring between two dye molecules, where excitation is transferred from a 
donor to an acceptor fluorophore resulting in the donor‟s fluorescence being 
quenched and the acceptor being excited (Didenko, 2001). The intensity of the 
donor‟s fluorescence decreases and the intensity of the acceptor‟s fluorescence 
increases (Didenko, 2001). Several types of probes exist, each with its own 
unique characteristics including hydrolysis probes, hybridization probes, 
molecular beacons, sunrise primers and scorpion primers, to name a few.  
Hydrolysis probes are sequence specific dually fluorophore-labeled DNA 
oligonucleotides, with one fluorophore named the quencher and the other the 
reporter. When the probe is intact the quencher reduces the reporter fluorescence 
intensity by FRET (Livak et al., 1995; Heid et al., 1996; Houghton & Cockerill, 
2006). When annealed to the target sequence, the bound and quenched probe 
will be degraded by the DNA polymerase‟s 5′ nuclease ability during the 
extension step of the PCR. Probe degradation or hydrolysis allows for separation 
of the reporter from the quencher dye, resulting in increased fluorescence 
emission of reporter which corresponds to the specific amplification of DNA (Livak 
et al., 1995; Heid et al., 1996; Houghton & Cockerill, 2006).  
Hybridization probes also rely on FRET to alter the intensity of fluorescence 
emission; however the energy transfer works in an opposite manner as compared 
to hydrolysis probes. FRET reduces fluorescence intensity in hydrolysis probes 
and increases intensity in hybridization probes (Wong & Medrano, 2005).  
Molecular beacons, sunrise primers, and scorpion primers keep the reporter and 
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quencher together before amplification while separating them and generating the 
fluorescence signal during amplification (Valazek & Repa, 2005; Kubista et al., 
2006). Peptide nucleic acid containing thiazole orange fluorophores (called light-
up probes) also emits greater signal upon binding of DNA. Many other specific 
and nonspecific chemistries exist and new fluorescent chemistries are continually 
developed with a focus on increasing sensitivity and specificity (Valazek & Repa, 
2005).  
The choice of detection chemistry is highly dependent on the experimental 
design. Non-specific detection using intercalating dyes such as SYBR Green that 
bind any dsDNA have two advantages over probe-based ones: (1) they can be 
incorporated into optimized and long-established protocols simply by adding the 
dye as a reagent to the PCR cocktail of standard reactions; (2) they are 
significantly cheaper, as there is no probe-associated cost (Bustin & Nolan, 
2004). Disadvantages include their indiscriminate binding to any dsDNA, which 
can result in fluorescence readings in the “no template controls” (NTC) due to dye 
molecules binding to primer dimers. This can be minimized by using separate RT 
and PCR steps. This problem can also be addressed by using software capable 
of melting curve analysis (Bustin, 2000). This method makes use of plotting 
fluorescence as a function of temperature to generate a melting curve. This is 
done by slowly increasing the temperature above the melting temperature (Tm) of 
the amplicon and measuring the fluorescence. A characteristic melting peak at 
the Tm of the amplicon will distinguish it from the shorter primer-dimers that melt 
at lower temperatures in broader peaks (Bustin, 2000). Another drawback is that 
the fluorescent signal generated is dependent on the mass of dsDNA because 
multiple dye molecules bind to a single amplified molecule. Assuming the same 
amplification efficiencies, amplification of a longer product will generate more 
signal than a shorter one. If amplification efficiencies are different, quantification 
will be inaccurate. This is in contrast to fluorogenic probes in which the signal 
from a single fluorophore is observed for each amplified molecule synthesized 
regardless of its length (Bustin & Nolan, 2004). 
The main advantage of specific detection chemistries is that specificity no longer 
resides in the primers as with non-specific binding dyes; instead, the use of a 
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probe introduces an additional level of specificity (Bustin & Nolan, 2004). Non-
specific amplification due to mispriming or primer–dimer artifacts does not 
generate a signal and is ignored by the fluorescence detector. However the 
absence of detection does not mean the absence of artifacts or non-specific 
amplification that can affect amplification efficiency and any subsequent 
quantification. Thus a major disadvantage has arisen from this specificity: artifacts 
that can interfere with amplification efficiency cannot be detected. Another 
advantage of specific detection is that these probes can be differentially labeled 
with distinguishable fluorescent dyes that allow the detection of amplification 
products from several distinct sequences in a single PCR reaction (multiplex). 
This is not possible with binding dyes. A disadvantage is the cost associated with 
these chemistries as each target requires a unique probe or modified primer 
(Bustin & Nolan, 2004; Rickert et al., 2004). 
In summary, binding dyes can only be used for monoplex reactions as the dyes 
bind in a non-specific manner to any dsDNA. Whereas probe-based chemistries 
can be used for monoplex and multiplex reactions as the probes only bind to 
specific amplicons and probe design for different amplicons can allow the 
detection of several different amplicon products in the same reaction. In the 
present study both non-specific and specific detection chemistries are used. In 
this chapter multiplex reactions are described which used differentially labeled 
fluorescent primers.  
The Multiplex qRT-PCR performed in the present study was performed using the 
PlexorTM Two-Step qRT-PCR system. The PlexorTM Two-Step qRT-PCR system 
takes advantage of the specific interaction between two modified nucleotides to 
achieve quantitative RT-PCR analysis (PlexorTM Two-Step qRT-PCR system 
Technical Manual). One of the primers contains a modified nucleotide (iso-dC) 
linked to a fluorescent label at the 5‟ end (Figure 4.1). The other primer is 
unlabelled. The reaction mix includes deoxynucleotides and iso-dGTP modified 
with the quencher dabcyl. Dabcyl-iso-dGTP is incorporated opposite the iso-dC 
residue in the primer. The incorporation of the dabcyl-iso-dGTP at this position 
results in quenching of the fluorescent dye on the complementary strand and a 
reduction in fluorescence, which allows quantitation during amplification. With the 
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PlexorTM Two-Step qRT-PCR system, the accumulation of product is 
accompanied by a decrease in fluorescence (PlexorTM Two-Step qRT-PCR 
system Technical Manual) (Figure 4.1). 
 
Figure 4.1 Schematic diagram illustrating the Plexor
TM
 System real-time PCR 
process.  
The incorporation of the dabcyl-iso-dGTP results in quenching of the fluorescent dye on the 
complementary strand and a reduction in fluorescence. The accumulation of product is 
accompanied by a decrease in fluorescence 
(Figure taken from Plexor
TM
 Two-Step qRT-PCR system Technical Manual). 
4.2 QUANTITATION 
To evaluate gene expression RNA must first be isolated from the samples. After 
isolation RNA is linearly converted to cDNA, which can be used in qRT-PCR 
(Bustin & Nolan, 2004; Valasek & Repa, 2005). The reverse transcription (RT) 
reaction and the PCR reaction can be performed in a one-step reaction where the 
entire reaction from cDNA synthesis to PCR amplification is performed in a single 
tube, or a two-step reaction where the RT and PCR amplification occur in 
Iso-
dGTP 
Flourescent Reporter 
iso-dC 
Taq 
Taq 
Primer Annealing and Extension 
Dabcyl 
Incorporation of Dabcyl-iso-dGTP 
Fluorescence Quenching 
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separate tubes (Bustin, 2000). In all of the experiments described in this thesis, 
the two step reaction was performed.  
Amplification curves are generated from the PCR reactions to determine the Ct-
value, which is inversely proportional to the amount of specific nucleic acid 
sequence in the original sample (Valasek & Repa, 2005).  The amount of PCR 
template can be determined in two ways: (1) Relative quantification; (2) Absolute 
quantification (Wong & Medrano, 2005). Relative quantitation measures changes 
in the steady-state levels of a gene of interest relative to an invariate control gene 
(Valasek & Repa, 2005). Absolute quantitation requires a sample of known 
quantity (copy number) of the gene of interest that can be diluted to generate a 
standard curve. Unknown samples are compared with the standard curve for 
absolute quantitation (Valasek & Repa, 2005). The PCR standard is a fragment of 
dsDNA, ssDNA or cRNA (RNA derived from cDNA) bearing the target sequence 
(Wong & Medrano, 2005). DNA standards have a larger quantification range, 
greater sensitivity, reproducibility and stability than RNA standards; however DNA 
standards cannot be used for one-step qRT-PCR due to the absence of a control 
for the reverse transcription efficiency (Wong & Medrano, 2005). 
Although absolute quantification seems more appealing because exact copy 
number can be determined, it is also more labor intensive because of the 
necessity to generate stable and reliable standards which need to be precisely 
quantified (Peirson et al., 2003). Peirson et al (2003) have developed a 
mathematical model to calculate amplification efficiency. To test the validity of 
their method they used both absolute and relative approaches to qRT-PCR. They 
demonstrated that absolute (copy number) and relative (fold change) approaches 
to qRT-PCR produce very similar results. Pfaffl (2001) also concluded that a 
relative expression ratio is adequate for most purposes in the investigation of 
physiological changes in gene expression. The relative approach to quantification 
of qRT-PCR was taken in the present study. Relative expression is strongly 
dependent on the control or reference genes and the normalization procedure 
used. Several variables need to be controlled in gene expression analysis, 
including amount of starting material, enzymatic efficiency, and differences 
between tissues or cells in overall transcription activity (Vandesompele et al., 
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2002). Various strategies have been applied to normalize these variations 
however, to date, internal control genes are most frequently used to normalize the 
mRNA fraction. The internal control gene often referred to as a housekeeping 
gene or reference gene, should not vary in the tissues or cells under 
investigations or in response to experimental treatment. Normalization 
procedures will be discussed in greater detail in Chapter 5.  
4.3 MULTIPLEX REACTIONS 
Multiplex reactions using differentially labeled fluorescent primers were used to 
analyze the gene expression profile of PPARα and SREBP over time in the 
presence of two reference genes β-Actin and TATA box binding protein 
(TATABP).  
 Muliplex qRT-PCR is a greater challenge than singleplex qRT-PCR, but in the 
study by Persson et al., (2005) a multiplex optimization method is described. 
They suggest that in optimizing a multiplex qRT-PCR assay the performance of 
the individual primer sets must first be verified with SYBR Green. Once the primer 
pair has shown a single peak in SYBR Green melting curves, or a single band on 
agarose gels and a PCR efficiency of greater than 92% the probes can be 
designed and synthesized. The next step is to evaluate the performance of the 
primer-probe set using a fivefold serial dilution of template cDNA concentration 
spanning over at least three orders of magnitude. Ideally the PCR efficiency for 
the dilution series should be 100%, but a PCR efficiency of 92-102% is 
acceptable. The success of the multiplex optimization is measured by analyzing 
in parallel the performance of both singleplex and multiplex assays. If multiplex 
and singleplex assays performed simultaneously on the same plate produce 
similar Ct-values for the amplification of a particular gene, the multiplex reaction is 
successful. Ct differences of 0.5 cycles between single and multiplex data are 
acceptable. In addition successful multiplex assays can only be achieved when 
the exponential phase of the multiplex reaction can be superimposed over that of 
the singleplex reactions, i.e both single and multiplex reaction amplify with near 
identical efficiency (Persson et al., 2005). 
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4.4 MATERIALS AND METHODS 
4.4.1 Optimizing for Multiplex reactions 
4.4.1.1 RNA extraction  
Cells were seeded in six 10cm diameter cell culture dishes at 2x105 cells/plate in 
RPMI 1640: 10%FCS and grown to 70-80% confluence after which the growth 
medium was replaced with fresh RPMI 1640:10% FCS. After 48 hours the growth 
medium was removed and cells were washed twice with PBSA (Sigma, UK) 
before RNA was extracted using an RNeasy Mini Kit (Qiagen, Germany). A 
volume of 1ml trizol lysis buffer, contained in the extraction kit, was added to 
three dishes (330μl/dish) of Chang liver cells cultured for 48 hours with RPMI 
1640: 10%FCS. A cell scraper was used to loosen the cells off the plate, and the 
scraped cells were then transferred to a sterile 2ml eppendorf capped tube. Cells 
pooled from three plates were homogenised with a 2ml syringe and 21 gauge 
needle for one minute, and the standard RNA extraction protocol, including 
DNase treatment, as indicated by the manufacturer was followed. Total RNA was 
eluted from the columns in 40μl of sterile RNase-, DNase-free water. Total RNA 
concentration was calculated by determining absorbance (A) at 260nm and 
protein contamination was monitored by A260/280 ratio. The integrity of RNA was 
assessed by denaturing agarose gel stained with ethidium bromide (Sigma, UK). 
RNA is very easily degraded by endogenous RNases, so treatment with 
diethylpyrocarbonate (DEPC) (Sigma, UK) was used to destroy RNases. All 
solutions used in the analysis of RNA were prepared in DEPC-treated water 
(0.1% DEPC in water stored overnight at 37°C and autoclaved at 15Lb for a 
minimum of 15 minutes). 
In order to run a denaturing agarose gel the following solutions were prepared: 
Five times 3-(N-morpholino) propanesulfonic acid (MOPS) gel buffer; Ten times 
Gel loading buffer; 1.5% Agarose in DEPC treated water. The five times MOPS 
buffer [0.1M MOPS (pH 7), 40mM sodium acetate; 5mM EDTA (pH 8)] was 
prepared and stored at 4°C in a dark container. The ten times gel loading buffer 
[50% glycerol, 1mM EDTA (pH 8), 0.125% bromo phenol blue, 0.125% Xylene 
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cyanol FF] was prepared and stored at room temperature. The 1.5% agarose gel 
was prepared by adding 50ml DEPC water to 0.75g agarose, and boiling in a 
microwave to dissolve. The agarose was cooled to 60°C before use. The 
denaturing agarose gel was prepared by mixing 35ml of the 1.5% prepared 
agarose gel, 10ml 37% formaldehyde, 11ml 5XMOPS buffer, 5μl of a 10mg/ml 
ethidium bromide stock solution in a fume hood. The gel was mixed gently by 
swirling and poured in a pre-cleaned gel plate and allowed to set for 30 minutes. 
Plates were cleaned with RNAzap (Ambion, USA), and rinsed with DEPC water. 
Samples were prepared by adding 200ng RNA to 2μl 5XMOPS, 3.5μl 37% 
formaldehyde and 10μl formamide. Prepared samples were incubated at 65°C for 
15 minutes, chilled on ice, pulse spun down, and 2μl 10X gel loading dye added 
followed by a further spin in a microfuge for 10 seconds. Samples were loaded on 
the prepared gel and run in 1XMOPS buffer at 100V for one hour. The gel was 
viewed and photographed under a UV transilluminator.  
4.4.1.2 Reverse transcription      
The multiplex qRT-PCR was performed using the PlexorTM Two-Step qRT-PCR 
system (Promega, USA). Thus the RT step and the PCR step are performed as 
separate reactions. cDNA was prepared from 1μg RNA using oligo(dT) primers in 
a 20μl reaction volume. A negative control sample was included in which the 
template RNA was substituted with MOPS/EDTA buffer (included in PlexorTM 
Two-Step qRT-PCR kit), this is called the no template control (NTC) (Table 4.1). 
A positive control to verify that reagents and instrumentation perform consistently 
was also included. The 1.2Kb Kanamycin RNA (included in the PlexorTM Two-
Step qRT-PCR system), served as a positive cDNA synthesis control template. 
To test for inhibitors in the experimental RNA preparation, experimental RNA was 
added to the positive control RNA and cDNA synthesized using oligo(dT) primers. 
The final control was the no reverse transcriptase control (no-RTC), where 
reverse transcriptase was omitted to test the experimental RNA sample for the 
presence of DNA or amplicon contamination (Table 4.1).  The experimental RNA 
(1μg), or the RNA of the various control samples respectively, was mixed with 
oligo(dT) primers in MOPS/EDTA buffer in a final volume of 5μl per reverse 
transcrition reaction and placed in a preheated 70°C heat block for five minutes 
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(Table 4.1). After the reverse transcription reaction the samples were chilled 
immediately for five minutes on ice and spun down for ten seconds in a 
microfuge.  
Table 4:1 Preparation of RNA for RT Reaction 
Components 
Experimental 
RNA 
Positive 
Control 
RNA 
No 
Template 
control 
Inhibitor 
Control 
RNA 
RNA (1μg/reaction) xμl - - xμl 
1.2kb Kanamycin Positive 
Control RNA 
- 2μl - 2μl 
Oligo(dT) primers 1μl 1μl 1μl 1μl 
MOPS/EDTA Buffer To 5μl 2μl 4μl To 5μl 
The RT reaction mix was prepared by combining 4μl ImProm-IITM 5X reaction 
buffer, 1.6μl 25mM MgCl2, 1μl dNTP mix, 10mM of each dNTP, 0.5μl RNasin
® 
Plus ribonuclease inhibitor and 1μl ImProm-IITM reverse transcriptase in a final 
volume of 15μl (Table 4.2). The RT reaction mix was then gently mixed and kept 
on ice before it was dispensed into the individual reactions of prepared 
experimental RNA or control sample mixed with oligo(dT) primers in MOPS/EDTA 
buffer. The no-RTC mix was prepared in the same manner as the RT reaction mix 
with the omission of 1μl ImProm-IITM reverse transcriptase and added to the 
experimental RNA mixed with oligo(dT) primers in MOPS/EDTA buffer. The 
reaction was annealed at 25°C for five minutes, extended at 45°C for 45 minutes, 
and the reverse transcriptase was inactivated at 70°C for 15 minutes.   
Table 4:2 Preparation of the RT Reaction Mix  
Component RT Reaction Mix 
No - RT Reaction 
Mix 
Nuclease-free Water (to final volume of 15 μl) x μl x μl 
ImProm-IITM 5X Reaction Buffer 4μl 4μl 
MgCl2 25mM 1.6μl 1.6μl 
dNTP Mix, 10mM each dNTP 1μl 1μl 
RNasin®Plus Ribonuclease Inhibitor 0.5μl 0.5μl 
ImProm-IITM Reverse Transcriptase 1μl - 
Final Volume 15μl 15μl 
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4.4.1.3 Primer Design and Primer preparation 
Primers were designed using the PlexorTM Primer Design Software. The software 
assists in selecting the appropriate fluorescent labels for the primers used in 
single and multiplex qRT-PCR assays, and matches the fluorescent reporter to 
the specific real-time instrument used, Bio-rad iCycler (Bio-rad, UK) in the present 
study. Fluorescently labelled oligonucleotides for use as primers with the PlexorTM 
System assays must be synthesized with an iso-dC residue adjacent to the 5‟ 
fluorescent label. Multiplex primers were designed for PPARα, SREBP-1, and 
TATA binding protein (TATABP) (Table 4.3). The sequence of the reference gene 
incorporated into the PlexorTM Primer Design Software, β-Actin was also included 
in the multiplex primer design. The primers were obtained from a licensed 
oligonucleotide supplier (Integrated DNA Technologies, Inc, SA). 
Iso-dC –containing primers are sensitive to pH and must be resuspended and diluted 
in MOPS/EDTA buffer to maintain primer integrity. The fluorescently labelled primers 
are light-sensitive and must be stored in the dark. Lyophilized primers were pulse 
spun down and reconstituted in MOPS-EDTA buffer to prepare a 100μM stock 
solution. Before use, a primer pair mix containing a final concentration of 5μM of 
sense and 5μM antisense primer was prepared with MOPS/EDTA buffer as a 
working solution.  
4.4.1.4 Multiplex qRT-PCR 
The first step in optimizing a multiplex reaction is to optimize the primer 
concentration for each gene. A starting primer concentration of 200nM (1μl of 
working primer pair mix) was used in a 25μl total reaction volume. Depending on 
the outcome of the PCR reaction, lower primer concentrations could be used if 
primer dimers were present or higher concentrations if low copy numbers were 
detected. A primer concentration of 200nM was optimum for most reactions if, 
however this concentration was not effective, primer concentration ranging 
between 100-500nM was tested.  
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Table 4:3   Fluorescently labelled multiplex primers designed with Plexor
TM
 Primer 
Design Software 
 
The prepared cDNAs of experimental or control samples were diluted 1:5 with 
MOPS/EDTA buffer. Sufficient PCR reaction mix for the desired number of 
reactions was prepared containing 12.5 μl of PlexorTM master mix, 1μl primer pair  
mix made up to a final volume of 20μl per sample. For each of the control 
samples and the experimental sample 20μl of the bulk prepared PCR reaction 
mix was aliquoted into an eppendorf and to each aliquot, 5μl of the 1:5 diluted 
cDNA was added. Care was taken not to cross contaminate the respective 
cDNAs and plugged tips were used. Each reaction was performed in duplicate. 
The PCR reaction was carried out in the Bio-rad iCycler and the amplification 
conditions used were: initial three minute enzyme activation at 95°C, followed by 
40 cycles consisting of denaturation at 95°C for 30 seconds, annealing at 56°C 
for 30 seconds and elongation at 72°C for 30 seconds. After the amplification, a 
melt curve analysis was performed. A melt curve is generated by heating the 
 
Accession 
number 
Primer Sequence (5’→3’) 
Amplicon 
Size (bp) 
Region 
of Gene 
(nt) 
PPARα 
 
NM_005036 
5‟-FAM
TM
-iso-dC 
CTCTTAGAAGTACTGGTTAAAACAAAGATATG
GAATAATATG-3‟ 
5‟CAAATATCCACCACTTTAACCTTAGAGCTTG-
3‟ 
98 bp 
 
1759-
1857 
TATABP BT019657 
5‟-HEX
TM
-iso-dC- 
ATAAGGCATCATTGGACTAAAGATAGGGA-3‟ 
5‟GAACAACAGCCTGCCACCTTAC-3‟ 
94 bp 9-103 
SREBP-1 NM_004176 
5‟AACAGCCCATTGAGCAGCCAGA-3‟ 
5‟-TexasRed®-iso-dC- 
CCAGCGTCTACCATACCATAGCCCTG-3‟ 
112 bp 
1750-
1862 
β-Actin  Plexor Human β-actin Primer Set, Cy5   
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PCR product to the annealing temperature and then increasing the temperature in 
0.5°C increments up to 95°C, for eight seconds at each increment. 
After the optimum primer concentration was determined the next step was to 
establish the PCR efficiency for each gene analyzed. A standard curve was 
generated using four dilutions in a five fold serial dilution of template cDNA, 
starting at 50ng per 25μl PCR reaction. Theoretically from 1μg of RNA 1μg of 
cDNA can be synthesized. Absolute cDNA concentration was not determined, but 
was based on maximum capacity of cDNA synthesis. Thus the concentration of 
1μg of cDNA in the 20μl reaction volume of the reverse transcribed reaction is 
50ng/μl. cDNA was diluted 1:5 and 5μl of the diluted cDNA was used in the PCR 
reaction. 
If the amplification of each of the target genes analyzed in singleplex showed a 
single peak with the meltcurve analyses and a PCR efficiency of between 92-
102% it was ready to be multiplexed. First duplex reactions were performed, 
where two combinations of the primer pairs analyzed (PPARα, TATABP, SREBP-
1 and β-Actin) were included in the reaction mix, with subsequent adjustment of 
the amount of nuclease free water added in the reaction. Given the four genes, 
six combinations of duplex reactions were performed. A singleplex reaction of 
each of the genes analyzed was included in the duplex assay. If the duplex assay 
was successful, triplex and four way multiplex reactions were performed. In each 
case a singleplex reaction for each target gene was run in parallel. 
4.4.2 Analyzing Experimental Samples 
After the multiplex reactions were optimized using RNA extracted from Chang 
liver cells cultured under normal growth conditions, RNA was extracted from 
experimental samples. Experimental samples were prepared by seeding Chang 
liver cells in 10cm diameter cell culture dishes at 2x105 cells/plate in RPMI 1640: 
10%FCS medium and grown to 70-80% confluence. At confluence RPMI 1640: 
10%FCS medium was replaced with one of the following media: RPMI 1640: 
10%FCS; MCBD-201; MCBD-201+0.1μM insulin and 1mM fructose (MIF); 
MIF+Plant extract 1 (MIF+P1); MIF+Plant extract 2 (MIF+P2) and MIF 
+Ciglitazone (MIF+Ciglit) Table 4.4 shows the culture conditions for each of the 
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six experimental samples analyzed.  
Table 4:4  Culture conditions for Chang liver cells used for qRT-PCR  
Medium Insulin Fructose 
Plant extracts or anti-
diabetic agent added 
Abreviation 
RPMI 1640     RPMI 
MCBD-201     MCBD 
MCBD -201 medium  0.1μM  1mM   MIF 
MCBD -201 medium  0.1μM  1mM  Plant extract 1(12.5μg/ml) MIF+P1 
MCBD -201 medium  0.1μM  1mM  Plant extract 2(12.5μg/ml) MIF+P2 
MCBD -201 medium  0.1μM  1mM  Ciglitazone (1μM) MIF+Ciglit 
Sufficient culture plates (60, 10cm diameter cell culture plates) were set up with 
Chang liver cells grown under normal growth conditions at the beginning of the 
experiment to allow for replacement with the six different experimental medium 
conditions at confluence as indicated in Table 4.4. RNA was extracted at four 
different time points for each of the experimental medium conditions. RNA 
extraction was performed after 2, 6, 24 and 48 hours of exposure to the different 
medium conditions indicated in Table 4.5. At the two and six hour time points 
three 10cm diameter plates were pooled for each experimental sample. At the 24 
and 48 hour time points two plates were pooled for each experimental sample, 
because these cultures contain more cells. RNA was extracted using the RNeasy 
Mini Kit (Qiagen, Germany) as described in section 4.4.1.1.  
The yield and quality of the extracted RNA was assessed with RNA 6000 Nano 
chips in the Agilent 2100 Bioanalyer. The Agilent 2100 Bioanalyzer uses a 
fluorescent assay involving electrophoretic separation to evaluate RNA samples 
qualitatively and quantitatively. The amount of fluorescence is measured as the 
RNA sample is pulsed through a microchannel and the Agilent Bioanalyzer 
software creates an electropherogram. The electropherogram is a diagram 
showing the fluorescence changes over time. For each sample the software 
creates a gel image to accompany the graph. It also displays the sample 
concentration and the ratios of the 18S and 28S ribosomal subunits.   
 
 85 
85 
 
Table 4:5 Layout of Sequence of Experimental Samples preparation 
2 Hours 
Pool Chang liver 
cells from three 
culture dishes for 
each medium 
condition.  
6 Hours 
Pool Chang liver 
cells from three 
culture dishes for 
each medium 
condition.  
24 Hours 
Pool Chang liver 
cells from two culture 
dishes for each 
medium condition.  
48 Hours 
Pool Chang liver 
cells from two culture 
dishes for each 
medium condition.  
RPMI RPMI RPMI RPMI 
MCBD  MCBD MCBD MCBD 
MIF MIF MIF MIF 
MIF+P1 MIF+P1 MIF+P1 MIF+P1 
MIF+ P2 MIF+ P2 MIF+ P2 MIF+ P2 
MIF+Ciglit MIF+Ciglit MIF+Ciglit MIF+Ciglit 
↓ ↓ ↓ ↓ 
Extract RNA 
↓ ↓ ↓ ↓ 
Determine RNA Yield and Quality 
↓ ↓ ↓ ↓ 
Synthesized  cDNA from 1μg of total RNA for each experimental sample 
↓ ↓ ↓ ↓ 
Perform Multiplex qRT-PCR 
In order to standardize the process of RNA integrity interpretation, Agilent 
Technologies has developed the RNA Integrity Number (RIN) to remove 
individual interpretation in RNA quality control. RIN is based on a software 
algorithm that works with the Agilent 2100 Bioanalyzer and the RNA 6000 
LabChip kit. The algorithm was developed from a large database of eukaryote 
total RNA samples (mainly human, mouse and rat) to enable the classification of 
eukaryotic total RNA, based on a numbering system from one to ten, with one 
being the most degraded profile and ten being the most intact. In the present 
study only samples with a RIN value greater than eight were used. 
cDNA was synthesized from 1μg of total RNA using the ImProm-IITM Reverse 
Transcriptase (Promega) following the manufacturers protocol as described in 
section 4.4.1.1 and 4.4.1.2. Multiplex qRT-PCR was performed with experimental 
samples using the optimized method. 
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4.4.3 Data Analysis 
The key to the PlexorTM technology is the quenching of a fluorescent reporter due 
to the site specific incorporation of dabcyl-iso-dGTP. As a result, the fluorescent 
signal from a PlexorTM System reaction decreases as PCR products accumulate. 
The Bio-rad iCycler software can record the quenching data, but cannot convert 
the data into cycle thresholds or melt temperatures. To this end data was 
exported to the PlexorTM Analysis Software to generate the Ct-values and melt 
curve analysis. 
Data generated with qRT-PCR on the PlexorTM Analysis Software were then 
exported to Microsoft Office Excel, and converted to the format to be imported 
into to the RT-PCR analytical program qBase v1.3.1. Data were normalized and 
fold expression was calculated using this program. The Relative Expression 
Software Tool (REST) 2008 for group wise comparison and statistical analysis of 
relative expression results in qRT-PCR was used to determine statistical 
significance. 
The purpose of REST 2008 is to determine whether there is a significant 
difference between samples and controls, while taking into account issues such 
as reaction efficiency and reference gene normalization (Pfaffl et al., 2002; 
Vandersomple et al., 2002; Davidson & Hinkley, 2002). As normalization and 
efficiency calculations involve ratios and multiple sources of error, it is difficult to 
devise traditional statistical tests and so randomisation techniques are used 
instead by REST. A hypothesis test P(H1) is calculated, which represents the 
probability of the alternate hypothesis that the difference between sample and 
control groups is due only to chance. To calculate the P(H1) a large number of 
reallocations of samples and controls between the groups are performed and the 
number of times the relative expression of the randomly assigned group is greater 
than the sample data are counted. The P(H1) allows for a test of significance of 
the derived results (Pfaffl et al., 2002; Vandersomple et al., 2002; Davidson & 
Hinkley, 2002). 
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4.5 RESULTS AND DISCUSSION 
4.5.1 Multiplex optimizing 
4.5.1.1 RNA concentration and quality  
RNA extracted from Chang liver cells under normal growth conditions yielded a 
concentration of 1.32μg/μl and the OD260/280 ratio was 2.21, indicating a good 
yield and purity of the RNA extracted. Two discreet bands at the 28S and 18S 
position on the denaturing agarose gel also confirmed the integrity and quality of 
the RNA. 
4.5.1.2      Singleplex reaction 
The first step in the optimization of the multiplex qRT-PCR was to optimize the 
primer concentration for each gene analyzed. A singleplex reaction must be 
generated that shows a single amplification product with a single peak in the melt 
curve analysis of reactions in which template is included, and no amplification and 
no melt peak in the NTC. The starting primer concentration was 200nM and three 
of the four target genes analyzed (PPARα, TATABP and β-Actin) gave a single 
amplification product and melt peak at this concentration with no product 
formation or melt peak in the NTC (Figure 4.2-4.4). These targets did not need 
further optimization for their primer concentration. However primers amplifying the 
SREBP-1 target generated primer dimers in the NTC sample and needed further 
optimization (Figure 4.5). This reaction was repeated with primer concentrations 
ranging from 50nM-300nM. Primer dimers were present at all concentrations 
tested. In an effort to eliminate primer dimers, a temperature gradient qRT-PCR 
ranging from 58- 60°C annealing temperature was performed using a primer 
concentration of 100nM, but primer dimers were still present. Because a PCR 
mastermix was used, the only variables that could be manipulated were the 
primer concentration and the annealing temperature. Failure of these 
manipulations left two options; excluding this primer set from the multiplex 
reaction or redesigning primers. Multiplex primers are designed as a set of 
primers, thus redesigning means the other three primer pairs must also be 
redesigned. The Ct-values for SREBP-1 were approximately 25 when template 
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was present in the reaction mix and 32 in the NTC samples, thus there was a 
difference of seven cycles between the two Ct-values (Figure 4.5). Melt peaks 
with a lower Tm characteristic of primer dimers were present in the NTC and not 
in the reactions containing template, suggesting that primer dimers did not form 
when template was present. However this primer pair has the ability to form 
primer dimers, as is evident in the NTC sample, and could influence amplification 
in samples containing very little template. Therefore the analysis of this target 
was excluded from further analyses.       
 
Figure 4.2 Amplification and meltcurve graphs of singlex reaction for β-Actin sense 
primer was labeled with Cy5 fluorescent reporter.  
No amplification was detected in NTC samples (green and orange) and the amplification of the β-
Actin target generated an amplification product at Ct 22 with a single melt peak at Tm 87.5
0
C.     
 
Figure 4.3 Amplification and meltcurve graphs of singlex reaction for PPARα, sense 
primer was labeled with FAM fluorescent reporter.  
No amplification was detected in the NTC (green and orange) and the amplification of PPARα 
target generated an amplification product at Ct 27.5 with a single melt peak at Tm 76.5
0
C (blue 
and red) 
 89 
89 
 
 
Figure 4.4 Amplification and meltcurve graphs of singlex reaction for TATABP, 
sense primer was labeled with HEX fluorescent reporter.  
No amplification was detected in the NTC (green and orange) and the amplification of TATABP 
target generated an amplification product at Ct 26 with a single melt peak at Tm 82.5
0
C (blue and 
red) 
 
 
Figure 4.5 Amplification and meltcurve graphs of singlex reaction for SREBP-1, 
antisense primer was labeled with Texas Red fluorescent reporter  
An amplification product was detected in the NTC at a Ct of 32, which showed a melt peak at a 
Tm of approximately 76
0
C (green and orange). The sample generated an amplification product at 
Ct 25 with a single melt peak at Tm of 89
0
C (red and blue).   
 90 
90 
4.5.1.3 Standard Curves 
The second step in optimizing multiplex reactions is to determine the PCR 
amplification efficiency. Assuming that the amplification efficiency of a PCR 
reaction is ideal, an efficiency value of 1 or 100% means the PCR product 
concentration doubles during every cycle within the exponential phase of the 
reaction. However many PCR reactions do not have ideal amplification 
efficiencies. Traditionally, amplification efficiency of a reaction is calculated using 
data collected from a standard curve with the following formula: 
 E = (10[-1/slope]-1)*100.  
In the present study the traditional approach was used to calculate the PCR 
amplification efficiency. PCR amplification efficiency of 107.5% and 102,7% was 
generated for TATABP and PPARα respectively (Figure 4.6 and 4.7). β-Actin and 
SREBP generated very high PCR amplification efficiencies of 132.6% and 
208.6% (Figure 4.8 and 4.9). The high PCR amplification efficiency of SREBP-1 
could possibly be because of the presence of primer dimers seen in the monoplex 
reaction, and thus further contributed to the definitive exclusion of this primer pair 
from further analysis.  
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Figure 4.6  PPARα Standard curve.  
Concentration was based on maximum cDNA synthesis that generated 1μg cDNA from 1μg RNA 
in a 20μl reaction volume resulting in a theoretical concentration of 50ng/μl.  A standard curve was 
generated using four dilutions in a fivefold serial dilution of the template cDNA starting at 50ng 
cDNA per 25μl PCR reaction volume. PCR efficiency = 102.7% 
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Figure 4.7 TATABP Standard Curve.  
Concentration was based on maximum cDNA synthesis that generated 1μg cDNA from 1μg RNA 
in a 20μl reaction volume resulting in a theoretical concentration of 50ng/μl.  A standard curve was 
generated using four dilutions in a fivefold serial dilution of the template cDNA starting at 50ng 
cDNA per 25μl PCR reaction volume. PCR efficiency = 107.5% 
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Figure 4.8 β-Actin Standard Curve.  
Concentration was based on maximum cDNA synthesis that generated 1μg cDNA from 1μg RNA 
in a 20μl reaction volume resulting in a theoretical concentration of 50ng/μl.  A standard curve was 
generated using four dilutions in a fivefold serial dilution of the template cDNA starting at 50ng 
cDNA per 25μl PCR reaction volume. PCR efficiency 132.7%. 
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Figure 4.9  SREBP-1 Standard Curve.  
Concentration was based on maximum cDNA synthesis that generated 1μg cDNA from 1μg RNA 
in a 20μl reaction volume resulting in a theoretical concentration of 50ng/μl.  A standard curve was 
generated using four dilutions in a fivefold serial dilution of the template cDNA starting at 50ng 
cDNA per 25μl PCR reaction volume. PCR efficiency = 208% 
4.5.1.4 Duplex Assay 
Three duplex reactions were performed. Table 4.6 shows the combinations of the 
duplex reactions, showing the target gene and the fluorescent reporter attached.  
 Table 4:6 Combinations of the Duplex reactions 
 
 
 
In the duplex combinations PPARα-FAM + TATABP-HEX a mean Ct-value of 
29.1 was recorded for the FAM fluorescent reporter (PPARα) (Figure 4.10). The 
PPARα-FAM + β-Actin-Cy5 duplex recorded a mean Ct-value of 29.3 for the FAM 
fluorescent reporter (PPARα). In the singleplex reaction the PPARα target 
generated a mean Ct-value of   29.5. The Ct-values generated for the duplex and 
singleplex reaction were within 0.5 Ct-values apart as recommened and a single 
melt peak was recorded at a Tm of 76.50C for all the reactions (Figure 4.10). 
DUPLEX REACTIONS 
PPARα-Fam +TATA-Hex 
PPARα-Fam + β-Actin-Cy5 
TATA-Hex + β-Actin-Cy5 
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Figure 4.10 Amplification and meltcurve graphs of duplex reactions PPARα-FAM 
+TATABP-HEX and PPARα-FAM + β-Actin-Cy5 and singleplex reaction 
PPARα-FAM.  
Data for the fluorescent reporter FAM (PPARα) are shown in the figure.The duplex reaction in 
which PPARα and TATABP was amplified in one reaction (FAM+HEX Chang: Ct-values 28.9, 
29.3) are indicated in red. The duplex reaction in which PPARα and β-Actin was amplified in one 
reaction (FAM+CY5 Chang: Ct-values 29.5, 29.1) are indicated in blue. The singleplex reaction 
(FAM Chang: Ct-values 29.2, 29.8) are indicated in orange. A single meltpeak at 76.5°C was 
generated for singleplex and duplex reactions. No amplification products or melt peaks was 
detected in the NTCs.  
Analysis of the HEX fluorescent reporter (TATABP) for the combination of 
PPARα-FAM +TATA-HEX showed a single meltpeak at the correct Tm (Tm 
82.50C) with no amplification or melt peaks in the NTC (Figure 4.11). The 
difference between the mean Ct-values of the duplex and the singleplex reaction 
was smaller then 0.5. In the TATABP-HEX + β-Actin-Cy5 duplex an amplification 
product was formed in the NTC appearing at a Ct-value of between 34 and 35 
(Figure 4.11). This product formed a melt peak at a lower Tm suggesting primer 
dimer formation. The singleplex reaction of the target genes TATABP and β-Actin 
did not show any primer dimer formation (Figure 4.2, 4.4), however when these 
two targets were amplified together in one reaction, primer dimers were formed in 
the NTC; no primer dimers were formed when template was present in the 
reaction.  
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Figure 4.11 Amplification and meltcurve graphs of duplex reactions PPARα-FAM 
+TATA-HEX and TATABP-HEX+β-Actin-Cy5 singleplex reaction TATABP-
HEX.  
Data for the fluorescent reporter HEX (TATABP) are shown in the figure The duplex reaction in 
which TATABP and PPARα was amplified in one reaction (FAM+HEX Chang) showed an 
amplification product at the correct Tm with no products formed in the NTC. The duplex in which 
TATABP and β-Actin was amplified in the same reaction (HEX+Cy5 Chang) showed primer dimer 
formation in the NTC. The mean Ct-values of singleplex and duplex reaction were less then 0.5 
Ct-values apart.   
Analyzing the Cy5 fluorescent reporter (β-Actin) showed that the mean Ct-value 
difference between the singleplex reaction and the duplex reaction, (PPARα-FAM 
+ β-Actin-Cy5) was 0.8. The mean Ct-value difference between the singleplex 
reaction and the duplex reaction (TATABP-HEX + β-Actin-Cy5) was 0.25. Both 
duplex reactions showed no amplification products in the NTC (Figure 4.12). The 
meltcurve analysis showed two melt peaks for both the the duplex reactions. The 
Tm of the one melt peak of both duplex reactions corresponds to the Tm of the 
target (β-Actin) that was recorded with the Cy5 fluorescent reporter. The Tm of 
the duplex in which β-Actin and PPARα were amplified together was 
approximately 76.50C, thus similar to the Tm of PPARα. The Tm of the duplex in 
which β-Actin and TATABP were amplified together was approximately 82.50C, 
thus similar to the Tm of TATABP. This suggests that there was some bleed 
through of the HEX and FAM fluorphores into the Cy5 channel. To address this, 
new β-actin primers labeled with Calfluor with the same emission and excitation 
spectrum as Texas Red was used.  
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Figure 4.12 Amplification and meltcurve graphs of duplex reactions PPARα-FAM + β-
Actin-Cy5 TATA-HEX + β-Actin-Cy5 and singleplex reaction β-Actin-Cy5.  
Data for the fluorescent reporter CY5 (β-Actin) are shown in the figure Duplex reaction in PPARα 
and β-Actin was amplified together (FAM+CY5 Chang) indicated in blue. Duplex reaction in which 
TATABP β-Actin was amplified together (HEX+CY5 Chang) indicated in red. No amplification 
product was detected in NTC. The melt curve analysis showed two melt peaks for both duplex 
reactions.   
The duplex assay was repeated using β-Actin primers labeled with Calfluor. The 
Bio-rad iCyler was not calibrated for Calfluor, but because Calfluor has the same 
emission and excitation spectrum as Texas Red it was detected using the Texas 
Red filters in the assay. Labeling the β-Actin primers with a different fluorphore 
removed the bleed through seen previously (Figure 4.13).  
The primer dimer formed when β-Actin and TATABP were amplified together was 
addressed by replacing the β-Actin reference gene from Plexor with an alternative 
reference gene from Plexor (18SrRNA) labeled with Texas Red. The 18SrRNA 
gene is a high copy number gene and therefore was used at a primer 
concentration of 100nM instead of 200nM, as used for the other primers in the 
duplex assay. The 18SrRNA primer set labeled with Texas Red also led to primer 
dimer formation. A primer concentration of 50nM was also tested (Figure 4.14). 
The lower primer concentration also did not remove primer dimmers. However, 
this reference gene was included to perform the triplex reaction because there 
were a greater than 10 cycle difference between primer dimer formation and 
product formation. 
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Figure 4.13 Amplification and meltcurve graphs of duplex reactions PPARα-FAM + β-
Actin-TexasRed TATABP-HEX+β-Actin-TexasRed and singleplex reaction 
β-Actin-TexasRed.  
Data for the fluorescent reporter TexasRed (β-Actin). Duplex reactions in which PPARα and β-
Actin were amplified together indicated in red. Duplex reaction in which TATABP and β-Actin were 
amplified together indicated in pink. Singleplex reaction indicated in orange.      
 
   
Figure 4.14  Amplification and meltcurve graphs of duplex reaction TATABP-HEX + 
18SrRNA-TexasRed.  
Duplex reaction in which TATABP and 18SrRNA were amplified in one reaction. The 18SrRNA 
target was used at a primer concentration of 50nM. 
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4.5.1.5 Triplex Assay 
A triplex reaction in which all three targets (PPARα, TATABP and 18SrRNA) were 
amplified in a single reaction was performed.  Primer dimer formation, so prominent 
when the HEX fluorescent reporter (TATABP) was analyzed in the duplex assay, 
was absent in the triplex assay (Figure 4.15). The difference between mean Ct-
values generated with the singleplex and triplex reactions was less than 0.5 Ct-
values.  
The data generated with the FAM fluorescent reporter (PPARα) showed that the 
difference between the mean Ct-values generated with the singleplex reaction and 
the multiplex reaction was greater than one Ct-value. In the NTC traces of non-
specific amplification products are seen that appear after Ct 37 in the amplification 
cycle (Figure 4.16). These amplification products also showed a melt peak with a 
lower Tm as the target in the melt curve analysis.   
 
Figure 4.15 Triplex assay (PPARα-Fam + TATABP-Hex + 18sRNA-Texas Red) data 
show the fluorescent reporter Hex (TATABP) 
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Figure 4.16 Triplex assay (PPARα-Fam + TATABP-Hex + 18sRNA-Texas Red) data 
show the fluorescent reporter FAM (PPARα) 
 
The 18SrRNA target, primer pair was used at 100mM in the triplex reaction. The 
primer dimers seen in the NTC of the duplex reaction were also present in the triplex 
reaction (Figure 4.17). The difference in Ct-values between the singleplex and the 
triplex reactions was smaller than 0.5 Ct-values.  
 
Figure 4.17 Triplex assay (PPARα-Fam + TATABP-Hex + 18SrRNA-Texas Red) data 
show the fluorescent reporter TexasRed (18SrRNA). 
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Multiplex qRT-PCR is a greater challenge than singleplex. Although primer design 
is aimed to reduce the formation of non-specific amplification products by 
avoiding primer-primer interactions it cannot predict the performance of the primer 
pair in a multiplex reaction (Persson et al., 2005). Therefore primer pairs in a 
multiplex setup are empirically tested and a trial-and-error approach is used. In 
the current study primers were designed to perform a multiplex reaction in which 
four genes were amplified simultaneously. However one of the four genes 
(SREBP) showed primer dimers in the NTC in a singleplex reaction (Figure 4.5). 
Primer dimers were still present after various interventions to remove them, and 
the SREBP gene was subsequently excluded from further analysis.  
The other three genes were good candidates for multiplexing, as they each 
showed a single amplicon with a single melt peak, and no primer dimers in NTC. 
The duplex reaction in which PPARα and TATABP were amplified together was 
successful, because it generated similar Ct-values to the singleplex reaction, a 
single meltpeak in the reaction containing template and no meltpeaks in the NTC. 
The same was found for the duplex of PPARα and β-Actin, after the β-Actin 
fluorescent marker reporter was changed from Cy5 to Calfluor. However the 
duplex of TATABP and β-Actin was problematic as there seemed to be primer-
primer interactions that generated non-specific amplification products. Singleplex 
analysis of the two genes separately did not show these non-specific products, as 
seen in the duplex reactions. Exchanging the β-Actin gene for another Plexor 
housekeeping gene 18sRNA also did not remove these non-specific amplification 
products.   
Despite the non-specific amplification products formed in the duplex reactions, 
triplex assay was performed as these products formed at a late stage of the 
amplification cycles (after Ct 37),  and only appeared in NTC samples not in 
reactions containing template as is indicated by the appearance of only a single 
meltpeak in these samples. There was also a ten cycle difference in the 
appearance of the correct amplification product and the non-specific amplification 
product.   
The triplex assay showed similar Ct-values for singleplex and triplex reactions 
and a single meltpeak for all genes in reactions containing template. No non-
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specific amplification was found in the NTC of the TATABP gene, but non-specific 
amplification was present in the NTC of PPARα and 18sRNA in the triplex 
reaction.  
Multiplex proved to be a great challenge. It is crucial that all primer pairs used in 
the multiplex reaction should be designed together. The PCR amplification 
efficiency is also a good indication of a primer pair‟s ability to be used in a 
multiplex reaction. Given the results generated with the singleplex, duplex and 
triplex reaction and comparing the PCR amplification efficiencies it was decided 
to analyze all experimental samples in the present study using a duplex assay. 
4.5.1.6 Analysis of Experimental Samples 
The duplex in which PPARα and TATABP were amplified in the same tube was 
chosen, because (1) the PCR efficiencies generated were close to 100%; (2) 
singleplex reactions run in parallel to the duplex reactions gave similar Ct-values; 
(3) single meltpeaks were generated at the correct Tm in the meltcurve analyses 
of samples containing template; (4) no meltpeaks were formed in the NTC; and 
(5) the PCR efficiency generated with the duplex reaction was similar to the one‟s 
generate with the singleplex reaction. All experimental samples were analyzed 
using this duplex assay. Amplification and meltcurve graphs for experimental 
samples analyzed with the duplex assay are shown in Figure 4.18 and 4.19.  
Figures 4.20-4.24 show the fold normalized expression of PPARα after 2, 6, 24 
and 48 hours exposure of Chang liver cells to the different medium conditions 
specified in Table 4.4 and 4.5. The TATABP expression is shown on the same 
graph as the PPARα expression (Figure 4.20-4.24) and it was demonstrated that 
under the experimental conditions TATABP remained relatively stable.    
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Figure 4.18 Duplex reaction (PPARα-Fam + TATA-Hex) performed with experimental 
samples showing the Fam fluorescent reporter 
 
Figure 4.19 Duplex reaction (PPARα-Fam + TATA-Hex) performed with experimental 
samples showing the Hex fluorescent reporter 
Two hours after Chang liver cells were treated with insulin and fructose to induce 
insulin resistance, PPARα expression was decreased in cells cultured in MCBD-
201 medium supplemented with 0.1μM insulin and 1mM fructose (MIF) compared 
to cells cultured in MCBD-201 (Figure 4.20). Plant extract 1, plant extract 2 or 
ciglitazone in MIF medium significantly increased PPARα expression compared to 
the expression of Chang liver cells cultured in MIF only (P(H1)<0.0001) (Figure 
4.20).  
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Figure 4.20 The relative expression levels of PPARα and TATABP after 2 hours of 
exposure of Chang liver cells to insulin resistance inducing medium and 
the effect of the presence of plant extract 1 and 2 and ciglitazone in this 
medium on gene expression.  
Fold normalized relative expression is shown on the Y-axis, values are means ± SEM. Each 
sample was analyzed in duplicate and the experiment was repeated. MIF treatment decreased 
PPARα expression compared to control MCBD-201 treatment. MIF+P1, MIF+P2 or MIF+Ciglit 
treatment increased PPARα expression compared to MIF treatment only (***(P(H1))<0.0001).  
After six hours no significant difference in PPARα expression was detected 
between Chang liver cells cultured in MCBD-201 or MIF medium (Figure 4.21). 
The inclusion of plant extract 1, plant extract 2 and ciglitazone in MIF also did not 
significantly alter PPARα expression compared to exposure to MIF only (Figure 
4.21). 
After 24 hours of exposure of Chang liver cells to MIF medium, PPARα 
expression was significantly decreased compared to cells cultured in MCBD-201 
medium (Figure 4.22). Chang liver cells cultured in MIF medium supplemented 
with plant extract 1 showed a significant reduction in PPARα expression 
compared to cells grown in MIF medium only. MIF medium supplemented with 
plant extract 2 or ciglitazone did not lead to a change in PPARα expression 
compared to MIF treatment.  
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Figure 4.21 The relative expression levels of PPARα and TATABP after six hours of 
exposure of Chang liver cells to insulin resistance inducing medium and 
the effect of the presence of plant extract 1 and 2 and ciglitazone in this 
medium on gene expression.  
Fold normalized relative expression is shown on the Y-axis, values are means ± SEM. Each 
sample was analyzed in duplicate and experiment was repeated. Data are shown of one 
representative experiment.There were no significant difference in the PPARα expression between 
the different media conditions tested after six hours of exposure. 
 
Figure 4.22 The relative expression levels of PPARα and TATABP after 24 hours of 
exposure of Chang liver cells to insulin resistance inducing medium and 
the effect of the presence of plant extract 1 and 2 and ciglitazone in this 
medium on gene expression.  
Fold normalized relative expression is shown on the Y-axis, values are means ± SEM. Each 
sample was analyzed in duplicate and experiment was repeated. Data are shown of one 
representative experiment. PPARα expression was significantly decreased in Chang liver cells 
cultured in MIF medium compared to cells grown in MCBD-201 medium. MIF medium 
supplemented with plant extract 1 led to a further reduction in PPARα expression compared to 
MIF treatment only. (***P(H1)<0.0001) 
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Chang liver cells cultured in MIF for 48 hours showed a significant down-
regulation in PPARα expression compared to the cells exposed for the same time 
period to MCBD-201 medium (P(H1)<0.0001) (Figure 4.23). PPARα expression in 
Chang liver cells cultured in MIF medium supplemented with plant extract 1 was 
significantly increased up to the level seen in cells cultured in control medium. 
PPARα expression was increased but not significantly in Chang liver cells 
cultured in MIF medium supplemented with plant extracts 2 or ciglitazone. 
   
Figure 4.23 The relative expression levels of PPARα and TATABP after 48 hours of 
exposure of Chang liver cells to insulin resistance inducing medium and 
the effect of the presence of plant extract 1 and 2 and ciglitazone in this 
medium on gene expression.  
Fold normalized relative expression is shown on the Y-axis, values are means ± SEM. Each 
sample was analyzed in duplicate and experiment was repeated. Data are shown of one 
representative experiment. MIF treatment significantly decreased PPARα expression in Chamg 
liver cells compared to MCBD-201 treatment. PPARα expression in cells cultured in MIF medium 
supplemented with plant extract 1 was significantly upregulated compared to cells grown in MIF 
medium only. (***(P(H1))<0.0001) 
The mean normalized fold expression of PPARα in Chang liver cells cultured in 
MIF was 0.66 fold compared to the fold expression set at one for control cells 
grown in MCBD-201 medium after two hours of exposure to the experimental 
conditions (Figure 4.24). After six hours the expression of PPARα in Chang liver 
cells cultured in MIF was higher compared to the levels at two hours, relative to 
control cells at six hours. PPARα expression declined significantly after 24 and 48 
hours of exposure to MIF treatment, relative to the fold expression of PPARα in 
control cells at these time points. Thus the exposure of Chang liver cells with MIF 
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medium  decreased PPARα expression compared to cells cultured in MCBD-201 
medium after 2, 24 and 48 hours of exposure. 
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Figure 4.24  Timecourse of PPARα expression in Chang liver cells cultured in MCBD 
medium supplemented with 0.1μM insulin and 1mM fructose (MIF) and 
the influence of the presence of plant extract 1, plant extract 2 and 
ciglitazone in MIF on PPARα expression  
This is in agreement with a study by Kelly and Azhar (2005) that showed that 
hypertriglyceridemia induced by a high fructose diet in rats greatly reduced the 
hepatic expression of both PPARα protein and mRNA levels. Nagai et al, (2002) 
also found that eight weeks of a high fructose diet decreased PPARα mRNA and 
protein levels in rats. In addition this group also showed that primary rat 
hepatocytes treated with fructose also decreased PPARα expression, suggesting 
that fructose or its metabolites can directly regulate lipid metabolism. Decreased 
PPARα expression can result in reduced oxidation, leading to cellular lipid 
accumulation (Nagai et al., 2002). PPARα null mice have extensive hepatic 
steatosis because of diminished β-oxidation capacity (Barak & Kim, 2007). Thus 
the down-regulation of PPARα expression seen in Chang liver cells treated with 
MIF compared to control cells in the present study, could reduce β-oxidation and 
lead to cellular lipid accumulation. The Nile Red and Oil-red-O assays showed 
that Chang liver cells treated with MIF have a greater lipid accumulation than 
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control cells (Figure 3.7 and 3.8).  
One of the objectives of the present study was to develop an insulin resistance 
cell culture model. Inappropriate accumulation of lipids in muscle, and ectopic 
lipid accumulation in liver are both involved in the development of insulin 
resistance in these tissues (Savage et al., 2005). The MIF treatment reduced 
PPARα expression after 24 and 48 hours of exposure, which could result in a 
reduction in β-oxidation and contribute to lipid accumulation in the liver cells, 
indicating that insulin resistance was established.     
The next question was whether or not the plant treatment and ciglitazone could 
reverse the change in PPARα expression introduced by the MIF treatment. After 
two hours of culture in MIF medium containing plant extract 1, plant extract 2 or 
ciglitazone PPARα expression was equal to or above expression in the control 
cells. The mean normalized fold expression levels for these three treatments 
were 0.96 fold, 1.19 fold and 1.16 fold respectively (Figure 4.24). In comparison 
cells cultured in MIF medium only, to induce insulin resistance, showed a 
significant decrease in PPARα expression. After six hours the PPARα mean 
normalized fold expression in Chang liver cells cultured in MIF medium containing 
plant extract 1, plant extract 2 or ciglitazone was 0.82 fold, 0.50 fold and 0.68 fold 
respectively (Figure 4.24). As mentioned, PPARα plays a role in β-oxidation and 
under normal conditions would be expected to be down regulated upon feeding 
and upregulated during fasting. In the present study PPARα expression is 
decreased in Chang liver cells cultured with MIF medium after two hours, in cells 
cultured in MIF containing plant extract 1, plant extract 2 or ciglitazone a 
decrease in PPARα expression is seen after six hours. Thus the presence of 
plant extract 1, plant extract 2 and ciglitazone in MIF led to a delay in the decline 
in PPARα expression. However the decline in PPARα expression early in time 
course is expected as the addition of fresh medium (refeeding) would lead to a 
decrease in PPARα expression.   
In Chang liver cells cultured in MIF supplemented with plant extract 1, plant 
extract 2 or ciglitazone PPARα expression was still decreased compared to the 
control cells and MIF treated cells after 24 hours of exposure. After 48 hours 
PPARα expression was increased in Chang liver cells cultured in MIF medium 
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supplemented with plant extract 1, plant extract 2 or ciglitazone compared to cells 
grown in MIF treatment. However this increase in expression was only significant 
in Chang liver cells cultured in MIF medium supplemented with plant extract 1. 
The presence of the plant extract 1 in the MIF medium protect against the down-
regulation in PPARα expression seen in cells cultured in MIF medium only. As the 
plant extract 1 could lead to up-regulation of PPARα expression, it could also 
increase β-oxidation and have implications for the cellular lipid accumulation in 
the Chang liver cells. In accordance with this Nile-red and Oil-red-O lipid 
accumulation analysis showed that Chang liver cells cultured in MIF medium 
supplemented with plant extract 1   have reduced lipid accumulation compared to 
cell grown with  MIF medium for 48 hours (Figure 3.7 and 3.8).  
For further gene expression studies singleplex qRT-PCR was performed. 
Although multiplexing has many advantanges, and in the present study would 
have allowed the investigation of three to four molecular targets at the same time, 
it also proved to require a lot of time to optimize. Based on the difficulties 
experienced with multiplexing, singleplex qRT-PCR proved to be better for the 
present study.  
The same experimental samples analyzed in the multiplex reactions will be 
analyzed in subsequent singleplex reactions. The molecular targets PPARγ and 
SREBP were investigated using singleplex reaction. Singleplex reactions for 
PPARα were also performed to confirm results found with the multiplex assay. 
The first step in performing qRT-PCR is to identify stable housekeeping genes for 
normalization, as will be described in Chapter 5.     
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Chapter 5:  
Validation of housekeeping genes for normalization of 
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CHAPTER 5: VALIDATION OF HOUSEKEEPING GENES FOR 
NORMALIZATION OF GENE EXPRESSION 
5.1 NORMALIZATION OF GENE EXPRESSION 
Like other methods used in expression studies qRT-PCR data need to be 
normalized to compensate for differences in the amount of biological material in 
the tested samples (Bustin, 2000; Kubista et al., 2006). These differences could 
be introduced because of variation in initial sample amount, RNA recovery, RNA 
integrity, efficiency of cDNA synthesis, or differences in the overall transcriptional 
activity of the tissues or cells analyzed (Andersen et al., 2004). Various strategies 
have been employed to normalize these variables, for example normalization 
against the total cell number, against the mass of the input material or against the 
RNA mass (Vandesompele et al., 2002). Exogenously added mRNA or “spikes” 
added before the RNA extraction can also be used for standardization (Donnison 
& Pfeffer, 2004). To date, the most frequently used approach for normalization of 
RT-qPCR is the use of internal control genes (De Ketelaere et al., 2006).  
Internal control genes or reference genes are not a new concept. They have been 
used as references in Northern blots and conventional RT-PCR assays (De 
Ketelaere et al., 2006). Traditional reference genes were chosen in the pre-
genomic era, based on their known or suspected housekeeping roles in basic 
cellular processes (e.g. protein translation, ubiquitin-dependent protein 
degradation), cell structure maintenance (e.g. cytoskeleton), or primary 
metabolism (e.g. glycolysis) (Czechowski et al., 2005). The most commonly used 
reference genes include actin, tubulin, albumin, ubiquitin, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), hypoxanthine-quanine phosphoribosyl 
transferase (HPRT), and 18S or 28S ribosomal RNA (De Ketelaere et al., 2006). 
The use of these genes in non- or semi-quantitative techniques, such as Northern 
blots and conventional RT-PCR, in which a qualitative change was measured, 
was acceptable. The stability of the reference genes was not validated as they 
were believed to undergo little or no variation in expression under most 
experimental conditions (De Ketelaere et al., 2006). However, the increased 
sensitivity, reproducibility and large dynamic range of qRT-PCR increase the 
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requirements for the internal control gene.  Reference genes previously 
considered to be stable in various tissues even under experimental treatments 
have been shown to be regulated and to vary under experimental conditions with 
qRT-PCR (Bustin, 2000; Czechowski et al., 2005).   
The biggest challenge of qRT-PCR is the identification of valid reference genes 
(Bustin, 2002). Reference genes are considered to be valid control genes if they 
are expressed at a constant level in the tissues or cells under investigation 
(Goossens et al., 2005). In practice though, all genes will show some variation, 
because all genes are regulated to some extent, and none are constitutively 
expressed in all cell types and under all conditions, independently of experimental 
design (Bustin et al., 2005). There is no one gene that meets the criterion for 
every experimental condition; therefore it is imperative to validate the expression 
stability of a reference gene for the specific requirements of an experiment, prior 
to its use for normalization (Wong & Medrano, 2005).  
Most experiments include only a single reference gene (Bustin et al., 2005). 
Vandesompele et al. (2002) demonstrated that the conventional use of a single 
gene for normalization leads to relatively large errors. They validated the 
geometric mean of multiple carefully selected reference genes as an accurate 
normalization factor. To date, it is generally accepted, that the selection of valid 
reference genes in gene expression analysis has to be done for each individual 
experimental setting by evaluating several genes and using the best two or three 
of these genes as a reference (Radonić et al., 2005). 
Different methods for identifying the most suitable combination of reference 
genes have been proposed (Bustin et al., 2005). In this study seven reference 
genes were investigated. The analytical programme geNorm was used to 
establish a set of reference genes that is suitable to use in qPCR experiments 
performed in Chang liver cells supplemented with insulin and fructose in MCBD 
medium to make them insulin resistant. GeNorm is a bioinformatics tool designed 
to rank candidate reference genes by using a normalization factor calculated on 
the basis of the geometric mean of the expression level of each of the candidate 
reference genes in an array of representative samples.  
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5.2 MATERIALS AND METHODS 
5.2.1 RNA extraction and cDNA synthesis 
RNA was extracted as previously described in Chapter 4. The same media 
conditions as for the experimental samples in Chapter 4 section 4.4.2 were used 
with the omission of cells treated with MCBD medium supplemented with insulin, 
fructose and plant extract 2. Table 5.1 shows the medium conditions of the cells 
used for RNA extraction to test the stability of expression of 7 reference genes.  
Cells were seeded in 10cm diameter cell culture dishes at 2x105 cells/plate in 
RPMI 1640: 10%FCS and grown to 70-80% confluence after which the growth 
medium was replaced with the medium conditions indicated in table 5.1. RNA 
extraction was performed after 48 hours of culture in the medium conditions 
indicated in table 5.1 Medium was removed and cells were washed with PBSA 
(Sigma, UK), cultures were harvested and total RNA isolated using the Qiagen 
Lipid Tissue RNeasy Mini Kit (Qiagen, Germany). Cells were harvested by the 
addition of 500μl lysis buffer from the Qiagen kit and scraping cells in the lysis 
buffer. Scraped cells were then transferred into a 2ml eppendorf tube and 
homogenized with a 2ml syringe and 21 gauge needle. Cells from plates with the 
same treatment were pooled (see Table 4.5) whereafter RNA was extracted with 
the Qiagen RNeasy Lipid Tissue Mini Kit following the protocol of the 
manufacturer as described in section 4.4.1.1. RNA was treated with RNAse free 
DNAse1 (Qiagen, Germany), as instructed by the manufacturer to remove any 
residual contaminating genomic DNA.  
Table 5:1 Medium conditions of Chang cells for qRT-PCR to test stability of 
housekeeping genes. 
Medium Insulin Fructose 
Plant extracts or anti-diabetic 
agent added 
 
RPMI 1640    RPMI 
MCBD-201    MCBD 
MCBD -201 medium  0.1μM  1mM   MIF 
MCBD -201 medium  0.1μM  1mM  Plant extract 1(12.5μg/ml) MIF+P1 
MCBD -201 medium  0.1μM  1mM  Ciglitazone (1μM) MIF+Ciglit 
The yield and quality of the extracted RNA was assessed with the RNA 6000 
Nano LabChips kit in the Agilent 2100 Bioanalyer according to the protocol of the 
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manufacturer. cDNA synthesis was performed with good quality RNA as indicated 
by RIN values above 8. cDNA was synthesized from 1μg of total RNA in a 20μl 
reaction volume using the iScriptTMcDNA Synthesis Kit (Bio-rad) following the 
manufacturer‟s protocol. The kit is provided with an iScript reverse transcriptase, 
5X iScript reaction mix and nuclease free water. The iScript is a modified MMLV-
derived reverse transcriptase, the enzyme is provided preblended with RNAase 
inhibitor. The 5X iScript reaction mix contains a mixture of oligo (dT) and random 
hexamer primers. The reaction was annealed at 25°C for five minutes, extended 
at 42°C for 30 minutes and the reverse transcriptase was inactivated at 85°C for 
15 minutes.     
5.2.2 Quantitative Real-Time PCR 
The PrimerDesign geNorm kit containing a panel of six candidate reference 
genes (Table 5.2) was used to identify the reference genes which show the least 
variation under the experimental conditions of this study. Primers designed for 
TATABP were also included in the analysis. The lyophilized primer mixes 
contained in the kit were pulse spun down and reconstituted in 220μl PCR-grade 
water, as instructed by the manufacturer.  
Table 5:2 The six reference genes chosen from the housekeeping gene geNorm kit   
Gene description  Gene Symbol 
1. Homo sapiens topoisomerase I DNA mRNA TopI 
2. Homo sapiens 18S rRNA gene   18SrRNA 
3. Homo sapiens phospholipase A2 mRNA YWAS 
4. Homo sapiens ubiquitin C mRNA UBC 
5. Homo sapiens beta, actin mRNA ActB 
6. Homo sapiens ATP synthase mRNA ATP5B 
 
Quantitative RT-PCR was carried out using iQTMSYBR green Supermix in a 20 μl 
total reaction mix. Each reaction was performed in duplicate and contained 10μl 
2X iQ SYBR Green Supermix, 1μl reconstituted primer mix (400nM in 20μl 
reaction), and 4μl PCR grade water. The cDNA was diluted 1:5 and 5μl was 
added to the reaction mix. The PCR reaction was performed using the Bio-rad 
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iCycler and the amplification conditions used were an initial three minute enzyme 
activation at 95°C followed by 40 cycles of denaturation at 95°C for 15 seconds 
and annealing at 60°C for 30 seconds (Table 5.3). After the amplification a melt 
curve analysis was also performed by heating the thermal cycler to the annealing 
temperature and then increasing the temperature in 0.5°C increments up to 95°C, 
for 30 seconds at each increment. Amplification efficiencies for the most stable 
reference genes (highest rank) were determined by generating standard curves 
for each of these genes.  
Table 5:3 Thermal Cycling Program for qRT-PCR of the geNorm kit Housekeeping 
genes  
Step Temperature Time 
Number of 
Cycles 
Enzyme activiation 95°C 3 minutes 1 cycle 
 
Denturation 95°C 5 seconds 
40 cycles * 
Annealing and extension 60°C 30 seconds 
 
Melt Curve 
60°C initially, 
increasing in 0.5°C 
increments 
10 seconds 70 cycles 
* Fluorogenic data collected during this step through SyBR green channel  
5.2.3 Data analysis 
For accurate gene expression measurements it is essential to normalize results 
from qRT-PCR experiments to a fixed reference. In the present study PCR data 
was analyzed using the geNorm software.  
The geNorm VBA applet for Microsoft Excel determines the most stable reference 
genes from a set of tested genes in a given cDNA sample panel. It calculates a 
gene expression normalization factor for each tissue sample based on the 
geometric mean of a user-defined number of housekeeping genes 
(Vandesompele et al., 2002). GeNorm calculates the gene expression stability 
measure (M) for a control gene as the average pairwise variation (V) for that gene 
with all other tested control genes. Stepwise exclusion of the gene with the 
highest M value allows ranking of the tested genes according to their expression 
stability. 
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Before Ct-values from the qRT- PCR are used in the geNorm program, all Ct-
values must be transformed into relative quantification data. To achieve this, the 
highest Ct-value for each gene measured was subtracted from all other Ct-values 
for that gene, transforming each Ct-value into a delta Ct (∆Ct). The highest ∆Ct will 
be 0 and all other values will be less then 0. The equation 2(∆Ct) was then applied for 
each sample; these values were used in geNorm. GeNorm calculates an array 
containing the log2-transformed expression level ratios of every combination of two 
internal control genes in every sample. The standard deviation of all elements of the 
array was calculated for each combination of control genes. The arithmetic mean of 
all standard deviations involving a particular control gene was calculated and termed 
M. The control genes with the highest M value were sequentially removed from the 
calculation; after each removal the M value was recalculated and the results were 
used to determine the next candidate gene for omission. The removal of candidate 
genes continued until only two control genes were left in the array calculation 
(Vandesompele et al., 2002).  
5.3 RESULTS AND DISCUSSION 
Very good quality RNA was extracted as indicated by RIN values and the 
electropherograms generated with the Agilent 2100 Bioanalyzer (Figure 5.1). 
Clear 28S and 18S peaks were seen, with low noise between the peaks and 
minimal low molecular weight contaminations.  Ribosomal subunit ratios of close 
to two and RIN values of between eight and ten were seen in most samples.  
Amplification and meltcurve curves generated with qRT-PCR assays showed a 
single product, as indicated by a single peak in the meltcurve analysis in 
reactions containing template and no amplification of non-specific products in the 
NTC. The relative expression was calculated by using ∆Ct as described in section 
5.2.3. Cells grown under normal growth conditions showed the highest 
expression for the majority of tested genes.  The reference genes analyzed 
showed M values between 0.968 and 1.764 when all genes were included in 
calculation of the M values. A summary of M values based on the calculation of all 
pairs of housekeeping genes is presented in Table 5.4. Reference genes with M 
value of smaller than 1.5 could be used for normalization. The analytical programme 
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geNorm identified M values of reference genes greater than the prescribed M value 
with red and the reference gene with the lowest M value with green.  
 
 
Figure 5.1 Electropherogram summaries of 4 RNA samples analyzed using the RNA 
6000 Nano LabChips kit in the Agilent 2100 Bioanalyer.  
For each sample a graph of the electrogram showing the 18S and 28S peaks of rRNA are shown 
accompanied by a gel image next to the graph. At the bottom of the electrogram the results of each 
sample is displayed which include the RNA concentration, 28S/18S ratio and the RIN value 
respectively.   
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Table 5:4 Expression stability of 7 housekeeping genes as measured with the M 
value calculated with geNorm 
 Topl 18SrRNA YWAS UBC ActB ATP5B TATABP 
RPMI         1.00E+00 6.37E-01 1.00E+00 1.00E+00 6.60E-01 1.00E+00 1.00E+00 
MCBD         3.30E-01 1.00E+00 2.97E-01 7.07E-01 1.00E+00 9.33E-01 4.67E-01 
INS+fruc     2.21E-02 8.71E-01 5.26E-02 3.19E-01 6.60E-01 3.42E-01 1.89E-01 
INS+fruc+ 
Plant1  
1.51E-02 7.32E-01 4.12E-02 2.03E-01 6.60E-01 8.54E-02 7.43E-02 
INS+fruc+ 
Ciglit   
3.47E-02 6.16E-01 8.84E-02 3.54E-01 7.32E-01 2.33E-01 1.77E-01 
 0.082469244 0.757858283 0.141610486 0.438302861 0.732042848 0.363493129 0.258816231 
M < 1.5 1.764 1.458 1.220 0.968 1.384 1.059 0.968 
 
 
 
Figure 5.2 Determination of M values upon sequential exclusion of housekeeping 
genes with the largest expression level variance.  
M values were calculated and the housekeeping gene with the highest M value was excluded 
from the analysis and M values were recalculated using the remaining reference genes. This 
process was repeated until only 2 reference genes were left, which could not be further ranked. 
ATP5B and TATABP represent the most stable pair of reference genes. 
Following stepwise omission of the housekeeping gene with the highest M value 
and subsequent recalculation of average expression stability values for the 
remaining control genes, TATABP and ATP5B were identified as the most stable 
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among the genes examined (Figure 5.2). TopI was found to have the lowest 
expression stability and was, therefore, the first gene to be omitted from the 
calculation of M in the stepwise exclusion (Figure 5.2).   
Figure 5.3 illustrates the levels of variation in average housekeeping gene 
stability with the sequential addition of each housekeeping gene to the equation 
(for calculation of the normalization factor). The pairwise variation (V) for the two 
most stable genes (TATABP and ATP5B) with the inclusion of the third most 
stable gene (UBC) (V2/3) was 0.186 (Figure 5.3). A V score of below 0.15 is 
recommended as ideal; however the proposed 0.15 value must not be taken as 
too strict a cut-off (geNorm handbook). Results from this graph are only intended 
to be a guide for determination of the optimal number of reference genes. 
However using the three best reference genes is in most cases a valid 
normalization strategy.   
 
Figure 5.3 Determination of the optimal number of housekeeping genes for 
normalization by calculation of the pairwise variation (V) of normalization 
factor ratios.  
The established ranking (Figure 5.2), was used to illustrate the contribution of each gene to the 
variance of normalization factor ratios by adding that specific gene to the final set of reference 
genes. Addition of UBC to the two most stable genes generates a V value of 0.186 (V2/3). 
Addition of Actin (V3/4) increase V to 0.298 addition of a fifth housekeeping gene (18SrRNA) 
reduces the value of V to 0.196.  
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In the present study the combination of the two most stable reference genes was 
chosen to be used as reference genes for normalization in all experimental 
samples. Standard curves were generated for these genes, which all showed 
PCR efficiencies of close to 100%.     
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CHAPTER 6:   
SINGLEPLEX: PPARγ, PPARα, SREBP-1 AND TOPI 
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CHAPTER 6: SINGLEPLEX: PPARγ, PPARα, SREBP-1 AND TOPI 
EXPRESSION IN AN INSULIN RESISTANT CHANG LIVER CELL 
LINE  
There has been a shift from the traditional “glucocentric” view of diabetes, which 
defines insulin resistance in terms of the effect of insulin on glucose metabolism, 
to an increasingly acknowledged lipocentric viewpoint (Savage et al., 2005). This 
hypothesis holds that abnormalities in fatty acid metabolism may result in 
inappropriate accumulation of lipids in muscle and liver, and that this ectopic lipid 
accumulation is involved in the development of insulin resistance in these tissues 
(Savage et al., 2005).  
Diets high in fructose have been shown to induce insulin resistance in animal 
models and are also associated with insulin resistance, impaired glucose 
tolerance, high blood pressure, and dyslipidaemia in humans (Dirlewanger et al., 
2000; Elliott et al., 2002; Schaalan et al., 2009). There is considerable evidence 
supporting the ability of high fructose diets to upregulate the lipogenesis pathway, 
leading to increased TG production. Borra et al. (2008) have demonstrated that 
there is an inverse relationship between liver fat content and hepatic glucose 
metabolism. In T2DM patients liver fat content was significantly increased and 
hepatic glucose uptake was decreased compared to control healthy subjects 
(Borra et al., 2008).   
PPARs are transcription factors that have important effects on lipid homeostasis 
via regulation of the expression of genes involved in lipid metabolism (Kersten, 
2001; Rakhshandehroo et al., 2007). The SREBP family is another group of 
transcription factors that activate a cascade of enzymes required for endogenous 
cholesterol, FA, TG and phospholipid synthesis (Eberlè et al., 2004). In the 
present study qRT-PCR was employed to follow the gene expression of PPARα, 
PPARγ and SREBP-1c over time in the insulin resistant model developed in the 
Chang liver cell line. The effects of two different extracts of the plant S.frutescens 
and of ciglitazone a PPARγ agonist over time in this model were also 
investigated.  
 119 
11
9 
6.1 MATERIALS AND METHODS 
6.1.1  RNA extraction and cDNA synthesis 
The same experimental samples from which RNA was extracted for the multiplex 
assays, (described in section 4.4.2) were used. Instead of the ImProm-IITM 
Reverse Transcriptase (Promega, USA) used in the multiplex reactions,  cDNA 
was synthesized from 1μg of total RNA in a 20μl reaction volume using the 
iScriptTMcDNA Synthesis Kit (Bio-rad) (see section 5.2.1).     
6.1.2  Primer Design 
Primers were designed for PPARγ, PPARα and SREBP1 with the Beacon 
Designer Software.  Table 6.1 shows the primer sequences, amplicon size and 
region of the gene where the primers were designed. Primers were obtained from 
Inqba Biotechnical Industries (South Africa). The lyophilized primers were pulse 
spun down and reconstituted in appropriate volumes of TE buffer to a stock 
solution with a final concentration of 100μM.  A 1:10 dilution of the 100μM primer 
stock solution was made in nuclease free water for each primer prior to use.  
The TopI primers used in the reference gene analysis showed the biggest 
variation in expression in the experimental samples analyzed. DNA 
topoisomerases are enzymes that remove DNA supercoiling generated during 
transcription and replication (Rothenberg, 1997; Champoux, 2002; Cartei et al., 
2006). These enzymes work by breaking the DNA backbone to allow strand 
passage through the nicked DNA and resealing the break afterwards. There are 
two types of topoisomerases TopI and TopII, TopI relaxes supercoiling by forming 
DNA single strand breaks and TopII introduces DNA double-strand breaks. 
Inhibitors of both TopI and TopII are widely used in cancer chemotherapy as 
these agents can prevent the DNA strand breaks induced by these enzymes and 
thereby convert the enzymes into DNA-damaging agents (Rothenberg, 1997; 
Cartei et al., 2006). 
S.frutescens the plant analyzed in this study has been reported to have anti-
cancer activity (reviewed by Sia, 2004). Given the variability in TopI expression in 
the limited number of experimental samples analyzed for reference genes its 
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potential as a molecular target for S.frutescens was investigated in further 
analyses with qRT-PCR.   
Table 6:1 Primer sequences for PPARα, PPARγ and SREBP-1 designed with the 
Beacon Design Software. 
Gene 
name 
GenBank 
Accession 
Number 
Primer Sequence (5’→3’) 
Amplicon 
Size (bp) 
Region of 
Gene (nt) 
PPARα NM_005036 Sense: 
TTGGTGAAACTGACATTGG 
Anti-sense: 
GAAGAGGTGAAGAGGAGAG 
121bp 5863-5963 
PPARγ NM_005037 Sense: 
AGGTTTGCTGAATGTGAAG 
Anti-sense: 
AATCTGTCTGAGGTCTGTC 
142bp 1292-1433 
SREBP-1 
 
NM_004176 Sense: 
GCACCGAGAGCAGAGATG 
Anti-Sense: 
AAGAGAAGCACCAAGGAGAC 
103bp 1786-1888 
6.1.3 qRT-PCR 
qRT-PCR was carried out using the iQTMSYBR green Supermix in a 20 μl total 
volume reaction mix. Each reaction was performed in duplicate and contained 
10μl 2X iQ SYBR Green Supermix, 1μl diluted primer mix, and 4μl PCR grade 
water. The cDNA was diluted 1:5 and 5μl was added to the reaction mix. The 
PCR reaction was performed using the Bio-rad iCycler using the amplification 
conditions indicated in the Table 6.2 for PPARγ and SREBP-1, a temperature 
gradient was initially used to determine the optimum amplification conditions for 
PPARα. 
Amplification efficiencies for each of the genes analyzed were determined by 
generation of a standard curve. Standard curves were generated using a tenfold 
serial dilution of template cDNA. cDNA concentration was not determined, but 
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theoretically 1μg of cDNA can be synthesized from 1μg of RNA, so cDNA 
concentration was based on the maximum capacity of cDNA synthesis. Thus the 
concentration of 1μg of cDNA in 20μl reaction volume was 50ng/μl.The 
concentrations used to generate the standard curve ranged from 10ng/ul-
0.001ng/ul.  
Table 6:2 Thermocycle program for PPARγ and SREBP 
Gene name Number of cycles Temperature Time 
PPAR γ 1 Cycle 95°C 3 minutes 
 40 Cycles 95°C 
60°C 
15 seconds 
30 seconds 
SREBP1 1 Cycle 95°C 3 minutes 
 40 Cycles 95°C 
58°C 
15 seconds 
30 seconds 
 
All experimental samples were amplified on the same plate for each specific 
gene. After the amplification a melt curve analysis was also performed by heating 
the thermal cycler to the annealing temperature and then increasing the 
temperature in 0.5°C increment up to 95°C for 30 seconds at each increment. 
6.1.4  Data Analysis 
Amplication data was analyzed using qBase v1.3.1. The Relative Expression 
Software Tool (REST) 2008 for group wise comparison and statistical analysis of 
relative expression results in qRT-PCR was used to determine statistical 
significance. 
6.2 RESULTS AND DISCUSSION 
6.2.1 Normalization with TATABP and ATP5B 
Seven reference genes were analyzed to determine the most stable reference 
genes. In this analysis ATP5B and TATABP represented the most stable pair of 
reference genes. Consequently all experimental samples were analyzed with 
these two reference genes to determine the normalization factor for each 
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experimental sample. The fold gene expression of ATP5B and TATABP of all 
experimental samples are shown on the same graph for each of the four time 
points analyzed (Figure 6.1-6.4). The normalization factors calculated for each 
sample based on TATABP and ATP5B expression in all experimental samples 
are shown in Figure 6.5-6.8. Two parameters are calculated by qBase to verify 
the selected housekeeping genes, the coefficient of variation (CV) and the M 
value. The M value is the gene expression stability parameter as calculated by 
geNorm and CV represents the variation of the normalized relative quantities of a 
housekeeping gene across all samples. The lower the M value, the more stably 
expressed the housekeeping gene, and lower CV values also denote higher 
stability (Figure 6.1-6.4). M values of lower then 1.5 were generated for all 
experimental conditions, confirming that ATP5B and TATABP are validated 
reference genes under the experimental conditions of the present study as M=1.5 
is considered the cut off value for validation of reference genes (GeNorm 
handbook).    
 
Figure 6.1 Fold expression of the 
two reference genes 
ATP5B and TATABP in 
Chang liver cells after 
two hours of exposure 
to the experimental 
conditions 
A mean M value of 0.5561 and a CV value of 
19.21% were generated using these two 
reference genes. 
 
Figure 6.2 Fold expression of the 
two reference genes 
ATP5B and TATABP in 
Chang liver cells after 
six hours of exposure 
to the experimental 
conditions 
A mean M value of 0.4693 and a CV value of 
16.23% were generated using these two 
reference genes. 
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Figure 6.3 Fold expression of the 
two reference genes 
ATP5B and TATABP in 
Chang liver cells after 
24 hours of exposure to 
the experimental 
conditions 
A mean M value of 0.6520 and a CV value of 
22.60% were generated using these two 
reference genes. 
 
Figure 6.4 Fold expression of the 
two reference genes 
ATP5B and TATABP in 
Chang liver cells after 
48 hours of exposure to 
the experimental 
conditions 
A mean M value of 1.0521 and a CV value of 
37.20% were generated using these two 
reference genes. 
The fold expression levels of ATP5B in Chang liver cells exposed for two hours to 
the experimental conditions varied between 1 and 1.69 (1.22; 1; 1.19; 1.69; 1.44) 
(Figure 6.1.). The fold TATABP expression levels at the two hour time point in the 
experimental samples also vary between 1 and 1.69 (1.39; 1.69; 1.42; 1; 1.17) 
(Figure 6.1.). The variations seen in the fold expression of these genes when 
compared individually illustrate the problems associated with using only a single 
reference gene for normalization. Vandesompele et al. (2002) suggested that the 
use of the geometric mean of multiple carefully selected reference genes is a 
more accurate method of normalization than using a single reference gene. In the 
present study the normalization factor for each experimental sample was 
calculated based on the geometric mean of the fold expression of ATP5B and 
TATABP for each experimental sample analyzed (Figure 6.5-6.8). 
The identification of valid reference genes is the biggest challenge of qRT-PCR, 
because in practice all genes show some variation, because all genes are 
regulated to some extent (Bustin, 2002; Bustin et al., 2005). The use of the 
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geometric mean of the two most stably expressed reference genes identified 
under the experimental conditions (Figure 6.5-6.8) considerably improve the 
normalization factor as compared to the use of the expression of these two genes 
individually for normalization (Figure 6.1-6.4).   
Reference genes that are expressed at a constant level under the experimental 
conditions would generate a normalization factor of one or very close to one. 
Variation in the normalization factors could be attributed to differences in the 
amount of input biological material in the PCR reaction due to factors such as 
efficiency of cDNA synthesis, RNA integrity and accurate pipeting. Although RNA 
concentration was determined for each sample analyzed and qRT-PCR was 
based on equal input of RNA for all samples analyzed, factors such as efficiency 
of cDNA synthesis, RNA integrity and accurate pipeting could influence the 
expression of the reference genes analyzed and thus have to be compensated for 
with normalization. These factors would equally influence reference genes and 
target genes investigated.   
The normalization factor calculated for samples after two hours of exposure to the 
experimental conditions were 0.61, 0.83, 0.83, 1.09 and 1.00 respectively (Figure 
6.5). After six hours of exposure to experimental conditions the normalization 
factor for the samples analyzed were 1.09, 1.04, 1.11, 0.70, and 0.86 (Figure 
6.6). After 24 of exposure to the experimental conditions the normalization factors 
calculated for the experimental samples were 0.76, 0.91, 1.03, 0.80, and 1.5 
(Figure 6.7).  The normalization factors after 48 hours of exposure to the 
experimental conditions were 0.88, 0.97, 1.14, 0.87, and 1.54 (Figure 6.8). The 
normalization factors for all experimental samples at these two time points were 
relatively constant, except for Chang liver cells treated with MIF supplemented 
with ciglitazone, which showed a much higher normalization factor both after 24 
hours and 48 hours of exposure. The presence of the ciglitazone in the culture 
medium could have influenced the expression of ATP5B and TATABP. 
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Figure 6.5 Normalization factor for 
experimental samples 
after two hours of 
exposure. 
Normalization factor calculated based on 
ATP5B and TATABP expression in 
experimental samples. 
 
Figure 6.6  Normalization factor for 
experimental samples 
after six hours of 
exposure. 
Normalization factor calculated based on 
ATP5B and TATABP expression in 
experimental samples. 
 
 
Figure 6.7 Normalization factor for 
experimental samples 
after 24 hours of 
exposure. 
Normalization factor calculated based on 
ATP5B and TATABP expression in 
experimental samples. 
 
 
Figure 6.8 Normalization factor for 
experimental samples 
after 48 hours of 
exposure. 
Normalization factor calculated based on 
ATP5B and TATABP expression in 
experimental samples. 
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The normalization factors calculated based on the geometric mean of the most 
stable pair of reference genes, ATP5B and TATBP were used for normalization of 
the expression of the four candidate genes SREBP-1, TopI, PPARγ and PPARα. 
6.2.2 Amplification and Meltcurve analysis of SREBP-1, TopI, PPARγ 
and PPARα 
Amplification with primer pairs for SREBP-1 and for TopI, using the thermocycling 
program shown in Table 6.2, each generated a single amplification product, 
indicated by one melt peak in the meltcurve analysis of the reactions containing 
template, and no melt peaks in the NTC (Figure 6.9 and 6.10). A non-specific 
amplification product was formed after 36 cycles in the NTC using the PPARγ 
primers, however the meltpeak analysis showed a single peak for the reaction 
containing template (Figure 6.11). The highest Ct-value of the correct 
amplification product was Ct 25 thus there was a bigger than 10 cycle difference 
between the non-specific product formed and the correct product, indicating that 
this was a late minor reaction that would not affect the specific amplification of 
cDNA in the sample preparation. 
(a)          (b) 
 
 
 
 
 
Figure 6.9 Amplification (a) and meltcurve graph (b) for SREBP-1 showing no non-
specific amplification in NTC in the amplification graph and a single peak 
at the correct Tm in the meltcurve graph. 
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(a)       (b) 
 
 
 
 
 
Figure 6.10 Amplification (a) and meltcurve graph (b) of TopI showing no non-
specific amplification in NTC in the amplification graph and a single peak 
at the correct Tm in the meltcurve graph. 
 
(a)       (b) 
 
 
 
 
 
 
Figure 6.11 Amplification (a) and meltcurve graph (b) of PPARγ showing non-specific 
amplification in NTC appearing after Ct 36 in the amplification graph. The 
meltcurve graph show a single peak at the correct Tm in the meltcurve 
graph. 
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The primer pair designed to amplify PPARα generated primer dimers when the 
thermocycling program indicated in Table 6.2 was used. To optimize the reaction, 
the primer concentration was varied between 100mM and 500mM and 
amplification repeated. In addition a temperature gradient PCR was performed 
between 56°C and 60°C. Although optimization made the primer dimers appear in 
later amplification cycles, it did not remove them completely. A seven cycle 
difference between the correct amplification product and the non-specific product 
in the NTC was recorded. Seven cycle difference is on the border of what is 
acceptable. Therefore it was decided to use the PPARα primer pair used for the 
multiplex reactions for further analysis, because it did not generate primer dimers.  
6.2.3 Standard curve analysis  
Standard curves were generated for each gene to determine the PCR efficiency 
using a tenfold serial dilution of template cDNA. cDNA concentration was not 
determined, but theoretically 1μg of cDNA can be synthesized from 1μg of RNA, 
so cDNA concentration was based on the maximum capacity of cDNA synthesis. 
Thus the concentration of 1μg of cDNA in 20μl reaction volume was 50ng/μl. The 
concentrations used to generate the standard curve ranged from 10ng/ul-
0.001ng/ul (mass 200ng-0.02ng). The PCR efficiencies calculated based on the 
standard curves were within the 95% to 105% cut off for acceptable PCR 
efficiencies. Figures 6.12 and 6.13 show the standard curves generated for 
PPARγ and SREBP-1. 
 
Figure 6.12 Standard curve generated for PPARγ using a tenfold serial dilution of 
cDNA starting at 2ng/μl. PCR efficiency was 99.7%.   
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Figure 6.13 Standard curve generated for SREBP-1 using a tenfold serial dilution of 
cDNA starting at 2ng/μl. PCR efficiency was 102.2%. 
6.2.4 SREBP-1 Regulation 
SREBPs are considered to be master regulators of lipid homeostasis as SREBPs 
activate transcription of a cascade of enzymes required for endogenous 
cholesterol, FA, TG and phospholipid synthesis (Eberlè et al., 2004). Three 
members of the SREBP family have been described, SREBP-1a and SREBP-1c 
and SREBP2. SREBP-1a and SREBP-1c are encoded by a single gene through 
the use of alternative start sites and differ by their first exon. SREBP2 is encoded 
from a different gene and shows 50% homology with the amino acid sequence of 
SREBP-1.     
The amount of SREBP transcripts varies among different tissues and cell lines. 
Shimano et al., (1997) quantified the SREBP-1a and SREBP-1c transcripts in five 
cultured cell lines, including 3T3-L1, HepG2, a human fibrobast and a mouse 
fibroblast cell line and compared expression to the amount of transcript found in 
mouse tissues. SREBP-1a transcript predominates in the cell lines and SREBP-
1c transcript predominates in liver, white and brown adipose tissue, adrenal gland 
and several other tissues of the adult mouse. SREBP2 is intermediate and found 
in both intact tissues of mouse and humans and also in cultured cell lines 
(Shimano et al., 1997). 
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SREBP target genes can be categorized into two groups: the cholesterol 
biosynthetic genes and the lipogenic enzyme genes. Although all three SREBPs 
are capable of activating each of the known target genes, the relative degree of 
stimulation varies, showing differential effects on the pathways of cholesterol, as 
opposed to fatty acid synthesis (Horton et al., 2002). Over expression of dominant 
positive forms of SREBP-1a and SREBP-1c in transgenic mice favour triglyceride 
synthesis, over cholesterol synthesis. SREBP-1a is a stronger activator of 
SREBP-responsive genes because of its long transactivation domain, compared 
to its splice variant SREBP-1c, that encodes a shorter transactivation domain 
(Shimano et al., 1997). Transgenic mice over-expressing SREBP-1a develop 
massive fatty liver engorged with both TG and cholesterol esters, with genes 
controlling fatty acid synthesis more dramatically activated than those for 
cholesterol synthesis (Shimano et al., 1997; Horton et al., 1998b). Over-
expression of SREBP-1c in the liver of transgenic mice produces a TG-enriched 
fatty liver with no increase in cholesterol. Over-expressing of SREBP2 increases 
the mRNAs encoding all cholesterol biosynthetic enzymes (Horton et al., 1998b). 
In the present study the expression of SREBP-1 was analyzed in the 
experimental samples over time. The term SREBP-1 is used as the primers were 
designed to anneal to a region homologous to both SREBP-1a and SREBP-1c. 
Physiological regulation of hepatic lipogenic genes is most dramatic during fasting 
and refeeding. Fasting reduces the substrate flux through the fatty acid synthesis 
pathway, and refeeding a fat-free high carbohydrate diet induces the synthesis of 
fatty acid to levels significantly higher then the normal fed state (Horton et al., 
1998a). Horton et al., (1998a) employed the fasting/refeeding protocol in wild-type 
mice to determine the regulation of SREBP-1a, SREBP-1c and SREBP2 under 
these metabolic conditions. Mice were fasted for 24h and refed a high 
carbohydrate/low fat diet for 12h, after which liver extracts were assayed by 
immunoblotting.  After the 24h fasting, the precursor and the nuclear forms of 
SREBP-1 proteins declined markedly. After refeeding for 12h the precursor form 
of SREBP-1 returned to normal and the nuclear form was markedly increased. A 
time course experiment revealed that the nuclear form of SREBP-1 declined 
perceptibly after a 3h fast and was barely detectable after 6h. Refeeding after 24h 
fasting led to increased expression of SREBP-1 reaching prefasting level after 3h 
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and exceeding this level at 6-24h. mRNA levels of SREBP, as assessed by 
Northern Blot analysis, paralleled those seen at the nuclear protein level. Fasting 
reduced mRNA for SREBP-1 by 40% and refeeding led to a 5 fold overshoot in 
mRNA SREBP-1 (Horton et al., 1998b).   
 In the present study a fasting/refeeding protocol was not followed. Chang liver 
cells were grown to subconfluence under normal growth conditions, followed by 
the addition of differential media conditions as specified in Table 4.2. mRNA 
levels of SREBP-1 were then assessed after 2, 6, 24 and 48 hours by qRT-PCR. 
The normalized fold expression of SREBP-1 after 2, 6, 24 and 48h for all 
experimental samples is displayed in Figures 6.14-6.19. The data are displayed in 
three different ways to illustrate different aspects. In Figure 6.14 the normalized 
expression of SREBP-1 in Chang liver cells exposed to MCBD-201 medium for 
two hours was used as the calibrator and this was set as a fold expression of one. 
SREBP-1 expression in all experimental samples at the four time points analyzed 
was calculated relative to the calibrator‟s (two hours of exposure to MCBD-201) 
expression.  Using this method the data clearly showed the decrease in SREBP-1 
expression over time in all experimental samples (Figure 6.14). 
The mRNA levels of SREBP-1 were much higher in all experimental samples 
after two and six hours of exposure to the differential medium, as compared to 24 
and 48 hours of exposure (Figure 6.14). Thus, shortly after fresh medium was 
added to the cultures SREBP-1 expression was raised (2 and 6 hour exposure), 
but after a longer exposure (24 and 48 hours) as nutrients become depleted 
SREBP-1 expression declines. This is in accordance with the findings of Horton 
et al. (1998a) and indicates that refeeding increases mRNA levels. Nutritional 
status regulates the expression of SREBP in the liver, as demonstrated by the 
decrease in SREBP-1 expression during fasting and its marked increase when 
refed a high carbohydrate diet (Ferre & Foufelle, 2007). Excess cardohydrates 
are converted to FA for storage as TG. Insulin stimulates this fatty acid synthesis 
in response to excess carbohydrates. Foretz et al., (1999) found that heptocytes 
cultured for 16 h without insulin did not express SREBP-1 cmRNA. Addition of insulin 
led in six hours to a clear-cut increase in its expression. Foretz et al., (1999) also 
showed that glucagon, through the production of cAMP, inhibits the effect of insulin 
 132 
13
2 
on SREBP-1c expression. This hormonal regulation explains why SREBP-1c 
expression is low in livers of starved rodents, but greatly increased after a 
carbohydrate refeeding (Foretz et al., 1999; Horton et al., 1998a). In the present 
study the higher SREBP-1 expression two hours and six hours after exposure of 
Chang liver cells to MCBD-201 medium supplemented with insulin and fructose 
could possibly also be explained by the presence of insulin in the medium, as 
insulin has been shown to induce SREBP-1 expression. 
 
Figure 6.14 The time course of the normalized relative expression of SREBP in all 
experimental samples.  
The expression of SREBP-1 in Chang liver cells cultured in MCBD-201 medium for two hours was 
used as calibrator sample, and the fold expression set as one. Fold normalized relative 
expression are shown on the Y-axis, values are means ± SEM. Each sample was performed in 
duplicate and experiment was repeated. Data are shown of one representative experiment. 
To compare the effect of the different treatments to the control sample, for each 
time point, the expression of SREBP-1 in Chang liver cells cultured in MCBD-201 
medium, was set as the calibrator for each time point individually (Figure 6.15-
6.18). The expression of SREBP-1 for all the experimental samples at each time 
point was then determined relative to the calibrator for that time point. After two 
hours of exposure Chang liver cells grown in MIF medium had a significantly 
lower SREBP-1 expression (P(H1)<0.0001) relative to the control sample (Figure 
6.15).  The presence of plant extract 1 and ciglitazone in the MIF medium did not 
significantly affect SREBP-1 expression after two hours of exposure compared to 
MIF treatment only (Figure 6.15).  
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After six hours SREBP-1 expression in Chang liver cells cultured in MIF medium 
increased to a level equal to the level of expression detected in cells grown in 
control medium (Figure 6.16). MIF medium supplemented with plant extract 2 or 
ciglitazone increased SREBP1 expression significantly more than MIF only. 
Nutritional status regulates SREBP-1 expression thus an increase in SREBP-1 
expression is expected. Ciglitazone is a PPARγ agonist and the increased 
SREBP-1 expression could be related to PPARγ activation. Plant extract 2 could 
also contain components that stimulate SREBP-1.  
 
Figure 6.15 The normalized relative 
expression levels of 
SREBP-1 in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for two hours. 
The fold SREBP-1 expression was 
determined relative to the expression of the 
calibrator sample. SREBP-1 expression in 
Chang liver cells cultured in MIF medium for 
two hours was significantly reduced 
compared to cells cultured in MCBD-201 
medium. (***P(H1)<0.0001) 
 
Figure 6.16  The normalized 
relative expression 
levels of SREBP-1 in 
Chang liver cells 
exposed to five 
different medium 
conditions respectively 
for six hours. 
The fold SREBP-1 expression was 
determined relative to the expression of the 
calibrator sample.  SREBP-1 expression in 
Chang liver cells cultured in MIF medium 
supplemented with plant extract 2 or 
ciglitazone for six hours was significantly 
increased compared to MIF treatment only. 
(***P(H1)<0.0001) 
After 24h of exposure there was no significant difference in SREBP-1 expression 
in Chang liver cells cultured in MCBD-201 medium compared to cells cultured in 
MIF medium only (Figure 6.17). Chang liver cells cultured in MIF medium 
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containing plant extract 1 or ciglitazone showed significantly reduced SREBP-1 
expression, compared to Chang liver cells cultured in MIF medium only. In 
contrast, cells cultured in MIF containing plant extract 2 again showed a 
significant increase in SREBP-1 expression compared to MIF treatment only.   
SREBP-1 has been shown to activate the hepatic expression of glucokinase and 
lipogenesis related genes (Foretz et al., 1999). SREBPs are known as master 
regulators of lipid homeostasis and overexpression of these genes lead to 
development of massive fatty liver engorged with both TG and cholesterol esters 
(Shimano et al., 1997; Horton et al., 1998b; Eberlè et al., 2004). Thus the ability 
of plant extract 1 and ciglitazone to down regulate SREBP-1 expression could 
also affect lipogenesis related genes which could have positive implications for 
lipid homeostasis. 
After 48 hours of exposure no significant difference in SREBP-1 expression was seen 
between Chang liver cells cultured in MCBD-201, MIF or MIF supplemented with plant 
extract 1 medium (Figure 6.18). SREBP-1 expression in Chang liver cells exposed to 
MIF supplemented with plant extract 2 was still significantly increased compared to 
MIF medium. MIF supplemented with ciglitazone still significantly decreased SREBP-1 
expression compared to MIF treatment (Figure 6.18). 
 Figure 6.19 shows the pattern of expression of each of the experimental 
treatments over time relative to the calibrator sample at each time point. After two 
hours of exposure SREBP-1 expression was lower in Chang liver cells cultured in 
all MIF containing media compared to MCBD-201 medium. This lower expression 
could possibly be because MIF contained fructose, and the metabolism of 
fructose could take longer than the metabolism of glucose in the MCBD-201 
medium to induce SREBP-1 expression. After 24 and 48 hours of exposure no 
significant difference in SREBP-1 expression was detected between cells cultured 
in MIF medium and MCBD-201 medium.   
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Figure 6.17 The normalized relative 
expression levels of 
SREBP-1 in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 24 hours. 
The fold SREBP-1 expression was 
determined relative to the expression of the 
calibrator sample.  Chang liver cells cultured 
in MCBD for 24 hours.  ***P(H1)<0.0001 
compared to MCBD. 
 
 
 
Figure 6.18 The normalized relative 
expression levels of 
SREBP-1 in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 48 hours. 
The fold SREBP-1 expression was 
determined relative to the expression of the 
calibrator sample.  Chang liver cells cultured 
in MCBD for 48 hours.  ***P(H1)<0.0001 
compared to MCBD. 
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Figure 6.19 Timecourse of SREBP-1 expression in Chang liver cells cultured in 
MCBD-201 medium supplemented with 0.1μM insulin and 1mM fructose 
(MIF) and the influence of the presence of plant extract 1 (P1), plant 
extract 2 (P2) and ciglitazone (Ciglit) in MIF medium on SREBP-1 
expression.  
Thus SREBP-1 expression in Chang liver cells cultured in MIF medium was not 
significantly different from the expression detected in cells cultured in MCBD-201 
medium after six hours, 24 hours or 48 hours of exposure. Koo et al. (2009) also 
showed that there was no statistical significance in hepatic SREBP-1 mRNA 
expression between fructose-fed and glucose-fed rats. However, Western blot 
analysis showed that protein levels of nuclear SREBP-1 were significantly 
increased in the fructose-fed group compared to the glucose-fed group indicating 
that the effect of fructose on SREBP-1 is post-transcriptional (Koo et al., 2009). 
This could explain why no significant differences in SREBP-1 expression are 
seen between Chang liver cells treated with MCBD-201 medium and MIF medium 
which contains added fructose and insulin.  
After six hours of exposure, SREBP-1 expression increased in Chang liver cells 
cultured in all MIF containing media compared to the two hour time point relative 
to the calibrator sample. After 24 hours SREBP-1 expression decreased in Chang 
liver cells cultured in all MIF containing medium compared to the six hour time 
point relative to the calibrator sample. After 48 hours SREBP-1 increased in 
6 hour 24 hour 48 hour 
R
e
la
ti
v
e
 F
o
ld
 E
x
p
re
s
s
io
n
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
1.8 
2 
2 hour 
MCBD 
MIF 
MIF+P1 
MIF+P2 
MIF+Ciglit 
 137 
13
7 
Chang liver cells in all MIF containing media with the exception of MIF medium 
supplemented with ciglitazone, when compared to the 24 hour time point relative 
to the calibrator sample.  
The pattern of expression of Chang liver cells cultured in MIF medium or MIF 
medium supplemented with plant extract 1, or plant extract 2 relative to the 
calibrator sample at each time point was similar over the time course analyzed.  
There was an increase of SREBP-1 expression relative to the calibrator after six 
hours of expression, decrease after 24 hours and increased after 48 hours of 
exposure. After six hours the increase in SREBP-1 expression was more 
significant in cells cultured in MIF medium supplemented with plant extract 2 than 
plant extract 1 and after 24 hours the decrease in expression was smaller in plant 
extract 2 than plant extract 1.  Both plant extracts tested in the present study are 
extracts of S. frutescens, although the same pattern of expression relative to the 
calibrator sample are followed, the relative fold up or down-regulation induced by 
these two plant extracts differ. The two S.frutescens extracts were prepared using 
different methods (section 3.2.1). The method of preparation could have 
influenced the active component present in the crude extract that could stimulate 
or inhibit SREBP-1 expression. This could possibly explain the differential fold 
expression of SREBP-1 seen between the two plant extracts.  
To summarize, Chang liver cells grown in MIF containing medium took longer to 
induce SREBP-1 expression, most likely because the fructose metabolism takes 
longer to induce SREBP-1 expression than glucose metabolism. No significant 
differences in SREBP-1 expression were seen between MCBD-201 and MIF 
treatment in Chang liver cells over the time course analyzed. This in aggreement 
with other studies which showed that fructose diets don‟t significantly increase 
SREBP-1 mRNA expression (Koo et al., 2009). SREBP-1 expression in Chang 
liver cells cultured in MIF medium supplemented with plant extract 1 or ciglitazone 
was significantly reduced compared to cells grown in MCBD-201 medium after 24 
hours. SREBP-1 expression in Chang liver cells cultured in MIF medium 
supplemented with plant extract 2 was significantly increased after six 24 and 48  
hours compared to cells grown in MIF medium.  
 138 
13
8 
6.2.5  PPARγ regulation 
PPARs regulate most of the pathways associated with lipid metabolism, the two 
isotypes α and γ have balanced regulatory actions, PPARα regulates FA oxidation in 
the liver and PPARγ regulates FA storage in the adipose tissue (Wahli, 2002). 
PPARγ is considered the master regulator of adipogenesis, and accordingly has 
been extensively studied in the context of obesity (Stienstra et al., 2006). In humans, 
PPARγ is most highly expressed in adipose tissue. High expression is also found in 
the large intestine. Other tissues such as liver, kidney and small intestine contain 
lower but considerable, levels of PPARγ (Fajas et al., 1997). PPARγ activation 
promotes adipose differentiation and induces the expression of numerous genes 
specific for fatty acid metabolism (Fajas et al., 2001).  
The development of white adipose tissue (WAT) is the result of a continuous 
differentiation process, in which PPARγ plays a central role. However this is a complex 
process in which several other proteins and transcription factors also contribute 
(Rosen et al., 2000). Excessive accumulation of adipose tissue leads to obesity whilst 
the absence of adipose tissue is associated with lipodystrophic syndromes (Fajas et 
al., 2001). In obesity, the adipose tissue as a whole is under enormous pressure to 
expand to accommodate an unprecedented quantity of nutrients (Sethi & Vidal-Puig, 
2007). Limited adipose capacity and disrupted adipose function underlie the 
mechanisms linking obesity to insulin resistance. Two theories are emerging that 
provide a molecular understanding of obesity-related insulin resistance: (1) When 
adipose tissue expandability becomes a limiting factor and nutrients cannot be stored 
safely in the adipocyte, nutrients are redirected toward other organs, such as muscle, 
liver, heart, or pancreas; (2) Excessive nutritional overload on the adipose tissue 
triggers qualitative and/or quantitative changes in adipokine production (Sethi & Vidal-
Puig, 2007). 
Vidal-Puig et al., (1996) investigated the physiological regulation of PPARγ gene 
expression in vivo. They found that fasting provokes a substantial decrease in the 
the levels of PPARγ mRNA and corresponding protein levels in adipose tissue 
from normal mice, and in three mice obesity models. Thus PPARγ expression is 
physiologically regulated by food intake. This regulation is conserved in the obese 
animal models studied Vidal-Puig et al. (1996). PPARγ expression is also 
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increased in obese humans, whilst a low calorie diet specifically down regulates 
the expression of PPARγ mRNA in the adipose tissue of obese humans (Vidal-
Puig et al., 1997). However, expression increases again during weight 
maintenance (Vidal-Puig et al., 1997). Insulin-deficient (streptozotocin) diabetic 
mice also showed suppressed PPARγ with partial restoration during insulin 
treatment. Insulin stimulation of 3T3F442A adipocytes also induced an increase 
in expression of PPARγ expression (Vidal-Puig et al., 1996). Exposure of normal 
control mice to high fat diet resulted in a modest induction of PPARγ mRNA and 
enlargement of adipose cells.  Administration of a high fat diet to UCP-DTA obese 
mice (obese mice generated by brown fat ablation via toxigene expression) did 
not induce a further increase in adipose tissue PPARγ expression, but resulted in 
specific induction of hepatic PPARγ expression (Vidal-Puig et al., 1996).  
Basal PPARγ expression in liver is low. However, in mouse models of steatosis, 
the development of fatty liver is associated with increased hepatic expression of 
PPARγ (Edvardsson et al., 1999; Matsusue et al., 2003).  During the 
development of steatosis hepatocytes become lipid-laden and gain phenotypic 
characteristics of adipocytes.The development of steatosis and progression into 
steatohepatitis is closely linked to an increased inflammatory state of the liver 
(reviewed by Stienstra et al., 2007). Hepatic PPARγ activation by rosiglitazone 
under steatotic conditions results in downregulation of multiple proinflammatory 
genes (Stienstra et al., 2007).     
In the present study PPARγ expression was analyzed in the insulin resistance 
Chang liver cell culture model. The rationale for investigating PPARγ expression 
is based on the emerging theory that limited adipose capacity would redirect 
nutrient storage toward other organs such as muscle, liver, heart or pancreas. It is 
hypothesized that faced with excess nutrients as in MIF medium and in the 
absence of adipose tissue (liver cell culture), the Chang liver cells will become 
adipogenic, resulting in the induction of hepatic PPARγ expression.  
The normalized fold expression of PPARγ after 2, 6, 24 and 48 hours in Chang liver 
cells under the media conditions indicated in Table 4.2 are displayed in three 
different ways to illustrate different aspects of the data (Figure 6.20-6.25). In Figure 
6.20 the normalized expression of PPARγ in Chang liver cells exposed to MCBD-
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201 medium for two hours was used as the calibrator and its expression was set as 
a fold expression of one. In all other experimental samples at the four time points 
analyzed, expression of PPARγ was calculated relative to the calibrator‟s 
expression.  
The time course of PPARγ expression in Chang liver cells cultured in MCBD-201 
medium showed no significant differences over time (Figure 6.20). Chang liver cells 
cultured with MIF medium showed a significant increase in PPARγ expression after 
six hours of exposure (P(H1)<0.0001). No significant difference in expression was 
seen in PPARγ expression between six and 24 hours (P(H1)=0.511), and 24 and 48 
hours of exposure (P(H1)=0.166). PPARγ expression increased after six hours of 
exposure to MIF medium and remains at this increased level of expression over the 
remainder of the time course. 
Chang liver cells cultured in MIF medium containing plant extract 1 show no 
significant difference in PPARγ expression between two and six hours of exposure 
(P(H1)=0.328) (Figure 6.20). However after 24 hours of exposure PPARγ expression 
decreased significantly (P(H1)<0.0001) in Chang liver cells compared to the six 
hours exposure of MIF medium supplemented with plant extract 1. This decrease in 
expression was still present after 48 hours of exposure to MIF medium 
supplemented with plant extract 1. Cells cultured in MIF containing plant extract 2 did 
not show significant differences in expression over the time course used.  
Chang liver cells cultured in MIF containing ciglitazone showed a significant increase 
in PPARγ expression after six hours of exposure (P(H1)<0.0001) (Figure 6.20). This 
increase was followed by a significant decrease after 24 hours of exposure 
(P(H1)<0.0001) that was maintained at 48 hours of exposure. The increase in 
PPARγ expression seen after 6 hours of exposure to MIF medium supplemented 
with ciglitazone is expected; as ciglitazone is a synthetic agonist of PPARγ. The 
TZD ciglitazone acts by improving insulin sensitivity, by the redistribution of WAT 
from visceral to subcutaneous depots which induce the appearance of small, 
newly differentiated adipocytes at the expense of large mature adipocytes 
(Shulman, 2000; Bays et al., 2004). PPARγ is physiologically regulated by food 
intake and therefore the decrease in PPARγ expression after 24 and 48 hours of 
exposure could also be explained by the depletion of nutrients over time. 
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Figure 6.20 The time course of the normalized relative expression of PPARγ in all 
experimental samples.  
The expression of PPARγ in Chang liver cells cultured in MCBD-201 medium for two hours was 
used as calibrator sample, and the fold expression set as 1. Fold normalized relative expression 
are shown on the Y-axis, values are means ± SEM. Each sample was performed in duplicate and 
experiment was repeated. Data are shown of one representative experiment. (**P(H1)<0.0001)  
In Figure 6.21-6.24 the expression of PPARγ in Chang liver cells exposed to MCBD-
201 at each time point (2h, 6h, 24h, or 48h) was set as the calibrator sample 
respectively. The expression of PPARγ in all the experimental samples at each 
time point was then determined relative to the calibrator for that time point. No 
significant difference in expression of PPARγ was seen between Chang liver cells 
cultured in MCBD-201 medium or MIF medium after 2 hours of exposure 
(P(H1)=0.335) (Figure 6.21). Cells cultured in MIF medium containing plant extract 1, 
plant extract 2 or ciglitazone showed an increase in PPARγ expression compared to 
MIF treatment only; however the increase was only significant for MIF medium 
supplemented with plant extract 2 or ciglitazone (P(H1)<0.0001) (Figure 6.21). 
Ciglitazone is a PPARγ agonist and would increase PPARγ expression as discussed 
previously. The induction in PPARγ expression in Chang liver cells cultured in MIF 
medium containing plant extract 2 could imply that plant extract 2 also contains a 
PPARγ agonist. Although the effect of plant extract 1 was not significant it also 
increased PPARγ expression so this means it contains an agonist perhaps at a 
lower concentration. 
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Figure 6.21 The normalized relative 
expression levels of 
PPARy in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 2 hours. 
The fold PPARy expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 2 hours. (***P(H1)<0.0001)  
 
Figure 6.22 The normalized relative 
expression levels of 
PPARy in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 6 hours. 
The fold PPARy expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 6 hours. (***P(H1)<0.0001) 
After six hours of exposure to MIF medium Chang liver cells showed significantly 
upregulated expression of PPARγ compared to cells grown in MCBD-201 
medium only (P(H1)<0.0001) (Figure 6.22). This upregulation in PPARγ 
expression is in agreement with the hypothesis that, in the presence of excess 
nutrients as found in MIF medium, Chang liver cells will increase PPARγ 
expression and activate lipogenic metabolic pathways. PPARγ expression in 
Chang liver cells cultured in MIF medium supplemented with plant extract 1, plant 
extract 2 or ciglitazone was significantly increased compared to cells cultured in 
control medium but not to MIF treated cells.  
After 24 hours PPARγ expression continued to be significantly upregulated in 
Chang liver cells cultured in MIF medium compared to cells cultured in MCBD 
medium (P(H1)<0.001) (Figure 6.23). In Chang liver cells cultured in MIF medium 
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supplemented with plant extract 1 or ciglitazone PPARγ expression was 
significantly reduced compared to MIF cultured cells (P(H1)<0.0001). PPARγ 
expression was reduced to the basal level of expression seen in cells cultured in 
MCBD-201 medium. Cells cultured in MIF medium containing plant extract 2 also 
showed reduced PPARγ expression compared to MIF treatment only, however this 
decrease was not significant (P(H1)=0.177) (Figure 6.23).  
 
Figure 6.23 The normalized relative 
expression levels of 
PPARy in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 24 hours. 
The fold PPARy expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 24 hours.  (***P(H1)<0.0001) 
 
Figure 6.24 The normalized relative 
expression levels of 
PPARy in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 48 hours. 
The fold PPARy expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 48 hours. (***P(H1)<0.0001) 
After 48 hours the PPARγ expression pattern for MIF cultures was similar to that at 
24 hours of exposure. Chang liver cells cultured in MIF medium maintained 
increased PPARγ expression levels relative to cells grown in MCBD-201 medium 
(P(H1)<0.0001) (Figure 6.24). PPARγ expression in cells cultured in MIF medium 
supplemented with plant extract 1 or ciglitazone remained significantly reduced 
compared to MIF cultured cells. There was no significant change in expression 
between cells cultured in MIF medium and cells cultured in MIF medium 
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supplemented with plant extract 2.  
In the present study it is hypothesized that in the presence of excess nutrients in 
MIF medium and in the absence of adipose tissue (liver cell culture), the Chang 
liver cells will become adipogenic resulting in the induction of hepatic PPARγ 
expression. The increased levels of PPARγ expression seen after 6, 24 and 48 
hours of exposure of Chang liver cells to MIF medium confirm this hypothesis.  
Two opposite PPARγ activity states, activation of PPARγ expression and 
reduction in expression could enhance insulin sensitivity (Yamauchi et al., 
2001).Yamauchi et al. 2001 proposed the following hypothesis to explain the 
mechanism of how PPARγ activity can regulate insulin sensitivity. They proposed 
that “normal” amounts of PPARγ activity could increase TG content in WAT, 
skeletal muscle and liver due to increased influx of FFA into these tissues. 
Supraphysiological activation of PPARγ promotes the flux of FFA from liver and 
skeletal muscle into WAT. This improves insulin sensitivity at the expense of 
increased WAT mass. Activation of PPARγ stimulates adipocyte differention and 
apoptosis thereby increasing the amount of small adipocytes which could 
contribute to the alleviation of insulin rsistance. In contrast, moderate reduction of 
PPARγ activity decreases TG content in WAT, skeletal muscle and liver and thus 
also improves insulin sensitivity.   
In the present study MIF treatment upregulates PPARγ expression after six hours 
of exposure and this increased level of expression is maintained over the 
remainder of the time course studied in MIF treated cells compared to cells 
cultured in control medium (Figure 6.25). Thus the MIF medium used to induce 
insulin resistance in Chang liver cells increased PPARγ expression which could 
activate the transcription of lipogenic enzymes that could convert the excess 
nutrients to be stored as fat. The accumulation of lipids in the Chang liver cells 
could comprise their capacity to take up glucose, and respond to insulin and 
contribute to the development of insulin resistance. The presence of plant extract 
1, plant extract 2 or ciglitazone in the MIF medium increased PPARγ expression 
after two and six hours of exposure and decreased PPARγ expression after 24 
and 48 hours of exposure. PPARγ expression is also regulated by nutritional 
status and the increase in expression seen after two and six hours could possibly 
 145 
14
5 
be due to the presence of excess nutrients in the medium shortly after addition of 
fresh media. PPARγ expression remained increased in Chang liver cells cultured 
in MIF medium after 24 and 48 hours of exposure, however when plant extract 1, 
plant extract 2 or ciglitazone were included in the MIF medium PPARγ expression 
was reduced. Thus the presence of the two plant extracts or ciglitazone in the 
MIF medium could protect against the increase in PPARγ expression and its 
effects on the lipid metabolism in Chang liver cells. 
Figure 6.25 illustrates the time course of PPARγ expression under each of the 
experimental medium conditions relative to the control sample at each time point. 
Chang liver cells cultured in MIF medium show similar PPARγ expression levels 
as cells cultured in MCBD-201 medium after two hours of exposure which 
increased significantly after six hours and remained significantly increased 
compared to the calibrator sample after 24 hours and 48 hours.    
The pattern of expression of PPARγ in cells cultured in MIF medium 
supplemented with plant extract 1 or plant extract 2 compared to the calibrator at 
each time point, was similar over the time course studied. PPARγ expression was 
increased after two and six hours compared to the calibrator sample followed by a 
decrease after 24 and 48 hours of exposure. Chang liver cells cultured in MIF 
medium supplemented with ciglitazone also showed a similar pattern of 
expression compared to the calibrator as cells cultured in MIF medium 
supplemented with the two plant extracts. The fact that the plant extracts also 
increase PPARγ in the same manner as ciglitazone after two hours of exposure 
implies that the plant extracts also contain PPARγ agonists, as this increase in 
expression was absent in cells cultured in MIF medium only. MIF medium 
supplemented with ciglitazone showed a greater and more significant increase in 
PPARγ expression after six hours of exposure, this is expected as ciglitazone is a 
pure PPARγ agonist whilst the plant extracts are crude extracts that contain 
PPARγ agonists but perhaps at a much lower concentration. 
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Figure 6.25 Timecourse of PPARγ expression in Chang liver cells cultured in MCBD 
medium supplemented with 0.1μM insulin and 1mM fructose (MIF) and 
the influence of the presence of plant extract 1 (P1), plant extract 2 (P2) 
and ciglitazone (Ciglit) in MIF medium on PPARγ expression  
6.2.6 PPARα regulation 
The PPARα expression was analyzed in Chapter 4 using a duplex reaction, in 
which PPARα and TATABP were amplified together in the same reaction. 
However literature has demonstrated that the conventional usage of a single 
gene for normalization leads to relatively large errors and that the geometric 
mean of multiple carefully selected reference genes is a more accurate 
normalization factor. Consequently PPARα expression was analyzed again using 
the two housekeeping genes TATABP and ATP5B.   
PPARα is highly expressed in the liver and it plays a crucial role in the regulation 
of β-oxidation of fatty acids during fasting. PPARα can reduce hepatic fat 
accumulation in the liver during the development of fatty liver disease, and thus 
prevents steatosis by inducing mitochondrial, peroxisomal, and microsomal fatty 
acid oxidation (reviewed by Stienstra et al., 2007). In addition to stimulating 
hepatic fatty acid oxidation and ketogenesis PPARα also controls 
gluconeogenesis (Patsouris et al., 2004). Patsouris et al., (2004) identified the 
gluconeogenic gene glycerol-3-phosphate dehydrogenase (GPDH) as a direct 
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target gene of PPARα.  
Synthetic ligands for PPARα include the fibrate drugs, phthalate ester 
plasticizers, herbicides, food flavours, and leukotriene D4 receptor antagonists 
(Francis et al., 2003). PPARα agonists in the form of fibrates (clofibrate, 
gemfibrozil, fenofibrate, bezafibrate and ciprofibrate) have been in use for over 40 
years for the treatment of dyslipidaemia. These drugs lower TG levels, raise high 
density lipoprotein (HDL) and decrease the levels of small dense low density 
lipoprotein (LDL) particles (Figure 1.5) (Francis et al., 2003).  
In Figure 6.26-6.31 the normalized fold expression of PPARα after 2, 6, 24 and 
48 hours in Chang liver cells under the media conditions indicated in Table 4.2 
are displayed in three different ways to illustrate different aspects of the data. In 
Figure 6.26 the normalized expression of PPARα in Chang liver cells exposed to 
MCBD-201 medium for two hours were used as the calibrator with a fold 
expression set as one. In all other experimental samples at the four time points 
analyzed, PPARα expression was calculated relative to the calibrator‟s 
expression.  
 
Figure 6.26 The time course of the normalized relative expression of PPARα in all 
experimental samples.  
The expression of PPARα in Chang liver cells cultured in MCBD medium for 2 hours was used as 
calibrator sample, and the fold expression set as 1. Fold normalized relative expression are 
shown on the Y-axis, values are means ± SEM. Each sample was performed in duplicate and 
experiment was repeated. Data are shown of one representative experiment.  
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In accordance with its role in β-oxidation PPARα expression was lower two and 
six hours after fresh medium was added compared to after 24 and 48 hours when 
nutrients in medium are more depleted (Figure 6.26).  
In Figure 6.27-6.30 the effect of the different experimental conditions on the 
expression of PPARα in Chang liver cells relative to the calibrator sample at each 
time point is illustrated. The calibrator sample at each time point was Chang liver 
cells cultured in MCBD-201 medium for 2, 6, 24 or 48 hours respectively. No 
significant difference in PPARα expression was seen between Chang liver cells 
cultured in MCBD-201 medium and MIF medium after two hours of exposure to 
these conditions (Figure 6.27). The presence of plant extract 1, plant extract 2 or 
ciglitazone in the MIF medium did not significantly change PPARα expression 
compared to MIF treatment only. PPARα expression determined with the duplex 
reaction after 2 hours of exposure (Figure 4.20) differed from these results. In the 
duplex reaction PPARα expression in Chang liver cells cultured in MIF medium 
was significantly reduced compared to cells cultured in MCBD-201 medium. MIF 
medium supplemented with plant extract 1, plant extract 2 or ciglitazone 
significantly increased PPARα expression in Chang liver cells compared to MIF 
cultured cells. In the duplex reaction only one reference gene was used for 
normalization and in the singlex reaction two reference genes were used for 
normalization. In the singleplex reaction a decrease in PPARα expression in cells 
cultured in MIF medium was seen compared to MCBD-201 treatment. There was 
also an increase in PPARα expression in cells cultured in MIF medium 
supplemented with plant extract 1, plant extract 2 or ciglitazone. However these 
changes were not significant in the singleplex reaction. 
After six hours of exposure no significant difference in PPARα expression was 
seen between Chang liver cells cultured in MCBD-201 and MIF medium (Figure 
6.28). The presence of plant extract 1, plant extract 2 or ciglitazone in the MIF 
medium did also not significantly influence PPARα expression compared to MIF 
treatment only. The duplex reaction also showed no significant changes in 
PPARα expression between the tested conditions after six hours of exposure 
(Figure 4.21).  
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Figure 6.27 The normalized relative 
expression levels of 
PPAR in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for two hours. 
The fold PPAR expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 2 hours.   
 
Figure 6.28 The normalized relative 
expression levels of 
PPAR in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for six hours. 
The fold PPAR expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 6 hours. 
After 24 hours PPARα expression was reduced in Chang liver cells cultured in 
MIF medium and MIF supplemented with plant extract 1, plant extract 2 or 
ciglitazone (Figure 6.29). Others have shown that fructose feeding greatly 
reduced PPARα protein and mRNA levels (Nagai et al., 2002; Kelley & Azhar, 
2005). In agreement to this PPARα expression was significantly reduced in 
Chang liver cells cultured in all media containing additional fructose and insulin. 
This phenomenon was also seen in the duplex reaction analysis of PPARα 
expression reported in Chapter 4 (Figure 4.22; 4.24). 
The reduced expression of PPARα in Chang liver cells cultured MIF medium was 
maintained at 48 hours of exposure compared to cells grown in control medium 
(Figure 6.30). MIF medium supplemented with plant extract 1 or plant extract 2 
increased PPARα expression in Chang liver cells compared to cells grown in MIF 
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medium only.The increase in PPARα was only significant for cells cultured in MIF 
medium supplemented with plant extract 1 and this increase was up to the level 
of the control MCBD-201 medium. PPARα plays a crucial role in β-oxidation and 
is normally upregulated during fasting. PPARα null mice have extensive hepatic 
steatosis because of diminished β-oxidation capacity (Barak & Kim 2007). Thus 
this reduced PPARα expression in cells cultured in MIF medium could reduce β-
oxidation cells and contribute to the accumulation of lipids in Chang liver cells. 
The presence of plant extract 1 and plant extract 2 in the MIF medium prevent 
this decrease in PPARα expression. After 48 hours, PPARα expression was not 
significantly altered by growth of Chang liver cells in MIF medium containing 
ciglitazone compared to culture in MIF medium only (Figure 6.30). Ciglitazone did 
not alter PPARα expression as it is a known PPARγ agonist, however the plant 
extracts can activate both PPARγ and PPARα expression and thus could contain 
dual PPARγ/PPARα agonists. PPARα expression analysis recorded with the 
duplex reaction in Chapter 4 also was reduced in MIF cultured cells compared to 
cells grown in MCBD-201 medium. Similar results as the singleplex reaction was 
also generated when Chang liver cells were cultured in MIF supplemented 
medium with plant extract1, plant extract 2 or ciglitazone.   
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Figure 6.29 The normalized relative 
expression levels of 
PPAR in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 24 hours. 
The fold PPAR expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 24 hours. (***P(H1)<0.0001) 
 
Figure 6.30 The normalized relative 
expression levels of 
PPAR in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 48 hours. 
The fold PPAR expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 48 hours. (***P(H1)<0.0001) 
Figure 6.31 illustrates the time course of PPARα expression under each of the 
experimental medium conditions relative to the control sample at each time point. 
Chang liver cells cultured in MIF medium showed a reduction in PPARα 
expression relative to the calibrator sample over the time course studied (Figure 
6.31). Nutritional status regulates PPARα expression and PPARα expression is 
normally upregulated upon fasting. In agreement to this all samples analyzed 
showed an increase in expression after 48 hours of exposure. MIF medium 
supplemented with plant extract 1 increases PPARα expression almost up to the 
level of MCBD-201 cultures. Although PPARα expression was increased in MIF 
treated cells after 48 hours PPARα expression still remains significantly reduced 
compared to the calibrator.  
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Figure 6.31 Timecourse of PPARα expression in Chang liver cells cultured in MCBD 
medium supplemented with 0.1μM insulin and 1mM fructose (MIF) and 
the influence of the presence of plant extract 1 (P1), plant extract 2 (P2) 
and ciglitazone (Ciglit) in MIF medium on PPARα expression  
6.2.7 TopI regulation 
TopI was one of the genes analyzed in the housekeeping gene analysis, which 
showed the greatest variation between the samples. This gene was subsequently 
included in further analysis to determine the cause of the variation seen.  
TopI plays a crucial role in the normal replication of DNA, as it removes DNA 
supercoiling generated during transcription and replication (reviewed by 
Rothenberg, 1997; Hardy et al., 2004). TopI cleaves one strand of the 
phosphodiester backbone of the duplex DNA by forming a covalent tyrosyl-
phosphodiester bond with the 3‟-end of the broken DNA (Champoux & 
McConaughy 1976; Madden et al., 1995). The intermediate formed is reversible 
and is called the TopI/DNA covalent complex. These TopI-linked breaks allow 
controlled rotation of the broken DNA around the intact strand. Immediately after 
the DNA is relaxed, TopI spontaneously re-ligates the breaks and restores intact 
duplex DNA. Under normal conditions, the covalent TopI-cleaved DNA 
intermediates, TopI cleavage complexes, are transient and almost undetectable 
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because the DNA re-ligation (closing) step is much faster than the DNA cleavage 
(nicking) step (Pourquier et al., 2001; Kuo et al., 2006; Sordet et al., 2006). 
Topoisomerases are fundamentally dualistic in nature, as has been highlighted by 
Larsen and Gobert (1999). TopI catalyzes essential reactions through the 
formation of these TopI cleavage complexes, which are normally present at low 
steady-state concentrations because they are transient catalytic intermediates. 
However, conditions that significantly increase the physiological concentration or 
lifetime of these TopI cleavage complexes breaks could also potentially be 
dangerous to the cell, due to their ability to mediate illegitimate recombination, 
which can lead to genomic instability and oncogenesis (Froelich-Ammon & 
Osheroff, 1995; Larsen & Gobert, 1999). The massive breakage of DNA by 
topoisomerases readily explains the widespread use of inhibitors of 
topoisomerases as antibacterial and anticancer agents (Hardy et al., 2004). 
TopI is the primary intracellular target of camptothecin (CPT), a plant alkaloid that 
was isolated from Camptotheca accumulate (Hsiang et al., 1985; Hsiang & Liu, 
1988 Garcia-Carbonero & Supko, 2002). The cytotoxic mechanism of CPT-
derived TopI inhibitors involves at least two successive steps. First, the drug 
stabilizes the covalent enzyme-DNA intermediate through inhibition of re-ligation 
without affecting the cleavage reaction (Hsiang et al., 1985; Garcia-Carbonero & 
Supko, 2002). Second, cleavable complexes are converted to DNA double-
stranded breaks by interaction with moving replication forks, and these DNA 
breaks are responsible for observed CPTs cytotoxicity (Hsiang et al., 1989; 
Garcia-Carbonero and Supko, 2002; Kuo et al., 2005). 
The normalized fold expression of TopI in Chang liver cells exposed to the 
different experimental media conditions indicated in Table 4.2 after 2, 6, 24 and 
48 hours are shown in Figure 6.32-6.36. In Figure 6.32 the normalized expression 
of TopI in Chang liver cells exposed to MCBD medium for two hours were used 
as the calibrator and its expression was set as a fold expression of one. In all 
other experimental samples at the four time points analyzed, expression of TopI 
was calculated relative to the calibrator‟s expression. Chang liver cells cultured in 
MCBD, MIF or MIF supplemented with plant extract 1 show an increase in TopI 
expression with time. The marked increase in TopI expression was not so 
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prominent in cells cultured in MIF supplemented with plant extract 2 and 
ciglitazone.    
 
Figure 6.32 The time course of the normalized relative expression of TopI in all 
experimental samples.  
The expression of TopI in Chang liver cells cultured in MCBD medium for 2 hours was used as 
calibrator sample, and the fold expression set as 1. Fold normalized relative expression are 
shown on the Y-axis, values are means ± SEM. Each sample was performed in duplicate and 
experiment was repeated. Data are shown of one representative experiment.  
In Figures 6.33-6.36 the effect of the different experimental conditions on the 
expression of TopI in Chang liver cells relative to the calibrator sample at each 
time point is illustrated. The calibrator sample at each time point was Chang liver 
cells cultured in MCBD medium for 2, 6, 24 or 48 hours, respectively.  
After two hours of exposure TopI expression in Chang liver cells cultured in MIF 
medium was significantly reduced compared to cells grown in MCBD-201 medium 
only (Figure 6.33). The presence of plant extracts 1, 2 or ciglitazone in MIF 
medium increases TopI expression significantly compared the expression seen in 
cells cultured in MIF medium only. The increase in TopI expression seen in cells 
cultured in MIF medium supplemented with plant extract 1 or ciglitazone was also 
significantly higher than the expression in cells cultured in the control 
medium.TopI plays a important role in the normal replication of DNA. The higher 
expression of TopI in cells cultured in MIF medium containing plant extracts and 
ciglitazone could possibly be explained by increased cell grown after fresh 
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medium was added to the cells which would lead to increased replication. 
Another explanation could be that the MIF medium caused stress to the Chang 
liver cells which could lead to DNA damage. The presence of the plant extracts 
and ciglitazone could compensate for the injury to the cells by increasing TopI 
expression to repair DNA.   
 
Figure 6.33  The normalized 
relative expression 
levels of Topl in Chang 
liver cells exposed to 
five different medium 
conditions respectively 
for 2 hours. 
The fold Topl expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD 
for 2 hours. (***P(H1)<0.0001)  
 
Figure 6.34 The normalized relative 
expression levels of 
Topl in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 6 hours. 
The fold Topl expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD 
for 6 hours. (***P(H1)<0.0001) 
 
After six hours no significant differences in TopI expression was seen between 
cells cultured in MCBD-201 medium and MIF medium or MIF medium 
supplemented with plant extract 1 or ciglitazone (Figure 6.34). However TopI 
expression was reduced in cells cultured in MIF medium supplemented with plant 
extract 2 compared to MIF cultured cells. One of the medical uses of S.frutescens 
includes the treatment of cancer. TopI inhibitors could act as anti-cancer agents 
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(Hardy et al., 2004). The ability of plant extract 2 to inhibit TopI expression could 
possibly be linked to its anti-cancer activity.  
After 24 hours of exposure TopI expression was increased in cells cultured in MIF 
medium compared to cells grown in MCBD-201 medium (Figure 6.35). TopI 
expression in Chang liver cells cultured in MIF medium supplemented with plant 
extract 1, plant extract 2 or ciglitazone was significantly decreased compared to 
MIF cultured cells. TopI has a crucial role in replication of DNA, however too high 
as well as   too low expressions of TopI can be dangerous to the cell (Larsen and 
Gobert, 1999). TopI concentrations higher than their physiological concentration 
could be potentially dangerous to the cell due to their ability to mediate illegitimate 
recombination. MIF treatment caused stress to the cells and the increase in TopI 
expression could be the result of this stress. The inhibition of TopI expression in 
the presence of the plant extracts and ciglitazone could possibly contribute to 
apoptosis of injured cells. The inhibition of TopI by the plant extracts could 
possibly also imply that the plant extracts could contain TopI inhibitors.  
After 48 hours no significant changes in TopI expression were seen in Chang liver 
cells cultured in the different media conditions tested. However MIF medium 
supplemented with ciglitazone showed a significant decrease in TopI expression 
compared to MIF treatment.  
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Figure 6.35 The normalized relative 
expression levels of 
Topl in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 24 hours. 
The fold Topl expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in MCBD 
for 24 hours. (P(H1)<0.0001)   
 
Figure 6.36 The normalized relative 
expression levels of 
Topl in Chang liver 
cells exposed to five 
different medium 
conditions respectively 
for 48 hours. 
The fold Topl expression was determined 
relative to the expression of the calibrator 
sample.  Chang liver cells cultured in 
MCBD for 48 hours. (P(H1)<0.0001) 
  
In summary the expression of three transcription factors, SREBP-1, PPARγ and 
PPARα were investigated over a time course in a model of insulin resistance in 
Chang liver cells. These transcription factors were investigated because of their 
important role in the regulation of lipid metabolism 
In the present study it is hypothesized that in the presence of excess nutrients in 
MIF medium and in the absence of adipose tissue (liver cell culture), the Chang 
liver cells will become adipogenic and accumulate lipids in the cells. The 
increased lipid content will compromise the cells‟ ability to take up glucose and 
respond to insulin and thus result in insulin resistance. 
SREBP-1 expression was not significantly altered in MIF cultured cells compared 
to cells grown in control medium. SREBP-1 expression was significantly 
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increased in cells cultured in MIF medium supplemented with plant extract 2, after 
6, 24 and 48 hours of exposure. In contrast MIF medium supplemented with plant 
extract 1 showed a decrease in SREBP-1 expression after 24 hours of exposure.   
MIF treatment significantly increased PPARγ expression after six hours of 
exposure compared to expression in cells cultured in MCBD-201 medium. PPARγ 
expression remained increased in cells cultured in MIF medium after 24 and 48 
hours of exposure compared to cells grown in MCBD-201 medium. MIF medium 
supplemented with plant extract 1 or plant extract 2 showed an increase in 
PPARγ expression after two hours of expression which is not seen in cells 
cultured in MIF only or MCBD-201 medium. PPARγ epression in cells cultured in 
MIF medium supplemented, with the PPARγ agonist, ciglitazone were also 
increased after two hours. This could imply that as the plant extracts can 
activivate PPARγ in the same manner as ciglitazone, the plant extracts must also 
contain PPARγ agonists.      
PPARα expression was not significantly changed after two hours and six hours of 
exposure to the different media. After 24 hours PPARα expression was 
significantly decreased in all cells cultured in MIF containing media compared to 
cells grown in control media this decreased PPARα expression was still present 
after 48 hours. PPARα expression of cells cultured in MIF medium supplemented 
with plant extract 1 or plant extract 2 was increased compared to cells grown in 
MCBD-201 medium only after 48 hours of exposure. However the increase in 
PPARα expression was only significant for MIF medium supplemented with plant 
extract 1. Thus MIF treatment reduced PPARα expression and addition of plant 
extract 1 or plant extract 2 prevented this decrease of expression and in the case 
of plant extract 1 increased PPARα to the level seen in cells cultured in control 
medium.  
Both plant extracts can activate PPARγ and PPARα expression in Chang liver 
cells, this increase in expression is not present when cells were cultured in MIF 
only. Thus the plant extracts must contain substances that can activate both 
PPARγ and PPARα, dual PPARγ/α agonists.   
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CHAPTER 7:  EXPRESSION PROFILE OF 84 DIABETES 
RELATED GENES USING A qRT-PCR ARRAY IN THE INSULIN 
RESISTANT MODEL 
7.1 INTRODUCTION 
A panel of 84 diabetes related genes was screened in the insulin resistant Chang 
hepatocyte model to determine the effect of the insulin resistance inducing 
agents, insulin and fructose, on gene expression. In addition, the effect on gene 
expression in the insulin resistant cells cultured with the insulin resistant inducing 
medium supplemented with plant extract 1 was also determined. The 
RT2ProfilerTM PCR Array was used for this analysis. The RT2ProfilerTM PCR Array 
combines the advantages of real-time PCR with the ability of microarrays to 
detect the expression of many genes simultaneously. The PCR Array is a 96- or 
384-well plate containing RT2 qPCR Primer Assays for a set of 84 relevant 
pathway or disease associated genes, plus five housekeeping genes, and three 
controls. A complete system includes an instrument specific master mix and an 
optimized first strand synthesis kit. 
The human diabetes RT2ProfilerTM PCR Array used in the present study profiled 
the expresson of 84 genes related to onset, development and progression of 
diabetes. They included genes that contribute to obesity, IR, the early onset of 
diabetes and complications of diabetes mellitus. These genes were grouped into 
6 functional categories: receptors, transporters and channels, nuclear receptors, 
metabolic enzymes, secreted factors, signal transduction proteins and 
transcription factors. Table 7.1 shows the genes with a full description of the gene 
names, symbols, position on the 96 well plate and reference sequence number.    
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1 
  Table 7:1 Gene table showing the symbols and complete description of the 84 genes analyzed 
Well UniGene RefSeq Symbol Description Gene Name 
A01 Hs.54470 NM_000352 ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 ABC36/HHF1 
A02 Hs.298469 NM_152831 ACE Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 ACE1/CD143 
A03 Hs.387567 NM_001096 ACLY ATP citrate lyase ACL/ATPCL 
A04 Hs.2549 NM_000025 ADRB3 Adrenergic, beta-3-, receptor BETA3AR 
A05 Hs.19383 NM_000029 AGT Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) ANHU/SERPINA8 
A06 Hs.631535 NM_001626 AKT2 V-akt murine thymoma viral oncogene homolog 2 PKBBETA/PRKBB 
A07 Hs.130730 NM_000486 AQP2 Aquaporin 2 (collecting duct) AQP-CD/WCH-CD 
A08 Hs.514821 NM_002985 CCL5 Chemokine (C-C motif) ligand 5 D17S136E/RANTE
S 
A09 Hs.644637 NM_000648 CCR2 Chemokine (C-C motif) receptor 2 CC-CKR-2/CCR2A 
A10 Hs.591629 NM_006139 CD28 CD28 molecule Tp44 
A11 Hs.512682 NM_001712 CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 
(biliary glycoprotein) 
BGP/BGP1 
A12 Hs.76171 NM_004364 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha C/EBP-alpha 
B01 Hs.247824 NM_005214 CTLA4 Cytotoxic T-lymphocyte-associated protein 4 CD152/CELIAC3 
B02 Hs.417962 NM_057158 DUSP4 Dual specificity phosphatase 4 HVH2/MKP-2 
B03 Hs.527295 NM_006208 ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase 1 M6S1/NPP1 
B04 Hs.494496 NM_000507 FBP1 Fructose-1,6-bisphosphatase 1 FBP 
B05 Hs.436448 NM_005251 FOXC2 Forkhead box C2 (MFH-1, mesenchyme forkhead 1) FKHL14/LD 
B06 Hs.632336 NM_005249 FOXG1B Forkhead box G1B BF1/FKH2 
B07 Hs.247700 NM_014009 FOXP3 Forkhead box P3 AIID/DIETER 
B08 Hs.212293 NM_000151 G6PC Glucose-6-phosphatase, catalytic subunit G6PT/GSD1a 
B09 Hs.461047 NM_000402 G6PD Glucose-6-phosphate dehydrogenase G6PD1 
B10 Hs.516494 NM_002054 GCG Glucagon GLP1/GLP2 
B11 Hs.208 NM_000160 GCGR Glucagon receptor GGR 
B12 Hs.1270 NM_000162 GCK Glucokinase (hexokinase 4, maturity onset diabetes of the 
young 2) 
GK/GLK 
C01 Hs.389103 NM_002062 GLP1R Glucagon-like peptide 1 receptor MGC138331 
1
6
1
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Well UniGene RefSeq Symbol Description Gene Name 
C02 Hs.524418 NM_005276 GPD1 Glycerol-3-phosphate dehydrogenase 1 (soluble) FLJ26652 
C03 Hs.445733 NM_002093 GSK3B Glycogen synthase kinase 3 beta GSK3 
C04 Hs.517581 NM_002133 HMOX1 Heme oxygenase (decycling) 1 HO-1/bK286B10 
C05 Hs.116462 NM_178849 HNF4A Hepatocyte nuclear factor 4, alpha HNF4/HNF4a7 
C06 Hs.643447 NM_000201 ICAM1 Intercellular adhesion molecule 1 (CD54), human rhinovirus 
receptor 
BB2/CD54 
C07 Hs.500546 NM_004969 IDE Insulin-degrading enzyme INSULYSIN 
C08 Hs.856 NM_000619 IFNG Interferon, gamma IFG/IFI 
C09 Hs.635441 NM_000599 IGFBP5 Insulin-like growth factor binding protein 5 IBP5 
C10 Hs.413513 NM_001556 IKBKB Inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta 
IKK-beta/IKK2 
C11 Hs.193717 NM_000572 IL10 Interleukin 10 CSIF/IL-10 
C12 Hs.674 NM_002187 IL12B Interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic 
lymphocyte maturation factor 2, p40) 
CLMF/CLMF2 
D01 Hs.513457 NM_000418 IL4R Interleukin 4 receptor CD124/IL4RA 
D02 Hs.512234 NM_000600 IL6 Interleukin 6 (interferon, beta 2) BSF2/HGF 
D03 Hs.523875 NM_001567 INPPL1 Inositol polyphosphate phosphatase-like 1 SHIP2 
D04 Hs.89832 NM_000207 INS Insulin PROINSULIN 
D05 Hs.465744 NM_000208 INSR Insulin receptor CD220/HHF5 
D06 Hs.32938 NM_000209 PDX1 Pancreatic and duodenal homeobox 1 IDX-1/IPF1 
D07 Hs.471508 NM_005544 IRS1 Insulin receptor substrate 1 HIRS-1 
D08 Hs.442344 NM_003749 IRS2 Insulin receptor substrate 2 IRS2 
D09 Hs.588289 NM_001315 MAPK14 Mitogen-activated protein kinase 14 CSBP1/CSBP2 
D10 Hs.138211 NM_002750 MAPK8 Mitogen-activated protein kinase 8 JNK/JNK1 
D11 Hs.21160 NM_002395 ME1 Malic enzyme 1, NADP(+)-dependent, cytosolic HUMNDME/MES 
D12 Hs.72981 NM_002500 NEUROD1 Neurogenic differentiation 1 BETA2/BHF-1 
E01 Hs.431926 NM_003998 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1 (p105) 
DKFZp686C01211/
EBP-1 
E02 Hs.653170 NM_000603 NOS3 Nitric oxide synthase 3 (endothelial cell) ECNOS/NOS III 
E03 Hs.298069 NM_005011 NRF1 Nuclear respiratory factor 1 ALPHA-PAL 
     1
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Well UniGene RefSeq Symbol Description Gene Name 
E04 Hs.431279 NM_006178 NSF N-ethylmaleimide-sensitive factor SKD2 
E05 Hs.177766 NM_001618 PARP1 Poly (ADP-ribose) polymerase family, member 1 ADPRT/ADPRT1 
E06 Hs.497487 NM_002646 PIK3C2B Phosphoinositide-3-kinase, class 2, beta polypeptide C2-
PI3K/DKFZp686G1
6234 
E07 Hs.518451 NM_005026 PIK3CD Phosphoinositide-3-kinase, catalytic, delta polypeptide P110D 
E08 Hs.132225 NM_181504 PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) GRB1/p85-ALPHA 
E09 Hs.103110 NM_005036 PPARA Peroxisome proliferative activated receptor, alpha NR1C1/PPAR 
E10 Hs.162646 NM_015869 PPARG Peroxisome proliferator-activated receptor gamma NR1C3/PPARG1 
E11 Hs.527078 NM_013261 PPARGC1
A 
Peroxisome proliferator-activated receptor gamma, coactivator 1 
alpha 
LEM6/PGC-1(alpha) 
E12 Hs.591261 NM_133263 PPARGC1
B 
Peroxisome proliferator-activated receptor gamma, coactivator 1 
beta 
PERC/PGC-1(beta) 
F01 Hs.43322 NM_006251 PRKAA1 Protein kinase, AMP-activated, alpha 1 catalytic subunit AMPK/AMPKa1 
F02 Hs.549162 NM_016203 PRKAG2 Protein kinase, AMP-activated, gamma 2 non-catalytic subunit AAKG/AAKG2 
F03 Hs.460355 NM_002738 PRKCB1 Protein kinase C, beta 1 PKC-beta/PKCB 
F04 Hs.417549 NM_002827 PTPN1 Protein tyrosine phosphatase, non-receptor type 1 PTP1B 
F05 Hs.282417 NM_002863 PYGL Phosphorylase, glycogen; liver (Hers disease, glycogen storage 
disease type VI) 
PYGL 
F06 Hs.296169 NM_004578 RAB4A RAB4A, member RAS oncogene family RAB4 
F07 Hs.283091 NM_020415 RETN Resistin ADSF/FIZZ3 
F08 Hs.82848 NM_000655 SELL Selectin L (lymphocyte adhesion molecule 1) CD62L/LAM-1 
F09 Hs.380691 NM_001042 SLC2A4 Solute carrier family 2 (facilitated glucose transporter), member 
4 
GLUT4 
F10 Hs.511149 NM_003825 SNAP23 Synaptosomal-associated protein, 23kDa HsT17016/SNAP23
A 
G01 Hs.83734 NM_004604 STX4 Syntaxin 4 STX4A/p35-2 
G02 Hs.288229 NM_003165 STXBP1 Syntaxin binding protein 1 MUNC18-1/UNC18 
G03 Hs.534352 NM_006949 STXBP2 Syntaxin binding protein 2 Hunc18b/MUNC18-
2 
     1
6
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Well UniGene RefSeq Symbol Description Gene Name 
G04 Hs.191144 NM_006481 TCF2 Transcription factor 2, hepatic; LF-B3; variant hepatic nuclear 
factor 
FJHN/HNF1B 
G05 Hs.645227 NM_000660 TGFB1 Transforming growth factor, beta 1 CED/DPD1 
G06 Hs.94367 NM_003317 TITF1 Thyroid transcription factor 1 BCH/BHC 
G07 Hs.241570 NM_000594 TNF Tumor necrosis factor (TNF superfamily, member 2) DIF/TNF-alpha 
G08 Hs.279594 NM_001065 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A CD120a/FPF 
G09 Hs.516826 NM_021158 TRIB3 Tribbles homolog 3 (Drosophila) C20orf97/NIPK 
G10 Hs.66708 NM_004781 VAMP3 Vesicle-associated membrane protein 3 (cellubrevin) CEB 
G11 Hs.653207 NM_194434 VAPA VAMP (vesicle-associated membrane protein)-associated 
protein A, 33kDa 
VAP-33/VAP-A 
G12 Hs.73793 NM_003376 VEGFA Vascular endothelial growth factor A VEGF/VEGF-A 
H01 Hs.534255 NM_004048 18SrRNA Human 18S ribosomal RNA 18SrRNA 
H02 Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan 
syndrome) 
HGPRT/HPRT 
H03 Hs.546356 NM_012423 RPL13A Ribosomal protein L13a RPL13A 
H04 Hs.544577 NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase G3PD/GAPD 
H05 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H06 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H07 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H08 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H09 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H10 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H11 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
H12 Hs.520640 NM_001101 ACTB Actin, beta PS1TP5BP1 
   1
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7.2 MATERIAL AND METHODS 
Figure 7.1 shows the layout of the PCR array experiment. After RNA isolation the 
mRNAs were reverse transcribed into first strand cDNA, the template for the PCR 
reaction. The template was then mixed with ready to use PCR master mix and the 
PCR mixture aliquoted into each well of the same plate containing pre-dispensed 
gene-specific primer sets.  
7.2.1 RNA Extraction 
RNA was extracted from Chang liver cells grown to 70% confluence in RPMI medium 
and then exposed for 24 hours to either (1) MCBD-201 medium, (2) MCBD-201 
medium with added insulin and fructose or (3) MCBD-201 medium with added insulin 
and fructose in the presence of plant extract 1.   
 
Figure 7.1 Illustration of the layout of PCR Array experiment.  
1. Isolate total RNA 
5. Perform 
Thermal 
Cycling 
  
2. Reverse Transcribe RNA 
4. Aliquot the PCR 
mixture across the PCR 
Arrays 
3. Add cDNA Directly to 
RT
2
 PCR Master Mix 
1 
2 
3 
4 
5 
Chang liver cells cultured for 24 hours in: 
MCBD-201 MCBD-201+insulin+fructose      MCBD+Iinsulin +fructose +plant extract1 
 
Cultured in: 
  
cultured in: 
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RNA was isolated, then reverse transcribed and the resulting cDNA added to PCR master mix. The 
PCR mixture was aliqoted across the PCR array plate and, after the thermal cycling step, the fold 
expression was determined with the ∆∆Ct method.   
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7.2.2 First Strand cDNA Synthesis 
The reverse transcriptase reaction was performed using the ReactionReadyTM First 
Strand cDNA Synthesis Kit (Bioscience Corporation) following the manufacturer‟s 
instructions.The kit contained all the reagents needed to synthesize first strand cDNA 
from the RNA sample. It also contained a genomic DNA elimination buffer that 
removed any residual genomic DNA from the RNA sample.  The ReactionReadyTM 
First Strand cDNA Synthesis Kit used random hexamers and oligo-dT primers to 
prime cDNA synthesis. 
For each RNA sample 1μg of RNA was combined with 1μl of Buffer P, included in 
cDNA synthesis kit,  and made up to a final volume of 10μl with RNase free H2O. The 
contents were mixed gently with a pipet and briefly centrifuged; whereafter they were 
placed at 70°C for three minutes, cooled to 37°C and incubated at 37°C for ten 
minutes to prepare the RNA for reverse transcription.  
The RT cocktail was prepared as indicated in Table 7.2 for each sample and warmed 
at 37°C for one minute. A 10μl aliquot of the RT cocktail was added to each of the 
10μl RNA sample preparations, mixed well and incubated at 37°C for 60 minutes. At 
the end of the reaction period the mixture was heated at 95°C for five minutes to 
degrade the RNA and to inactivate the reverse transcriptase. The prepared cDNA 
was either stored overnight at -20°C or used immediately in the qRT-PCR reaction. 
Table 7:2 Preparation of the RT Cocktail mixture 
RT Cocktail Reagents 1 Reaction 
Buffer BC (5 X RT Buffer) 4μl 
RNase-free H2O 4μl 
RI (RNase Inhibitor) 1μl 
RE (Reverse Transcriptase) 1μl 
Final Volume 10μl 
7.2.3  qRT-PCR 
The RT2 Real-Time SYBR Green/Fluorescein PCR master mix specifically designed 
for BioRad iCycler and MyiQ was used (Bioscience Corporation). This kit contained a 
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HotStart Taq polymerase which only gained full activity after its activation step.  
For each sample analyzed, 20μl of prepared cDNA was diluted with 80μl of RNase-
free water and used as the template for the PCR reaction. PCR reaction mix was 
prepared as indicated in the instruction manual. Figure 7.2 shows the layout of the 
PCR Array plate.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 
B G13 G14 G15 G16 G17 G18 G19 G20 21 G22 G23 G24 
C G25 G26 G27 G28 G29 G30 G31 G32 G33 G34 G35 G36 
D G37 G38 G39 G40 G41 G42 G43 G44 G45 G46 G47 G48 
E G49 G50 G51 G52 G53 G54 G55 G56 G57 G58 G59 G60 
F G61 G62 G63 G64 G65 G66 G67 G68 G69 G70 G71 G72 
G G73 G74 G75 G76 G77 G78 G79 G80 G81 G82 G83 G84 
H HK1 HK2 HK3 HK4 HK5 HK5 HK5 HK5 HK5 HK5 NRT NTC 
Figure 7.2 Layout of PCR Array.  
Wells A1 through G12 contained primers for genes of the Human Diabetes RT
2
 Profiler
TM
 shown in 
Table 7.1 (G1-G84). Wells H1 to H5 contained a panel of housekeeping genes (HK1-HK5) for 
normalizing the PCR Array data. Wells H6 to H10 contained the same housekeeping gene primers as 
in well H5. These wells were used to estimate the linear dynamic range of the assay and a different 
serial 10-fold dilution of the cDNA template was added to each of these wells. Well H11 contained 
RNA diluted into master mix and served as NRT (*) control. Well H12 contained the same reference 
gene primers as H5, and only master mix was added to this well to serve as NTC (**).      
(* = No Reverse Transcription Control; ** = No Template control) 
The PCR master mix cocktail was prepared by adding the volumes of reagents as 
indicated Table 7.3 to a 5ml tube, mixing well and centrifuging briefly. A 1XPCR 
master mix was prepared by combining 100μl of 2XSuperArray PCR master mix with 
100μl of RNase free H2O; this was mixed well and centrifuged briefly. To prepare the 
10-fold serial dilutions of cDNA; 3μl of the PCR master mix cocktail was added to 27 
μl of 1XPCR master mix. Four more 10-fold serial dilutions of this mixture were 
generated in 1XPCR master mix. The NRT control was prepared by mixing 1μl of a 
1:100 dilution of the original input total RNA with 24 μl of 1XPCR master mix, and a 
25 μl aliquot of the 1XPCR master mix was used as the NTC.  
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Table 7:3 Preparation of PCR Master Mix 
PCR Master Mix Reagents Volume 
2X SuperArray PCR master mix 1225μl 
Diluted first strand cDNA synthesis reaction     98 μl 
RNase free H2O 1127 μl 
Total Volume 2450 μl 
After all the different cocktails were prepared the plate seal was carefully removed 
and 25μl of the appropriate cocktail was added to each well. To wells A1 through H5 
PCR master mix cocktail was added, the five 10-fold serial dilutions generated as 
described above were added to wells H6 through H10 (Figure 7.2). Well H11 
contained the NRT control and H12 the NTC. The array was sealed tightly with 
optical thin wall eight cap strips and thermal cycling was performed as indicated in 
Table 7.4. After the amplification a melt curve was also performed. An initial step at 
950C for 30 seconds was followed by 600C for 30sec, thereafter the temperature was 
increased by 0.50C increments up to 950C, during which the meltcurve data was 
collected. No technical replicates, but two biological replicates were performed for 
the experiment.       
Table 7:4 Thermal Cycling Program 
Cycles Duration Temperature 
1 10 min 95°C 
40 
15 sec 95°C 
30sec 55°C 
30sec 72°C 
7.2.4 Data Analysis 
The data were analyzed using the integrated software package for the PCR Super 
Array System, RT2 Profiler PCR Array Data Analysis Template v2.0 
(http://www.superarray.com/pcrarraydataanalysis). This program automatically 
performed all ∆∆Ct based fold-change calculations from uploaded raw threshold 
cycle data and displayed results in multiple formats annotated to the gene list. 
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7.3 RESULTS AND DISCUSSION 
The RT2 Profiler PCR Array Data Analysis Template v2.0 allowed pair-wise 
comparison between groups. In the present study three variables were analyzed: 
(1) Chang liver cells cultured in MCBD-201 medium (MCBD). 
(2) Chang liver cells cultured in MCBD-201 medium supplemented with insulin and 
fructose to induce insulin resistance (MIF)  
(3) Chang liver cells cultured in MCBD-201 medium supplemented with insulin, 
fructose and plant extract 1 (MIF+P1) 
7.3.1 The effect of the insulin resistance inducing medium on 84 
Diabetes related genes 
A pair-wise comparison between cells cultured in MCBD-201 medium (control 
sample) and cells cultured in MCBD-201 medium supplemented with 0.1μM insulin 
and 1mM fructose (test sample) was performed to determine the effect of insulin and 
fructose treatment on the gene expression profile (Table 7.5). Table 7.5 shows the 
results in alphabetical order as analyzed by the RT2 Profiler PCR Array Data 
Analysis Template v2.0. In all the following tables genes showing more then 3-fold 
down-regulation are marked with blue, genes showing more then 3-fold up-regulation 
are marked with green  and genes showing significant p-values (p<0.05) are marked 
with red.  
Changes in the expression of two genes, Vesicle-associated membrane protein 3 
(VAMP3) and N-ethylmaleimide-sensitive factor (NSF) showed significant p-values of 
0.0151 and 0.0213 respectively (Table 7.6). NSF and VAMP3 both play an important 
role in vesicle-mediated transport. Vesicle-mediated transport delivers membrane–
impermeable molecules, including membrane proteins, secretory factors and lipids, 
from one organelle to another and in and out of cells (Wilson et al., 1992). This 
process involves successive steps of transport on cytoskeleton, tethering, docking 
and finally membrane fusion (May et al., 2001). 
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Table 7:5 Gene expression profile showing the fold change between cells treated with MCBD medium                                    
(Control sample) and the MCBD medium with insulin and fructose added to induce insulin                   
resistance (Test sample). 
Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down 
1
regulation 
Test 
Sample 
Contr
ol 
Sampl
e 
Test 
Sample
2
 
Control 
Sample
3
 
Test sample/ 
control 
sample 
P-value 
Test 
sample / 
control 
sample 
ABCC8 A01 35.00 34.90 1.2E-05 1.0E-05 1.12 0.4226 1.12 
ACE A02 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A
4
 1.20 
ACLY A03 29.35 29.25 5.9E-04 5.2E-04 1.12 0.9047 1.12 
ADRB3 A04 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
AGT A05 34.90 35.00 1.3E-05 9.7E-06 1.29 0.4226 1.29 
AKT2 A06 30.70 30.60 2.3E-04 2.1E-04 1.12 0.9437 1.12 
AQP2 A07 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
CCL5 A08 31.85 33.10 1.0E-04 3.6E-05 2.85 0.5955 2.85 
CCR2 A09 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
CD28 A10 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
CEACAM1 A11 35.00 34.45 1.2E-05 1.4E-05 0.82 0.4226 -1.22 
CEBPA A12 32.65 31.85 5.9E-05 8.6E-05 0.69 0.6005 -1.45 
CTLA4 B01 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
                                            
1 Alternative method to present fold change, a positive fold change means upregulation, a negative fold change means down-regulation. 
2 Test sample: Chang cells grown in MCBD medium with insulin and fructose added for 24 hours to induce insulin resistance. 
3 Control sample: Chang cells grown in MCBD medium for 24 hours. 
4
 N/A: Program unable to calculate p-value if Ct-value is 35. All Ct-values of 35 and above recorded as Ct 35 by the data analyis                   
program and read as no expression 
1
7
0
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down 
1
regulation 
Test 
Sample 
Contr
ol 
Sampl
e 
Test 
Sample
2
 
Control 
Sample
3
 
Test sample/ 
control 
sample 
P-value 
Test 
sample / 
control 
sample 
DUSP4 B02 29.40 28.30 5.7E-04 1.0E-03 0.56 0.2667 -1.79 
ENPP1 B03 33.75 33.50 2.8E-05 2.8E-05 1.01 0.8766 1.01 
FBP1 B04 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
FOXC2 B05 33.55 33.85 3.2E-05 2.2E-05 1.48 0.8650 1.48 
FOXG1B B06 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
FOXP3 B07 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
G6PC B08 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
G6PD B09 27.90 28.20 1.6E-03 1.1E-03 1.48 0.7202 1.48 
GCG B10 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
GCGR B11 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
GCK B12 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
GLP1R C01 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
GPD1 C02 33.95 34.10 2.4E-05 1.8E-05 1.33 0.4929 1.33 
GSK3B C03 27.95 26.80 1.5E-03 2.9E-03 0.54 0.2396 -1.85 
HMOX1 C04 31.70 31.50 1.1E-04 1.1E-04 1.04 0.7937 1.04 
HNF4A C05 34.05 34.45 2.3E-05 1.4E-05 1.58 0.6237 1.58 
ICAM1 C06 34.45 32.65 1.7E-05 5.0E-05 0.34 0.0826 -2.90 
IDE C07 28.30 29.20 1.2E-03 5.4E-04 2.24 0.5365 2.24 
IFNG C08 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
IGFBP5 C09 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
IKBKB C10 29.55 29.00 5.1E-04 6.2E-04 0.82 0.6229 -1.22 
IL10 C11 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
IL12B C12 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
IL4R D01 34.45 32.90 1.7E-05 4.2E-05 0.41 0.1553 -2.44 
     1
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down 
1
regulation 
Test 
Sample 
Contr
ol 
Sampl
e 
Test 
Sample
2
 
Control 
Sample
3
 
Test sample/ 
control 
sample 
P-value 
Test 
sample / 
control 
sample 
IL6 D02 29.05 28.40 7.2E-04 9.4E-04 0.76 0.4741 -1.31 
INPPL1 D03 30.20 27.40 3.2E-04 1.9E-03 0.17 0.3508 -5.81 
INS D04 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
INSR D05 29.60 28.60 4.9E-04 8.2E-04 0.60 0.4168 -1.67 
PDX1 D06 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
IRS1 D07 33.50 34.10 3.3E-05 1.8E-05 1.82 0.5343 1.82 
IRS2 D08 29.00 30.05 7.5E-04 3.0E-04 2.48 0.4590 2.48 
MAPK14 D09 28.65 30.45 9.5E-04 2.3E-04 4.18 0.4299 4.18 
MAPK8 D10 29.30 29.70 6.1E-04 3.8E-04 1.58 0.8275 1.58 
ME1 D11 27.85 28.60 1.7E-03 8.2E-04 2.02 0.4541 2.02 
NEUROD1 D12 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
NFKB1 E01 32.20 28.75 8.1E-05 7.4E-04 0.11 0.3502 -9.11 
NOS3 E02 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
NRF1 E03 30.85 30.60 2.1E-04 2.1E-04 1.01 0.7686 1.01 
NSF E04 28.70 27.25 9.2E-04 2.1E-03 0.44 0.0151 -2.28 
PARP1 E05 27.45 30.80 2.2E-03 1.8E-04 12.23 0.5146 12.23 
PIK3C2B E06 31.35 27.70 1.5E-04 1.5E-03 0.10 0.4317 -10.46 
PIK3CD E07 34.30 34.00 1.9E-05 1.9E-05 0.97 0.8288 -1.03 
PIK3R1 E08 32.55 33.30 6.4E-05 3.2E-05 2.02 0.7202 2.02 
PPARA E09 29.55 30.15 5.1E-04 2.8E-04 1.82 0.2978 1.82 
PPARG E10 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
PPARGC1A E11 29.70 29.25 4.6E-04 5.2E-04 0.88 0.6885 -1.14 
PPARGC1B E12 33.30 31.65 3.8E-05 9.9E-05 0.38 0.4343 -2.62 
PRKAA1 F01 29.60 27.75 4.9E-04 1.5E-03 0.33 0.4508 -3.01 
      1
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down 
1
regulation 
Test 
Sample 
Contr
ol 
Sampl
e 
Test 
Sample
2
 
Control 
Sample
3
 
Test sample/ 
control 
sample 
P-value 
Test 
sample / 
control 
sample 
PRKAG2 F02 31.50 29.60 1.3E-04 4.1E-04 0.32 0.3525 -3.11 
PRKCB1 F03 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
PTPN1 F04 29.70 27.00 4.6E-04 2.5E-03 0.18 0.3040 -5.42 
PYGL F05 29.55 29.15 5.1E-04 5.6E-04 0.91 0.5039 -1.10 
RAB4A F06 27.90 26.45 1.6E-03 3.6E-03 0.44 0.2258 -2.28 
RETN F07 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
SELL F08 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
SLC2A4 F09 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
SNAP23 F10 32.70 31.55 5.7E-05 1.1E-04 0.54 0.5981 -1.85 
SNAP25 F11 33.05 33.45 4.5E-05 2.8E-05 1.58 0.8206 1.58 
SREBF1 F12 30.20 27.75 3.2E-04 1.5E-03 0.22 0.3089 -4.56 
STX4 G01 30.55 28.70 2.5E-04 7.7E-04 0.33 0.2145 -3.01 
STXBP1 G02 28.05 25.85 1.4E-03 5.5E-03 0.26 0.4221 -3.83 
STXBP2 G03 31.15 29.00 1.7E-04 6.2E-04 0.27 0.2603 -3.70 
TCF2 G04 34.80 32.10 1.3E-05 7.3E-05 0.18 0.3113 -5.42 
TGFB1 G05 33.35 31.90 3.7E-05 8.3E-05 0.44 0.4621 -2.28 
TITF1 G06 35.00 34.95 1.2E-05 1.0E-05 1.16 0.4226 1.16 
TNF G07 35.00 34.95 1.2E-05 1.0E-05 1.16 0.4226 1.16 
TNFRSF1A G08 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
TRIB3 G09 28.10 29.85 1.4E-03 3.5E-04 4.03 0.2726 4.03 
VAMP3 G10 30.95 27.75 1.9E-04 1.5E-03 0.13 0.0213 -7.66 
VAPA G11 26.00 25.25 6.0E-03 8.4E-03 0.71 0.2999 -1.40 
VEGFA G12 29.50 28.30 5.3E-04 1.0E-03 0.52 0.2751 -1.92 
18SrRNA H01 9.15 9.15 7.1E+02 5.9E+02 1.20 1.0000 1.20 
     1
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down 
1
regulation 
Test 
Sample 
Contr
ol 
Sampl
e 
Test 
Sample
2
 
Control 
Sample
3
 
Test sample/ 
control 
sample 
P-value 
Test 
sample / 
control 
sample 
HPRT1 H02 26.55 25.75 4.1E-03 5.9E-03 0.69 0.0883 -1.45 
RPL13A H03 25.00 23.30 1.2E-02 3.2E-02 0.37 0.2405 -2.71 
GAPDH H04 18.85 19.00 8.5E-01 6.4E-01 1.33 0.4226 1.33 
ACTB H05 19.90 19.50 4.1E-01 4.5E-01 0.91 0.5076 -1.10 
ACTB H06 23.00 19.95 4.8E-02 3.3E-01 0.14 0.4981 -6.90 
ACTB H07 26.10 24.15 5.6E-03 1.8E-02 0.31 0.4834 -3.22 
ACTB H08 30.75 30.05 2.2E-04 3.0E-04 0.74 0.6193 -1.35 
ACTB H09 33.15 29.35 4.2E-05 4.9E-04 0.09 0.4688 -11.61 
ACTB H10 35.00 31.00 1.2E-05 1.6E-04 0.07 0.4226 -13.34 
ACTB H11 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
ACTB H12 35.00 35.00 1.2E-05 9.7E-06 1.20 N/A 1.20 
1
7
4
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Table 7:6 Expression of NSF and VAMP3 in Chang cells treated with MCBD 
medium (control sample) and MCDB medium with added insulin and fructose (test 
sample) 
 
The finding that key molecules in various intracellular vesicular transport steps 
are conserved from yeast to man prompted Rothman and colleagues to propose 
a universal “docking and fusion particle” to explain docking and fusion at all 
locations (Rothman, 1996).The Rothman proposal or Soluble N-ethylmaleimide-
sensitive factor attachment protein receptor proteins (SNARE) hypothesis 
proposes that the pairing of vesicular SNARES (v-SNARES) from transport 
vesicles with target SNARES (t-SNARES) from target membranes provides a 
core docking interaction and erects a scaffold on which general fusion  machinery 
such as NSF and N-ethylmaleimide- sensitive factor attachment proteins (SNAPs) 
can assemble (Figure 7.3) (Rothman, 1996). SNAREs can be reused after fusion. 
NSF and α/γSNAPs dissociate SNARE complexes prior to fusion (in vitro 
organelle fusion) or after fusion (regulated secretion) (Figure 7.3) (May et al., 
2001; Ungerman & Langosch, 2005). 
 
 
SYMBOL 
TEST 
SAMPLE 
CONTROL 
 SAMPLE 2^∆Ct 
Fold 
Difference 
T-
TEST 
Fold 
 Up-or 
Down-
regulation Replicate Replicate 
1 2  1  2 
Test 
Sample 
Control 
Sample 
Test/Control 
P-
value 
Test/Control 
NSF 
28.8 28.6 27.4 27.1 
9.2E-
04 
2.1E-
03 0.44 0.0151 -2.28 
VAMP3 
31.4 30.95 27.9 27.6 
1.9E-
04 
1.5E-
03 0.13 0.0213 -7.66 
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Figure 7.3 Vesicle mediated transport following the SNARE hypothesis.  
A unique vesicle bound SNARE (v-SNARE) exists that specifically recognizes and interacts with a 
t-SNARE localized to the target membrane. The assembled v-t- SNARE complex can then bind 
the soluble NSF attachment protein (α-SNAP)and NSF. Subsequent ATP-hydrolysis by NSF 
disassembles the complex and recycles individual SNAREs for another round of transport.  
(Taken from May et al., 2001). 
NSF and VAMPs are involved in GLUT4 translocation therefore they have been 
mostly studied in skeletal muscle and adipose tissue which are insulin sensitive 
tissues. Although GLUT4 is absent in liver, mouse liver expresses most of the 
GLUT4 trafficking machinery, but not VAMP2 (Oh et al., 2005). The VAMP2 
homologue VAMP3 is abundantly expressed in the liver (Calvo et al., 2000). The 
glucose transporter predominantly expressed in the liver is GLUT2 which allows 
facilitated diffusion across the hepatocyte plasma membrane. In addition Doege 
et al. (2000) identified and described a novel glucose transporter located in the 
liver named GLUT8. GLUT8 is a high-affinity glucose transporter that cycle 
between intracellular vesicles and the plasma membrane (Gorovits at al., 2003). 
Thus VAMP3 could be involved in the formation of SNARE complexes; and NSF 
in the dissociation of these complexes in the membrane fusion processes of 
GLUT8. 
Vesicle transport mediated by specific v-SNAREs and t-SNAREs is not restricted 
to GLUT4 translocation. Fusion by formation of SNARE complexes involves many 
other exocytic and intracellular vesicular pathways. Proteins involved in vesicle 
trafficking have also been implicated in lipid droplet fusion and movement
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(Ducharme & Bickel, 2008; Olofsson et al., 2009). There are several possible 
hypotheses of how lipid droplets can grow larger; one possible mechanism is 
homolytic fusion of lipid droplets by a similar mechanism as vesicular fusion (Puri 
& Czech, 2008).  Proteins involved in vesicle trafficking namely NSF, VAMP4, α-
SNAP and SNAP23 have been shown to be associated with lipid droplets and are 
likely to be involved in lipid droplet movement and fussion (Figure 7.4).  
 
Figure 7.4 Lipid fusion process in adipocyte.  
The fusion process of lipid proplets might be activated by proteins involved in cell membrane 
fusion processes (e.g., N-ethylmaleimide–sensitive factor (NSF), soluble NSF attachment protein 
(α-SNAP), and SNAP receptors (SNAREs)  
(Taken from Puri & Czech, 2008) 
NSF and VAMP2 expression has been shown to be significantly decreased in 
MIRKO mice in an analysis using an oligonucleotide array of 12488 genes 
(Yechoor et al., 2004). Thus the disruption in the insulin signalling cascade by the 
muscle specific disruption of the IR gene reduced components of the vesicle 
transport mechanism. In the present study the decrease in NSF and VAMP3 
expression could possibly also be linked to disruption in the insulin signalling 
cascade.  
In the present study NSF and VAMP 3 were significantly down regulated when 
Chang liver cells were cultured in MCBD-201 medium supplemented with insulin 
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and fructose. Thus key elements playing a role in membrane trafficking 
mechanisms were significantly down regulated when the insulin resistance 
inducing medium was use as culture medium. These membrane trafficking 
mechanisms delivers membrane-impermeable molecules, including membrane 
proteins, secretory factors and lipids, from one organelle to another and in and 
out of cells, thus these processes could be down-regulated in cells cultured in 
MCBD-201 medium supplemented with insulin and fructose.       
7.3.2 Assay efficiency 
Table 7.7 summarizes the general performance of the experiment by analyzing 
the controls and housekeeping genes used for normalization. The data generated 
with the NRT control showed that the RNA samples from the test and control 
samples were free of any genomic DNA contamination. In the NTC samples the 
Ct-value was greater than 35, which also implies that no genomic DNA 
contamination was present that could affect the expression of the tested genes. 
The data analysis program calculated a normalization factor by averaging the Ct-
values of the five housekeeping genes. This value should not differ by more than 
one across compared samples. The normalization factor calculated for Chang 
liver cells cultured with MCBD-201 medium and MBCD-201 medium 
supplemented with insulin and fructose was 0.26, which was acceptable as it is 
less than one.  
One drawback of this assay is that only one sample is analyzed with 84 different 
genes on one plate in one run. This may result in increased variability between 
samples. Theoretically one should do the opposite, to eliminate inter-run 
variation, and analyze all experimental samples with one gene on the same plate.  
Alternatively when all samples cannot be included in one run, an internal control 
sample can be included that is used in all separate runs to correct for run to run 
variation. 
Accurate pipetting is very critical for the success of the PCR Array and could 
contribute to variation in replicates. To test the degree of reproducibility of the 
PCR Array System the manufacturer has performed technical replicates (n=4) by 
two different end users with the same universal total RNA sample, and two 
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separate manufacturing lots of catalogued PCR Arrays on two separate days 
(http://www.superarray.com/mamuals/pcrarraywhitepaper.pdf). The raw Ct-values 
for the entire array gene panel were then compared between each user‟s 
replicates. Each comparison yielded the predicted ideals of straight lines with 
slopes of 1.0 and correlation coefficients of 0.99 or greater. Thus a high degree of 
plate-to-plate, run-to-run, and replicate-to-replicate reproducibility was 
demonstrated to be inherent in the PCR Array System technology, even at the 
level of raw data. 
Based on this knowledge, no technical replicates were included in the present 
study. In the present study biological replicates from total RNA samples extracted 
on two different occasions from cells treated in the same manner were analyzed. 
A high level of specificity of the PCR Array was demonstrated by the single, gene 
specific amplicons, without the coamplification of primer dimers or other non-
specific secondary products, in the melt curve analysis in the present study. 
Given the knowledge of the inherent problems associated with this type of assay, 
this technique was used in the present study as an means to screen  known 
diabetic related genes for possible molecular targets for plant extract 1. The 
genes that generated significant p-values were investigated further with qRT-PCR 
to validate the findings of the Micro Array. 
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 Table 7:7 Overview of the PCR Array performance 
 Test Sample = MCBD + insulin+ fructose    
Control Sample = MCBD    
       
1. Negative Control Wells:  
Well Control 
MCBD + 
insulin+ 
fructose  MCBD  
Comments 
H11 NRT 35.00 35.00 
RNA is clean of genomic 
DNA. 
H12 NTC 35.00 35.00 PCR system is clean. 
       
2: Housekeeping Genes Chosen for Normalization:   
Well Symbol 
Ct  
MCBD + 
insulin + 
fructose 
MCBD  
(MCBD+insulin 
+fructose) -
(MCBD)  
H01 18SrRNA 9.15 9.15 0.00  
H02 HPRT1 26.55 25.75 0.80  
H03 RPL13A 25.00 23.30 1.70  
H04 GAPDH 18.85 19.00 -0.15  
H05 ACTB 19.90 19.50 0.40  
          
  
MCBD + 
insulin + 
fructose MCBD 
(MCBD 
+insulin+fructose) -
(MCBD)  
Average Ct 18.61 18.35 0.26  
7.3.3 Effect of treatment with plant extract 1 and fructose and insulin 
on the 84 Diabetes related genes analyzed 
As described previously, three conditions were compared by Micro Array 
analysis: (1) Chang liver cells cultured in MCBD-201 medium (MCBD), (2) MCBD-
201 medium supplemented with added fructose and insulin (MIF) and (3) MCBD-
201 medium supplemented with insulin, fructose and plant extract 1 (MIF+P1). 
The pair-wise comparison between cells cultured with MCBD-201 medium 
(control sample) and cells cultured with MIF medium (test sample) showed that 
NSF and VAMP3 were significantly down regulated by the addition of insulin and 
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fructose to the medium.  
Next the ability of plant extract 1 to protect against the development of insulin 
resistance, by regulating the expression of diabetes related genes, was 
determined. A pair-wise comparison between Chang liver cells cultured in MIF 
medium (control) and cells cultured in MIF medium supplemented with plant 
extract 1 (test) was performed (Table 7.8). Table 7.8 shows the results in 
alphabetical order as analyzed by the RT2 Profiler PCR Array Data Analysis 
Template v2.0. Genes showing more then 3-fold up-regulation are marked with 
green, genes showing more then 3-fold down-regulation are marked with blue 
and genes showing significant p-values are marked with red.  
The five reference genes included in the assay were not stably expressed 
between treatments, indicating that the plant treatment affected the expression of 
some of the reference genes. Consequently the normalization factor was more 
than one and thus not acceptable (Table 7.9). Under these conditions the 
manufacturer suggests excluding the housekeeping genes and using consistent 
input RNA as normalization factor i.e. constant concentration RNA for generating 
cDNA and constant input of cDNA for PCR reaction. Reference genes are 
selected based on their stability under the tested conditions and identifying 
universal reference genes is extremely difficult. The reference genes included in 
this assay, β-actin and GAPDH have been previously shown do be regulated and 
vary under experimental conditions with qRT-PCR (Bustin, 2000). The 18SrRNA 
gene was included in the seven reference genes tested to identify the most stably 
expressed reference gene for the experimental conditions of the present study. 
The M value generated for 18SrRNA was 1.45 close to the cut-off value of 1.5 for 
usage as a reference gene.     
The PCR Array assay was used as a screening method to determine if a panel of 
diabetes related genes are differentially regulated in the presence of plant extract 
1. Thus the results generated with this assay only identified potential molecular 
targets of plant extract 1. To confirm if the changes seen with the Micro Array 
were consistent, additional qRT-PCR assays were performed using the two 
housekeeping genes previously shown to be stable under the test conditions of 
this study.  
  
 Table 7:8 Gene expression profile showing the fold change between cells treated with MIF                                                   
(Control sample) and the MIF+P1 (Test sample). 
Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down-
regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
sample/ 
control 
sample 
P- value 
Test sample / 
control sample 
ABCC8 A01 31.40 35.00 5.7E-05 2.8E-05 2.03 0.0121 2.03 
ACE A02 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
ACLY A03 23.40 29.35 1.5E-02 1.4E-03 10.34 0.0104 10.34 
ADRB3 A04 34.20 35.00 8.2E-06 2.8E-05 0.29 0.3140 -3.43 
AGT A05 30.25 34.90 1.3E-04 3.0E-05 4.20 0.0097 4.20 
AKT2 A06 26.35 30.70 1.9E-03 5.6E-04 3.41 0.0715 3.41 
AQP2 A07 34.70 35.00 5.8E-06 2.8E-05 0.21 0.4226 -4.86 
CCL5 A08 28.05 31.85 5.8E-04 2.5E-04 2.33 0.1678 2.33 
CCR2 A09 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
CD28 A10 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
CEACAM1 A11 31.45 35.00 5.5E-05 2.8E-05 1.96 0.0909 1.96 
CEBPA A12 27.05 32.65 1.2E-03 1.4E-04 8.11 0.0658 8.11 
CTLA4 B01 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
DUSP4 B02 25.40 29.40 3.7E-03 1.4E-03 2.68 0.0194 2.68 
ENPP1 B03 27.05 33.75 1.2E-03 6.7E-05 17.39 0.0395 17.39 
FBP1 B04 34.30 35.00 7.7E-06 2.8E-05 0.27 0.4226 -3.68 
1
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down-
regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
sample/ 
control 
sample 
P- value 
Test sample / 
control sample 
FOXC2 B05 29.45 33.55 2.2E-04 7.7E-05 2.87 0.1014 2.87 
FOXG1B B06 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
FOXP3 B07 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
G6PC B08 34.85 35.00 5.2E-06 2.8E-05 0.19 0.4226 -5.39 
G6PD B09 23.20 27.90 1.7E-02 3.9E-03 4.35 0.0129 4.35 
GCG B10 33.55 35.00 1.3E-05 2.8E-05 0.46 0.3014 -2.19 
GCGR B11 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
GCK B12 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
GLP1R C01 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
GPD1 C02 29.30 33.95 2.5E-04 5.9E-05 4.20 0.0229 4.20 
GSK3B C03 23.15 27.95 1.7E-02 3.7E-03 4.66 0.0417 4.66 
HMOX1 C04 26.90 31.70 1.3E-03 2.8E-04 4.66 0.0144 4.66 
HNF4A C05 28.90 34.05 3.2E-04 5.5E-05 5.94 0.0327 5.94 
ICAM1 C06 28.80 34.45 3.5E-04 4.1E-05 8.40 0.0093 8.40 
IDE C07 24.10 28.30 9.0E-03 2.9E-03 3.07 0.0746 3.07 
IFNG C08 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
IGFBP5 C09 33.55 35.00 1.3E-05 2.8E-05 0.46 0.0012 -2.19 
IKBKB C10 25.55 29.55 3.3E-03 1.2E-03 2.68 0.0835 2.68 
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down-
regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
sample/ 
control 
sample 
P- value 
Test sample / 
control sample 
IL10 C11 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
IL12B C12 34.95 35.00 4.9E-06 2.8E-05 0.17 0.4226 -5.78 
IL4R D01 28.10 34.45 5.6E-04 4.1E-05 13.64 0.0091 13.64 
IL6 D02 26.40 29.05 1.8E-03 1.7E-03 1.05 0.0828 1.05 
INPPL1 D03 23.20 30.20 1.7E-02 7.9E-04 21.41 0.0933 21.41 
INS D04 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
INSR D05 25.25 29.60 4.1E-03 1.2E-03 3.41 0.0607 3.41 
PDX1 D06 32.10 35.00 3.5E-05 2.8E-05 1.25 0.0536 1.25 
IRS1 D07 30.20 33.50 1.3E-04 8.0E-05 1.65 0.0323 1.65 
IRS2 D08 26.15 29.00 2.2E-03 1.8E-03 1.21 0.0015 1.21 
MAPK14 D09 25.25 28.65 4.1E-03 2.3E-03 1.77 0.0784 1.77 
MAPK8 D10 25.70 29.30 3.0E-03 1.5E-03 2.03 0.0692 2.03 
ME1 D11 23.85 27.85 1.1E-02 4.0E-03 2.68 0.0347 2.68 
NEUROD1 D12 34.60 35.00 6.2E-06 2.8E-05 0.22 0.4226 -4.53 
NFKB1 E01 25.20 32.20 4.2E-03 2.0E-04 21.41 0.1330 21.41 
NOS3 E02 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
NRF1 E03 26.30 30.85 2.0E-03 5.0E-04 3.92 0.0305 3.92 
NSF E04 23.50 28.70 1.4E-02 2.2E-03 6.15 0.0354 6.15 
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down-
regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
sample/ 
control 
sample 
P- value 
Test sample / 
control sample 
PARP1 E05 22.55 27.45 2.6E-02 5.3E-03 4.99 0.0342 4.99 
PIK3C2B E06 24.30 31.35 7.9E-03 3.5E-04 22.16 0.2131 22.16 
PIK3CD E07 29.55 34.30 2.1E-04 4.6E-05 4.50 0.0236 4.50 
PIK3R1 E08 28.65 32.55 3.9E-04 1.5E-04 2.50 0.0873 2.50 
PPARA E09 26.35 29.55 1.9E-03 1.2E-03 1.54 0.0338 1.54 
PPARG E10 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
PPARGC1A E11 26.50 29.70 1.7E-03 1.1E-03 1.54 0.0739 1.54 
PPARGC1B E12 28.25 33.30 5.1E-04 9.2E-05 5.54 0.0972 5.54 
PRKAA1 F01 24.30 29.60 7.9E-03 1.2E-03 6.59 0.1521 6.59 
PRKAG2 F02 27.60 31.50 8.0E-04 3.2E-04 2.50 0.0538 2.50 
PRKCB1 F03 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
PTPN1 F04 24.90 29.70 5.2E-03 1.1E-03 4.66 0.0718 4.66 
PYGL F05 24.75 29.55 5.8E-03 1.2E-03 4.66 0.0417 4.66 
RAB4A F06 23.15 27.90 1.7E-02 3.9E-03 4.50 0.0853 4.50 
RETN F07 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
SELL F08 33.15 35.00 1.7E-05 2.8E-05 0.60 0.4013 -1.66 
SLC2A4 F09 31.80 35.00 4.3E-05 2.8E-05 1.54 0.0853 1.54 
SNAP23 F10 27.15 32.70 1.1E-03 1.4E-04 7.84 0.0702 7.84 
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down-
regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
sample/ 
control 
sample 
P- value 
Test sample / 
control sample 
SNAP25 F11 28.25 33.05 5.1E-04 1.1E-04 4.66 0.0180 4.66 
SREBF1 F12 25.45 30.20 3.5E-03 7.9E-04 4.50 0.0771 4.50 
STX4 G01 26.80 30.55 1.4E-03 6.2E-04 2.25 0.0371 2.25 
STXBP1 G02 24.80 28.05 5.6E-03 3.5E-03 1.59 0.1118 1.59 
STXBP2 G03 27.00 31.15 1.2E-03 4.1E-04 2.97 0.0628 2.97 
TCF2 G04 30.40 34.80 1.1E-04 3.2E-05 3.53 0.1007 3.53 
TGFB1 G05 29.20 33.35 2.6E-04 8.9E-05 2.97 0.0155 2.97 
TITF1 G06 33.25 35.00 1.6E-05 2.8E-05 0.56 0.1147 -1.78 
TNF G07 32.80 35.00 2.2E-05 2.8E-05 0.77 0.1107 -1.30 
TNFRSF1A G08 32.60 35.00 2.5E-05 2.8E-05 0.88 0.1385 -1.13 
TRIB3 G09 26.40 28.10 1.8E-03 3.4E-03 0.54 0.0422 -1.84 
VAMP3 G10 25.10 30.95 4.5E-03 4.7E-04 9.65 0.0448 9.65 
VAPA G11 22.00 26.00 3.9E-02 1.4E-02 2.68 0.0206 2.68 
VEGFA G12 25.25 29.50 4.1E-03 1.3E-03 3.18 0.0536 3.18 
18SrRNA H01 7.75 9.15 7.5E+02 1.7E+03 0.44 0.0316 -2.27 
HPRT1 H02 23.15 26.55 1.7E-02 9.9E-03 1.77 0.1018 1.77 
RPL13A H03 22.50 25.00 2.7E-02 2.9E-02 0.95 0.2744 -1.06 
GAPDH H04 15.80 18.85 2.8E+00 2.1E+00 1.39 0.0644 1.39 
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Symbol Well 
AVF Ct without 
normalization 
2
A
 t 
Fold 
differences 
T-TEST 
Fold up- or 
down-
regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
sample/ 
control 
sample 
P- value 
Test sample / 
control sample 
ACTB H05 17.35 19.90 9.7E-01 9.9E-01 0.98 0.0955 -1.02 
ACTB H06 20.60 23.00 1.0E-01 1.2E-01 0.88 0.2197 -1.13 
ACTB H07 24.05 26.10 9.4E-03 1.4E-02 0.69 0.1374 -1.44 
ACTB H08 28.35 30.75 4.7E-04 5.4E-04 0.88 0.0830 -1.13 
ACTB H09 30.95 33.15 7.8E-05 1.0E-04 0.77 0.0777 -1.30 
ACTB H10 34.05 35.00 9.1E-06 2.8E-05 0.32 0.2814 -3.10 
ACTB H11 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
ACTB H12 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
 
   1
8
7
 
  
Table 7:9 Overview of the PCR Array performance  
Test Sample = MCBD + insulin +fructose +plant extract 1   
Control Sample = MCBD +insulin +fructose   
      
1. Negative Control Wells:  
Well Control Test Sample Control Sample Comments 
H11 NRT 35.00 35.00 RNA is clean of genomic DNA. 
H12 NTC 35.00 35.00 PCR system is clean. 
      
2: Housekeeping Genes Chosen for Normalization:  
Well Symbol 
Ct 
Test Sample Control Sample Test Sample – Control Sample 
H01 18SrRNA 7.75 9.15 -1.40 
H02 HPRT1 23.15 26.55 -3.40 
H03 RPL13A 22.50 25.00 -2.50 
H04 GAPDH 15.80 18.85 -3.05 
H05 ACTB 17.35 19.90 -2.55 
         
  Test Sample Control Sample Test Sample – Control Sample 
Average Ct 17.31 19.89 -2.58 
We do not recommend using the selected housekeeping genes for normalization, because the difference 
between the two samples are  too large (>2 fold). To use your consistent input RNA as a normalization factor 
instead, do not select any housekeeping gene. 
1
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The 84 diabetes related genes of the human diabetes RT2ProfilerTM PCR 
Array can be grouped into six functional categories: (1) receptors, transporters 
and channels; (2) nuclear receptors; (3) metabolic enzymes; (4)secreted 
factors; (5) signal transduction proteins and (6) transcription factors.  Table 
7.8 shows all 84 genes in alphabetic order and table 7.10-7.15 shows these 
genes grouped into the six functional categories. 
7.3.4 The effect of plant extract 1 on Diabetes Related Receptors, 
Transporters and Channels  
7.3.4.1 Genes involved in vesicle transport 
The two genes NSF and VAMP3 that play important roles in vesicle transport 
were significantly down regulated in Chang liver cells cultured in MIF medium 
compared to cells cultured in MCBD-201 medium, by -2.28 fold  and -7.66 fold 
respectively (Table 7.5). These two genes (NSF and VAMP3) were 
significantly upregulated in Chang liver cells cultured in MIF medium 
supplemented with plant extract 1 (Table 7.8 and Table 7.10). Three more 
genes also playing a role in vesicle transport, (1) Syntaxin 4 (STX4), (2) 
Synaptosomal-associated protein, 25kDa (SNAP25), and (3) VAMP-
associated protein (VAPA) were also upregulated in Chang liver cells cultured 
in MIF medium supplemented with plant extract 1 (Table 7.10). All of these 
genes are SNAREs or SNARE accessory proteins, playing a role in GLUT4 
translocation. However these SNAREs are not unique to GLUT4 translocation 
and likely to regulate many different exocytic steps in a variety of cell types 
(James, 2005). 
STX4 is the plasma membrane t-SNARE which acts as the docking protein for 
GLUT4, interacting with the v-SNARE VAMP2. This binding is regulated by 
SNAP23, in skeletal musle (Figure 7.5) and SNAP25 in adipose tissue (Gorovits 
& Charron, 2003; Dugani & Klip, 2005, James, 2005). In the present study STX4 
was 2.25 fold upregulated, (p = 0.0371) in the presence of plant extract1 in the 
insulin resistance inducing medium, compared to MIF treatment. 
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Table 7:10 Receptors, Transporters and Channels 
Symbol Well 
AVG Ct without 
normalization 
2^-ΔCt 
Fold 
Difference 
T-
TEST 
Fold Up- or 
Down-
Regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
Sample 
/Control 
Sample 
P-
value 
Test 
Sample 
/Control 
Sample 
ABCC8 A01 31.40 35.00 5.7E-05 2.8E-05 2.03 0.0121 2.03 
ADRB3 A04 34.20 35.00 8.2E-06 2.8E-05 0.29 0.3140 -3.43 
AQP2 A07 34.70 35.00 5.8E-06 2.8E-05 0.21 0.4226 -4.86 
CCR2 A09 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
CD28 A10 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
CEACAM1 A11 31.45 35.00 5.5E-05 2.8E-05 1.96 0.0909 1.96 
CTLA4 B01 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
GCGR B11 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
GLP1R C01 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
ICAM1 C06 28.80 34.45 3.5E-04 4.1E-05 8.40 0.0093 8.40 
IL4R D01 28.10 34.45 5.6E-04 4.1E-05 13.64 0.0091 13.64 
INSR D05 25.25 29.60 4.1E-03 1.2E-03 3.41 0.0607 3.41 
NSF E04 23.50 28.70 1.4E-02 2.2E-03 6.15 0.0354 6.15 
RAB4A F06 23.15 27.90 1.7E-02 3.9E-03 4.50 0.0853 4.50 
SELL F08 33.15 35.00 1.7E-05 2.8E-05 0.60 0.4013 -1.66 
SLC2A4 F09 31.80 35.00 4.3E-05 2.8E-05 1.54 0.0853 1.54 
SNAP23 F10 27.15 32.70 1.1E-03 1.4E-04 7.84 0.0702 7.84 
SNAP25 F11 28.25 33.05 5.1E-04 1.1E-04 4.66 0.0180 4.66 
STX4 G01 26.80 30.55 1.4E-03 6.2E-04 2.25 0.0371 2.25 
STXBP1 G02 24.80 28.05 5.6E-03 3.5E-03 1.59 0.1118 1.59 
STXBP2 G03 27.00 31.15 1.2E-03 4.1E-04 2.97 0.0628 2.97 
TNFRSF1A G08 32.60 35.00 2.5E-05 2.8E-05 0.88 0.1385 -1.13 
VAMP3 G10 25.10 30.95 4.5E-03 4.7E-04 9.65 0.0448 9.65 
VAPA G11 22.00 26.00 3.9E-02 1.4E-02 2.68 0.0206 2.68 
The role of SNAP25 has been extensively studied in the process of synaptic 
vesicle exocytosis in neurons, and in the pancreatic β cell for its involvement 
in insulin exocytosis (Nagamatsu et al., 1999; Jeans et al., 2007; Holt et al., 
2008). Membrane fusion is driven by v-SNAREs and t-SNAREs forming trans-
SNARE complexes that draw the two membranes towards each other when 
transport vesicles traffic to the vicinity of the target organelles (Hu et al., 2007). In 
insulin secretion, Syntaxin 1A and SNAP25 comprise the specific t-SNARE 
binary complex (Nagamatsu et al., 1999; Thurmond et al., 2003). Judging by the 
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Ct-values generated by the PCR Microarray in the present study, SNAP25 was 
expressed at very low copy numbers when Chang liver cells were cultured in 
MCBD-201 medium (Ct- 33.45) or MIF medium (Ct-33.05). When Chang liver 
cells were cultured in MIF medium supplemented with plant extract 1 the mean 
Ct-value increased to 28.25, a 4.66 fold upregulation of gene expression 
(p=0.0180) (Table 7.7 and 7.9.1). 
Figure 7.5 Schematic of GLUT4 translocation.  
Two distinct intracellular GLUT4 compartments exist in rat skeletal muscle, one that shows a 
reduction in GLUT4 after insulin treatment (GLUT4 storage vesicle) and a second pool 
represent a constitutively recycling between the plasma membrane and the early endosome 
(recycling endosome). The VAMP3 is enriched in the recycling endosome and VAMP2 on the 
GLUT4 storage vesicle. VAMP2 is the v-SNARE colocalized with GLUT4 on the GLUT4 
storage vesicle that guides the vesicle to the plasmamembrane docking site. Fusion of the 
vesicle with the plasma membrane depends on the interaction of the SNARE proteins VAMP2 
and STX4. Other SNARE modulating proteins also play a role in this fusion.  
(Taken from Gorovits and Charron 2003).    
VAP is a SNARE accessory protein and as the name indicates is a VAMP 
associated protein that interacts with the VAMPs (Weir et al., 1998; Foster & 
Klip, 2000). VAPA is one of the homologues of VAP.  It has been implicated in 
binding to a specific peptide motif, consisting of two phenylalanines (FF), in an 
acidic tract (the FFAT motif) in lipid proteins to target these proteins to the 
endoplasmic reticulum, the major site of lipid metabolism in cells (Loewen et 
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al., 2003; Loewen & Levine, 2005). Correct targeting of lipid binding proteins 
allows specific lipid transfer. The FFAT-VAP interaction enables the trafficking 
of a variety of different lipids from or to the ER, suggesting a significant role of 
VAP homologues in regulating lipid metabolism (Loewen et al., 2003; Loewen 
& Levine, 2005). Treatment with plant extract 1 led to a 2.68 fold upregulation 
(p = 0.0206) of VAPA, indicating that the plant extract can influence lipid 
metabolism (Table 7.8 and 7.10) 
Five genes involved in vesicle transport NSF, VAMP3, STX4, SNAP25 and 
VAPA were significantly upregulated in Chang liver cells cultured in MIF 
medium supplemented with plant extract 1, compared to cells grown in MIF 
medium only. Thus the presence of the plant extract 1 led to a significant 
increase in the expression of genes involved in vesicle transport.    
7.3.4.2 ATP-binding cassette, sub-family C, member 8 (ABCC8) 
The voltage-gated potassium channel (KATP) of the pancreatic β-cell is a key 
regulator of insulin release and is composed of two subunits that form the 
channel hetero-octamer: the high affinity beta-cell sulfonylurea receptor 
(SURI) and the inwardly rectifying potassium channel (KIR6.2) (Seino et al., 
2000; Polak & Cavé, 2007; Pinney et al., 2008). These two protein subunits 
are encoded by adjacent genes ABCC8 and Potassium channel inwardly 
rectifying subfamily J member 11 (KCNJ11) on chromosome 11.  
The KATP channel‟s activity is inhibited by binding of adenine nucleotides to 
KIR6.2 and nucleotide binding and/or hydrolysis of SUR1 leads to opening of 
the channel (Pinney et al., 2008). The antidiabetic drugs sulphonylureas 
promote insulin secretion by binding directly to SUR1 (Proks et al., 2006). 
Mutations in ABCC8 gene have also been shown to cause neonatal diabetes 
(Babenko et al., 2006; Proks et al., 2006; Polak and Cavé, 2007).  
In the present study the ABCC8 encoding SUR1 was significantly upregulated 
in Chang liver cells cultured in MIF medium containing plant extract 1, 
compared to growth in MIF medium alone. However, although there appears 
to be a significant upregulation of this gene in the presence of the plant 
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extract 1, the Ct-values recorded were very high (31.40) and corresponded to 
low expression (Table 7.8 and 7.10). Chang liver cells cultured in MCBD-201 
or MIF medium showed virtually no expression of ABCC8 (Ct-values 34.90 
and 35). Therefore whilst plant extract 1 in the culture medium induced 
ABCC8 expression 2.03 fold in Chang liver cells, the expression of ABCC8 
was still low. This low expression is expected as this gene plays a role in 
insulin secretion which is not functional in liver cells.    
7.2.4.3 Interleukin 4 receptor (IL4R) 
The IL4R gene was upregulated (13.64 fold; p=0.0091) in Chang liver cells 
cultured in MIF medium containing plant extract 1, compared to growth in MIF 
medium alone (Table 7.8 and 7.10). Interleukin 4 (IL4) plays a key role in 
inhibiting proinflammatory cytokine production in activated macrophages 
(Hartman et al., 2004). The biological functions of IL4 are mediated via its 
binding to a specific cell surface receptor, which is widely distributed and 
consists of two chains, the ligand-binding chain (IL4R) and the common γ 
chain shared with IL2, IL7, IL9 and IL15 (Pernis et al., 1995). The human IL4R 
contains a region which is essential for IRS1 phosphorylation and cell 
proliferation, this region contains an insulin receptor motif (Pernis et al., 1995; 
Hartman et al., 2004). 
IL4 has been shown to have a direct protective effect on the loss of β cell 
viability, mediated by proinflammatory cytokines (Kaminski et al., 2007). In 
animal models, IL4 protects against the development of T1DM (Rapoport et 
al., 1993; Cameron et al., 2000). Mirel et al., (2002) showed significant 
evidence of linkage and association of the IL4R to T1DM by genotyping 282 
T1DM multiplex families at eight SNPs in the IL4R gene. They found that the 
specific haplotype H-3 was associated with protection from T1DM. A study in 
a Filipino population also showed that this specific variant of IL4R protein 
confers protection to T1DM (Bugawan et al., 2003). 
As IL4 protects β-cells against the harmfull effects of proinflammatory 
cytokines, the increase in IL4R expression seen in the presence of plant 
extract 1 could most likely also have a protective effect against loss of viability 
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of liver cells.   
7.3.4.3 Intercellular adhesion molecule 1 (ICAM1) 
ICAM1 is significantly (p= 0.0093) upregulated (8.40 fold) in Chang liver cells 
cultured in MIF medium containing plant extract 1 (Table 7.8 and 7.10). 
ICAM1 is a member of the immunoglobulin superfamily, expressed on a wide 
variety of cells under conditions of inflammation, where it promotes 
inflammation by enhancing leukocyte infiltration and adherence (Blake & 
Ridker, 2001; Rubio-Guerra et al., 2007). Elevated levels of ICAM1 have been 
reported in patients with T2DM (El-Mesallamy et al., 2007). Endothelial 
dysfunction, as a result of elevated levels of ICAM1, and other cellular 
adhesion molecules (CAM) has been implicated in complications of diabetes 
such as nephropathy, atherosclerosis, retinopathy and cardiovasucular 
problems (Blake & Ridker, 2001; El-Mesallamy et al., 2007).  
Under normal conditions ICAM1 is not expressed in hepatocytes however 
inflammatory liver diseases of various etiologies stimulate its immunoreactivity 
(Volpes et al., 1992). In agreement with this, in the present study Chang liver 
cells cultured in MCBD medium showed a mean Ct-value of 32.65 for the 
ICAM1 gene, indicative of negligable expression of ICAM1. Chang liver cells 
cultured in MIF medium showed a mean Ct-value of 34.45 for ICAM1. In 
Chang liver cells cultured in MIF medium supplemented with plant extract 1, a 
mean Ct-value of 28.80 was recorded for the ICAM1 gene, showing an 8.40 
fold increase in ICAM1 expression compared to the expression in cells 
cultured in MIF medium. It is proposed that the increase in ICAM1 seen is not 
indicative of endothelial dysfunction, but that it is a normal response to injury 
of liver cells, triggered by the presence of plant extract 1. Chang liver cells are 
injured by the excess nutrients in the medium, as is evident in the reduced 
viability of the cells cultured in MIF medium.                  
Knittel et al., (1999) investigated the expression of ICAM1 in the carbon 
tetrachloride (CCL4) in vivo model for acute liver damage. Using this model 
ICAM1 was upregulated three hours after CCL4-induced liver injury, reaching 
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maximal mRNA steady state levels after 9-12 hours, and progressively 
diminishing afterwards, to baseline levels about 72 hours after CCL4    
application. After 72 hours, as the liver tissue entered the recovery phase due 
to regeneration, ICAM1 expression decreased (Knittel et al., 1999). In the 
current study ICAM1 expression was determined after 24 hours, which is in 
the early phase after liver injury, and an increase in ICAM expression is 
expected to be found.    
7.3.5 The effect of plant extract 1 on Nuclear Receptors,  
The transcription factor PPARα was upregulated 1.54 fold (p=0.0338) in the 
presence of the plant extract 1 (Table 7.11). PPARα expression was also 
determined as shown in Chapter 6 and a significant upregulation in PPARα 
expression was found in Chang liver cells cultured for 48 hours in MIF 
medium containing plant extract 1 when compared to cells cultured in MIF 
medium. This significant increase in PPARα expression could indicate that 
plant extract 1 contains PPARα agonists.  
Table 7:11 Nuclear Receptors 
Symbol Well 
AVG Ct without 
normalization 
2^-ΔCt 
Fold 
Difference 
T-TEST 
Fold Up- or 
Down-
Regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
Sample 
/Control 
Sample 
p-value 
Test 
Sample 
/Control 
Sample 
PPARA E09 26.35 29.55 1.9E-03 1.2E-03 1.54 0.0338 1.54 
PPARG E10 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
The PCR Array primers used to detect PPARγ did not detect any PPARγ 
transcripts. The basal expression of PPARγ in the liver is extremely low and 
the conditions were probably not optimized to detect such low levels of 
expression. The PPARγ expression analysis in the singleplex reaction also 
showed that PPARγ expression was down regulated after 24 hours of 
expression.   
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7.3.6 The effect of plant extract 1 on Signal Transduction  
Five genes involved in signal transduction were significantly upregulated when 
Chang liver cells were cultured in MIF medium containing plant extract 1, 
compared to cells grown in MIF medium only. These genes are Dual 
specificity phosphatase (DUSP4), Insulin-like growth factor binding protein 2 
(IGFB5), IRS1, IRS2 and Phosphoinositide-3-kinase, catalytic, delta 
polypeptide (PIK3CD). One gene, Tribbles homolog 3 (TRIB3) was 
significantly down regulated under the same conditions (Table 7.12).  
7.3.6.1 DUSP4 
DUSP4 has been shown to play a role in inhibiting gluconeogenesis (Berasi et 
al., 2006). DUSP4 repressed transcription of the two gluconeogenic genes; 
Glucose-6-phosphatase (G-6-P) and Phosphoenolpyruvate carboxykinase 
(PEPCK) to a similar extent as 5-aminoimidazole-4-carboxamide riboside 
(AICAR). AICAR is an agent that activates AMP-activated protein kinase 
(AMPK) and mimics the ability of insulin to suppress G-6-P and PEPCK 
expression (Lochhead et al., 2000). In the present study DUSP4 was 
upregulated 2.68 fold (p = 0.0194) in Chang liver cells cultured in MIF medium 
containing plant extract 1 (Table 7.12). Thus the presence of the plant extract 
increased the expression of DUSP4 which can repress gluconeogenesis. 
7.3.6.2 IGFBP5    
IGFBP5 is one of a family of six proteins that bind insulin growth factors 
(IGF)s with high affinity (Schneider et al., 2000; Beattie et al., 2006). IGFs 
share structural homology with insulin and are involved in regulation of cell 
growth, and differentiation and metabolism. IGFBP5 compete with the IGF 
receptors for binding to IGFs and thus act as carriers and modulators of IGF‟s 
activity and availability (Schneider et al., 2000; Beattie et al., 2006). In the 
present study IGFBP5 showed a 2.19 fold  down-regulation (p=0.0012), in 
Chang liver cells grown in MIF medium containing plant extract 1 when 
compared to growth in MIF medium only (Table 7.12). Although a down-
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regulation is seen in the presence of plant extract 1, the expression of IGFBP5 
in the present study was very low as reflected by the Ct-values (33.5; 35).   
Table 7:12   Genes involved in Signal Transduction 
Symbol Well 
AVG Ct without 
normalization 
2^-ΔCt 
Fold 
Difference 
T-TEST 
Fold Up- or 
Down-
Regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
Sample 
/Control 
Sample 
p-value 
Test 
Sample 
/Control 
Sample 
AKT2 A06 26.35 30.70 1.9E-03 5.6E-04 3.41 0.0715 3.41 
DUSP4 B02 25.40 29.40 3.7E-03 1.4E-03 2.68 0.0194 2.68 
IGFBP5 C09 33.55 35.00 1.3E-05 2.8E-05 0.46 0.0012 -2.19 
IKBKB C10 25.55 29.55 3.3E-03 1.2E-03 2.68 0.0835 2.68 
INPPL1 D03 23.20 30.20 1.7E-02 7.9E-04 21.41 0.0933 21.41 
IRS1 D07 30.20 33.50 1.3E-04 8.0E-05 1.65 0.0323 1.65 
IRS2 D08 26.15 29.00 2.2E-03 1.8E-03 1.21 0.0015 1.21 
MAPK14 D09 25.25 28.65 4.1E-03 2.3E-03 1.77 0.0784 1.77 
MAPK8 D10 25.70 29.30 3.0E-03 1.5E-03 2.03 0.0692 2.03 
PIK3C2B E06 24.30 31.35 7.9E-03 3.5E-04 22.16 0.2131 22.16 
PIK3CD E07 29.55 34.30 2.1E-04 4.6E-05 4.50 0.0236 4.50 
PIK3R1 E08 28.65 32.55 3.9E-04 1.5E-04 2.50 0.0873 2.50 
PTPN1 F04 24.90 29.70 5.2E-03 1.1E-03 4.66 0.0718 4.66 
TRIB3 G09 26.40 28.10 1.8E-03 3.4E-03 0.54 0.0422 -1.84 
7.3.6.3 IRS Proteins 
The two IRS proteins IRS1 and IRS2 were significantly upregulated in Chang 
liver cells cultured in MIF medium containing plant extract 1 compared to cells 
grown in only MIF medium. IRS1 and IRS2 are down regulated in the liver of 
diabetic animals and humans (Fröjdö et al., 2009). 
Insulin receptor (IR) autophosphorylation is followed by phosphorylation of the 
IRS proteins (Glund & Zierath, 2004). The IRS proteins link the IR to the PI3-
kinase and extracellular signal-regulated kinase (ERK) cascades (White, 
2002). IR (indicated as ISNR in Table 7.8) also showed an upregulation, 
although a significant p-value was not generated. The plant extract could 
enhance the insulin signalling cascade via the IRS/PI3-kinase pathway since 
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a number of components of the pathway are upregulated including IRS1, 
IRS2, and PIK3CD. IR is non-significantly upregulated (p=0.0607; 3.41fold), 
followed by a significant upregulation of IRS1 (1.65 fold; p=0.0323), IRS2 
(1.21 fold; 0.0015) and PIK3CD (4.50 fold; p= 0.0236) (Table 7.12). 
7.3.6.4 PI3K 
PI3K plays a central role in a diverse range of cellular responses, including 
cell growth and differentiation; synthesis and degradation of carbohydrates, 
lipids and proteins; platelet activation; cytoskeletal organization, cell motility 
and membrane trafficking (reviewed by Shepherd et al., 1998). There are 
eight PI3-kinase family members divided into three classes based on their 
lipid specificity and structure (Harada et al., 2005; Bilancio et al., 2006; Katso 
et al., 2006). Class I PI3-kinases exist as heterodimers consisting of a p110 
catalytic subunit (classified as α, β, γ or δ) and a regulatory subunit (p55, p85 
or p101).  Class I PI3-kinases have been further divided into two subclasses 
Class-1A and –1B, based on their mechanism of action (Harada et al., 2005; 
Bilancio et al., 2006; Katso et al., 2006). PIK3CD encodes the p110δ isoform 
of Class IA PI3-kinase. The catalytic subunit encoded by PIK3CD is present in 
endothelial cells and contributes to neutrophil accumulation in inflammation. 
This neutrophil trafficking is enabled by migration towards chemoattractants 
and modulation of the proadhesive state of these cells in response to TNFα 
(Sadhu et al., 2003; Puri et al., 2004). PIK3CD was significantly 4.50 fold 
upregulated in Chang liver cells cultured in MIF medium supplemented with 
plant extract 1 compared to cells grown in MIF medium alone (p=0.0236) 
Table 7.12). 
PIK3C2B is a class II PI3-kinase isoform. In the present study it was 22.16 
fold upregulated; however no significant p-value was generated because of 
variation in the biological replicates (Table 7.12). PIK3C2B have been 
implicated in cytoskeletal organization and cell migration (Maffucci et al., 
2005; Katso et al., 2006). Class II PI3K isoforms, such as PIK3C2B have been 
reported to be overexpressed in human tumor cells (Arcaro et al., 2002). The 
malignant phenotype of various cancers could be explained by the ability of 
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this gene to enhance migration and protect cells from anoikis, apoptosis 
induced by cell detachment from extracellular matrix (Katso et al., 2006).  
7.3.6.5 TRIB3 
In the present study TRIB3 expression was down regulated (1.84 fold; p= 
0.0422) (Table 7.12) in Chang liver cells cultured in MIF medium containing 
plant extract 1, compared to cells grown in MIF medium. TRIB3 is induced by 
various forms of ER stress and has been shown to be involved in cell death 
during ER stress (Ohoka et al., 2005). Down-regulation of TRIB3 is associated 
with decreased ER stress-dependent cell death. The decreased expression of 
TRIB3 in cells cultured in MIF medium supplemented with plant extract 1 is 
probably a compensatory mechanism induced by the plant extract that protect 
against the stress incured by the MIF medium. 
7.3.7 The effect of plant extract 1 on Metabolic Enzymes 
7.3.7.1 Lipogenic enzymes 
The lipogenic metabolic enzymes ATP citrate lyase (ACLY), Glycerol-3-
phosphate dehydrogenase 1 (GPD1) and Malic enzyme 1 (ME1) were 
upregulated (Table 7.13) in Chang liver cells cultured in MIF medium 
containing plant extract 1, compared to cells grown in MIF medium only. In the 
presence of abundant carbohydrates de novo lipogenesis pathways are 
activated (Postic & Girard, 2004). Insulin also induces lipogenic pathways by 
increasing expression of SREBP-1c (Shimomura et al., 1999).  
7.3.7.2 Glucose-6-phosphatase dehydrogenase (G6PD) 
Xu et al., (2005) hypothesized that diabetes inhibits G6PD activity. G6PD is 
the first and rate-limiting enzyme of the pentose phosphate pathway, which 
results in the production of ribose-5-phosphate and NADPH. An adequate 
supply of NADPH is needed for the antioxidant system, as well as other 
reductant-requiring processes, as NADPH is the principal intracellular 
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reductant for all cells. Therefore, a decrease in G6PD activity would lead to a 
decrease in NADPH and make cells sensitive to oxidative damage (Xu et al., 
2005; Zhang et al., 2000). Increased oxidative stress has been implicated to 
play a major role in complications of diabetes (reviewed by Johansen et al., 
2005). 
In the present study G6PD expression was increased in Chang liver cells 
cultured in MIF medium containing plant extract 1, compared to cells grown in 
MIF medium (Table 7.13). Thus the increase in G6PD seen in the presence of 
plant extract could protect the cells from oxidative damage.  
7.3.7.3 Glycogen enzymes 
The multifunctional serine/threonine kinase Glycogen synthase kinase 3 
(GSK3B) was significantly (p=0.0417) upregulated in Chang liver cells 
cultured in MIF medium containing plant extract 1 compared to cells grown in 
MIF medium (Table 7.13). GSK3B is a key regulator of numerous signalling 
pathways and is involved in a wide range of cellular processes including 
glycogen metabolism (Doble and Woodgett, 2003). The rate limiting enzyme 
in glycogen synthesis, glycogen synthase (GYS) is phosphorilated and 
inactivated by GSK3B. An enzyme that catalyzes glycogen breakdown to 
glucose-1-phosphate liver phosphorylase glycogen (PYGL) was also 
significantly (p=0.0417) upregulated in the present study (Table 7.13). After 24 
hours the expression of genes that inhibit glycogen synthesis (GSK3B) and 
stimulate glycogen degradation (PYGL) was upregulated in Chang liver cells 
cultured in MIF medium supplemented with plant extract 1 compared to cells 
grown in MIF medium alone.   
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Table 7:13 Metabolic Enzymes 
Symbol Well 
AVG Ct without 
normalization 
2^-ΔCt 
Fold 
Difference 
T-TEST 
Fold Up- 
or Down-
Regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
Sample 
/Control 
Sample 
p-value 
Test 
Sample 
/Control 
Sample 
ACE A02 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
ACLY A03 23.40 29.35 1.5E-02 1.4E-03 10.34 0.0104 10.34 
ENPP1 B03 27.05 33.75 1.2E-03 6.7E-05 17.39 0.0395 17.39 
FBP1 B04 34.30 35.00 7.7E-06 2.8E-05 0.27 0.4226 -3.68 
G6PC B08 34.85 35.00 5.2E-06 2.8E-05 0.19 0.4226 -5.39 
G6PD B09 23.20 27.90 1.7E-02 3.9E-03 4.35 0.0129 4.35 
GCK B12 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
GPD1 C02 29.30 33.95 2.5E-04 5.9E-05 4.20 0.0229 4.20 
GSK3B C03 23.15 27.95 1.7E-02 3.7E-03 4.66 0.0417 4.66 
HMOX1 C04 26.90 31.70 1.3E-03 2.8E-04 4.66 0.0144 4.66 
IDE C07 24.10 28.30 9.0E-03 2.9E-03 3.07 0.0746 3.07 
ME1 D11 23.85 27.85 1.1E-02 4.0E-03 2.68 0.0347 2.68 
NOS3 E02 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
PARP1 E05 22.55 27.45 2.6E-02 5.3E-03 4.99 0.0342 4.99 
PRKAA1 F01 24.30 29.60 7.9E-03 1.2E-03 6.59 0.1521 6.59 
PRKAG2 F02 27.60 31.50 8.0E-04 3.2E-04 2.50 0.0538 2.50 
PRKCB1 F03 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
PYGL F05 24.75 29.55 5.8E-03 1.2E-03 4.66 0.0417 4.66 
7.3.7.4 Ectonucleotide pyrophosphate/phosphodiesterase 1 (ENPP1) 
ENPP1 expression was upregulated in Chang liver cells cultured in MIF 
medium containing plant extract 1, compared to cells grown in MIF medium 
only. ENPP1 is an insulin receptor inhibitor that is elevated in cells and tissues 
of insulin resistant animals and humans (reviewed by Goldfine et al., 2008). 
ENPP1 has a wide tissue distribution and is expressed in the major targets of 
insulin action: liver, skeletal muscle and adipose tissue. In the present study, 
Chang liver cells cultured with MCBD medium or MIF medium showed 
virtually no expression of ENPP1, as indicated by their Ct-values (mean Ct-
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values of 33.75 and 33.50 respectively) (Table7.13). In Chang liver cells 
cultured in MIF medium containing plant extract 1 the mean Ct-value was 
27.05.  ENPP1 is normally expressed in liver cells; however when Chang liver 
cells were cultured with MCBD and MIF medium ENPP1 expression was 
totally suppressed. Thus the upregulation in ENPP1 expression seen in 
Chang liver cells cultured in MIF medium containing plant extract 1 compared 
to the other two medium conditions was not an elevated level of expression 
but just an induction of the ENPP1 expression which is normally expressed in 
the liver.     
7.3.7.5 Heme oxygenase (HMOX1)  
In the present study HMOX1 expression was upregulated in Chang liver cells 
cultured in MIF medium containing plant extract 1, compared to cells grown in 
MIF medium (Table 7.13) . HMOX1 plays an important role in cellular defense 
against oxidative stress and the negative effects of proinflammatory cytokines 
(Soares et al., 2004; Cao et al., 2008). HMOX1 is a direct target gene of 
PPARα and PPARγ (Krönke et al., 2007). SREBP-1 also induced the 
expression of HMOX1 (Kallin et al., 2007). In the present study PPARα 
expression was increased in the presence of plant extract 1 thus the increase 
in HMOX1 could be the consequence of the transcriptional regulation by 
PPARα.   
7.3.7.6 Poly (ADP-ribose) polymerase family member 1 (PARP1) 
In the present study PARP1 was significantly (p=0.0342) upregulated by 4.99 
fold in Chang liver cells cultured in MIF medium containing plant extract 1, 
compared to cells grown in MIF medium only (Table 7.13). PARP1 is involved 
in the regulation of DNA repair, gene transcription, cell-cycle progression, cell 
death, chromatin function and genomic stability (Szabó et al., 2006). Moderate 
genotoxic stimuli could activate PARP1 expression leading to DNA repair by 
signalling cell cycle arrest and interacting with other DNA repair enzymes 
(Pacher and Szabó, 2007). An additional role of PARP1 is its involvement in 
the regulation of the expression of various proteins implicated in inflammation 
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at the transcriptional level (Pacher & Szabó, 2007). 
Cells exposed to damaging agents can enter one of three major pathways, 
based on the intensity of the injury (Virág & Szabó, 2002; Pacher & Szabó, 
2007). Moderately damaging stimuli would trigger the first pathway in which 
PARP1 is activated, leading to DNA repair by signalling cell cycle arrest and 
interaction with other DNA repair enzymes. The second pathway is triggered 
by more severe DNA damage leading to apoptotic cell death; during which 
caspases inactivate PARP1 and destroy its ability to respond to DNA strand 
breaks. The third pathway is triggered by extensive oxidative stress, extensive 
DNA breakage and overactivation of PARP1 and depletion of cellular ATP, 
leading to cell death due to necrosis (Virág & Szabó, 2002; Pacher & Szabó, 
2007). In the present study it is proposed that the increase in PARP1 
expression in the presence of plant extract 1 would trigger the first pathway. 
The presence of plant extract 1 in the MIF medium may somehow protect the 
cells from the extensive unrepairable damage incurred by the excess nutrients 
in the medium and activate PARP1 expression to repair DNA.  
PARP1 activation also plays a role in the development of inflammatory cell 
injury. The increased expression of PARP1 in the present study could also 
explain the upregulation of proinflammmatory gene ICAM1 under the same 
media conditions, as PARP1 activation is also known to increase ICAM1 
expression (Virág and Szabó, 2002). 
7.3.8 The effect of plant extract 1 on Secreted factors 
Two secreted factors generated significant p-values under the test conditions, 
Angiotensinogen (AGT) and Transforming growth factor beta 1 (TGFB1). The 
AGT gene encodes the prohormone of angiotensin II (ANGII) (Li & Brasier 
1996; Lim et al., 2004). AGT is secreted principally by the liver. One 
physiological activator of AGT is the hepatic acute phase response, a highly 
species-conserved specific response of mammalian liver to the initiation of 
inflammation (Li & Brasier 1996; Weber, 2004). In the present study AGT 
expression was upregulated 4.20 fold (p=0.0097) in Chang liver cells cultured 
in MIF medium supplemented with plant extract 1, compared to cells grown in 
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MIF medium only (Table 7.14). Thus the presence of the plant extract 
activated the hepatic acute phase response by increasing AGT expression.   
 TGFB1, a growth factor that modulates fibrosis in wound repair, was 2.97 fold 
upregulated in the present study (p=0.0155) (Table 7.14). Hepatic fibrosis is a 
dynamic process caused by chronic liver injury due to various etiologies 
including viral, toxic, metabolic, autoimmune factors (Li et al., 2006; Zhao et 
al., 2006). PPARγ was shown to inhibit TGFB1 activity and expression of 
TGFB1 regulated genes (Li et al., 2006; Zhao et al., 2006). In the present 
study PPARγ expression was decreased in Chang liver cells after 24 hour of 
exposure to MIF medium supplemented with pant extract 1 and no PPARγ 
expression was detected with the PCR Array assay. The decrease in PPARγ 
expression could result in the increase in TGFB1 expression, because of the 
inhibitory effect of PPARγ on TGFB1.    
Table 7:14 Secreted factors 
Symbol Well 
AVG Ct without 
normalization 
2^-ΔCt 
Fold 
Difference 
T-TEST 
Fold Up- 
or Down-
Regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
Sample 
/Control 
Sample 
p-value 
Test 
Sample 
/Control 
Sample 
AGT A05 30.25 34.90 1.3E-04 3.0E-05 4.20 0.0097 4.20 
CCL5 A08 28.05 31.85 5.8E-04 2.5E-04 2.33 0.1678 2.33 
GCG B10 33.55 35.00 1.3E-05 2.8E-05 0.46 0.3014 -2.19 
IFNG C08 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
IL10 C11 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
IL12B C12 34.95 35.00 4.9E-06 2.8E-05 0.17 0.4226 -5.78 
IL6 D02 26.40 29.05 1.8E-03 1.7E-03 1.05 0.0828 1.05 
INS D04 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
RETN F07 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
TGFB1 G05 29.20 33.35 2.6E-04 8.9E-05 2.97 0.0155 2.97 
TNF G07 32.80 35.00 2.2E-05 2.8E-05 0.77 0.1107 -1.30 
VEGFA G12 25.25 29.50 4.1E-03 1.3E-03 3.18 0.0536 3.18 
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7.3.9  The effect of plant extract 1 on Transcription factors 
7.3.9.1  Hepatocyte Nuclear factor 4 alpha (HNF4A)  
In the present study HNF4A was significantly upregulated in Chang liver cells 
cultured in MIF medium containing plant extract 1, compared to cells grown in 
MIF medium only.  HNF4A is expressed at high levels in the liver, where it is 
localized exclusively in the nucleus (reviewed by Gonzalez, 2008). HNF4A 
regulates constitutively a number of critical metabolic pathways in the liver 
including glycolysis, gluconeogenesis, ureagenesis, fatty acid metabolism, 
hepatocyte differentiation, bile acid synthesis, drug metabolism, 
apolipoproteins, blood coagulation (Stoffel and Duncan, 1997; Hayhurst et al., 
2001; Schrem et al., 2002; Rhee et al., 2003; Gonzalez, 2008). HNF4A knock 
out mice exhibit high hepatic lipids that result from altered expression of fatty 
acid transporters and fatty acid metabolism (Hayhurst et al., 2001; Gonzalez 
2008). 
In the present study there was virtually no expression of HNF4A in Chang liver 
cells cultured in MCBD-201 and MIF medium, as indicated by the Ct-values of 
34.45 and 34.05 respectively, under these media conditions (Table 7.15). 
HNF4A expression was 5.94 fold upregulated (p=0.0327) if plant extract 1 
was included in MIF medium. Thus the presence of the plant extract induced 
the expression of HNF4A which in turn regulated several genes involved in 
glucose and fatty acid metabolism.  This emphasizes the important role the 
plant extract might play in glucose and lipid metabolism as has also been 
illustrated by regulation of other genes that also control these metabolic 
pathways such as the PPARs, SREBP-1, glycolytic enzymes and lipogenic 
enzymes.   
7.3.9.2 Nuclear respiratory factor 1 (NRF1) 
In the present study NRF1 was significantly upregulated when Chang liver 
cells were grown in MIF medium supplemented with plant extract 1, compared 
to growth in MIF medium only (Table 7.15). NRF1 is a transcriptional activator 
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of nuclear genes that encodes a range of mitochondrial proteins (Baar et al., 
2003). PPARγ coactivator (PPARGC1) α co-ordinates with NRF1. PPARGC1 
and NRF1 regulate genes involved in oxidative metabolism in skeletal muscle 
of T2DM patients (Baar et al., 2003). In the liver, NRF1 serves a protective 
role against oxidative stress and potentially also functions in lipid homeostasis 
as mice with somatic inactivation of NRF1 gene show oxidative stress, 
steatohepatitis, and spontaneous development of liver cancer (Xu et al., 2005; 
Parola & Novo, 2005).   
The upregulation of NRF1 in the presence of the plant extract protect the cell 
against the oxidative stress introduced by the insulin resistance inducing 
medium.  
Table 7:15 Transcription factors 
Symbol Well 
AVG Ct without 
normalization 
2^-ΔCt 
Fold 
Difference 
T-TEST 
Fold Up- 
or Down-
Regulation 
Test 
Sample 
Control 
Sample 
Test 
Sample 
Control 
Sample 
Test 
Sample 
/Control 
Sample 
p-value 
Test 
Sample 
/Control 
Sample 
CEBPA A12 27.05 32.65 1.2E-03 1.4E-04 8.11 0.0658 8.11 
FOXC2 B05 29.45 33.55 2.2E-04 7.7E-05 2.87 0.1014 2.87 
FOXG1B B06 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
FOXP3 B07 35.00 35.00 4.7E-06 2.8E-05 0.17 N/A -5.98 
HNF4A C05 28.90 34.05 3.2E-04 5.5E-05 5.94 0.0327 5.94 
PDX1 D06 32.10 35.00 3.5E-05 2.8E-05 1.25 0.0536 1.25 
NEUROD1 D12 34.60 35.00 6.2E-06 2.8E-05 0.22 0.4226 -4.53 
NFKB1 E01 25.20 32.20 4.2E-03 2.0E-04 21.41 0.1330 21.41 
NRF1 E03 26.30 30.85 2.0E-03 5.0E-04 3.92 0.0305 3.92 
PPARGC1A E11 26.50 29.70 1.7E-03 1.1E-03 1.54 0.0739 1.54 
PPARGC1B E12 28.25 33.30 5.1E-04 9.2E-05 5.54 0.0972 5.54 
SREBF1 F12 25.45 30.20 3.5E-03 7.9E-04 4.50 0.0771 4.50 
TCF2 G04 30.40 34.80 1.1E-04 3.2E-05 3.53 0.1007 3.53 
TITF1 G06 33.25 35.00 1.6E-05 2.8E-05 0.56 0.1147 -1.78 
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7.3.9.3 PCR Array Summary 
The PCR Array assay showed that 28 genes were significantly up or down 
regulated when Chang liver cells were cultured in MIF medium supplemented 
by plant extract 1, compared to culture in MIF medium only (Table 7.16). Four 
genes, PIK3C2B, CEBPA, PPARGC1A and PPARGC1B were also included in 
Table 7.16 even though a significant change was not detected. These genes 
were included, because a great fold upregulation was present and no 
significance was detected because of variation in the biological duplicates.  
The short comings of PCR Array assays that can lead to the generation of 
false positives is acknowledged, however the PCR Array assay was used as a 
quick and easy screening technique. In a subsequent analysis, five of the 32 
genes identified with the PCR Array assay were further analyzed with qRT-
PCR using the reference genes identified in Chapter 5.  
The 32 genes identified included genes involved in the development of 
inflammation, oxidative stress, DNA repair and cell death (ICAM1, PIK3CD, 
AGT, TGFB1). However genes protecting against the development of 
inflammation, oxidative stress and cell death were also upregulated (IL4R, 
PIK3D2B, TRIB3, G6PD, HMOX1, NRF1). Genes involved in vesicle transport 
were down regulated by the insulin resistance inducing medium (NSF, 
VAMP3), and upregulated when plant extract 1 was added to this medium 
(NSF, VAMP3, SNAP25, STX4, VAPA). Lipogenic metabolic enzymes were 
upregulated (ACLY, GPD1, ME1), genes capable of inhibiting gluconeogenic 
enzymes were up regulated (DUSP4), and enzymes that inhibit glycogen 
synthesis (GSK3B) and stimulate glycogen degradation (PYGL) were also 
upregulated. Insulin signalling transduction via PI3K pathway was upregulated 
by plant extract 1 as the expression of a number of genes in this pathway 
were upregulated (IGFBP5, IRS1, IRS2, PIK3CD, PIK3C2B).   
 
 
 
  208 
Table 7:16 Comparison of the fold up or down-regulation of the genes showing 
significant p-values in the PCR Array analysis 
 
Gene Name  
 
Function 
MCBD compared to MIF MIF compared to 
MIF+Plant extract 1 
Fold up- or 
down-regulation 
P-value 
Fold up- or 
down-regulation 
P-value 
1. ABCC8 
Sulphonylurea antidiabetic 
drugs binding site 
1.12 0.423 2.03 0.012 
2. ICAM1 
Inflammation; Endothelial 
dysfunction 
-2.90 0.082 8.40 0.009 
3. IL4R 
Inhibiting proinflamamtory 
cytokines 
-2.44 0.155 13.64 0.009 
4. NSF Vesicle Transport -2.28 0.015 6.15 0.035 
5. SNAP25 Vesicle Transport 1.58 0.821 4.66 0.018 
6. STX4 Vesicle Transport -3.01 0.215 2.25 0.037 
7. VAMP3 Vesicle Transport -7.66 0.021 9.65 0.045 
8. VAPA Vesicle Transport -1.40 0.300 2.68 0.021 
9. PPARA Β-Oxidation 1.82 0.300 1.54 0.034 
10. DUSP4 Inhibit gluconeogenesis -1.79 0.267 2.68 0.019 
11. IGFBP5 Potentiates the effect of IGF 1.20 NA -2.19 0.001 
12. IRS1 Link IR to P13-Kinase 1.82 0.534 1.65 0.032 
13. IRS2 Link IR to P13-Kinase 2.48 0.460 1.21 0.002 
14. PIK3CD 
Neutrophil accumulation 
during inflammation 
-1.03 0.828 4.50 0.024 
15. PIK3C2B 
Cytoskeletal organization 
and cell migration 
-10.46 0.432 22.16 0.213 
16. TRIB3 
Cell death; induced by ER 
stress 
4.03 0.273 -1.84 0.042 
17. ACLY Lipogenic metabolic enzyme 1.12 0.905 10.34 0.010 
18. ENPP1 Insulin receptor inhibitor 1.01 0.877 17.39 0.040 
19. G6PD Oxidative damage 1.48 0.720 4.35 0.013 
20. GPD1 Lipogenic metabolic enzyme 1.33 0.403 4.20 0.023 
21. GSK3B Inhibit glycogen synthesis -1.85 0.240 4.66 0.042 
22. HMOX1 
Protect against oxidative 
stress and proinflammatory 
cytokines 
1.04 0.794 4.66 0.014 
23. ME1 Lipogenic metabolic enzyme 2.02 0.454 2.68 0.035 
24. PARP1 
DNA repair; regulation of 
transcription of inflammation 
proteins 
12.23 0.515 4.99 0.034 
25. PYGL 
Catalyse glycogen 
degradation 
-1.10 0.504 4.66 0.042 
26. AGT 
Activated by hepatic acute 
phase response 
1.29 0.423 4.20 0.010 
27. TGFB1 
Modulates fibrosis in wound 
repair 
-2.28 0.462 2.97 0.016 
28. HNF4A 
Regulates genes involve in 
glucose and fatty acid 
metabolism 
1.58 0.624 5.94 0.033 
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Gene Name  
 
Function 
MCBD compared to MIF MIF compared to 
MIF+Plant extract 1 
Fold up- or 
down-regulation 
P-value 
Fold up- or 
down-regulation 
P-value 
 
29. NRF1 
Protective role against 
oxidative stress; Lipid 
homeostasis 
1.01 0.769 3.92 0.031 
30. CEBPA 
Liver nitrogen, glucose, lipid 
and iron metabolism and 
hepatocyte proliferation 
-1.45 0.601 8.11 0.066 
31. PPARGC1A 
Co-activator of NRF, HNF4, 
PPARα 
-1.14 0.689 1.54 0.0739 
32. PPARGC1B 
Co-activator of NRF, HNF4, 
PPARα 
-2.62 0.434 5.54 0.0972 
 
The objective of the present study was firstly to develop a model of insulin 
resistance in the Chang liver cell line, and secondly to identify the molecular 
targets of S. frutescence in this insulin resistant model. The first objective to 
develop a model of insulin resistance was achieved by culturing the Chang 
liver cell MCBD-201medium supplemented with 0.1 μM insulin and 1mM 
fructose. The Chang liver cells were considered to be insulin resistant 
because of their decreased glucose uptake and increased lipid accumulation. 
In the present study it is hypothesized that faced with excess nutrients as in 
MIF medium and in the absence of adipose tissue (liver cell culture), the 
Chang liver cells will become adipogenic. This hypothesis is based on the 
emerging theory that limited adipose capacity would redirect nutrient storage 
towards other organs such as muscle, liver, heart or pancreas.  
Driven by the more lipocentric approach to T2DM, it is hypothesized that 
genes playing a major role in lipid metabolism would be affected in the model 
of insulin resistance. It is further hypothesized that the S.frutescens plant 
extracts would reverse the effect of the insulin resistance inducing medium on 
the Chang liver cells. Consequently the expressions of genes involved in 
regulating lipid metabolism, such as PPARα, PPARγ and SREBP-1c were 
investigated.  
In the PCR Array assay 84 diabetes related genes were investigated. In 
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Chang liver cells cultured in MIF medium for 24 hours two genes involved in 
vesicle transport (NSF and VAMP3) were significantly down regulated, 
compared to growth in MCBD medium only. No other genes were significantly 
up or down regulated. If plant extract 1 was included in the MIF medium, a 
larger amount of genes was significantly up or down regulated. It is 
hypothesized that more significant changes in gene expression were seen in 
the presence of plant extract because the plant extract provided some form of 
protection against the stress introduced to the cell by the MIF treatment.  
Three transcription factors (HNF4A, NRF1, CEBPA) regulating lipid 
metabolism, glucose metabolism and oxidative stress pathways in the liver 
were activated when the S.frutescens extract 1 was included the insulin 
resistance inducing medium (Figure 7.6). The current therapeutic application 
of S.frutescens includes anti-diabetic, anti-inflammatory, anti-cancer, wound 
healing activies and these three transcription factors identified as potential 
molecular targets of S.frutescens could explain these activities. 
 
Figure 7.6 Transcription factors and metabolic pathways affected by 
S.frutescens plant extract1. 
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Figure 7.7-7.9 shows how the genes identified with the PCR Array influence 
glucose, lipid and oxidative stress pathways in the liver. In the insulin 
resistance state, flux through glycolysis, glycogenesis and the pentose 
phosphate pathways are normally decreased. Insulin signalling is also down-
regulated and gluconeogenesis and lipogenesis are upregulated (Figure 7.7).   
In the presence of S.frutescens genes that could upregulate the flux through 
the glycolysis and pentose phosphate pathways were activated (SREBP-1, 
G6PDH) as well as genes in the insulin signalling pathway (IRS1, IRS2, 
PI3K).   Genes involved in glycogen degradation and inhibition of glycogen 
synthesis were also upregulated in the presence of the plant extract (GSK3B, 
PYGL). Genes involved in inhibiting gluconeogenesis (DUSP4) as well as 
stimulating gluconeogenesis were increased (HNF4A). The glucose uptake 
assays performed in Chapter 2 and 3 showed huge variation. The gene 
expression profile of genes regulating glucose metabolism in the cell under 
the experimental conditions of the present study could possibily explain this 
variation.  
Lipogenic enzymes were upregulated; however genes playing a role in β-
oxidation and transport of lipids that can protect against accumulation of lipids 
in the cell were also upregulated (Figure 7.8). The high levels of fructose and 
insulin in the medium is a stressor for the cell and can lead to cell injury and 
the development of oxidative stress. Genes that play a role in the 
development of oxidative stress and inflammation were upregulated as well as 
genes that protect against the development of oxidative stress (Figure 7.9). 
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Figure 7.7 The influence of genes identified with PCR Array on glucose metabolism in Liver.  
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Figure 7.8 The influence of genes identified with PCR Array on lipid metabolism in Liver.  
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 Figure 7.9 The influence of genes identified with PCR Array on 
oxidative stress in the Liver.  
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CHAPTER 8:  VALIDATION OF FIVE GENES IDENTIFIED 
IN THE MICROARRAY ANALYSIS AS POSSIBLE 
TARGETS OF S.FRUTESCENS.  
In the present study it was hypothesized that genes regulating lipid metabolism 
could be affected by the extracts of the plant S.frutescens, consequently these 
genes have been investigated. To screen for other potential molecular targets of 
the S.frutescens a PCR Array assay was performed which identified 32 candidate 
genes. Due to time and financial constraints only five of these genes were chosen 
for analysis using qRT-PCR in the insulin resistance model of Chang liver cells. 
The five genes chosen were VAMP3, G6PDH, ACLY, PIK3C2B and CEBPA.   
VAMP3 was chosen because in the PCR Array study it showed a decrease in 
expression following insulin and fructose treatment of Chang liver cells and an 
increase in expression when plant extract 1 was included in the MCBD-201 
medium in addition to insulin and fructose. VAMP3 expression was followed over 
a time period of two to 48 hours in the Chang liver cell insulin resistant model to 
validate the results found in the Micro Array assay and to determine the time 
course of VAMP3 expression.  
Oxidative damage has been implicated in the complications of T2DM and several 
genes playing a role in protection against oxidative damage were up regulated in 
response to the plant extract 1 in the insulin resistance inducing medium. G6PDH 
was chosen because of its role in the pentose phosphate pathway that produces 
NADPH, the principal intracellular reductant for all cells.     
The lipogenic enzymes ACLY, GPD1 and ME1 showed an increase in expression 
in response to plant extract 1 treatment of insulin resistant Chang liver cells. This 
is in contrast to the findings of Nile red and Oil-red-O assays, which showed a 
reduction in lipid accumulation in response to plant extract 1 in the insulin 
resistance inducing medium. However GPD1 and ME1 also play a role in redox 
reactions and could be up regulated because these reactions are increased in 
response to oxidative damage. ACLY was chosen to confirm the change in 
expression over time in the insulin resistant Chang heptocyte model.  
  216 
The class II PI3K isoform PI3KC2B showed a huge up-regulation in the Micro 
Array analysis of insulin resistant Chang liver cells, but did not generate a 
significant p-value because of variation in the replicates. This gene was further 
analyzed to confirm the changes in PI3KC2B expression in the insulin resistant 
Chang liver cells. 
CEBPA showed an 8.11 fold upregulation following plant treatment but did not 
generate a significant p-value (0.0658), probably because of the variation in the 
replicates (MIF Ct 33.9, 31.4; and MIF+ P1 Ct 26.2, 27.9). CEBPA plays a very 
important role in regulating glucose and lipid metabolism in the liver and because 
of the inconclusive results generated with the PCR Array analysis this gene was 
further investigated in the insulin resistant Chang liver cell model.           
8.1 MATERIALS AND METHODS 
8.1.1 RNA extraction cDNA synthesis 
The same experimental samples from which RNA was extracted for the multiplex 
assay, as described in section 4.4.2 were used. cDNA was synthesized from 1μg 
of total RNA in a 20μl reaction volume using the iScriptTMcDNA Synthesis Kit 
(Bio-Rad) (see section  5.2.1).     
8.1.2 qRT- PCR 
RT2 qPCR primer assays for VAMP3, G6PDH, ACLY, PIK3C2B and CEBPA were 
obtained from Bioscience Corporation. The assay contained the 10μM RT2 primer 
sets and a 2XRT2 SYBR Green Fluorescein qPCR mastermix. The mastermix 
contained all reagents and buffers required for qRT-PCR in the BioRad iCycler, 
including a high performance HotStart DNA Taq polymerase, nucleotides, 
SYBR®Green dye and the fluorescein reference dye needed to calibrate the 
instrument.    
The qRT-PCR reaction was carried out in a 20μl reaction mix. Each reaction was 
performed in duplicate and contained 10μl of the 2XRT2 SYBR Green Fluorescein 
qPCR mastermix and 0.8μl of the RT2 primer set. The cDNA was diluted 1:5 and 
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5μl was added to the reaction mix. The PCR reaction was performed using the 
Bio-Rad iCycler using the amplification conditions as indicated in the Table 8.1 All 
experimental samples were amplified on the same plate for each specific gene. 
After the amplification a melt curve analysis was also performed by heating the 
thermal cycler to the annealing temperature and then increasing the temperature 
in 0.5°C increments up to 95°C for 30 seconds at each increment. 
Table 8.1  Thermocycling program RT
2
 primer set 
Number of cycles Temperature Duration 
1 95°C 10 minutes
5
 
40 95°C 
60°C 
15 seconds
6
 
1 minute 
8.1.3 Data Analysis 
Amplication data was analyzed using qBase v1.3.1. The Relative Expression 
Software Tool (REST) 2008 for group wise comparison and statistical analysis of 
relative expression results in qRT-PCR was used to determine statistical 
significance. 
The purpose of REST 2008 is to determine whether there is a significant 
difference between samples and controls, while taking into account issues such 
as reaction efficiency and reference gene normalization (Pfaffl et al., 2002; 
Vandersomple et al., 2002; Davidson & Hinkley, 2002).  A hypothesis test P(H1) 
is calculated, which represents the probability of the alternate hypothesis that the 
difference between sample and control groups is due only to chance. The P(H1) 
allows for a test of significance of the derived results. The mean factor (mean) 
and 95% confidence intervals was also calculated with the program. 
 
                                            
5 The 10 minute step at 950C is required to activate the HotStart DNA polymerase.  
6 Detect and record SYBR®Green fluorescence from every well during the annealing step of each cycle. 
  218 
8.2 RESULTS AND DISCUSSION 
8.2.1 VAMP3 Expression 
In the present study the PCR Array assay showed that VAMP3 expression was 
down-regulated in Chang liver cells cultured for 24 hours in MIF medium 
compared to cells cultured in MCBD-201 medium (Table 7.5 and 7.6). Chang liver 
cells cultured for 24 hours in MIF medium supplemented with plant extract 1 
showed an increase in VAMP3 expression compared to cells cultured in MIF 
medium only (Table 7.8 and 7.10). The RT2 qPCR primer assay for VAMP3 was 
used to confirm this finding with qRT-PCR.  
As in the PCR Array analysis, VAMP3 expression was down-regulated in Chang 
liver cells treated with MIF for 24 hours compared to Chang liver cells treated with 
MCBD-201 medium only, mean factor 0.673, 95% confidence interval (C.I.) 
0.584-0.777, P(H1)<0.0001 (Figure 8.3). The increase in VAMP3 expression in 
response to plant extract 1 in the insulin resistance inducing medium seen in the 
PCR Array assay was not confirmed with the qRT-PCR assay. No significant 
change in VAMP3 expression was seen after 2, 6, 24 or 48 hours of exposure 
when comparing Chang liver cells cultured with MIF medium supplemented with 
plant extract 1 or plant extract 2 with cells cultured in MIF medium only (Figure 
8.1-8.4). After six hours of exposure there was an increase in VAMP3 expression 
in cells cultured in MIF medium supplemented with plant extract 1 relative to cells 
cultured in MIF medium alone; however this increase was not significant.   
After two hours of exposure cells cultured with all MIF containing media showed a 
decrease in VAMP3 expression relative to cells cultured under control conditions 
(Figure 8.1). This decrease was significant only for MIF medium supplemented 
with plant extract 2 or ciglitazone (P(H1)< 0.0001). After six hours VAMP3 
expression was higher in cells treated with MIF medium or MIF medium 
supplemented with plant extract 1, plant extract 2 or ciglitazone compared to after 
2 hours relative to the cells grown in control medium (Figure 8.2). After 24 hours 
Chang liver cells cultured in all MIF containing media showed a significant 
decrease in VAMP3 expression relative to cells grown in control MCBD-201 
medium (Figure 8.3). 
  219 
 
Figure 8.1 The normalized relative 
expression of VAMP3 in 
Chang liver cells 
exposed to five 
different medium 
conditions respectively 
for two hours. 
The fold VAMP3 expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD-
201 medium for two hours. 
(***P(H1)<0.0001)   
 
Figure 8.2 The normalized relative 
expression of VAMP3 in 
Chang liver cells 
exposed to five 
different medium 
conditions respectively 
for six hours. 
The fold VAMP3 expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD-
201 medium for six hours. 
   
After 48 hours of exposure VAMP3 expression in cells cultured in all MIF 
containing media increased again to the level seen in cells grown in control 
medium (Figure 8.4). However this increase in VAMP3 expression is not 
significantly more than what is seen in cells cultured in control conditions.  
The RT2 qPCR primer assay using VAMP3 primers was used to validate the 
results generated with the PCR Array. The down-regulation of VAMP3 expression 
seen in the PCR Array when Chang liver cells were cultured in MIF medium for 
24 hours compared to cells cultured in MCBD-201 medium was confirmed with 
the qRT-PCR. VAMP3 expression was not increased in cells cultured in MIF 
medium suppplemented with plant extract 1 compared to MIF cultures. VAMP3 
plays an important role in vesicle transport. Liver cells are metabolically very 
active; a down-regulation in a gene important in vesicle transport could have 
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important implications for its metabolic regulation. However this decrease in 
VAMP3 expression seen in MIF cultures after 24 hours of exposure was not 
maintained over the entire time course, after 6 and 48 hours VAMP3 expression 
increases and return to the level seen in control cells. 
 
Figure 8.3 The normalized relative 
expression of VAMP3 in 
Chang liver cells 
exposed to five 
different medium 
conditions respectively 
for 24 hours. 
The fold VAMP3 expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD-
201 medium for 24 hours. (***P(H1)<0.0001) 
 
Figure 8.4 The normalized relative 
expression of VAMP3 in 
Chang liver cells 
exposed to five 
different medium 
conditions respectively 
for 48 hours. 
The fold VAMP3 expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD-
201 medium for 48 hours. 
8.2.2 ACLY Expression  
In the PCR Array assay Chang liver cells cultured in MIF medium supplemented 
with plant extract 1 ACLY expression was significantly increased after a 24 hour 
exposure compared to the cell cultured in MCBD-201 medium only (Table 7.13). 
To validate this result the RT2 qPCR primer assay for ACLY was performed in all 
experimental samples indicated in section 4.4.2 and data was normalized with the 
two reference genes ATP5B and TATBP. The results found with the qRT-PCR 
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differ from what was found with the PCR Array data. Chang cells cultured in MIF 
medium for 24 hours showed an increase in ACLY expression compared to cells 
grown in MCBD medium (P(H1)= 0.168) (Figure 8.7). The addition of plant extract 
1 to MIF did not lead to a further increase or decrease in ACLY expression in 
Chang liver cells compared to treatment with MIF only.   
ACLY expression was significantly decreased in Chang liver cells cultured in all 
MIF medium for two hours compared to cells treated with MCBD-201 medium 
alone (P(H1)<0.0001) (Figure 8.5). ACLY expression in cells cultured with MIF 
medium supplemented with plant extract 1, plant extract 2 or ciglitazone was not 
significantly altered compared to the expression in MIF cultured cells after two 
hours.  
Six hours after exposure, ACLY expression was significantly increased in Chang 
liver cells cultured in all MIF containing media compared to cells grown in MCBD-
201 medium alone (P(H1)<0.0001) (Figure 8.6). There was no significant 
difference in expression between cells cultured in MIF medium supplemented 
with plant extract 1, plant extract 2, or ciglitazone compared to cells grown in MIF 
medium alone.    
The excess nutrients in the medium due to added fructose in the culture medium 
would stimulate lipogenesis; ACLY is a lipogenic enzyme responsible for 
production of acetyl CoA and consequencly would also be upregulated. However 
after two hours of exposure to MIF medium, ACLY expression in Chang liver cells 
was decreased in all MIF containing media compared to cells cultured in control 
medium. The reason for this decreased expression could possibly be because 
metabolism of fructose takes some time to upregulate lipogenic pathways 
involving ACLY expression. However, after six hours ACLY expression was 
significantly increased in cells cultured in all MIF containing media compared to 
cells cultured in MCBD-201 medium alone.  
The increased ACLY expression above the level seen in cells cultured in MCBD-
201 medium was maintained after 24 hours of exposure in Chang liver cells 
cultured in MIF, MIF medium supplemented with plant extract 1 or plant extract 2. 
ACLY expression was down-regulated in cells cultured in MIF medium 
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supplemented with ciglitazone compared to cells cultured in MCBD-201 or MIF 
medium after 24 hours.  
After 48 hours of exposure there was no difference in expression between cells 
cultured in MCBD-201 medium, MIF medium and MIF medium supplemented with 
plant extract 1 or plant extract 2. This could possibly be attributed to the fact that 
after 48 hours, nutrients become depleted in all the tested media conditions, 
leading to inhibition of lipogenesis under all conditions. ACLY expression 
remained down-regulated in cells cultured in MIF medium supplemented with 
ciglitazone compared to cells cultured in MCBD-201 or MIF medium after 48 
hours of exposure. This down-regulation in the presence of ciglitazone could 
possibly be linked to the down-regulation of PPARγ expression seen at 24 hours 
and 48 hours of exposure. 
 
Figure 8.5 The normalized relative 
expression of ACLY in 
Chang liver cells 
exposed to five 
different medium 
conditions respectively 
for two hours.  
The fold ACLY expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD-
201 medium for two hours. Fold expression 
are shown on the Y-axis, values are means 
±SEM. (***P(H1)<0.0001) 
 
Figure 8.6 The normalized relative 
expression of ACLY in 
Chang liver cells 
exposed to five 
different medium 
conditions respectively 
for six hours.  
The fold ACLY expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD-
201 medium for six hours. Fold expression 
are shown on the Y-axis, values are means 
±SEM. (***P(H1)<0.0001) 
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Figure 8.7 The normalized 
relative expression of 
ACLY in Chang liver 
cells exposed to five 
different medium 
conditions 
respectively for 24 
hours.  
The fold ACLY expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in 
MCBD-201 medium for 24 hours. Fold 
expression are shown on the Y-axis, 
values are means ±SEM. 
(***P(H1)<0.0001) 
 
 
Figure 8.8 The normalized 
relative expression of 
ACLY in Chang liver 
cells exposed to five 
different medium 
conditions 
respectively for 48 
hours.  
The fold ACLY expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in 
MCBD-201 medium for 48 hours. Fold 
expression are shown on the Y-axis, 
values are means ±SEM. 
(***P(H1)<0.0001) 
8.2.3 G6PD Expression 
The PCR Array study showed an increase in G6PD expression after 24 hours 
exposure of MIF medium supplemented with plant extract 1 compared to cells 
expose to only MIF (Table 7.8 and 7.13). The RT2 qPCR primer assay 
comparing the same medium conditions after 24 hour exposure also showed 
a significant increase in G6PD expression (P(H1)< 0.0001; mean factor 1.339; 
95% C.I 1.233-1.455) (Figure 8.11).  
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A comparison of the different media conditions after two hours of exposure 
showed that the MIF medium caused a down-regulation of G6PD expression 
in cells, compared to MCBD-201 exposure medium in Chang liver cell line 
(mean factor 0.608; 95% C.I.=0.561-0.660; P(H1)<0.0001) (Figure 8.9). The 
presence of plant extract 2 and ciglitazone in the medium further reduced 
G6PD expression compared to the insulin resistance inducing medium alone 
after two hours of exposure (P(H1)<0.0001).  
After six hours G6PD expression in Chang liver cells cultured in all MIF 
containing media increased to the basal level of G6PD expression seen in 
cells cultured in control medium (Figure 8.10). However, the different media 
conditions did not result in any significant differential G6PD expression 
between each other. 
After 24 hours G6PD expression in Chang liver cells cultured in MIF medium 
was not changed relative to MCBD-201. However additions of plant extract 1 
to MIF medium increased G6PD expression significantly in cells compared to 
MIF treatment alone (P(H1)<0.0001) (Figure 8.11). In contrast MIF medium 
supplemented with ciglitazone decreased G6PD expression.  After 48 hours 
no significant differences in G6PD expression were seen between the 
different medium conditions under which the Chang liver cells were cultured 
(Figure 8.12).  
G6PDH is the first, and rate limiting, enzyme in the pentose phosphate 
pathway. The primary functions of this pathway include (1) Production of 
NADPH for reductive biosynthesis, and providing ribose-5-phosphate for the 
synthesis of nucleotides and nucleic acids. NADPH produced by this pathway 
can be used in biosynthetic pathways such as FA synthesis and cholesterol 
synthesis; detoxification; to reduce glutathione as an antioxidant; and for the 
generation of superoxide. SREBPs positively regulate G6PD because of the 
central role they play in FA and cholesterol synthesis, which require the 
generation of NADPH. Thus the increase in G6PD expression in Chang liver 
cells treated with MIF+P1 compared to MIF treatment would increase the flux 
through the pentose phosphate pathway. Increased flux through pentose 
phosphate pathway could produce more NADPH, which could be used as 
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reductant in FA and cholesterol synthesis, or in antioxidant reactions. In the 
present study genes playing a role in DNA repair were also affected by plant 
extract 1 thus the function of the pentose phosphate pathway to produce 
ribose-5 phoshate for the synthesis of nucleotides and nucleic acids could 
also play a role when G6PD expression is upregulated.  
 
Figure 8.9 The normalized 
relative expression of 
G6PD in Chang liver 
cells exposed to five 
different medium 
conditions 
respectively for 2 
hours.  
The fold G6PD expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for 2 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
(***PH1<0.0001) 
 
Figure 8.10 The normalized 
relative expression of 
G6PD in Chang liver 
cells exposed to five 
different medium 
conditions 
respectively for 6 
hours.  
The fold G6PD expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for 6 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
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Figure 8.11 The normalized 
relative expression of 
G6PD in Chang liver 
cells exposed to five 
different medium 
conditions 
respectively for 24 
hours.  
The fold G6PD expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for 24 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
(PH1<0.0001) 
 
 
 
Figure 8.12 The normalized 
relative expression of 
G6PD in Chang liver 
cells exposed to five 
different medium 
conditions 
respectively for 48 
hours.  
The fold G6PD expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for 48 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
(PH1<0.0001) 
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8.2.4 PI3KC2B Expression 
In the Micro array assay PI3KC2B expression was hugely up-regulated after 
24 hours in response to plant extract 1 in the insulin resistance inducing 
medium (Table 7.8 and 7.12). This up-regulation was not significant as 
indicated by the p-value of 0.2131; however this could be due to the 
considerable variation in the replicates. PI3KC2B expression was analyzed 
using the RT2 qPCR primer assay in the model of insulin resistance in Chang 
liver cells. Suprisingly PI3KC2B expression was significantly down-regulated 
after 24 hours exposure of Chang liver cells to MIF medium compared 
exposure to control medium (P(H1)<0.0001) (Figure 8.15). However no 
significant change in PI3KC2B expression was seen in Chang liver cells 
cultured in MIF medium supplemented with plant extract 1 compared to 
culture in MIF medium only (P(H1)=0.350). MIF medium supplemented with 
ciglitazone reduces PI3KC2B expression significantly in Chang liver cells 
compared to MIF treatment alone (P(H1)<0.0001).  
After two hours of exposure Chang liver to MIF medium and MCBD-201 
medium no significant differences in PI3KC2B expression were detected 
(Figure 8.13). Cells cultured in MIF medium supplemented with plant extract 
1, plant extract 2 or ciglitazone decreased PI3KC2B expression compared to 
growth in MIF medium alone. The decrease in expression of PI3KC2B was 
significant only for MIF medium supplemented with plant extract 2 and MIF 
medium supplemented with ciglitazone. 
 After six hours PI3KC2B expression increased in Chang liver cells cultured in 
all medium conditions containing MIF to levels of PI3KC2B expression seen in 
cells cultured in MCBD-201 medium (Figure  8.14). However there were no 
significant differences in PIK3C2B expression induced by the different 
additives of the MIF medium. After 48 hours of exposure to the different media 
conditions no significant differences were seen in PI3KC2B expression 
(Figure 8.16).   
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Figure 8.13 The normalized 
relative expression of 
PI3KC2B in Chang 
liver cells exposed to 
five different medium 
conditions 
respectively for two 
hours.  
The fold PI3KC2B expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for two 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
(PH1<0.0001) 
 
Figure 8.14 The normalized 
relative expression of 
PI3KC2B in Chang 
liver cells exposed to 
five different medium 
conditions 
respectively for six 
hours.  
The fold PI3KC2B expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for six 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM.
After 2 hours and 24 hours PI3KC2B expression was decreased when Chang 
liver cells were exposed to MIF medium compared to culture in MCBD-201 
medium. After six hours there was a transient increase in PI3KC2B 
expression in Chang liver cells cultured in each of the MIF containing media 
compared to cells cultured in MCBD-201 medium. However after 24 hours the 
expression declined again below the level of expression in cells cultured in 
control medium. MIF medium supplemented with plant extract 1, plant extract 
2 or ciglitazone decreased PI3KC2B expression even more then the MIF 
medium only in Chang liver cells after two hours, 24 hours and 48 hours of 
exposure.  
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Figure 8.15 The normalized 
relative expression of 
PI3KC2B in Chang 
liver cells exposed to 
five different medium 
conditions 
respectively for 24 
hours.  
The fold PI3KC2B expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for 24 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
 
Figure 8.16 The normalized 
relative expression of 
PI3KC2B in Chang 
liver cells exposed to 
five different medium 
conditions 
respectively for 48 
hours.  
The fold PI3KC2B expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for 48 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
The PI3K is implicated in a diverse array of biological processes, including cell 
survival, proliferation, inflammation, adhesion, glucose metabolism, 
chemotaxis, and cancer (Shepherd et al., 1998).  There are eight PI3-kinase 
family members, divided into three classes based on their lipid specificity and 
structure (Harada et al., 2005; Bilancio et al., 2006; Katso et al., 2006).  
PI3KC2B is a class II PI3-kinase isoform and has been implicated in 
cytoskeletal organization and cell migration (Maffucci et al., 2005; Katso et al., 
2006). Class II PI3K isoforms, such as PI3KC2B have been reported to be 
overexpressed in human tumor cells (Arcaro et al., 2002). The decrease in 
PI3KC2B expression shown in response to MIF medium compared to MCBD 
medium could possibly be explained by the fact that the fructose and insulin 
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added to the medium compromised cell survival and proliferation. The further 
decline seen when plant extracts were added to MIF medium could possibly 
be linked to S.fruescens anti-cancer properties. 
8.2.5 CEBPA Expression 
The Micro Array assay showed an 8.11 fold up-regulation for CEBPA after 
Chang liver cells were treated with MIF medium supplemented with plant 
extract 1 for 24 hours compared to treatment with MIF only (Table 7.8 and 
7.15). However this increase in expression was not significant (p=0.0658). 
This could be because there was considerable variation in the replicates of 
the samples analyzed. Using qRT-PCR no significant difference in CEBPA 
expression was seen when comparing Chang liver cells treated with MCBD-
201 with cells treated with  MIF for 24 hours (P(H1)= 0.831) (Figure 8.19). 
Also no significant changes in CEBPA expression were seen when comparing 
cells cultured in MIF medium with cells cultured in MIF medium supplemented 
with plant extract 1 or plant extract 2 (P(H1)= 0.168 and P(H1)= 0.179 
respectively for 24 hours.  The only change in the expression of CEBPA after 
24 hours of exposure was seen between Chang liver cells cultured in MIF 
medium compared with cells cultured in MIF medium supplemented with 
ciglitazone. Chang liver cells cultured in MIF medium supplemented with 
ciglitazone show a decrease in CEBPA expression by a mean factor of 0.520, 
P(H1)<0.0001 95% C.I. 0.439-0.616. (Figure 8.19). 
After two hours of exposure, Chang liver cells treated with MCBD, MIF and 
MIF+P1 show similar CEBPA expression levels (Figure 8.17). In comparison 
to these groups, cells treated with MIF medium supplemented with plant 
extract 2 or ciglitazone showed a significant decrease in CEBPA expression 
(P(H1)<0.000). The decrease in CEBPA expression between cells cultured in 
MIF medium supplemented with plant extract 2 and cells cultured in MCBD-
201 had a mean factor of 0.453; 95% C.I. 0.396-0.518. The decrease in 
CEBPA expression induced by MIF medium supplemented with ciglitazone 
compared MIF treatment alone had a mean factor of 0.575 and 95% C.I. 
between 0.488 and 0.678 (Figure 8.17).  
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Figure 8.17 The normalized 
relative expression of 
CEBPA in Chang liver 
cells exposed to five 
different medium 
conditions 
respectively for two 
hours.  
The fold CEBPA expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for 2 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
(PH1<0.0001) 
 
 
Figure 8.18 The normalized 
relative expression of 
CEBPA in Chang liver 
cells exposed to five 
different medium 
conditions 
respectively for six 
hours.  
The fold CEBPA expression was 
determined relative to the expression of 
the calibrator sample, Chang liver cells 
cultured in MCBD-201 medium for 6 
hours. Fold expression are shown on the 
Y-axis, values are means ±SEM. 
(PH1<0.0001) 
After six hours Chang liver cells exposed to MCBD-201 and MIF medium still 
had similar expression (Figure 8.18). However MIFmedium supplemented 
with plant extract 1 treatment led to a significant upregulation of CEBPA 
expression compared to MIF treatment (P(H1)<0.0001; mean factor=1.336; 
95% C.I. 1.157-1.545). MIF medium supplemented with ciglitazone also led to 
a slight increase in CEBPA expression after six hours of exposure compared 
to MIF treatment (P(H1)< 0.0001; mean factor 1.314; 95% C.I. 1.154-1.497. 
After 48 hours, all groups showed similar CEBPA expression levels, except 
MIF supplemented with ciglitazone which showed a decrease in CEBPA 
expression compared to MCBD-201 and MIF treatment (P(H1)<0.0001; Mean 
factor=0.587; 95% C.I=0.443-0.780) (Figure 8.20). 
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Figure 8.19 The normalized relative 
expression of CEBPA in 
Chang liver cells 
exposed to five different 
medium conditions 
respectively for 24 
hours.  
The fold CEBPA expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD-
201 medium for 24 hours. Fold expression 
are shown on the Y-axis, values are means 
±SEM. 
 
Figure 8.20 The normalized relative 
expression of CEBPA in 
Chang liver cells 
exposed to five different 
medium conditions 
respectively for 48 
hours.  
The fold CEBPA expression was determined 
relative to the expression of the calibrator 
sample, Chang liver cells cultured in MCBD-
201 medium for 48 hours. Fold expression 
are shown on the Y-axis, values are means 
±SEM. 
CEBPA is essential for the maintenance of liver nitrogen, glucose, lipid and iron 
metabolism, and regulation of heptocyte proliferation (Inoue et al., 2004; Datta et 
al., 2007; Pederson et al., 2007). How CEBPA is able to independently regulate all 
these processes is not known.  Evidence provided in a study by Pederson et al. 
(2007) suggests that the coordinated expression of hepatic enzymes involved in 
specific metabolic pathways is controlled by distinct motifs within the CEBPA 
transactivation domain. By generation of two mouse strains with deletion of two 
specific motifs in the CEBPA gene, they showed that specific subsets of hepatic 
genes were affected. Two regulons (group of genes involved in a given metabolic 
pathway) were defined; involved in lipogenesis and gluconeogenesis respectively. 
The lipogenesis regulon is characterized by co-regulation of SREBP-1 and 
CEBPA. The gluconeogenesis regulon is composed of genes containing Insulin 
Response Elements (IREs) in their promoters (Pederson et al., 2007). 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
F
o
ld
 E
x
p
re
s
s
io
n
  
M
C
B
D
 
M
IF
 
M
IF
+
P
1
 
M
IF
+
P
2
 
M
IF
+
C
ig
lit
 
*** 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
1.8 
M
C
B
D
 
M
IF
 
M
IF
+
P
1
 
M
IF
+
P
2
 
M
IF
+
C
ig
lit
 
*** 
F
o
ld
 E
x
p
re
s
s
io
n
  
  233 
In the current study no significant difference in CEBPA expression was seen 
between Chang liver cells cultured in MIF or MCBD medium over the time course. 
Chang liver cells cultured in MIF supplemented with plant extract 1 for six hours 
showed a significant increase in CEBPA expression, compared to exposure to MIF 
only. In the absence of measuring all the targets genes of CEBPA, it is difficult to 
explain the role of the increase in CEBPA expression due to MIF medium 
supplemented with plant extract 1 treatment. However, the increase in expression 
could possibly be linked to CEBPA‟s role in lipogenesis, because faced with a 
carbohydrate overload; pathways that would help to store excess carbohydrates 
would probably be activated. The fact that SREBP-1 co-regulates lipogenesis with 
CEBPA and was also slightly increased at this time point (see section 6.2.4) 
strengthens this theory. The decrease after two hours in CEBPA expression in 
cells cultured MIF medium supplemented with plant extract 2 or ciglitazone, 
compared to MIF treatment could possibly be linked to ability of CEBPA to activate 
gluconeogenic enzymes that would be suppressed if CEBPA expression was 
decreased. Decreased in expression of CEBPA expression in MIF medium 
supplemented with cigltazone after 24 and 48 hours of exposure compared to MIF 
treatment could be linked to the role of CEBPA in lipogenesis, as its co-regulator 
SREBP-1 was also slightly decreased at these time points. A decrease in CEBPA 
expression would down regulate lipogenic capacity.   
Diminished CEBPA levels have been reported in hepatic tumors and ectopic 
CEBPA expression has been shown to inhibit hepatic tumor formation (Datta et al., 
2007). CEBPA is a downstream target of PI3K. Activation of PI3K/Akt causes 
dephosphorylation of CEBPA, which blocks CEBPA‟s growth inhibiting activity 
(Wang et al., 2004). In the current study the increase in CEBPA expression in 
Chang liver cells cultured in MIF+P1 compared to MIF only could possibly also be 
related to the anti-cancer properties of S.frutescens. 
The results of five genes identified in the PCR Array analysis, VAMP3, ACLY, 
G6PD, PIK3C2B, and CEBPA were validated with gRT-PCR. VAMP3 was down 
regulated in Chang cells cultured in MIF medium compared Cells cultured in 
MCBD-201 medium after 24 hours of exposure. This result was confirmed with the 
qRT-PCR. VAMP3 expression was increased in cells cultured in MIF medium 
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supplemented with plant extract 1 compared to MIF treatment only in the PCR 
array assay. VAMP3 was not increased in MIF medium supplemented with plant 
extract 1 after 24 hours of exposure with the qRT-PCR reaction; however a non-
significant increase in VAMP3 expression was seen after six hours in MIF medium 
supplemented with plant extract 1 compared to cells cultured in MIF medium.  
ACLY expression was increased in cells cultured in MIF medium supplemented 
with plant extract 1. In the qRT-PCR ACLY expression was increased in MIF 
medium supplemented with plant extract 1 compared to cells cultured in control 
medium, but not compared to MIF treatment. 
G6PD expression was increased in cells cultured in MIF medium supplemented 
with plant extract 1 compared to MIF treatment only in the PCR array. This was 
also seen in the qRT-PCR Array. 
PI3KC2B and CEBPA were hugely increased in cells cultured in MIF medium 
supplemented with plant extract 1 compared to MIF treatment only; however this 
increase was not significant, the qRT-PCR reaction was used to determine the 
expression of this to target genes. PI3KC2B was significantly down regulated in all 
MIF containing medium after two hours, 24 hours and 48 hours of exposure 
compared to cells cultured in MCBD-201 medium. 
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CONCLUSION  
The aims of the study were to develop an in vitro insulin resistant model of T2DM 
in Chang liver cells and to determine the capacity of S.frutescens to reverse the 
state of insulin resistance in this model. The mechanism by which S.frutescens 
may reverse this condition was then assessed by investigating the expression of 
potential molecular targets for S.frutescens.   
The first phase of the study was to develop insulin resistant Chang liver cells. By 
definition these cells will have compromised metabolism, given the importance of 
insulin in regulating metabolic and growth promoting functions in the liver. This will 
affect a number of cellular reactions and must be borne in mind when analysing 
the responses of these cells to insulin stimulation and to S.frutescens treatment. 
Cellular insulin resistance can be evaluated by measuring the phosphorylation of 
intermediate proteins, changes in activity of intermediate kinases of the insulin 
signal cascade, or modulation of target gene expression or target cellular function 
(Leclercq et al., 2007). In the present study a glucose oxidase assay was used in 
the screening that measured the target (liver) cellular function to clear a fixed 
amount of glucose from the medium as a measure of cellular insulin resistance. 
Hepatic insulin resistance refers to the impaired suppression of HGP as a 
consequence of a failure of insulin to inhibit gluconeogenesis and glycogenolysis.  
In Chapter 2 different culture media were used to induce insulin resistance, 
including different concentrations of human diabetic serum, high insulin 
concentrations, high fructose concentrations and a combination of high fructose 
and high insulin concentrations. Cells were exposed to these media conditions for 
48 hours after which the cells were exposed to a fixed amount of glucose for 3 
hours, followed by measurement of the amount of glucose left in the medium using 
an assay of glucose oxidase. The amount of glucose left in the medium after the 
48 hours exposure without the final glucose stimulation was also determined. 
Exposure of Chang liver cells to serum free medium (MCBD-201) supplemented 
with 1mM fructose and 0.1μM insulin (MIF) was identified in this screening as the 
method for further investigation. MIF treatment showed both increased amounts of 
glucose in the medium after 48 hours of exposure and more glucose left in the 
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medium after the 3 hour exposure to a fixed amount of glucose. These indicated 
possible increased HGP.  
In Chapter 3 addition of fructose and insulin to the culture medium to induce 
insulin resistance was further optimized. The glucose oxidase reaction was 
performed as in Chapter 2 with the amendment of including a 1 hour starvation 
period before treatment with a fixed amount of glucose and measurement of the 
amount of glucose left in the media every hour for 3 hours. Data generated with 
the glucose oxidase reaction showed huge variation, mostly because this 
treatment is not optimal for cell growth and stresses the cells. The compensatory 
mechanisms used by the cells to combat this stress may vary between different 
cultures and contribute to the variation.    
A (2-[3H]-DOG) assay was included that is more specific than the glucose oxidase 
reaction to measure glucose uptake by Chang cells. Although there was also 
variation in data more significant results were generated. The MIF treatment 
showed reduced glucose uptake compared to cells cultured in MCBD-201 medium 
alone. The two extracts of S.frutescens and the anti-diabetic drugs, metformin and 
ciglitazone, improved glucose uptake compared to the MIF treatment.        
Two lipid accumulation assays (Nile red and Oil-red-O) were also included as high 
fructose diets in rats have been shown to increase lipogenesis. Chang liver cells 
cultured in MIF medium for 48 hours showed increased lipid accumulation as 
measured with Oil-red-O and Nile red assay compared to the MCBD-201 control. 
The addition of S.frutescens extracts, metformin, ciprofibrate and ciglitazone 
decreased lipid accumulation.  
In conclusion a model of T2DM has been developed in Chang liver cells that 
showed reduced glucose uptake and increased lipid accumulation capacity. There 
is a clear association between the accumulation of lipids in hepatocytes and the 
development of insulin resistance.  S.frutescens extracts were shown to increase 
glucose uptake and reduce lipid accumulation in this model. 
Therefore, the next phase after establishment of the insulin resistance model was 
to investigate the potential molecular targets of S.frutescens in the model using 
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qRT-PCR. It was initially decided to use multiplex qRT-PCR (see Chapter 4), as it 
has the advantage of analyzing up to 4 gene targets at once. However optimizing 
multiplex reactions is very time consuming and costly. Although primers are 
designed to be used together in one reaction, primer dimer formation can still 
occur and the reaction must be optimized manually on a trial and error basis. 
Because the primer pairs are designed as a group, if a particular primer is not 
working optimally it should either be excluded or the whole set should be 
redesigned. Thus the multiplex reaction started with 4 target genes (SREBP-1, 
PPARα, β- Actin, TATABP) to be amplified together, but ended up as a duplex 
reaction in which only PPARα and TATABP were amplified together. The 
expression of these two genes was determined after 2 hours, 6 hours, 24 hours 
and 48 hours of exposure to the medium conditions as shown in Table 4.4. 
Singleplex reactions was used for all further qRT-PCR analysis as singleplexing is 
less time consuming to optimize and also more cost effective to perform.   
PPARα mRNA expression was decreased after 48 hours of exposure to MIF 
medium compared to cells cultured in MCBD-201 medium. The addition of plant 
extract 1 increased PPARα expression to the level seen in cells cultured in control 
medium. Addition of plant extract 2 and ciglitazone to the medium also increased 
PPARα expression, however this increase was not significant compared to MIF 
treatment alone. The decrease in PPARα expression in cells cultured in MIF 
medium is in accordance with other studies that showed PPARα mRNA 
expression was decreased in rats fed a high fructose diet (Kelley et al., 2004). The 
presence of plant extract in the MIF medium appeared to protect against this 
decrease in PPARα expression which could lead to lipid accumulation due to 
decreased β-oxidation.  
Singleplex qRT-PCR was used to further investigate potential molecular targets of 
S.frutescens because of the difficulties experienced with multiplex. In Chapter 5 
seven reference genes were analysed to identify the most stably expressed 
reference genes under the experimental conditions. ATP5B and TATABP were 
identified as the most stably expressed genes and were used for normalization in 
all singleplex reactions.  
 In Chapter 6 the expression of SREBP-1 and PPARγ was investigated with 
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singleplex qRT-PCR in the insulin resistance model over the 48 hour time course. 
PPARα was also included in the singleplex as its expression was normalized using 
only one reference gene in Chapter 4. The most unstable reference gene under 
the experimental conditions of the study, TopI, was also investigated with the 
singleplex reaction.  
There were no significant differences in SREBP-1 expression over the time course 
in cells cultured in MIF medium compared to MCBD-201 cultured cells. Cells 
cultured in MIF medium supplemented with plant extract 2 showed a sustained 
increased SREBP-1 expression after 6 hours, 24 hours and 48 hours of exposure. 
The presence of plant extract 1 in the MIF medium did not have the same effect; 
on the contrary it showed a decrease in expression after 24 hours. However this 
decrease in expression was not maintained after 48 hours of exposure. Addition of 
ciglitazone to the MIF medium led to an increase in SREBP-1 expression after 6 
hours of exposure followed by a decline in expression after 24 hours that was 
maintained up to 48 hours.  
MIF treatment increased PPARγ expression after 6 hours and this increased 
expression was maintained over the rest of the time course. MIF medium 
supplemented with plant extract 1, plant extract 2 or ciglitazone increased PPARγ 
expression after 2 hours of exposure compared to cells cultured in MCBD-201 and 
MIF medium. Ciglitazone is a PPARγ agonist. The fact that the two plant extracts 
also increased PPARγ expression in the same manner implies that they too 
contain PPARγ activators/agonists. After 24 hours and 48 hours of exposure 
PPARγ expression was decreased in cells cultured in MIF medium supplemented 
with plant extract 1 and ciglitazone. No significant decrease in expression was 
seen for plant extract 2. This could possibly be linked to the sustained increase in 
SREBP-1 expression seen after 24 and 48 hours of exposure, as SREBP-1 is a 
co-activator of PPARγ. The decrease in PPARγ expression seen after 48 hours of 
exposure with plant extract 1 could possibly be linked to the increase in PPARα 
expression after 48 hours of expression. 
The data generated with the singleplex reaction were similar to what was found 
with the duplex reaction. PPARα expression was decreased in cells cultured in 
MIF medium after 48 hours of exposure and the addition of plant extract 1 to MIF 
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medium protected against this decrease. MIF medium supplemented with plant 
extract 2 also increased the expression of PPARα; however this increase was not 
significant.   
Chang liver cells cultured in MIF medium supplemented with plant extract 2 
showed decreased expression of TopI expression after 6 hours, 24 and 4 hours of 
exposure. This decrease in TopI expression could be linked to S.frutescens anti-
cancer activity, as TopI inhibitors can act as anti-cancer agents. The presence of 
plant extract 1 only decreased TopI expression after 24 hours of exposure. 
The two extracts showed different expression patterns for SREBP-1 and TopI. 
Although the same relative fold expression was not recorded for PPARα and 
PPARγ expression the pattern of expression relative to the calibrator sample was 
similar for these two genes. The discrepancies in the expression of the genes 
analyzed between the two extracts could only be attributed to the preparation of 
the extracts. Plant extract 1 was prepared by drying the leaves away from sunlight 
and then mixing 2.5 g dried, crushed leaves with 100ml boiling water and allowing 
the tea to brew overnight. The extract was then filtered through a sieve with pores 
of approximately 1mm in diameter, and freeze dried, the powder was stored at 
40C.  Plant extract 2 was donated by a pharmaceutical company (Value Added 
Life, South Africa) that make capsules containing the S.frutescens plant extract. 
The exact preparative process was not revealed.  
To identify more molecular targets for S.frutescens a PCR Array assay containing 
84 Diabetes related genes was performed (see Chapter 7). Using this assay 28 
genes were identified that were significantly up- or down-regulated by S.frutescens 
and four genes that showed huge non-significant up-regulation in the presence of 
S.frutescens was also included as possible molecular targets of S.frutescens.  
The 32 genes identified included genes involved in the development of 
inflammation, DNA repair and cell death (ICAM1, PIK3CD, AGT, TGFB1, PARP1). 
However genes protecting against the development of inflammation, oxidative 
stress and cell death were also upregulated (IL4R, PIK3D2B, TRIB3, G6PD, 
HMOX1, NRF1). Genes involved in vesicle transport were down regulated by the 
insulin resistance inducing medium (NSF, VAMP3), and upregulated when plant 
  240 
extract 1 was added to this medium (NSF, VAMP3, SNAP25, STX4, VAPA). 
Lipogenic metabolic enzymes were upregulated (ACLY, GPD1, ME1), genes 
capable of inhibiting gluconeogenic enzymes were up regulated (DUSP4), and 
enzymes that inhibit glycogen synthesis (GSK3B) and stimulate glycogen 
degradation (PYGL) were also upregulated. Insulin signalling transduction via PI3-
kinase pathway was upregulated by plant extract 1, as indicated by the 
upregulation of the expression of a number of genes in this pathway (IGFBP5, 
IRS1, IRS2, PIK3CD, PIK3C2B).   
Five of the 32 identified genes were validated with qRT-PCR (VAMP3, ACLY, 
G6PD, PIK3C2B, CEBPA).  Down regulation of VAMP3 expression in Chang liver 
cells cultured in MIF medium, was confirmed with the qRT-PCR.  However cells 
grown in MIF medium supplemented with plant extract 1 did not show the 
significantly increased expression found in the PCR array analysis.   
In the PCR Array assay the lipogenic enzyme ACLY was shown to be increased in 
cells cultured in MIF medium supplemented with plant extract 1 compared to MIF 
treated cultures. The data from qRT-PCR showed that ACLY was increased in all 
cells cultured in the MIF medium or MIF supplemented medium after 6 hours, this 
increase in expression was still present after 24 hours of exposure. However, the 
presence of plant extract 1 did not increase ACLY expression over that found in 
MIF medium only as seen in the PCR Array results. 
The increased expression in G6PD seen in cells cultured in MIF medium 
supplemented with plant extract 1 was confirmed with the qRT-PCR reaction.  
The PCR Array showed a huge increase in PI3KC2B expression in cells cultured 
in MIF medium supplemented with plant extract1; however this increase was not 
significant because of great variation in replicates. In order to generate more 
conclusive results regarding the expression of this gene under the experimental 
conditions, its expression was measured over the full time course studied using 
qRT-PCR. These data showed that PI3KC2B expression was decreased in all the 
cultures grown in media containing MIF compared to control cells. PI3KC2B has 
been implicated in cytoskeletal organization and cell migration, thus culture in MIF 
containing medium can compromise cell proliferation.  
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CEBPA expression was transiently increased in Chang liver cells after 6 hours of 
exposure to MIF medium supplemented with plant extract 1. Thereafter expression 
decreased and was not significantly altered compared to control or MIF treated 
cells. CEBPA is a transcription factor thus a transient increase in expression is 
expected. CEBPA regulates the maintenance of liver nitrogen, glucose, lipid and 
iron metabolism and hepocyte proliferation.  Thus it is difficult to speculate on the 
impact of the increase in CEBPA expression. However in the PCR Array many 
genes regulating glucose and lipid metabolism were shown to be altered in the 
presence of plant extract 1 which could be the result of CEBPA activation.    
In summary in this study an in vitro insulin resistant cell culture model was 
developed. The progression of the development of insulin resistance was followed 
by analysing the change in gene expression over a time course of 48 hours. The 
method used to induce the insulin resistance was addition of 0.1μM insulin and 
1mM fructose to serum free medium. It is hypothesized that in the presence of 
excess nutrients in MIF medium and in the absence of adipose tissue (as found in 
liver cell culture), the Chang liver cells will become adipogenic and accumulate 
lipids in the cytoplasm. The increased lipid content will compromise the cell‟s 
ability to take up glucose and respond to insulin and thus result in insulin 
resistance. Genes crucial for lipid and glucose metabolism were investigated and 
the data obtained confirmed this hypothesis. PPARγ expression was constantly 
increased by MIF treatment and PPARα expression was decreased. The lipogenic 
enzyme ACLY, a target gene of PPARγ, was also increased in the cells cultured in 
MIF medium.  
The liver is a metabolically active organ, maintaining glucose and lipid 
homeostasis in the body. In cells cultured with MIF medium the expression of 
genes regulating vesicle transport were significantly down regulated, this could 
have negative implications for metabolism because substances needed in 
metabolism are normally transported using vesicle transport.  
The capacity of S.frutescens to reverse this condition of insulin resistance was 
confirmed with both biochemical assays and gene expression analysis. The gene 
expression studies were performed employing both multiplexing and singleplexing 
qRT-PCR reactions. It is concluded from this study that singleplexing is quicker, 
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easier, and more cost effective to perform than multiplexing. The gene expression 
studies showed that the plant extracts contained both PPARα and PPARγ 
activators. The activation of these transcription factors was time dependent, and 
transient.  A transient increase or decrease in transcription factor expression is 
expected as activation of transcription factors normally activates a cascade of 
other genes that promote increased flux through specific metabolic pathways, 
depending on the physiological state of the cell. The transcription factors are 
normally inactivated after sufficient activation of the target genes has occurred. In 
addition to transcription factors regulating lipid metabolism (PPARα, PPARγ) the 
PCR Array analysis identified 32 more molecular targets for S.frutescens.  
Acknowleding the short comings of PCR Array assays, which could lead to the 
generation of false positives, this assay proved to be a valuable screening assay 
for molecular targets of S.frutescens. The genes identified with the PCR array 
included a number of transcription factors which regulate glucose metabolism, lipid 
metabolism, oxidative stress, proliferation and inflammation pathways. The 
hypoglycaemic, anti-inflammatory, anti-oxidant and anti-cancer activities of 
S.frutescens reported previously could be explained by the gene expression profile 
seen with the PCR array assay. Based on the molecular targets of S.frutescens 
identified in the present study metabolic pathways showing possible mechanims of 
action of S.frutescens could be compiled.   
In the first edition of the IDF Diabetes Atlas in 2000, the estimated global diabetes 
prevalence was 151 million (http://www.diabetesatlas.org). In the latest edition 
(2010), the estimated diabetes prevalence has risen to 285 million with a 
prediction that by 2030 the number of people with diabetes will have risen to 439 
million. In Africa the estimated diabetes prevalence for 2010 is 12.1 million with a 
predicted increase of 98% to 23.9 million by 2030 (http://www.diabetesatlas.org). 
Despite the availability of several medications for the treatment of T2DM the 
epidemic is still increasing. There is therefore still a need for the development of 
novel anti-diabetic agents. S.frutescens could provide an alternative to current 
medications. The present study makes a valuable contribution to the 
understanding of the possible mechanisms of action of S.frutescens and its 
potential as novel treatment for T2DM.   
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Future Studies 
The aim of developing this model of insulin resistance model was to investigate 
the process of development of insulin resistance and to determine how it impacts 
on gene expression over the time taken to induce insulin resistance. The model of 
insulin resistance can also be used to screen other potential anti-diabetic 
treatments. One disadvantage of the in vitro insulin resistance model is that the 
treatment used to induce insulin resistance is a stressor that can impair the 
metabolism of the cell. Thus a prolonged investigation to follow the development of 
insulin resistance cannot be performed because the cell would simply not survive 
under these conditions. In future conditions could be adapted to slow the 
progression of the onset of insulin resistance and reduce cell damage, by 
gradually increasing the amount of insulin and fructose to the culture media over a 
longer period of time, potentially enabling a more detailed analysis.  
In the present study qRT-PCR was used to identify molecular targets of 
S.frutescens.  Although protein extractions made from the same cell culture 
samples from which RNA was extracted for qRT-PCR analysis, in the present 
study, the yield of proteins was too low to perform Western Blot analysis. In future 
the in vitro model of insulin resistance developed in the present study can be used 
to determine the protein expression of the molecular targets identified using 
specific monoclonal antibody binding detected and quantified by flow cytometry.  
In the present study a number of transcription factors (PPARα, PPARγ, CEBPA, 
NRF1 and HNF4A) were identified as molecular targets of S.frutescens. These 
transcription factors regulate pathways involved in glucose and lipid metabolism, 
oxidative stress, proliferation and inflammation.  Each of these transcription factors 
could activate more than one pathway, for example PPARα could stimulate β-
oxidaton and gluconeogenesis, as well as oxidative stress and anti-inflammatory 
processes. To further elucidate the mechanism of action of S.frutescens, specific 
target genes in the metabolic pathways activated by the transcription factors 
identified will be investigated using qRT-PCR and flow cytometry. For example the 
carnitine palmitoyl transferase and acyl-coenzymeA-oxidase genes could be 
investigated to determine if the increase in PPARα expression seen in the 
presence of plant extract 1 led to an increase in β-oxidation. The levels of the 
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cytokines TNF-α, IL-1 and IL-6 and the C-reactive protein (CRP), fibrinogen, and 
serum amyloid (SAA), can be determined using flow cytometry or ELISA 
techniques to see if the increase in PPARα expression is associated with a 
inhibition of pro-inflammatory molecules. PPARα has been shown to inhibit nitric 
oxide synthase (iNOS); qRT-PCR and flow cytometry can be used to determine 
iNOS expression.  
Target genes for each of the transcription factors identified could be investigated 
to determine the flux through which each metabolic pathway is activated or 
inhibited by the specific transcription factor in the presence of S.frutescens. 
The mechanisms of action identified in the in vitro model could be validated in in 
vivo animal models using qRT-PCR, Western blot and ELISA techniques. The 
knowledge of the potential targets of S.frutescens can also be used to aid in the 
identification of the key bioactive molecules in the plant extract.     
The in vitro model can also be used to compare the effect of the individual 
bioactive components or combinations thereof with that of the crude extract.  This 
will enable testing of the proposed mechanism of action of S.frutescens and allow 
us to determine if the single purified compounds have a greater effect or if the 
different compounds found in S.frutescens act synergistically to mediate a greater 
effect. 
 
 
 
 
 
 
 
  245 
REFERENCES 
Abbas Z.G., Archibald L.K. (2005). Epidemiology of the diabetic foot in Africa. 
Medicam Science Monitor journal 11 (8): RA262-270 
Ahrén B. (2008). Novel combination treatment of Type 2 Diabetes DPP-4 Inhibition + 
Metformin. Vascular Health and Risk Management 4 (2): 383-394 
American Diabetes Association (2006) Diagnosis and classification of Diabetes 
Mellitus. Diabetes Care 29 (1): S5-S10 
Andersen C.L., Jensen J.L., Ørntoft T.F. (2004). Normalization of real-time quantitative 
reverse transcription-PCR data: A model-based variance estimation 
approach to identify genes suited for normalization, applied to bladder and 
colon cancer data sets. Cancer Research 64: 5245–5250 
Arcaro A., Khanzada U.K., Vanhaesebroeck B., Tetley T.D., Waterfield M.D., Seckl M.J. 
(2002). Two distinct phosphoinositide 3-kinases mediate polypeptide growth 
factor-stimulated PKB activation. The European Molecular Biology Organization 
Journal 21 (19): 5097-5108 
Baar K.,  Song Z., Semenkovich C.F., Jones T.E., Han D.H., Nolte L.A., Ojuka O., Chen 
M., Holloszy J.O. (2003). Skeletal muscle overexpression of nuclear 
respiratory factor 1 increases glucose transport capacity. The Federation of 
American Societies fir Experimental Biology Journal 17: 1666-1673  
Babenko A.P., Polak M., Cave H., Busiah K., Czernichow P., Scharfmann R., Bryan J., 
Aguilar-Bryan L., Vaxillaire M., Froguel P. (2006). Activating mutations in the 
ABCC8 Gene in neonatal Diabetes Mellitus. New England Journal of Medicine 
355:456-66. 
Barak Y., Kim S. (2007). Genetic manipulations of PPARs: Effects on obesity and 
metabolic Disease. PPAR Research 2007:1-12 
Basciano H., Federico L., Adeli K. (2005). Fructose, insulin resistance, and metabolic 
dyslipidaemia. Nutrition and Metabolism 2:5-12 
Bates S.H., Jones R.B., Bailey C.J. (2000). Insulin-like effect of pinitol. British Journal 
of Pharmacology 130: 1944-1948 
Baudry A., Leroux L., Jackerott M., Joshi R.L. (2002). Genetic manipulation of insulin 
signalling, action and secretion in mice. Insight into glucose homeostasis 
and pathogenesis of Type 2 Diabetes. The European Molecular Biology 
Organization Reports 3 (4): 323-328 
Bays H., Mandarino L., Defronzo R.A. (2004). Mechanisms of Endocrine disease. Role 
of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of Type 2 
Diabetes Mellitus: Peroxisomal proliferator-activated receptor agonists 
  246 
provide a rational therapeutic approach. Journal of Clinical Endocrinology and 
Metabolism 89 (2):463–478 
Beattie J., Allan G.J., Lochrie J.D., Flint D.J. (2006). Insulin-like growth factor-binding 
protein-5 (IGFBP-5): a critical member of the IGF axis. Biochemical Journal 
395: 1-19 
Berasi S.P., Huard C., Li D., Shih H.H., Sun Y., Zhong W., Paulsen J.E., Brown E.L., 
Gimeno R.E., Martinez R.V. (2006). Inhibition of gluconeogenesis through 
transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. The 
Journal of Biological Chemistry 281 (37): 27167–27177 
Berger J.P., Akiyama T.E., Meinke P.T. (2005). PPARs: Therapeutic targets for 
metabolic disease. Trends in Pharmacological Sciences 26 (5): 244-251 
Bergman R.N. (2002). Pathogenesis and prediction of Diabetes Mellitus: Lessons 
from integrative physiology. The Mountsinai Journal of Medicine 69 (5): 280-290 
Bergman R.N., Kim S.P., Catalano  K.J., Hsu I.R., Chiu J.D., Kabir M., Hucking K., Ader 
M. (2006). Why viseral fat is bad: Mechanisms of the metabolic syndrome. 
Obesity 14: 16S-19S 
Bhat K.A., Shah B.A., Gupta K.K., Pandey A., Bani S., Taneja S.C. (2009). Semi-
synthetic analogs of pinitol as potential inhibitors of TNF-a cytokine 
expression in human neutrophils. Bioorganic and Medicinal Chemistry Letters 
19 (7): 1939-1943  
Bilancio A., Okkenhaug K., Camps M., Emery J.L., Ruckle T., Rommel C., 
Vanhaesebroeck B. (2006). Key role of the p110δ isoform of PI3K in β-cell 
antigen and IL-4 receptor signaling: comparative analysis of genetic and 
pharmacologic interference with p110δ function in β-cells. Blood 107: 642-
650 
Bishop-Bailey D., Bystrom J. (2009). Emerging roles of peroxisome proliferator-
activated receptor-β/δ in inflammation. Pharmacology and Therapeutics 124:  
141-150 
Blake G.J., Ridker P.M. (2001). Novel clinical markers of vascular wall inflammation. 
Circulation Research. 89: 763-771 
Blüher M., Patti M.E., Gesta S., Kahn B.B., Kahn C.R. (2004). Intrinsic heterogeneity in 
adipose tissue of fat-specific insulin receptor knock-out mice is associated 
with differences in patterns of gene expression.  The Journal of Biological 
Chemistry 279 (3): 31891-31901. 
Bluher M.L., Wilson-Fritch J., Leszyk P.G., Laustsen S., Corvera, and C. R. Kahn  (2004). 
Role of insulin action and cell size on protein expression patterns in 
adipocytes The Journal of Biological Chemistry 279 (30): 31902-31909. 
  247 
Borra R., Lautamäki R., Parkkola R., Komu M.,  Paul E. Sijens P.E., Hällsten K., Bergman 
J., Iozzo P., Pirjo Nuutila P. (2008). Inverse association between liver fat 
content and hepatic glucose uptake in patients with Type 2 Diabetes 
Mellitus. Metabolism Clinical and Experimental 57: 1445–1451 
Breen D.M., Sanli T., Giacca A., Tsiani E. (2008). Stimulation of muscle cell glucose 
uptake by resveratrol through sirtuins and AMPK. Biochemical and Biophysical 
Research Communications 374: 117-122  
Brownlee M. (2001). Biochemistry and molecular cell biology of diabetic 
complications. Nature 414: 813-820 
Bugawan T.L., Mirel D.B., Valdes A.M., Panelo A., Pozzilli P.,  Erlich H.A. (2003). 
Association and interaction of the IL4R, IL4, and IL13 loci with Type 1 
Diabetes among Filipinos. The American Journal of Human Genetics 72:1505–
1514 
Bustin S.A. (2000). Absolute quantification of mRNA using real-time reverse 
transcription polymerase chain reaction assays. Journal of Molecular 
Endocrinology  25: 169–193 
Bustin S.A. (2002). Quantification of mRNA using real-time reverse transcription 
PCR (RT-PCR): trends and problems. Journal of Molecular Endocrinology 29: 
23–39 
Bustin S.A., Benes V., Nolan T., Pfaffl M.W. (2005).  Quantitative real-time RT-PCR – a 
perspective. Journal of Molecular Endocrinology  34: 597–601 
Bustin S.A., Nolan T. (2004). Pitfalls of quantitative real-time reverse-transcription 
polymerase chain reaction. Journal of Biomolecular Techniques 15 (3): 155-166 
Calvo M., Pol A., Lu A., Ortega D., Pons M., Blasi J., Enrich C. (1999). Cellubrevin is 
present in the basolateral endocytic compartment of hepatocytes and 
follows the transcytotic pathway after IgA internalization. The Journal of 
Biological Chemistry 275(11): 7910-7917 
Cameron M.J., Arreaza G.A., Waldhauser L., Gauldie L., Delovitch T.L. (2000). 
Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice 
by systemic interleukin-4 treatment employing adenovirus vector-mediated 
gene transfer Gene Therapy 7: 1840–1846 
Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. (1987). Evaluation 
of a tetrazolium-based semiautomated colorimetrie Assay: Assessment of 
chemosensitivity testing. Cancer Research 47: 936-942 
Cartei G., Trestin A., Colombrino E., Nadai M., Richter S.N., Barzon L., Palu G., Palumbo 
M. (2006). Topoisomerase I, IIa and IIb mRNA expression in peripheral blood 
mononuclear cells of patients with solid tumor: preliminary results. Annals of 
  248 
Oncology 17 (5): v25–v28 
Carvalho E., Kotani K., Peroni O.D., Kahn B.B. (2005). Adipose-specific 
overexpression of GLUT4 reverses insulin resistance and diabetes in mice 
lacking GLUT4 selectively in muscle. American Journal of Physiology 
Endocrinology and Metabolism 289: E551–E561 
Chadwick W.A., Roux S., van de Venter M., Louw J., Oelofsen W. (2007). Anti-diabetic 
effects of S.frutescens in Wistar rats fed a diabetogenic diet.  Journal of 
Ethnopharmacology 109: 121–127 
Champoux J.J. & McConaughy B.L. (1976). Purification and characterization of the 
DNA untwisting enzyme from rat liver. Biochemistry 15: 4638-4642. 
Champoux J.J. (2002). Type IA DNA topoisomerases: Strictly one step at a time. 
Proceedings of the National Academy of Sciences  99 (19): 11998-12000 
Chang L., Chiang S.H., Saltiel A.R. (2004). Insulin Signalling and the regulation of 
glucose transport. Molecular Medicine 10 (7-12): 65-71 
Cheatham B. and Kahn C.R. (1995). Insulin action and the insulin signalling network. 
Endocrine Reviews 16 (2):117-142 
 Chen D., Mauvais-Jarvis F., Bluher M., Fisher S.J., Jozsi A., Goodyear L.J., Ueki K., 
Kahn C.R. (2004). p50α/p55α Phosphoinositide 3-Kinase knockout mice 
exhibit enhanced insulin sensitivity. Molecular and Cellular Biology 24 (1): 320-
329 
Chinkwo K.A. (2005). S.frutescens extracts can induce apoptosis in cultured 
carcinoma cells. Journal of Ethnopharmacology 98: 163–170 
Christodoulides C., Vidal-Puig A. (2009). PPARs and adipocyte function. Molecular and 
Cellular. Endocrinology 318 (1-2): 61-68 
Ciaraldi T.P., Carter L., Mudaliar S., Kern P.A., Henry R.R. (1998). Effects of tumor 
necrosis factor-α on glucose metabolism in cultured human muscle cells 
from nondiabetic and type 2 diabetic subjects. Endocrinology 139: 4793-4800 
Cao J., Drummond G., Inoue K., Sodhi K., Li  X.Y., Omura S. (2008). Upregulation of 
heme oxygenase-1 combined with increased adiponectin lowers blood 
pressure in diabetic spontaneously hypertensive rats through a reduction in 
endothelial cell dysfunction, apoptosis and oxidative stress. International 
Journal of Molecular Sciences 9: 2388-2406 
Collier J.J., Scott D.K. (2004). Sweet changes: glucose homeostasis can be altered by 
manipulating genes controlling hepatic glucose metabolism. Molecular 
Endocrinology 18: 1051–1063 
 Czechowski T., Stitt M., Altmann T., Udvardi M.K., Scheible W.R. (2005). Genome-wide 
identification and testing of superior reference genes for transcript 
  249 
normalization in arabidopsis. Plant Physiology 139: 5–17 
Daly M.E., Vale C., Walker M., Alberti K.G.M.M., Mathers J.C. (1997). Dietary 
carbohydrates and insulin sensitivity: a review of the evidence and clinical 
implications. American Journal of Clinical  Nutrition 66:1072- 1085 
Das S.K. and Elbein S.C. (2006). The genetic basis of Type 2 Diabetes. Cell science 2 
(4): 100-131 
Datta J., Majumder S., Kutay H., Motiwala T., Frankel W., Costa R., Cha H.C., 
MacDougald O.A., Jacob S.T., Kalpana Ghoshal K. (2007). Metallothionein 
expression is suppressed in primary human hepatocellular carcinomas and 
is mediated through inactivation of CCAAT/enhancer binding protein A by 
phosphatidylinositol 3-kinase signaling cascade. Cancer Research 67 (6): 
2736–46 
Davidson A.C., Hinkley D.V. (2002). Bootstrap Methods and their Application. 
Cambridge University Press ISBN 0-521-57391-2,  
Davis A., Christiansen M., Horowitz J.F, Klein S., Hellerstein M.K., Ostlund R.E. (2000). 
Effect of pinitol treatment on insulin action in subjects with insulin 
resistance. Diabetes Care  23:1000–1005 
De Alvaro C., Teruel T., Hernandez R., Lorenzo M. (2004). Tumor necrosis factorα 
produces insulin resistance in skeletal muscle by activation of inhibitor КB 
kinase in ap38 MAPK-dependent manner. The Journal of Biological Chemistry 
279 (17): 17070-17078 
De Ketelaere A., Goossens K., Peelman L., Burvenich C. (2006). Technical Note: 
Validation of internal control genes for gene expression analysis in bovine 
polymorphonuclear leukocytes. Journal of Dairy Science 89 (10): 4066–4069 
Desvergne B., Michalik L., Wahli W. (2006). Transcriptional regulation of metabolism. 
Physiological Reviews 86: 465-514 
Didenko V.V. (2001). DNA probes using fluorescence resonance energy transfer 
(FRET): Designs and applications Biotechniques 31 (5): 1106–1121. 
Dirlewanger M., Schneiter P., Jéquier E., Tappy L. (2000). Effects of fructose on 
hepatic glucose metabolism in humans. American Journal of Physiology, 
Endocrinology and Metabolism 279: E907-E911 
Doble B.W., Woodgett J.R. (2003). GSK-3: tricks of the trade for a multi-tasking 
kinase. Journal of Cell Science 116: 1175-1186  
Doege H., Schürmann A., Bahrenberg G., Brauers A., Joost H.G. (2000). GLUT8, a novel 
member of the sugar transport facilitator family with glucose transport 
activity. The Journal of Biological Chemistry 275 (21): 16275-16280 
Donnison M., Pfeffer P.L. (2004). Isolation of genes associated with developmentally 
  250 
competent bovine oocytes and quantitation of their levels during 
development. Biology of Reproduction 71: 1813–1821  
Ducharme N.A., Bickel P.E. (2008). Minireview: Lipid droplets in lipogenesis and 
lipolysis Endocrinology 149: 942–949 
Dugani C.B., Klip A. (2005). Glucose transporter 4: cycling, compartments and 
controversies third in the cycles review series. The European Molecular 
Biology Organization Journal  6 (12): 1137-1142 
Eberlé D., Hegarty B., Bossard P., Ferré P., Foufelle F. (2004). SREBP transcription 
factors: master regulators of lipid homeostasis. Biochimie 86: 839-848  
Eisenberg M.L., Maker A.V., Slezak L.A., Nathan J.D., Sritharan K.C., Jena B.P., Geibel 
J.P., Andersen D.K. (2005).  Insulin receptor (IR) and glucose transporter 2 
(GLUT2) proteins form a complex on the rat hepatocyte membrane. Cellular 
Physiology and Biochemistry 5: 51-58 
Elliot S.S., Keim N.L., Stern J.S., Teff K., Havel P.J. (2002). Fructose, weight gain, and 
the insulin resistance syndrome.  American Journal of Clinical Nutrition 76:911-
922. 
El-Mesallamy H., Suwailem S., Hamdy N. (2007). Evaluation of C-reactive protein, 
endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in 
Type 2 Diabetes Mellitus patients. Mediators of Inflammation  2007: 1-7 
Elsas L.J., Longo N., Langley S., Griffin L.D., Shuster R.C. (1989). Molecular genetics of 
severe insulin resistance. The Yale Journal of Biology and Medicine 62: 533-
547. 
Edvardsson, U., Bergström M., Alexandersson M., Bamberg K., Ljung B., Dahllöf B. 
(1999). Rosiglitazone (BRL49653), a PPARγ-selective agonist, causes 
peroxisome proliferator-like liver effects in obese mice. Journal of Lipid 
Research 40: 1177-1184 
Fajas L., Auboeuf D., Raspe´E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., 
Laville M., Fruchart J.C., Deebi S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., 
Vidal H., Auwerx J., (1997). The organization, promoter analysis, and 
expression of the human PPARγ gene. The Journal of Biological Chemistry 272 
(30): 18779–18789 
 Fajas L., Debril M.B., Auwerx J. (2001). Peroxisome proliferator-activated receptorγ: 
from adipogenesis to carcinogenesis. Journal of Molecular Endocrinology  
27:1–9. 
Fernandes A.C., Cromarty A.D., Albrecht C., Jansen van Rensburg C.E. (2004). The 
antioxidant potential of Sutherlandia frutescens. Journal of 
Ethnopharmacology 95: 1-5  
  251 
Ferré P., Foufelle F. (2007). SREBP-1c Transcription Factor and Lipid Homeostasis: 
Clinical Perspective. Hormone Research  68: 72-82 
Fisher, S.J., Kahn, S.R. (2003).  Insulin signaling is required for insulin’s direct and 
indirect action on hepatic glucose production. The Journal of Clinical 
Invesigation. 111: 463–468 
Foretz M., Guichard C., Ferré P., Foufelle F. (1999). Sterol Regulatory Element Binding 
Protein-1c is a major mediator of insulin action on the hepatic expression of 
glucokinase and lipogenesis-related genes. Proceedings of the National 
Academy of Sciences  96 (22): 12737-12742 
 Foster L.J., Klip A. (2000). Mechanism and regulation of GLUT-4 vesicle fusion in 
muscle and fat cells. Am J Physiology- Cell Physiology  279: 877-890 
Fowler S.D., Greenspan P. (1985). Application of Nile red a fluorescent hydrophobic 
probe, for the detection of neutral lipid deposits in tissue sections: 
comparison with Oil-red-O. The Journal of Histochemistry and Cytochemistry 33 
(8): 833-836 
Francis G.A., Annicotte J.S., Auwerx J. (2003). PPARγ effects on the heart and other 
vascular tissues. American Journal of Physiology- Heart and Circulatory 
Physiology 285: H1–H9. 
Froelich-Ammon S.J.,  Osheroff  N. (1995). Topoisomerase poisons: Harnessing the 
dark side of enzyme mechanism. The Journal of Biological Chemistry 270 (37): 
21429–21432 
Fröjdö S., Vidal H.,  Pirola L. (2009). Alterations of insulin signaling in Type 2 
Diabetes: A review of the current evidence from humans. Biochimica et 
Biophysica Acta 1792 (2): 83-92 
Gaby A.R. (2005). Adverse effects of dietary fructose. Alternative Medicine Reviews 10 
(4): 294-306.  
Garcia-Carbonero R., Supko J.G. (2002). Current perspectives on the clinical 
experience, pharmacology, and continued development of the 
camptothecins. Clinical Cancer Research 8: 641–661 
Gerich J.E. (1998). The genetic basis of Type 2 Diabetes Mellitus: Impaired insulin 
secretion versus impaired insulin sensitivity. Endocrine Reviews 19 (4): 491–
503. 
Gerich J.E. (2000). Insulin resistance is not necessarily an essential component of 
Type 2 Diabetes. The Journal of Clinical Endocrinology and Metabolism 85 (6): 
2113-2115 
Gerich J.E. and Dailey G. (2004). Advances in Diabetes for the millennium: 
understanding insulin resistance. Medscape General Medicine  3 (3): 11 
  252 
Gibson D.M., Harris R.A (2002). Metabolic regulation in mammals. Taylor and Francis, 
London.  
Glund S. R., Zierath J.R. (2004). Tackling the insulin-signalling cascade. Canadian 
Journal of Diabetes 29 (3): 239-245 
Goalstone M.L., Draznin B. (1997). Insulin signalling. Western Journal of Medicine 
167:166-173  
Goldfine A.B. (2001). Type 2 Diabetes: New drugs, new perspectives. Hospital Practice 
36 (9): 29-36 
Goldfine I.D., Maddux B.A., Youngren J.F., Reaven G., Accili D., Trischitta V., Vigneri R., 
Frittitta L. (2008). The role of membrane glycoprotein plasma cell antigen 
1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis 
of insulin resistance and related abnormalities. Endocrine Reviews 29 (1): 62–
75 
Gonzalez F.J. (2008). Regulation of hepatocyte nuclear factor 4a-mediated 
transcription. Drug Metabolism and Pharmacokinetics  23 (1): 2-7  
Goossens K., Van Poucke M., Van Soom A., Vandesompele J., Van Zeveren A., Peelman 
L.J. (2005). Selection of reference genes for quantitative real-time PCR in 
bovine preimplantation embryos. BMC Developmental Biology 5 (27): 1-9 
Gorovits N., Charron M.J. (2003).What we know about facilitative glucose 
transporters. Lessons from cultured cells, aninimal models, and human 
studies. Biochemistry and Molecular Biology Education 31 (3): 163-172  
Gorovits N., Cui L., Busik J.V., Ranalletta M., De-Mouzon S.H., Charron M.J. (2003). 
Regulation of hepatic GLUT8 expression in normal and diabetic models. 
Endocrinology 144 (5):1703–1711 
Greenspan P., Mayer E.P., Fowler S.D. (1985). Nile red a selective fluorescent stain 
for intracellular lipid droplets. The Journal of Cell Biology 100: 965-973 
Gurnell M. (2007) ‘Striking the right balance’ in targeting PPARγ in the metabolic 
syndrome: Novel insights from human genetic studies. PPAR Research 2007: 
1-12 
Gurnell M., Savage D.B., Chatterjee V.K., O‟Rahilly S. (2003). The metabolic syndrome: 
Peroxisome proliferator-activated receptor γ and its therapeutic modulation. 
Journal of Clinical Endocrinology and Metabolism 88: 2412-2421 
Hallfrisch J., Frances Lazar F., Jorgensen C.,Reiser S. (1979). Insulin and glucose 
responses in rats fed sucrose or starch. American Journal of Clinical Nutrition 
32: 787-793 
Harada K., Truong A.B., Cai T., Khavari P.A. (2005). The class II phosphoinositide 3-
kinase C2β is not essential for epidermal differentiation. Molecular and 
  253 
Cellular Biology. 25 (24): 11122-11130  
Hardy C.D., Crisona N.J., Stone M.D., Cozzarelli N.R. (2004). Disentangling DNA 
during replication: a tale of two strands Philosophical Transactions of the Royal 
Society London B: Biological Sciences 359: 39–47 
Hartman M.E., O‟Connor J.C., Godbout J.P., Minor K.D., Mazzocco V.R., Freund G.G. 
(2004). Insulin receptor substrate-2-dependent interleukin-4 signaling in 
macrophages is impaired in two models of Type 2 Diabetes Mellitus. The 
Journal of Biological Chemistry 279 (27): 28045–28050, 
Havsteen B.H. (2002). The biochemistry and medical significance of the flavonoids. 
Pharmacology and Therapeutics 96: 67-202 
Hayhurst G.P., Lee Y.H., Lambert G., Ward J.M., Gonzalez F.J. (2001). Hepatocyte 
nuclear factor 4a (Nuclear receptor 2A1) is essential for maintenance of 
hepatic gene expression and lipid homeostasis. Molecular and Cellular 
Biology. 21 (4): 1393–1403 
Hays N.P., Galassetti P.R., Coker R.H. (2008). Prevention and treatment of Type 2 
Diabetes: Current role of lifestyle, natural product, and pharmacological 
interventions. Pharmacology and Therapeutics 118: 181-191 
He W., Barak Y., Hevener A., Olson P., Liao D., Le J., Nelson M., Ong E.,  Olefsky J.M. 
Evans R.M. (2003). Adipose-specific peroxisome proliferator-activated 
receptor γ knockout causes insulin resistance in fat and liver but not in 
muscle. Proceedings of the National Academy of Sciences 100 (26): 15712-15717 
Heid C.A., Stevens J., Livak K.J., Williams P.M. (1996). Real time quantitative PCR. 
Genome Research 6: 986-994 
Herbert Tilg H., Moschen A.R. (2008). Insulin resistance, inflammation, and non-
alcoholic fatty liver disease. Trends in Endocrinology and Metabolism 19 (10): 
371-379 
Herman M.A. and Kahn B.B. (2006). Glucose transport and sensing in the 
maintenance of glucose homeostasis and metabolic harmony. The Journal of 
Clinical Investigation 116 (7):1767-1775  
Higuchi R, Dollinger G, Walsh PS, and Griffith R. (1992). Simultaneous amplification 
and detection of specific DNA sequences. Biotechnology 10: 413–417 
Hollenbeck C.B. (1993). Dietary fructose effects on lipoprotein metabolism and risk 
of coronary artey disease. American  Journal of Clinical Nutrition 58: 800S-
809S) 
Holt M., Riedel D., Stein A., Schuette C.,  Jahn R. (2008). Synaptic vesicles are 
constitutively active fusion machines, which function independently of Ca2+. 
Current Biology 18 (10): 715–722. 
  254 
Hone J., Accili D., Al-Gazali L.I., Lestringant G., Orban T., Taylor S.I. (1994). 
Homozygosity for a new mutation (Ile”9→Met) in the insulin receptor gene in 
five sibs with familial insulin resistance. Journal of Medical Genetics 31: 715-
716 
Horton J.D., Goldstein J.L., Brown M.S. (2002). SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. The Journal of 
Clinical Investigation 109:1125–1131 
Horton J.D.,Bashmakov Y.,Shimomura I., Shimano H. (1998a) Regulation of sterol 
regulatory element binding proteins in livers of fasted and refed mice. 
Proceedings of National Academy of Sciences of the USA  95: 5987–5992 
Horton J.D., Shimomura I., Brown M.S., Hammer R.E., Goldstein J.L., Shimano H. 
(1998b). Activation of cholesterol synthesis in preference to fatty acid 
synthesis in liver and adipose tissue of transgenic mice overproducing 
Sterol regulatory element-binding protein-2. The Journal of Clinical 
Investigation 101 (11): 2331-2339 
Howard S., Kruth M.D. (1984). Localization of unesterifed cholesterol in human 
atheroscierotic lesions demonstration of filipin-positive, Oil-red-O-negative 
particles. American Journal of Pathology 114: 201-208 
Houghton S.G., Cockerill F.R. (2006). Real-time PCR: Overview and applications. 
Surgery 139 (1): 1-5 
Hsiang Y.H., Hertzberg R., Hecht S., Liu L. (1985). Camptothecin induces protein-
linked DNA breaks via mammalian DNA Topoisomerase I. The Journal of 
Biological Chemistry 260 (27): 14873-14878 
Hsiang Y.H. & Liu L.F. (1988). Identification of mammalian DNA Topoisomerase I as 
an intracellular target of the anticancer drug Camptothecin 1. Cancer 
Research 48: 1722-1726 
Hsiang Y.H., Liu L.F., Wall M.E., Wani M.C., Nicholas A.W., Manikumar G., Kirschenbaum 
S., Silber R., Potmesil M. (1989). DNA Topoisomerase I-mediated DNA 
cleavage and cytotoxicity of Camptothecin analogues. Cancer Research 49: 
4385-4389 
Hu S.H., Latham C.F., Gee C.L., James D.E., Martin J.L. (2007). Structure of the 
Munc18c/Syntaxin4 N peptide complex defines universal features of the N-
peptide binding mode of Sec1/Munc18 proteins. Proceedings of the National 
Academy of Sciences 104 (21):  8773–8778 
Huang T.H.W., Teoh A.W., Lin B.L., Lin D.S.H., Roufogalis B. (2009). The role of herbal 
PPAR modulators in the treatment of cardiometabolic syndrome. 
Pharmacological Research 60: 195-206 
  255 
Hussain A., Claussen B., Ramachandran A., Williams R. (2007). Prevention of Type 2 
Diabetes: A review. Diabetes Research and Clinical Practice 76: 317–326 
Inoue Y., Inoue J., Lambert G., Yim S.H., Gonzalez F.J. (2004). Disruption of hepatic 
C/EBPα results in impaired glucose tolerance and age-dependent 
hepatosteatosis. The Journal of Biological Chemistry 279 (43): 44740–44748 
James D.E. (2005). MUNC-ing around with insulin action. The Journal of Clinical 
Investigation 115 (2): 219-221 
Jang M.H., Jun D.Y., Rue S.W., Han K.H., Park W., Kim Y.H. (2002). Arginine 
antimetabolite L-canavanine induces apoptotic cell death in human Jurkat T 
cells via caspase-3 activation regulated by Bcl-2 or Bcl-xLq. Biochemical and 
Biophysical Research Communications 295: 283-288 
Jeans A.F., Oliver P.L., Johnson R., Capogna M., Vikman J., Molnár Z., Babbs A., 
Partridge C.J., Salehi A., Bengtsson M., Eliasson L., Rorsman P., Davies K.E. 
(2007). A dominant mutation in Snap25 causes impaired vesicle trafficking, 
sensorimotor gating, and ataxia in the blind-drunk mouse. Proceedings of the 
National Academy of Sciences 104 (7):  2431–2436 
Johansen J.S., Harris A.K., Rychly D.J., Ergul A. (2005). Oxidative stress and the use 
of antioxidants in diabetes: Linking basic science to clinical practice 
Cardiovascular Diabetology 4: 1-11 
Jung U.J., Lee M.K., Park Y.B., Kang M.A., Choi M.S. (2006). Effect of citrus flavonoids 
on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 
diabetic mice. The International Journal of Biochemistry and Cell Biology 38: 
1134-1145 
Kadowaki T. (2000).Insights into insulin resistance and Type 2 Diabetes from 
knockout mouse models. The Journal of Clinical Investigation 106 (4): 459-465 
Kadowaki T., Kadowaki H., Taylor S.I. (1990). A nonsense mutation causing 
decreased levels of insulin receptor mRNA: Detection by a simplified 
technique for direct sequencing of genomic DNA amplified by the 
polymerase chain reaction. Proceedings of the National Academy of Sciences of 
the USA 87: 658-662 
Kahn B.B. and Flier J.S. (2000). Obesity and insulin resistance. The Journal of Clinical 
Investigation  106 (4): 473-481  
Kahn C.R and White M.F. (1988). The Insulin Receptor and the molecular mechanism 
of insulin action. The Journal of Clinical Investigation 82: 1151-1156  
Kahn C.R., Chen L., Cohen S.E. (2000). Unraveling the mechanism of action of 
thiazolidinediones. The Journal of Clinical Investigation 106 (11): 1305-1307 
Kallin A., Lene E. Johannessen L.E., Cani P.D., Marbehant C.Y., Essaghir A., Foufelle F., 
  256 
Ferre P., Heldin C.H., Delzenne N.M., Demoulin J.B. (2007). SREBP-1 regulates 
the expression of heme oxygenase 1 and the phosphatidylinositol-3 kinase 
regulatory subunit p55γ. Journal of Lipid Research 48:1628-1636 
Kaminski A., Kaminski E.R., Morgan N.G. (2007). Pre-incubation with interleukin-4 
mediates a direct protective effect against the loss of pancreatic b-cell 
viability induced by proinflammatory cytokines British Society for Immunology, 
Clinical and Experimental Immunology 148: 583-588 
Kanzaki M. and Pessin J.E. (2003) Insulin Signalling: GLUT4 vesicles exit via the 
exocyst. Current Biology 13: R574–R576 
Kasuga M., Fujita-Yamaguchi Y., Blitheo D.L., Kahn C.R. (1983). Tyrosine-specific 
protein kinase activity is associated with the purified insulin receptor. 
Proceedings of the National Academy of Sciences of the USA 80: 2137-2141 
Katso R.M., Pardo O.E., Palamidessi A., Franz C.M., Marinov M., De Laurentiis A., 
Downward J., Scita G., Ridley A.J., Waterfield M.D., Arcaro A. (2006). 
Phosphoinositide 3-Kinase C2β Regulates Cytoskeletal Organization and 
Cell Migration via Rac-dependent Mechanisms. Molecular Biology of the Cell 
17: 3729-3744 
Katz I., Schneider H., Shezi Z., Mdleleni G., Gerntholtz T., Butlera O., Manderson L., 
Naicker S. (2009). Managing type 2 diabetes in Soweto—The South African 
Chronic Disease Outreach Program experience. Primary Care Diabetes 3 (3): 
157-164 
Kelley G.L., Allan G., Azhar S. (2004). High dietary fructose induces a hepatic stress 
response resulting in cholesterol and lipid dysregulation. Endocrinology 145: 
548–555 
Kelley G.L., Azhar S. (2005). Reversal of high dietary fructose-induced PPARα 
suppression by oral administration of lipoxygenase/cyclooxygenase inhibitors. 
Nutrition and Metabolism 2:18 
Kengne A.P., Amoah A.G.B., Mbanya J.C. (2005). Cardiovascular complications of 
Diabetes Mellitus in Sub-Saharan Africa. Circulation 112: 3592-3601 
Kersten S. (2001) Mechanisms of nutrional and hormonal regulation of lipogenesis. 
European Molecular Biology Organization reports 21 (4): 282-286 
Kersten S., Seydoux J.,Peters J.M., Gonzalez F.J., Desvergne B., Wahli W. (1999). 
Peroxisome proliferator–activated receptor a mediatesthe adaptive response 
to fasting The Journal of Clinical Investigation 103:1489-498  
Kido Y., Burks D.J., Withers D., Bruning J.C., Kahn C.R., White M.F.,  Accili D. (2000). 
Tissue-specific insulin resistance in mice with mutations in the insulin 
receptor, IRS-1, and IRS-2. The Journal of Clinical Investigation 105:199-205  
  257 
Kim H.I. Ahn Y.H. (2004). Role of Peroxisome proliferator–activated receptor-γ in the 
glucose-sensing apparatus of liver and β-Cells. Diabetes 53 (1): S60–S65 
Kim J.K., Michael M.D., Previs S.F., Peroni O.D., Mauvais-Jarvis F., Neschen S., Kahn 
B.B., Kahn C.R., Shulman G.I. (2000). Redistribution of substrates to adipose 
tissue promotes obesity in mice with selective insulin resistance in muscle. 
The Journal of Clinical Investigation 105:1791–1797  
Kim J.K., Zisman A., Fillmore J.J., Peroni O.D., Kotani K., Perret P., Zong H.,  Dong J., 
Kahn C.R.,Kahn B.B., Shulman G.I. (2001). Glucose toxicity and the 
development of diabetes in mice with muscle-specific inactivation of GLUT4. 
The Journal of Clinical Investigation 108:153–160  
Kim M.J., Yoo K.H., Kim J.H., Seo Y.T., Ha B.W., Kho J.H., Shin Y.G., Chung C.H. 
(2007). Effect of pinitol on glucose metabolism and adipocytokines in 
uncontrolled type 2 diabetes. Diabetes Research and Clinical Practice 77S: 
S247-S251 
Kim Y.B., Peroni O.D., Aschenbach W.G., Minokoshi Y., Kotani K., Zisman A., Kahn C.R., 
Goodyear L.J., Kahn B.B. (2005). Muscle-specific deletion of the Glut4 glucose 
transporter alters multiple regulatory steps in glycogen metabolism. 
Molecular and Cellular Biology 25 (21): 9713-9723 
Knittel T., Dinter C., Kobold D., Neubauer K., Mehde M., Eichhorst S., Ramadori G. 
(1999). Expression and regulation of cell adhesion molecules by hepatic 
stellate cells (HSC) of rat liver. Involvment of HSC in recruitment of 
inflammatory cells during hepatic tissue repair. American Journal of Pathology  
154: 153–167 
Koo H.Y., Miyashita M., Cho B.H.S., Nakamura M.T. (2009). Replacing dietary glucose 
with fructose increases ChREBP activity and SREBP-1 protein in rat liver 
nucleus. Biochemical and Biophysical Research Communications 390: 285–289 
Kota B.P., Huang T.H.W., Roufogalis B.D. (2005). An overview on biological 
mechanisms of PPARs. Pharmacological Research 51: 85-94 
Kotani K., Peroni O.D., Minokoshi Y., Boss O., Kahn B.B. (2004). GLUT4 glucose 
transporter deficiency increases hepatic lipid production and peripheral lipid 
utilization. The Journal of Clinical Investigation 114 (11): 1666-1675 
Krönke G., Kadl A., Ikonomu E., Blüml S., Fürnkranz A., Sarembock I.J., Bochkov V.N., 
Exner M., Binder B.R., Leitinger N. (2007). Expression of heme oxygenase-1 in 
human vascular cells is regulated by Peroxisome proliferator-activated 
receptors. Arteriosclerosis, Thrombosi,s and Vascular Biology 27:1276-1282 
Kubista M., Andrade J.M., Bengtsson M., Forootan A., Jonák J.,  Lind K., Sindelka R., 
Sjöback R., Green B.S., Strömbom L., Stählberg A., Zoric N. (2006)The real-time 
  258 
polymerase chain reaction. Molecular Aspects of Medicine 27 95–125 
Kumar N., Dey C.S. (2002). Metformin enhances insulin signalling in insulin-
dependent and -independent pathways in insulin resistant muscle cells. 
British Journal of Pharmacology 137: 329-336 
Kumar N., Kaul C.L., Ishrath A., Dey C.S. (2004). Combination of metformin and 
thiazolidindiones restore insulin signalling in insulin-resistant cultured 
myotubes. Life Sciences 74: 1877-1888 
Kundu J.K., Mossanda K.S., Na H.K., Surh Y.J. (2005). Inhibitory effects of the extracts 
of Sutherlandia frutescens (L.) R. Br. and Harpagophytum procumbens DC. 
on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB 
as potential upstream targets. Cancer Letters 218: 21-31 
Kuo C.C., Liu J.F., Chang J.Y. (2006). DNA Repair Enzyme, O6-Methylguanine DNA 
Methyltransferase, Modulates Cytotoxicity of Camptothecin-Derived 
Topoisomerase I Inhibitors. The Journal of Pharmacology and Experimental 
Therapeutics 316 (2): 946-954   
Kusunoki M., Tsutsumi K., Hara T., Ogawa H., Nakamura T., Miyata T., Sakakibara F., 
Fukuzawa Y., Suga T., Kakumu S., Nakaya Y. (2002). Correlation between lipid 
and glycogen contents in liver and insulin resistance in high-fat-fed rats 
treated with the lipoprotein lipase activator NO-1886. Metabolism 51 (6): 792-
795  
Larsen A.K. & Gobert C. (1999). DNA Topoisomerase I in Oncology: Dr Jekyll or Mr 
Hyde? Pathology Oncology Research  5 (3): 171–178 
Leclercq I.A., Morais A.D.S, Schroyen, B., Van Hul N., Geerts, A. (2007). Insulin 
resistance in hepatocytes and sinusoidal liver cells: Mechanisms and 
consequences. Journal of Hepatology 47: 142–156 
Lefebvre P., Chinetti G., Fruchart J.C., Staels B. (2006). Sorting out the roles of PPARα 
in energy metabolism and vascular homeostasis. The Journal of Clinical 
Investigation 116 (3): 571-580 
Li J., Brasier A.R. (1996). Angiotensinogen gene activation by angiotensin II is 
mediated by the Rel A (Nuclear Factor-rcB ~65) transcription factor: One 
mechanism for the Renin angiotensin system positive feedback loop in 
hepatocytes. Molecular  Endocrinology 10 (3): 252-264 
Li Y., Wen X., Spataro B.C., Hu K., Dai C., Liu Y. (2006). Hepatocyte growth factor is a 
downstream effector that mediates the antifibrotic action of Peroxisome 
proliferator–activated receptor-γ agonists. Journal of the American Society of 
Nephrology 17(1): 54–65. 
Light M.E., Sparg S.G., Stafford G.I., van Staden J. (2005). Riding the wave: South 
  259 
Africa’s contribution to ethnopharmacological research over the last 25 
years. Journal of Ethnopharmacology 100: 127–130  
Lim H.S., MacFadyen R.J., Lip G.Y.H. (2004). Diabetes Mellitus, the Renin-
Angiotensin-Aldosterone system, and the heart. Archives of Internal Medicine 
164:1737-1748 
Livak K.J., Flood S.J., Marmaro J., Giusti W., Deetz K. (1995). Oligonucleotides with 
fluorescent dyes at opposite ends provide a quenched probe system useful 
for detecting PCR product and nucleic acid hybridization. PCR Methods and 
Applications  4: 357-362 
Lochhead P.A., Salt I.P., Walker K.S., Hardie D.G., Sutherland C. (2000).  5-
Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the 
expression of the 2 key gluconeogenic genes PEPCK and Glucose-6-
phosphatase. Diabetes 49: 896–903 
Loewen C.J.R., Levine T.P. (2005). A highly conserved binding site in vesicle-
associated membrane protein-associated protein (VAP) for the FFAT motif of 
lipid-binding proteins. The Journal of Biological Chemistry 280 (14):14097-
14104 
Loewen C.J.R., Roy A., Levine T.P. (2003). A conserved ER targeting motif in three 
families of lipid binding proteins and in Opi1p binds VAP 1. The European 
Molecular Biology Organization Journal 22 (9): 2025-2035 
Lombardo Y.B., Chicco A.G. (2006). Effects of dietary polyunsaturated n-3 fatty acids 
on dyslipidaemia and insulin resistance in rodents and humans. Journal of 
Nutritional Biochemistry 17: 1-13  
Luna M.T.T. (2005). Genes and Type 2 Diabetes Mellitus. Archives of Medical Research 
36: 210–222 
MacDonald I. (1968). Ingested glucose and fructose in serum lipids in healthy men 
and after myocardial infarction. The American Journal of Clinical Nutrition 21 
(12): 1366-137 
Madden K.R., Lance Stewart L., Champoux J.J. (1995). Preferential binding of human 
topoisomerase I to superhelical DNA. The European Molecular Biology 
Organization Journal 14 (21): 5399-5409 
Maffucci T., Cooke F.T., Foster F.M., Traer C.J., Fry M.J., Falasca M. (2005). Class II 
phosphoinositide 3 kinase defines a novel signaling pathway in cell 
migration. Journal of Cell Biology 169 (5): 789-799  
Malecki M.T. (2004). Type 2 Diabetes Mellitus and its complications: From the 
molecular biology to the clinical practice. Review of Diabetic Studies 1 (1): 5-8 
Mankovsky B., Kurashvili R.B. (2007). Glitazones: Beyond glucose lowering! Diabetes 
  260 
and Metabolic Syndrome: Clinical Research and Reviews 1: 197-207 
Matsusue K., Haluzik M., Lambert G., Yim S.H., Gavrilova O., Ward J.M., Brewer B., 
Reitman M.L., Gonzalez F.J. (2003). Liver-specific disruption of PPARγ in 
leptin-deficient mice improves fatty liver but aggravates diabetic 
phenotypes. The Journal of Clinical Investigation 111 (5): 737-747 
Matthaei S., Reibold J.P., Hamann A., Benecke H., Häring H.U., Greten H., Klein H.H. 
(1993). In vivo metformin treatment ameliorates insulin resistance: Evidence 
for potentiation of insulin-induced translocation and increased functional 
activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. 
Endocrinology 133:304-311 
Matthaei S., Stumvoll M., Kellerer M., Häring H.U. (2000). Pathophysiology and 
pharmacological treatment of insulin resistance. Endocrine Reviews 21 (6): 
585–618 
Mauvais-Jarvis F. and Kahn C.R. (2000). Understanding the pathhogenesis and 
treatment of insulin resistance and Type 2 Diabetes Mellitus: What can we 
learn from transgenic and knockout mice? Diabetes and Metabolism 26: 433-
448 
May A.P., Whiteheart S.W., Weis W.I. (2001). Unraveling the Mechanism of the Vesicle 
Transport ATPase NSF, the N Ethylmaleimidesensitive Factor. The Journal of 
Biological Chemistry 276 (25): 21991-21994 
Mayerson A.B., Hundal, R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., 
Inzucchi S.E., Shulman G.I, Petersen K.F. (2002). The effects of rosiglitazone 
on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride 
content in patients with Type 2 Diabetes Diabetes 51: 797–802 
Meshkani R.  and Adeli K. (2009). Hepatic insulin resistance, metabolic syndrome and 
cardiovascular disease. Clinical Biochemistry 42: 1331–1346  
Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., Kahn 
C.R. (2000). Loss of insulin signalling in hepatocytes leads to severe insulin 
resistance and progressive hepatic dysfunction. Molecular Cell  6: 87–97 
Mirel D.B., Valdes A.M., Lazzeroni L.C., Reynolds R.L., Erlich H.A., Noble J.A. (2002). 
Association of IL4R haplotypes with Type 1 Diabetes.  Diabetes 51: 3336-3341 
Mittra S., Bansal V.S., Bhatnagar P.K. (2008). From a glucocentric to a lipocentric 
approach towards metabolic syndrome.  Drug Discovery Today 13 (5/6): 211-
218 
Mlinar B., Marc J., Janež A., Pfeifer M. (2007). Molecular mechanism of insulin 
resistance and associated diseases. Clinica Chimica Acta 375: 20-35 
  261 
Mombereau C., Kaupmann K., Froestl W., Sansig G., van der Putten H., Cryan J.F. 
(2004). Genetic and pharmacological evidence of a role for GABAB Receptors 
in the modulation of anxiety- and antidepressant-like behavior 
Neuropsychopharmacology 29: 1050-1062 
Morrison T.B., Weis J.J., Wittner C.T. (1998). Quantification of low-copy transcripts by 
continuous SYBR Green I monitoring during amplification. Biotechniques 26 
(6): 954-958 
Mudaliar S. (2007). New frontiers in the management of Type 2 Diabetes. Indian 
Journal of Medical Research 125: 275-296 
Mukherjee P.K., Maiti K., Mukherjee K., Houghton P.J. (2006). Leads from Indian 
medicinal plants with hypoglycemic potentials. Journal of Ethnopharmacology 
106: 1–28 
Myers M.G. Wang L.M. Sun X.J., Zhang Y., Yenush L. (1994). Role of IRS-1-GRB-2 
complexes in insulin signalling. Molecular and Cellular Biology 14 (6): 3577-
3587 
Nadler S.T., Attie A.D. (2001). Please pass the chips: Genomic insights into obesity 
and Diabetes. The Journal of Nutrition 131: 2078-2081 
Nagai Y., Nishio Y., Nakamura T., Maegawa H., Kikkawa R., Kashiwagi A. (2002). 
Amelioration of high fructose-induced metabolic derangements by activation 
of PPARα. American Journal of Physiology, Endocrinology and Metabolism 282: 
E1180–E1190 
Nagamatsu S., Nakamichi Y., YamamuraC., Matsushima S., Watanabe T., Ozawa S., 
Furukawa H., Ishida H. (1999). Decreased expression of t-SNARE, Syntaxin 1, 
and SNAP-25 in pancreatic β-Cells is involved in impaired insulin secretion 
from Diabetic GK rat islets restoration of decreased t-SNARE proteins 
improves impaired insulin secretion. Diabetes 48: 2367-2373  
Nandi A., Kitamura Y., Kahn C.R., Accili D. (2004). Mouse models of insulin resistance. 
Physiological Reviews 84: 623-647 
Oh E., Spurlin B.A., Pessin J.E., Thurmond D.C. (2005). Munc18c heterozygous 
knockout mice display increased susceptibility for severe glucose 
intolerance. Diabetes 54: 638–647 
Ohoka N., Yoshii S., Hattori T., Onozaki K., Hayashi H. (2005). TRB3, a novel ER stress-
inducible gene, is induced via ATF4–CHOP pathway and is involved in cell 
death. The European Molecular Biology Organization Journal (2005) 24:1243–
1255 
  262 
Ojewole J.A.O. (2008). Anticonvulsant property of Sutherlandia frutescens R. BR. 
(variety Incana E. MEY.) [Fabaceae] shoot aqueous extract. Brain Research 
Bulletin 75: 126–132 
Okada T., Liew C.W., Hu J., Hinault C., Michael M.D., Krützfeldt J., Yin C., Holzenberger 
M., Stoffel M., Kulkarni R.N. (2007) Insulin receptors in β-cells are critical for 
islet compensatory growth response to insulin resistance. Proceedings of the 
National Academy Sciences 104 (21):  8977–8982 
Olofsson S.O., Boström P., Andersson L., Rutberg M., Perman J., Borén J. (2009). Lipid 
droplets as dynamic organelles connecting storage and efflux of lipids. 
Biochimica et Biophysica Acta 1791: 448-458 
Olivares-Reyes J.A., Arellano-Plancarte A., Castillo-Hernandez J.R. (2009). Angiotensin 
II and the development of insulin resistance:Implications for diabetes. 
Molecular and Cellular Endocrinology 302:128–139 
Ota S., Horigome K., Ishii T., Nakai M., Hayashi K., Kawamura T., Kishino A., Taiji M., 
Kimura T. (2009). Metformin suppresses glucose-6-phosphatase expression 
by a complex I inhibition and AMPK activation-independent mechanism. 
Biochemical and Biophysical Research Communications 388: 311–316 
Pacher P., Szabó C. (2007). Role of Poly(ADP-ribose) polymerase1 (PARP-1) in 
Cardiovascular Diseases: The Therapeutic Potential of PARP Inhibitors. 
Cardiovascular Drug Reviews. 25 (3): 235–260. 
Pai J., Guryev O., Brown M.S., Goldstein J.L. (1998). Differential stimulation of 
cholesterol and unsaturated fatty acid biosynthesis in cells expressing 
individual nuclear Sterol regulatory element-binding proteins. The Journal of 
Biological Chemistry 273 (40): 26138-26148 
Parola M., Novo E. (2005). Nrf1 gene expression in the liver: A single gene linking 
oxidative stress to NAFLD. Journal of Hepatology 43: 1096–1097 
Patsouris D., Mandard S., Vosho P.J.l, Escher P., Tan N.S., Havekes L.M., Koenig W., 
März W., Tafuri S., Wahli W., Müller M., Kersten S. (2004). PPARα governs 
glycerol metabolism. The Journal of Clinical Investigation 14 (1): 94-103  
Pedersen T.A., Bereshchenko O., Garcia-Silva S., Ermakova O., Kurz E., Mandrup S., 
Porse B.T., Nerlov C. (2007). Distinct C/EBPa motifs regulate lipogenic and 
gluconeogenic gene expression in vivo. The European Molecular Biology 
Organization Journal 26: 1081–1093 
Peirson S.N., Butler J.N., Foster R.G. (2003). Experimental validation of novel and 
conventional approaches to quantitative real-time PCR data analysis. Nucleic 
Acids Research 31 (14): 1-7 
  263 
Pernis A., Witthuhn B., Keegan A.D., Nelms K., Garfein E., Ihle J.N., Paul W.E., Pierce 
J.H., Rothman P. (1995). Interleukin 4 signals through two related pathways. 
Proceedings of the Natlional Academy Sciences 92: 7971-7975 
Persson K., Hamby K., Ugozzoli L.A. (2005). Four-color multiplex reverse transcription 
polymerase chain reaction: Overcoming its limitations. Analytical Biochemistry 
344: 33-42 
Pfaffl M.W. (2001). A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Research 29 (9): 2002-2007 
Pfaffl M.W., Horgan G.W., Dempfle L. (2002). "Relative Expression Software Tool 
(REST) for group-wise comparison and statistical analysis of relative 
expression results in Real-Time PCR." Nucleic Acids Research 30 (9): E36 
Pietilläinen K.H., Rissanen A., Kaprio J., Mäkimattila S., Häkkinen A.M., Westerbacka J., 
Sutinen J., Vehkavaara S., Yki-Järvinen H. (2004). Acquired Obesity is 
associated with Increased Liver fat, Intra-Abdominal Fat, and insulin 
Resistance in young adult Monozygotic Twins. American Journal of 
Physiology, Endrocrinology, and  Metabolism  288: 768-774 
Pinney S.E., MacMullen C., Becker S., Lin Y.W., Hanna C., Thornton P., Ganguly A., 
Shyng S.L., Stanley C.A. (2008). Clinical characteristics and biochemical 
mechanisms of congenital hyperinsulinism associated with dominant KATP 
channel mutations. The Journal of Clinical Investigation  118 (8): 2877-2886 
Plum L., Wunderlich F.T., Baudler S., Krone W., Brüning J.C. (2005). Transgenic and 
knockout mice in Diabetes research: Novel insights into pathophysiology, 
limitations, and perspectives. Physiology 20: 152-161  
Polak M., Cavé H. (2007). Neonatal diabetes mellitus: a disease linked to multiple 
mechanisms. Orphanet Journal of Rare Diseases  2:12 
Postic C., Dentin R., Girard J. (2004). Role of the liver in the control of carbohydrate 
and lipid homeostasis. Diabetes and Metabolism 30: 398-408 
Pourquier P., Waltman J.L., Urasaki Y., Loktionova N.A., Pegg A.E., Nitiss J.L, Pommier 
Y. (2001). Topoisomerase I-mediated cytotoxicity of N-Methyl-N-nitro-N-
nitrosoguanidine: Trapping of Topoisomerase I by the O6-Methylguanine. 
Cancer Research 61: 53-58 
Prevoo D., Swart P., Swart A.C. (2008). The influence of Sutherlandia frutescens on 
adrenal steroidogenic cytochrome P450 enzymes. Journal of 
Ethnopharmacology 118: 118-126 
Proks P., Arnold A.L., Bruining J., Girard C., Flanagan S.E., Larkin B., Colclough K., 
Hattersley A.T., Ashcroft F.M., Ellard S. (2006). A heterozygous activating 
  264 
mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal 
diabetes. Human Molecular Genetics 15 (11): 1793-1800 
Puri, V., Czech, M.P.  (2008).  Lipid droplets: FSP27 knockout enhances their sizzle.  
The Journal of Clinical Investigation 118 (8): 2693-2696. 
Puri K.D., Doggett T.A., Douangpanya J., Hou Y., Tino W.T., Wilson T., Graf T., Clayton 
E., Turner M., Hayflick J.S., Diacovo T.G. (2004). Mechanisms and implications 
of phosphoinositide 3-kinaseδ in promoting neutrophil trafficking into 
inflamed tissue. Blood 103 (9): 3448-3456 
Pryor P.R., Liu S.C.H., Clark A.E., Yang J., Holman G.D., Tosh D. (2000). Chronic 
insulin effects on insulin signalling and GLUT4 endocytosis are reversed by 
metformin.  Biochemical  Journal  348: 83-91. 
Radonić A., Thulke S., Bae H.G., Müller M.A., Siegert W., Nitsche A. (2005). Reference 
gene selection for quantitative real-time PCR analysis in virus infected cells: 
SARS corona virus, Yellow fever virus, Human Herpesvirus-6, Camelpox 
virus and Cytomegalovirus infections. Virology Journal  2:7-12 
Rakhshandehroo M., Sanderson L.M., Matilainen M., Stienstra R., Carlberg C., de Groot 
P.J., Müller M., Kersten S. (2007). Comprehensive analysis of PPARα-
dependent regulation of hepatic lipid metabolism by expression profiling. 
PPAR Research doi:10.1155/2007/26839 
Ralser M., Wamelinkb M.M., Struys E.A., Joppich C., Krobitsch S., Jakobs C., Lehrach H. 
(2008). A catabolic block does not sufficiently explain how 2-deoxy-D-
glucose inhibits cell growth. Proceedings of the National Academy of Sciences 
105 (46):  17807–17811 
Ranalletta M., Jiang H., Li J., Tsao T.S., Stenbit A.E., Yokoyama M., Katz E.B., Charron 
M.J. (2005). Altered hepatic and muscle substrate utilization provoked by 
GLUT4 ablation. Diabetes 54: 935–943 
Rapoport M.J., Jaramillo A., Zipris D., Lazarus A.H., Serreze D.V., Leiter E.H., Cyopick P., 
Danska J.S., Delovitch T.L. (1993). Interleukln 4 reverses T cell proliferative 
unresponsiveness and prevents the onset of Diabetes in nonobese Diabetic 
mice. Journal of Experimental Medicine 178: 1993 87-99 
Rencurel F., Waeber G., Antoine B., Rocchicciol F., Maulard P., Girard J., Leturque A. 
(1996).  Requirement of glucose metabolism for regulation of glucose 
transporter type 2 (GLUT2) gene expression in liver. Biochemical Journal 314: 
903-909  
Report of a WHO Consultation.  (1999). Definition, diagnosis and classification of 
Diabetes Mellitus and its complications Part 1: Diagnosis and classification 
of Diabetes Mellitus. 
  265 
Report of a WHO/IDF Consultation. (2006). Definition and diagnosis of Diabetes 
Mellitus and intermediate hyperglycaemia. 
Rhee J., Inoue Y., Yoon J.C., Puigserver P., Fan M., Gonzalez, F.J., Spiegelman B.M. 
(2003). Regulation of hepatic fasting response by PPARγcoactivator-1α 
(PGC-1): Requirement for hepatocyte nuclear factor 4α in gluconeogenesis. 
Proceedings of the National Academy of Sciences 100 (7): 4012–4017  
Rickert A.M., Lehrach H., Sperling S. (2004). Multiplexed real-time PCR using 
universal reporters. Clinical Chemistry 50(9): 1680-1883 
Romero C., García A., Medina E., Ruíz-Méndez V., de Castro A., Brenes M. (2010). 
Triterpenic acids in table olives. Food Chemistry 118: 670-674 
Rosen E.D., Walkey C.J., Puigserver P., Spiegelman B.M. (2000). Transcriptional 
regulation of adipogenesis. Genes and  Development 14: 1293-1307 
Rothenberg M.L. (1997). Topoisomerase I inhibitors: Review and update. Annals of 
Oncology 8: 837-855 
Rothman J.E. (1996). The protein machinery of vesicle budding and fusion. Protein 
science  5: 185-194 
Rubio-Guerra A.F., Vargas-Robles H., Ayala G.V., Escalante-Acosta B.A. (2007). 
Correlation between circulating adhesion molecule levels and albuminuria in 
Type 2 Diabetic normotensive patients. Medical Science Monitor 13 (8):  
CR349-352 
Rutter G.A. (2000). Diabetes: The importance of the liver. Current Biology 10: R736-
R738 
Sadhu C., Masinovsky B., Dick K., Sowell C.G., Staunton D.E. (2003). Essential role of 
phosphoinositide 3 kinase δ in neutrophil directional movement. The Journal 
of Immunology  170: 2647-2654 
Saklani A., Kutty S.K. (2008). Plant-derived compounds in clinical trials. Drug 
Discovery Today 13 (3/4): 161-171  
Saleem M. (2009). Lupeol, a novel anti-inflammatory and anti-cancer dietary 
triterpene. Cancer Letters 285: 109-115 
Savage D.B., Petersen K.F., Shulman G.I. (2005). Mechanisms of insulin resistance in 
humans and possible links with inflammation. Hypertension 45: 828-833 
Schaalan M., El-Abhar H.S., Barakat M., El-Denshary E.S. (2009). Westernized-like-diet-
fed rats: effect on glucose homeostasis, lipid profile, and adipocyte 
hormones and their modulation by rosiglitazone and glimepiride. Journal of 
Diabetes and its Complications 23: 199–208 
Schneider M.R., Lahm H., Wu M., Hoeflich A., Wolf E. (2000). Transgenic mouse 
models for studying the functions of insulin-like growth factor-binding 
  266 
proteins. Federation of American Societies for Experimental Biology Journal 14: 
629–640 
Schrem H., KLempnauer J., Borlak J. (2002). Liver-enriched transcription factors in 
liver function and development. Part I: The hepatocyte nuclear factor 
network and liver-specific gene expression. Pharmacology Reviews 54:129-
158 
Seino S., Iwanaga T., Nagashima K., Miki T. (2000). Diverse roles of KATP channels 
learned from Kir6.2 genetically engineered mice. Diabetes 49: 311-318 
Semple R.K., Chatterjee V.K.K., O‟Rahilly S. (2006). PPARγ and human metabolic 
disease. The Journal of Clinical Investigation 116 (3): 581-589  
Senn J.J., Klover P.J., Nowak I.A., Mooney R.A. (2002). Interleukin-6 induces cellular 
insulin resistance in hepatocytes. Diabetes 51: 3391-3399  
Seppälä-Lindroos A., Vehkavaara S., Häkkinen A.M., Goto T., Westerbacka J., Sovijärvi 
A., Halavaara J., Yki-Järvinen H. (2002). Fat accumulation in the Liver is 
associated with defects in insulin suppression of glucose production and 
serum free fatty acids independent of obesity in normal men. Journal of 
Clinical, Endocrinology, and Metabolism 87: 3023-3028 
Sethi J.K. & Vidal-Puig A.J. (2007). Adipose tissue function and plasticity orchestrate 
nutritional adaptation. Journal of Lipid Research 48: 1253-1262 
 Sharma S., Soowjanya A., Kumari M., Suryaprakash R., Cynthia G., Suresh J., 
Chakrabarti R., (2006). Biochemical mechanism of insulin sensitization, lipid 
modulation and anti-atherogenic potential of PPARα/γ dual agonist: 
Ragaglitazar. Life Sciences 80 (3): 235-244 
Shepherd P.R., Withers D.J., Siddle K. (1998). Phosphoinositide 3-kinase: the key 
switch mechanism in insulin signalling. Biochemical Journal 333: 471-490  
Shimomura I., Bashmakov Y., Horton J.D. (1999). Increased levels of nuclear SREBP-
1c associated with fatty livers in two mouse models of Diabetes Mellitus. The 
Journal of Biological Chemistry 274 (42): 30028-30032 
Shimano H., Horton J.D., Shimomura I., Hammer R.E., Brown M.S., Goldstein J.L. (1997). 
Isoform 1c of Sterol regulatory element binding protein is less active than 
isoform 1a in livers of transgenic mice and in cultured cells. The Journal of 
Clinical Investigation 99 (5): 846–854 
Sia C. (2004). Spotlight on Ethnomedicine: Usability of Sutherlandia Frutescens in 
the treatment of Diabetes. The Review of Diabetic Studies 1 (3): 145-149 
Singh R.K., Pandey B.L., Tripathi M., Pandey V.B. (2001). Anti inflammatory effect of 
(+)-pinitol. Fitoterapia 72: 168-170 
  267 
Sivakumar S., Subramanian S. P. (2009). Pancreatic tissue protective nature of D-
Pinitol studied in streptozotocin-mediated oxidative stress in experimental 
diabetic rats. European Journal of Pharmacology 622: 65-70 
Skrobuk P., Kuoppamaa H., Hiukka A., Koistinen H.A. (2009). Acute exposure to 
rosiglitazone does not affect glucose transport in intact human skeletal 
muscle. Metabolism Clinical and Experimental 10.1016/j.metabol.2009.07.016 
Soares M.P., Seldon M.P., Gregoire I.P., Vassilevskaia T., Berberat, P.O., Yu J., Tsui 
T.Y., Bach F.H. (2004). Heme oxygenase-1 modulates the expression of 
adhesion molecules associated with endothelial cell activation. The Journal 
of Immunology 172: 3553–3563. 
Sordet O., Goldman A., Pommier Y. (2006). Topoisomerase II and tubulin inhibitors 
both induce the formation of apoptotic Topoisomerase I cleavage 
complexes. Molecular Cancer Therapy 5 (12): 3139–44 
Spruss A., Bergheim I. (2009). Dietary fructose and intestinal barrier: potential risk 
factor in the pathogenesis of nonalcoholic fatty liver disease. Journal of 
Nutritional Biochemistry 20: 657–662 
Srinivasan K. and Ramarao P. (2007) Animal models in Type 2 Diabetes research: An 
overview. Indian Journal of Medical Research 125: 451-472 
Stafford J.M., Elasy T. (2007). Treatment update: thiazolidinediones in combination 
with metformin for the treatment of type 2 diabetes. Vascular Health and Risk 
Management 3 (4): 503–510 
Stander B.A., Marais S., Steynberg T.J., Theron D., Joubert F., Albrecht C., Joubert A.M. 
(2007). Influence of Sutherlandia frutescens extracts on cell numbers, 
morphology and gene expression in MCF-7 cells. Journal of 
Ethnopharmacology 112: 312-318 
Stander A., Marais S., Stivaktasa V., Vorster C., Albrecht C., Lottering M.L., Joubert A.M. 
(2009). In vitro effects of Sutherlandia frutescens water extracts on cell 
numbers, morphology, cell cycle progression and cell death in a tumorigenic 
and a non-tumorigenic epithelial breast cell line. Journal of 
Ethnopharmacology 124: 45–60 
Stanhope K.L.,Schwarz J.M., Keim N.L., Griffen S.C., Bremer A.A., Graham J.L., Hatcher 
B., Cox C.L., Dyachenko A., Zhang W., McGahan J.P., Seibert A., Krauss R.M., 
Chiu S., Schaefer E.J., Ai M., Otokozawa S., Nakajima K., Nakano T., Beysen C., 
Hellerstein M.K., Berglund L., Have P.J. (2009). Consuming fructose-
sweetened, not glucose sweetened, beverages increases visceral adiposity 
and lipids and decreases insulin sensitivity in overweight/obese humans. 
The Journal of Clinical Investigation 119 (5): 1322-1334  
  268 
Stienstra R., Duval C., Müller M, and Kersten S. (2007). PPARs, Obesity, and 
inflammation. PPAR Research 2007: 1-10 
Stoffel M., Duncan S.A. (1997). The maturity-onset diabetes of the young (MODY1) 
transcription factor HNF4a regulates expression of genes required for 
glucose transport and metabolism. Proceedings of the Natlional Academy of 
Sciences  94: 3209–13214 
St. Onge E.L., Miller S.A., Taylor J.R. (2009). Novel approaches to the treatment of 
Type 2 Diabetes. Journal of Pharmacy Practice 22 (3): 320-332 
Stumvoll M., Goldstein B.J., van Haeften T.W. (2005). Type 2 diabetes: principles of 
pathogenesis and therapy. Lancet 365: 1333–1346  
Szabo C., Pacher P., Swanson R.A. (2006). Novel modulators of poly(ADP-ribose) 
polymerase. Trends in Pharmacological Sciences 27 (12): 626–630 
Tan M.J., Ye J.M., Turner N., Hohnen-Behrens C., Ke C.Q., Tang C.P., Chen T., Weiss 
H.C., Gesing E.R., Rowland A., James D.E., Ye Y. (2008). Antidiabetic activities 
of Triterpenoids isolated from bitter melon associated with activation of the 
AMPK pathway. Chemistryand Biology 15: 263-273. 
Taniguchi C.M., Aleman J.O., Ueki K., Luo J., Asano T., Kaneto H., Stephanopoulos G., 
Cantley L.C., Kahn C.R. (2007). The p85α regulatory subunit of 
phosphoinositide 3-kinase potentiates c-Jun N-Terminal kinase-mediated 
insulin resistance. Molecular and Cellular Biology 27 (8): 2830-2840 
Terauchi Y., Iwamoto K., Tamemoto H.,Komeda K., Ishii,C., Kanazawa Y., Asanuma N., 
Aizawa T., Akanuma Y., Yasuda K.,Kodama T., Tobe K., Yazaki Y.,  Kadowaki T. 
(1997).  Development of non–insulin-dependent Diabetes Mellitus in the 
double knockout mice with disruption of insulin receptor substrate-1 and β 
cell glucokinase genes. Genetic reconstitution of Diabetes as a polygenic 
disease. The Journal of Clinical Investigation 99 (5): 861-866 
Thorburn A.W., Storlien L.H., Jenkins A.B., Khouri S., Kraegen E.W. (1989).  Fructose-
induced in vivo insulin resistance and elevated plasma triglyceride levels in 
rats. American Journal of Clinical Nutrition 49: 1155-1163.  
Thurmond D.C., Gonelle-Gispert C., Furukawa M., Halban P.A., Pessin J.E. (2003). 
Glucose-stimulated insulin secretion is coupled to the interaction of actin 
with the t-SNARE (Target Membrane Soluble N-Ethylmaleimide-Sensitive 
Factor Attachment Protein Receptor Protein) complex. Molecular 
Endocrinology 17 (4): 732–742 
Ueki K., Yballe C.M., Brachmann S.M., Vicent  D., Watt J.M., Kahn C.R., Cantley L.C. 
(2002). Increased insulin sensitivity in mice lacking p85α subunit of 
phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences 
  269 
99 (1): 419–424 
Ungermann C., Langosch D. (2005). Functions of SNAREs in intracellular membrane 
fusion and lipid bilayer mixing. Journal of Cell Science 118 (17): 3819-3828 
Tilg H., Moschen A.R. (2008). Insulin resistance, inflammation, and non-alcoholic 
fatty liver disease. Trends in Endocrinology and Metabolism 19 (10):371-379 
Valasek M.A., Repa J.J. (2005). The power of real-time PCR. Advances in Physiology 
Education 29: 151–159 
Van Wyk B.E. (2008). A broad review of commercially important southern African 
medicinal plants. Journal of Ethnopharmacology 119: 342–355 
Van Wyk B.E., Albrecht C. (2008). A review of the taxonomy, ethnobotany, chemistry 
and pharmacology of Sutherlandia frutescens (Fabaceae). Journal of 
Ethnopharmacology 119:  620–629 
Van Wyk B.E., van Oudtshoorn B., Gericke N. (1997). Medicinal Plants of South Africa. 
Briza Publications, Pretoria, South Africa. 
Vanden Heuvel J. (2009). PPAR resource page http://ppar.cas.psu.edu/. 
Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., 
Spleleman F. (2002). Accurate normalization of real-time quantitative RT-PCR 
data by geometric averaging of multiple internal control genes Genome 
Biology  3 (7): 0034.1–0034.11 
Vidal-Puig A.J., Considine R.V., Jimenez-Liñan M., Werman A., Pories W.J., Caro J.F., 
Flier J.S. (1997). Peroxisome proliferator–activated receptor gene expression 
in human tissues effects of obesity, weight loss, and regulation by insulin 
and glucocorticoids Journal of Clinical  Investigation 99: 2416–2422 
Vidal-Puig A., Jimenez-Liñan M., Lowell B.B., Hamann A., Hu E., Spiegelman B., Flier 
J.S., Moller D.E. (1996). Regulation of PPARγ gene expression by nutrition 
and obesity in rodents. Journal of Clinical Investigation 97 (11): 2553–2561 
Virág L., Szabó C. (2002). The therapeutic potential of poly(ADP-Ribose) polymerase 
inhibitors Pharmacology Reviews 54 (3): 375-429 
Virkamäki A., Ueki K., Kahn C.R. (1999). Protein-protein interaction and the molecular 
mechanisms of insulin resistance. The Journal of Clinical Investigation 103 (7): 
931-943 
Vivian A., Fonseca M.D., Karmeen D., Kulkarni M.S. (2008). Management of Type 2 
Diabetes: Oral agents, insulin, and injectables. Journal of the American Dietetic 
Association 108: S29-S33. 
Volpes R., Van den Oord J.J., Desmet V.J., Yap S.H. (1992). Induction of intercellular 
adhesion molecule-i (CD54) on human hepatoma cell line HepG2: influence 
  270 
of cytokines and hepatitis B virus-DNA transfection. Clinical and Experimental 
Immunology 87: 71-75 
Wahli W. (2002). Peroxisome proliferator-activated receptors (PPARs): from 
metabolic control to epidermal would healing. Swiss Medical Weekly 132: 83-
91 
Wang J., Li J., Zou Y., Cheng W., Lu C., Zhang L., Ge J., Huang C. Jin Y., Lv X., Hu C., 
Liu L. (2009). Preventive effects of total flavonoids of Litsea coreana leve on 
hepatic steatosis in rats fed with high fat diet. Journal of Ethnopharmacology 
121: 54-60 
Weber K.T. (2004). From inflammation to fibrosis: A stiff stretch of highway. 
Hypertension 43: 716-719 
Wei Y., Wang D., Topczewski F., Pagliassotti M.J. (2007). Fructose-mediated stress 
signaling in the liver: implications for hepatic insulin resistance. Journal of 
Nutritional Biochemistry 18: 1 –9 
Weir M.L., Klip A., Trimble W.S. (1998). Identification of a human homologue of the 
vesicle-associated membrane protein (VAMP)-associated protein of 33 kDa 
(VAP-33): a broadly expressed protein that binds to VAMP. Biochemical 
Journal  333: 247-251 
Welte M.A. (2007). Proteins under new management: lipid droplets deliver. Trends in 
Cell Biology 17 (8): 363-369 
White M. (2002). IRS Proteins and the Common Path to Diabetes. American Journal of 
Physiology, Endocrinology, and Metabolism 283: E413–E422 
Wilson D.W., Whiteheart S.W., Wiedmann M., Brunner M., Rothman J.E. (1992). A 
multisubunit particle implicated in membrane fusion. The Journal of Cell 
Biology 117 (3): 531-538 
Wong M.L., Medrano J.F. (2005). Real-time PCR for mRNA quantitation. 
BioTechniques 39 (1): 1-11  
Worthen D.R., Chien L., Tsuboi C.P., Mu X.Y., Bartik M.M., Crooks P.A. (1998). l-
Canavanine modulates cellular growth, chemosensitivity and P-glycoprotein 
substrate accumulation in cultured human tumor cell lines. Cancer Letters 
132: 229–239 
Xu Y., Osborne B.W., Stanton R.C. (2005). Diabetes causes inhibition of glucose-6-
phosphate dehydrogenase via activation of PKA, which contributes to 
oxidative stress in rat kidney cortex. American Journal of Physiology- Renal 
Physiology 289: F1040–F1047 
Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., Ide T., Kubota 
N., Terauchi Y., Tobe K., Miki H., Tsuchida A., AkanumaY., Nagai R., Kimura S., 
  271 
Kadowaki T. (2001). The Mechanisms by which both heterozygous 
Peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ 
agonist improve insulin resistance. The Journal of Biological Chemistry 276 
(44): 41245–41254 
Yaun L., Ziegler R., Hamann A. (2003). Metformin modulates insulin-postreceptor 
signalling transduction in chronically insulin-treatment HepG2 cells. Acta 
Pharmacologica Sinica 24 (1): 55-60 
Yechoor V.K., Patti M.E., Ueki K., Laustsen P.G., Saccone R., Rauniyar R., Kahn C.R. 
(2004). Distinct pathways of insulin-regulated versus diabetes-regulated 
gene expression: An in vivo analysis in MIRKO mice. Proceedings of the 
National Academy of Sciences 101 (47): 16525-16530 
Yellaturu C.R., Deng X., Cagen L.M., Wilcox H.G., Park E.A., Raghow R., Elam M.B. 
(2005). Posttranslational processing of SREBP-1 in rat hepatocytes is 
regulated by insulin and cAMP. Biochemical and Biophysical Research 
Communications 332: 174-180  
Yoshida T., Okuno A., Tanaka J., Takahashi K., Nakashima R., Kanda S., Ogawa J., 
Hagisawa Y., Fujiwara T. (2009). Metformin primarily decreases plasma 
glucose not by gluconeogenesis suppression but by activating glucose 
utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. European 
Journal of Pharmacology 623: 141–147 
Zehmer J.K., Huang Y.,1, Peng G.,1, Pu J., Anderson R.G.W., Liu P. (2009). A role for 
lipid droplets in inter-membrane lipid traffic. Proteomics 9 (4): 914–921 
Zhang Z., Apse K., Pang J., Stanton R.C. (2000). High glucose inhibits Glucose-6-
phosphate dehydrogenase via cAMP in aortic endothelial cells. The Journal of 
Biological Chemistry 275 (51): 40042–40047 
Zhao C., Chen W., Yang L., Chen L., Stimpson S.A., Diehl A.M. (2006). PPARγ Agonists 
Prevent TGFβ1/Smad3-Signaling in Human Hepatic Stellate Cells. 
Biochemical and Biophysical Research Communications 350 (2): 385–391 
